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ABSTRACT
Orofacial granulomatosis (OFG) is assuming increasing importance in the practice of 
Oral Medicine. This is particularly true in the west of Scotland where over 400 patients 
with the condition have been identified over a 10 year period. This study has analysed 
the clinical and immunological parameters in 301 patients with orofacial granulomatosis 
in an attempt to understand the underlying aetiopathogenesis and to develop a protocol 
for the investigation and management of such patients.
During the study, 140 patients were identified with OFG, 45 patients with 
gastrointestinal Crohn’s disease (CD) (20 having a pre-existing diagnosis; 25 having the 
diagnosis established during the study), ten patients with Melkersson-Rosenthal 
Syndrome (MRS), and six patients with sarcoidosis.
Gastrointestinal symptoms were found to be of practical value in identifying patients 
who may have gastrointestinal Crohn’s disease. Similarly, systemic examination of 
patients yielded findings which aided differentiation of CD and OFG.
An immunological (allergic) basis for OFG has been postulated in this study. Despite 
similar compliance scores and follow-up periods between the two groups (CD and OFG), 
dietary and environmental exclusion advice for substances identified on positive skin 
testing led to statistically significant differences in changes of both final symptom and 
sign scores.
Further weight to the allergic basis for OFG was added with the overall levels of IgE 
demonstrated by RAST testing being significantly higher in the OFG group (82.4%) over 
the CD group (58.6%). In addition, levels of IgG directed against unidentified proteins 
in the sera of the OFG group, comparable to coeliac disease and significantly higher than 
control groups, further strengthen the likelihood of immunological reactivity in the OFG 
group.
The consistent HLA haplotype (A2/3 B7 DR2/3/4) and results of lymphocyte studies 
suggest an immunological mechanism to the clinical presentation in OFG patients.
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The results of this study would suggest that the antigen may be dietary in origin. 
However, the negative findings in searching for Mycobacterium paratuberculosis require 
further analysis; the use of fresh tissue from orofacial biopsies instead of paraffin- 
processed sections would be a most appropriate next step using PCR technology.
Laboratory findings were also of practical value in differentiating the disease categories. 
Whereas haemoglobin concentrations and serum vitamin B12 levels were not statistically 
different between the groups, the mean corpuscular volume (lower in CD), ESR (higher 
in CD), whole blood folate, and serum ferritin (mean lower in CD) were statistically 
significant in highlighting differences between CD and OFG.
Biochemical parameters were largely redundant, with urea and electrolytes and calcium, 
albumin and phosphate levels revealing no real differences between the diagnostic 
groups.
Analysis of histological data revealed that patients with CD were much more likely to 
have lymphoedema (p=0.004) and/or granulomata (p=0.012), alone or in combination, 
on mucosal biopsy than patients with OFG. However, 20.0% of CD biopsies and 30.9% 
of OFG biopsies had no granulomas present; but only 6.7% of CD biopsies and 16.7% of 
OFG biopsies had no lymphoedema present. It therefore seems inappropriate to persist 
with the title Orofacial Granulomatosis, a histopathological term used to describe a 
clinical entity, and the alternative of Orofacial Lymphoedema is suggested on the basis 
of clinical findings alone.
The clinical findings in patients with OFG led to the helpful concept of Major and Minor 
diagnostic criteria for Orofacial Lymphoedema, with Major criteria being present in 
>30% of patients and Minor criteria being present in 7-29% of patients as follows:
Chronic lower lip swelling 52.2%
Chronic upper lip swelling 51.2%
Mucosal oedema and cobblestoning 48.8%
Aphthous ulceration 39.2%
Mucosal tags 31.2%
Full-thickness gingivitis 30.2%
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Minor: Chronic facial swelling 27.0%
Angular cheilitis 
Fissured tongue 
Non-aphthous ulceration 
Papillary hyperplasia
26.2%
11.3%
7.3%
8.0%
The diagnosis would be based on 2 major criteria (i.e. present in at least 60.4% of 
patients) or 1 major plus 3 minor criteria (i.e. present in at least 56.8% of patients).
On the basis of this study, OFG, sarcoidosis and Crohn’s disease are distinct clinical 
entities. OFG, or more appropriately Orofacial Lymphoedema, OFL, would appear to be 
primarily allergic in its pathogenesis (Type IV or delayed hypersensitivity), as would 
Melkersson-Rosenthal Syndrome.
Overall, 45 out of 301 patients in this study population had, or developed, evidence of 
gastrointestinal Crohn’s disease - some 15% over a 10-year period. The successful use 
of technetium-labelled leucocyte scanning of the gastrointestinal tract to identify 
gastrointestinal CD in patients with OFL in the paediatric population has been 
demonstrated in this study.
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INTRODUCTION & AIMS
Orofacial granulomatosis (OFG) is assuming increasing importance in the practice of 
Oral Medicine. This is particularly true in the west of Scotland where over 400 patients 
have been identified with the condition over a 10 year period. Such figures cannot, it 
would seem, be equalled anywhere else in the UK or abroad - hence the importance of 
this study based in Scotland.
However, in quoting such numbers of patients, one is immediately aware of the 
difficulties in rational diagnostic criteria since, as a chronic granulomatous disorder, 
some clinicians may be labelling this entity as Crohn’s disease, oral Crohn’s disease, 
sarcoidosis, Melkersson-Rosenthal Syndrome, cheilitis granulomatosa of Miescher or the 
remote possibilities of leprosy and tuberculosis. Some authors clearly use OFG as an 
“umbrella” term encompassing all the above granulomatous disorders and more; others 
use OFG, as Wiesenfeld et al (1985) first intended, as a term to describe a constellation 
of signs resembling those of Crohn’s disease clinically and histologically in patients who 
do not appear to have abnormalities at any other site in the gastrointestinal tract. But 
what evidence is there that these patients do not indeed have Crohn’s disease at other 
sites; or that these are simply local manifestations of some other granulomatous disorder 
such as sarcoidosis? What account is taken of the increasing evidence that OFG may be 
a Type IV hypersensitivity reaction quite distinct from other granulomatous disorders; or 
indeed that these are the orofacial manifestations of Crohn’s disease, which itself may be 
a gastrointestinal manifestation of allergy? Add to this the recently developed science of 
molecular biology with its claims about Mycobacterium paratuberculosis as an 
aetiological factor in Crohn’s disease and the scene is set for a life-long study into the 
possible aetiology of OFG.
Indeed the term OFG itself is hugely inadequate, since it uses a histopathological term to 
describe a clinical entity. This, then, is clearly a mine-field of mixed information, poorly 
applied nomenclature and inappropriately applied conclusions. How can we steer a 
course ahead which will take us into better charted waters?
Firstly, a number of logical assumptions must be made. OFG may be a “rag-bag” of 
assorted conditions, all simply presenting in the same or similar ways. However, its
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histology is consistently that of a non-caseating granulomatous disorder and hence 
tuberculosis would appear not to be worthy of consideration.
Similarly, leprosy is unlikely to be a major contender since it is primarily a disease of the 
tropics not of the West of Scotland. That leaves sarcoidosis, Crohn’s disease and the 
local entities of Melkersson-Rosenthal Syndrome and cheilitis granulomatosa of 
Miescher. Clearly, OFG could be a descriptive term for the orofacial manifestations of 
any or all of these entities; or it could be a disease state in its own right. The purpose of 
this thesis is to attempt to ascertain which is correct.
The null hypothesis is therefore stated that OFG is simply a clinically descriptive term 
for the orofacial manifestations of the numerous non-caseating granulomatous 
disorders which affect man, and is NOT a disease entity in its own right.
This thesis therefore aims to examine the clinical presentation of patients with OFG, the 
results of numerous investigations (both clinical and laboratory), the effects of 
therapeutic intervention, and outcome measurements in an attempt to disprove the above 
hypothesis.
AIMS
• To describe the clinical presentation of patients with OFG, detailing the prevalence 
of anatomical site involvement in each patient group.
• To analyse haematological, biochemical and immunological parameters in each 
patient group to evaluate any consistent differences.
•  To determine the clinical response to the exclusion of identified dietary and 
environmental allergens in each patient group.
• To establish an investigative protocol for all patients presenting with OFG in an 
attempt to identify the correct diagnostic label and prognosis for each individual 
patient.
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CHAPTER 1
REVIEW OF THE LITERATURE PERTAINING TO CHRONIC 
GRANULOMATOUS DISORDERS AND OROFACIAL 
GRANULOMATOSIS
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1.1 Historical review
1.1.1 Chronic granulomatous disorders
Chronic granulomatous disorders have been evident in man for thousands of years. 
Earliest confirmed examples of caseating variants (primarily tuberculosis) come from 
studies in skeletal tissues from Egyptian and Peruvian mummies (Meachen, 1936). 
Similarly, non-caseating variants are reported in Old Testament times with references to 
the Hebrew word sara'at, translated as “leprosy”, in Leviticus chapter 13 and elsewhere.
1.1.2 Leprosy
There is a description of leprosy in the Indian text Charaka Samhita, written between 
600 and 400 BC. It is thought that the disease was brought from India to Greece and on 
to continental Europe by the armies of Alexander the Great in the fourth century BC. 
The disease was termed elephantitis graecorum, probably due to the ichthyosis and 
wood-hard oedema of the legs of some sufferers. Other Greek names for the disease 
were leontiasis and satyriasis due to the facial abnormalities present in some sufferers 
(Grange, 1988).
1.1.3 Tuberculosis
There is evidence that tuberculosis has existed from earliest times. Ancient Chinese 
writings from as far back as 2698 BC describe “lung cough and lung fever” which are 
probably tuberculosis or lao-ping. In the Rig Veda (2500 BC) there is a hymn on the 
cure of Yakshma or consumption whilst Susruta in an ancient work on Hindu medicine, 
the Ayer Veda, speaks of the difficulty of curing the disease and even blames physicians 
for not treating it early enough. He also advised walking, horse or carriage exercise and 
good feeding (Meachen, 1936).
Osseous lesions of tuberculosis have been confirmed from the vertebral columns in an 
Egyptian mummy of about 1000 BC (Meachen, 1936). Hippocrates (460-377 BC) 
coined the term “phthisis” which he applied to “a diminution or shrinking of the body, 
following incurable ulcers of the lungs, accompanied with a small fever”. Aristotle
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(384-322 BC) first suggested that consumption might be a contagious disease (Meachen, 
1936).
Gaspard Laurent Bayle (1774-1816) was the first to employ the term tuberculosis. He 
described the relationship between pulmonary tuberculosis and tuberculosis of other 
organs. However, it was Rene Theodore Hyacinthe Laennec (1781-1826), the inventor 
of the stethoscope and himself a consumptive, who laid the foundation of our knowledge 
of the pathological anatomy of tuberculosis. He showed clearly the caseative nature of 
the lesions and recognised the latency of the disease. Rudolf Virchow (1821-1902) 
affirmed that the inflammation in phthisis might terminate in caseation. Klencke (1843) 
showed that cow’s milk could transmit tuberculosis but it was Jean Antoine Villemin 
(1827-1892) who conducted the well-known experiment demonstrating that human 
pulmonary tubercle could be inoculated into rabbits, showing clearly that tuberculosis 
was a specific infection (Meachen, 1936).
The Ziehl-Neelsen stain to identify the causative bacillus in sputum was introduced in 
1882 and, despite modification by various workers, remains a standard way of 
demonstrating Mycobacterium tuberculosis today (Meachen, 1936).
1.1.4 Sarcoidosis
Sarcoidosis has been known for over 100 years in increasingly protean manifestations. 
The first report of sarcoidosis is credited to Robert Willan who introduced the term 
“erythema nodosum” in a patient who also had oral manifestations. The description is in 
his classic work On Cutaneous Disorders published in parts between 1798 and 1808, and 
among the fine copperplate engravings in colour is an illustration of erythema nodosum 
(Sharma, 1985). His vivid description has never been bettered :
“In erythema nodosum, many of the red patches are large and rounded. The central parts 
of them are very gradually elevated and on the 6th or 7th day, form hard and painful 
protuberances. From the 7th to the 10th day, they constantly soften and subside without
ulceration. On the 8th or 9th day, the red colour changes to bluish or livid I have
only seen it in females, most of whom were servants. It is preceded by irregular 
shiverings, nausea, headaches and fretfulness with a quick unequal pulse and a whitish 
fur on the tongue.” (Sharma, 1985)
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In January 1869, a 58-year old coal wharf worker was seen by Jonathan Hutchinson at 
the Blackfriars Hospital for Diseases of the Skin complaining of purple skin plaques on 
his legs and hands. Hutchinson’s account of this patient appeared under the title “Case 
of Livid Papillary Psoriasis” in his Illustrations o f Clinical Surgery (1877). The patient 
died in 1875 from kidney disease and Hutchinson linked the skin and kidney diseases 
after treating the patient at King’s College Hospital, London (James, 1984). It is now 
recognised that patients with sarcoidosis, particularly those with chronic skin lesions, 
have disordered calcium metabolism leading to renal calculi and renal failure.
In 1889, Ernest Besnier coined the term “lupus pernio” to describe the cutaneous 
manifestation of sarcoidosis at the Saint Louis Hospital, Paris when he presented a paper 
entitled “Lupus Pernio de la Face - Synovites Fongueuses Symmetriques des Extremities 
Superieures” at a weekly hospital conference (Besnier, 1889). In 1892, Tenneson 
described the granulomatous histology of lupus pernio (Tenneson, 1892). Then, in 1899, 
Caesar Boeck as Professor of Dermatology in Oslo described “the sarcoid nodule” and 
used the term sarcoidosis for the first time (Boeck, 1899). The term sarcoid derives from 
two Greek words “sark” and “aid” which translate as “flesh-like”. Heerfordt, a Danish 
ophthalmologist, in 1909 drew attention to a condition characterised by uveitis and 
enlargement of the parotid glands, frequently complicated by seventh cranial nerve 
palsies.
The Kveim test was developed by Ansgar Kveim in Oslo. He made the observation that 
sarcoid lymph node tissue inoculated intradermally gave rise to sarcoid papules in 12 of 
his 13 patients with sarcoidosis. Simultaneous control injections of Frei antigen and 
tuberculin did not produce this response. Since this reaction did not occur in normal 
subjects, or in patients with lupus vulgaris, he concluded that the papules were specific 
lesions due to an unknown agent and that the test differentiated sarcoidosis from 
tuberculosis (Kveim, 1941). The Kveim test is occasionally referred to in the literature 
as the Kveim-Siltzbach test because of a chronological association between the work of 
the two authors and a refinement of Kveim’s methodology by Siltzbach (1974). For 
simplicity, the test will be referred to as the Kveim test.
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1.1.5 Crohn ’ s Disease
In 1761 a description appeared by Morgagni of ulceration and erosion of the terminal 
ileum and adjacent colon in his De Sedibus et Causis Morburum (Morgagni, 1769). The 
following is an abstract from Benjamin Alexander’s translation of this work dated 1769:
“In that part (the extremity of the ileum and the nearest part of the colon besides) the 
intestines were eroded and ulcerated on their internal surfaces ever affected with a 
gangrene so that you see they might be easily perforated. Near to this tract some of the 
mesentery had grown into a tumour, wherein was ichor, not unlike that which had burst 
forth into the cavity of the abdomen; but the very substance of this tumour was soft and 
flaccid and seemed to incline to corruption.”
In 1806 a case presented to the Royal College of Physicians of ileal stricture by Combe 
and Saunders and a report by Abercrombie in 1820, of a 13-year old girl with a 
thickened and ulcerated terminal ileum and ascending colon, may have been the first 
documented cases of what is now known as Crohn’s disease. At the time, these cases 
were likely considered as being due to tuberculosis. In 1901, however, Lartigua 
recognised the absence of caseative necrosis and other typical changes of tuberculosis.
In 1901 Sir T. Kennedy Dalziel, a Glasgow surgeon, operated on a colleague suffering 
from diarrhoea and “obstruction of the bowels of a fortnight’s duration”. At the 
operation, the small and large intestines were “rigidly fixed” and “chronically inflamed”. 
He could do nothing to help his physician colleague who died a few days later. Dalziel 
operated on another five similar cases over the next few years and published his findings 
in 1913 in a paper entitled “Chronic Interstitial Enteritis”. He commented on the 
pathology of these cases as showing “mucosa replaced by granulomatous tissue with a 
notable number of eosinophils throughout, and a few giant cells present”. He continued, 
“the cases gave the impression they were probably tuberculosis yet from the uniform 
character of the affection it evidently is not so. The affected bowel gives the consistence 
of an eel with rigor mortis and the glands, though enlarged, are evidently not caseous.” 
In 1932, Burrill Crohn published his landmark paper describing the disease which now 
bears his name.
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Dalziel was aware of the work of Johne and Frothingham (1895) describing Johne’s 
disease in cattle and noted the similar naked-eye appearance and histological features of 
the two diseases. Dalziel’s dilemma was that in the inflamed tissue of the human 
disease, no acid-fast bacteria could be seen. Despite this, he considered the “histological 
characters so similar that...the diseases may be the same.” (Dalziel, 1913)
Since Crohn’s disease was first reported as affecting the terminal ileum, the same disease 
has been reported everywhere in the gastrointestinal tract - in small bowel, colon and 
rectum (Lockhart-Mummery and Morson, 1960); in the stomach (Comfort et al, 1950); 
and in the oesophagus (Gelford and Krone, 1968). The first case of Crohn’s disease 
affecting the mouth was recorded by Dudeney and Todd in 1969, closely followed by 
Issa in 1971. Since then, numerous case reports and studies have demonstrated the fact 
that Crohn’s disease may occur at any point in the gastrointestinal tract from mouth to 
anus. These cases, however, were reported in patients with pre-existing intestinal 
Crohn’s disease. Subsequently, the assumption arose in the literature that such orofacial 
manifestations could exist without any evidence of intestinal Crohn’s disease. Such 
assumptions preclude the possibility that this may be an entirely separate disease process 
and not simply “oral Crohn’s disease” (Williams et al, 1990). This assumption may 
have hindered substantially the investigation of the aetiology of granulomatous 
inflammation of the orofacial region.
The first link between orofacial and gastrointestinal involvement may have been made 
some 200 years previously by Dr. Archibald Pitcairn (1652-1713) who was an eminent 
member of the medical profession in Edinburgh and a founder member of the Royal 
College of Physicians of Edinburgh. As Pitcairn was a well known supporter of the 
Jacobite cause, it would seem appropriate that a physician of these sympathies would be 
consulted by the Maxwell Stuart family, residing at Traquair House, a notable Scottish 
border property. The correspondence at Traquair discusses the health (or lack of it) of 
Lord Traquair, his Countess and their large family. In one particufcr letter, dated 1703, 
advice on the health of their daughter, Lady Anne, the eldest of 17 children, is given. 
She is described as suffering from “a little of a bloody flux” and an “old swelling on her 
lip”. For both of these symptoms, a prescription of cavew was offered by Pitcairn 
(MacFadyen and Ferguson, 1996).
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Cavew, cafew or catechu is the resin extracted from the acacia or uncaria tree (Salmon, 
1706). This material was widely used as an astringent to “stop all sorts of fluxes of the 
bowels, whether of blood or humours”. In addition, it was used to treat oral lesions, 
ulcers or a particular condition of a relaxed uvula or sore throat found in delicate 
females. In this description of Lady Anne’s illness, it is interesting to note the 
combination of bowel lesions and lip swelling. The relatively recent account by 
Dudeney and Todd (1969) may have been pre-empted by Pitcairn who, in 1703, related 
the bowel and lip disorders to a single disease for which one prescription sufficed. 
Unfortunately, there are no portraits of Lady Anne extant (Marshall, 1979). She died in 
1755 and her only records are embroideries and colfichets (fine silk needle painting on a 
paper background) (Swain, 1984).
1.1.6 Orofacial granulomatosis (OFG)
Wiesenfeld et al (1985) introduced the term orofacial granulomatosis (OFG) to describe
a constellation of signs resembling those of Crohn’s disease clinically and histologically 
in patients who do not appear to have abnormalities at any other site in the 
gastrointestinal tract. However, Wiesenfeld’s definition of OFG is wholly unsatisfactory 
since it fails to take into account the underlying pathophysiology of the condition and 
discern which granulomatous disorder is manifesting in each case. This has resulted in 
the term OFG being used in the literature as an “umbrella term” for all granulomatous 
disorders around the head and neck. This has led to confusion and little progress in 
developing a scientific understanding of the pathophysiology of the disease processes.
Similarly, the term OFG itself is unfortunate since it uses histopathological terms to 
define a clinical entity. For this reason, the term orofacial lymphoedema may be 
preferred and this new concept will be addressed in this thesis.
1.1.7 Melkersson-Rosenthal Syndrome (MRS)
Hubschamann (1894) and Rossolimo (1901) presented case reports of patients in whom
a transient lower motor neurone facial nerve palsy and facial oedema occurred. 
Melkersson (1928) reported an additional case and established the link between the facial 
palsy and facial oedema. Rosenthal (1931) reported a series of patients who had lingua 
plicata (fissured tongue) in addition to facial palsy and facial oedema. The triad of
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recurrent facial swelling, unilateral or bilateral facial palsy and fissured tongue comprise 
the Melkersson-Rosenthal syndrome (MRS). Numerous cases of MRS have been 
reported in the world literature (Worsaae et al, 1980; Levenson et al, 1984; Pisanty and 
Sharav, 1969; Nally, 1970; Vistnes and Kemahan, 1971; Alexander and James, 1972; 
Homstein,1973; Worsaae and Pindborg, 1980; Azaz and Nitzan,1984; Worsaae et al., 
1982; Storrs, 1975).
1.1.8 Cheilitis granulomatosa of Miescher
Miescher (1945) independently described cheilitis granulomatosa, a chronic enlargement 
of the lips that is a result of granulomatous infiltration and resultant lymphatic channel 
obstruction. Numerous cases of cheilitis granulomatosa of Miescher without facial palsy 
or fissured tongue have been reported (Shaikh et al., 1989; Doku et al., 1965; Laymon, 
1961; Rhodes, 1965; Alpert and Nelson, 1974; Krutchkoff and James, 1978a; Hernandez 
et al., 1986).
Some investigators have suggested that cheilitis granulomatosa of Miescher is an 
oligosymptomatic manifestation of MRS (Eisenbud et al., 1971; Bishop and Garcia, 
1979). However, although macrocheilia is a component of MRS, it may also be a sign of 
Crohn’s disease, sarcoidosis or other disseminated granulomatous disease such as 
tuberculosis (Wiesenfeld et al., 1985). This lack of clarity in the literature has hindered 
the furtherance of scientific scrutiny of these granulomatous disorders.
1.1.9 GLUS syndrome (granulomatous lesions of unknown 
significance)
Finally, mention must be made of the GLUS syndrome (granulomatous lesions of 
unknown significance). Brincker in 1989 suggested the existence of a specific syndrome 
where certain clinical features occurred with great regularity (Brincker, 1989). He 
highlighted the fact that all studies of granulomatous disease include a residual group of 
unclassifiable cases in which the presence of the granulomata (chiefly in liver, bone 
marrow or lymph nodes) remains unexplained in spite of all relevant histopathological, 
microbiological, biochemical and serological studies. Brincker further pointed out that 
such cases are often characterised by prolonged fever, a benign course and a tendency to 
recurrence (Brincker, 1990; Brincker and Pedersen, 1989). The existence of the GLUS
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syndrome has been ratified by several other authors in the 1990’s (Telenti and Hermans, 
1989; Friedland et a l, 1990).
Because of the caseating nature of the granulomata in tuberculosis, the mixed 
histological picture in leprosy and the fact that the infective aetiology is well established 
for each of these disease entities, this thesis, having placed them in the historical context 
of a literature review, will now dismiss them from further discussion in the presentation 
and aetiology of orofacial granulomatosis.
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1.2 Clinical and Laboratory aspects
1.2.1 Sarcoidosis
Sarcoidosis is a relatively common multi-system disorder of unknown aetiology. It is an 
extraordinary disease, not only in the very variable presentation and spectrum of tissues 
it may affect, but also in its duration. Although transient and asymptomatic in some 
individuals, it may become chronic for others, affecting multiple systems, causing organ 
dysfunction and failure, debilitating symptoms and premature death (Scadding, 1987).
A statement prepared in 1975 by the International Committee on Sarcoidosis serves as 
the most appropriate definition of the disease:
“Sarcoidosis is a multisystem granulomatous disorder of unknown aetiology most 
commonly affecting young adults and presenting most frequently with bilateral hilar 
lymphadenopathy, pulmonary infiltration, and skin or eye lesions. The diagnosis is 
established most securely when clinical or radiographic findings are supported by 
histological evidence of widespread non-caseating epithelioid cell granulomata in more 
than one organ or a positive Kveim-Siltzbach skin test. Immunological features are 
depression of delayed type hypersensitivity, suggesting impaired cell-mediated immunity 
and raised or abnormal immunoglobulins. There may also be hypercalciuria, with or 
without hypercalcaemia. The course and prognosis may correlate with the mode of 
onset. An acute onset with erythema nodosum heralds a self-limiting course and 
spontaneous resolution, while an insidious onset may be followed by relentless, 
progressive fibrosis. Corticosteroids relieve symptoms and suppress inflammation and 
granuloma formation.” (Mitchell, 1975)
To this may be added that the organs most frequently affected are the lymph nodes, 
lungs, skin, eyes, liver, spleen and salivary glands, although every organ has been 
reported to be involved, albeit at the level of case reports (Mayock et al, 1963). There 
are even reports of extra-pulmonary sarcoid nodules making an appearance in skin 
tattoos (Collins etal., 1994).
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There is an extremely diverse number of clinical presentations and recent UK experience 
is summarised in Table 1.1. The percentage frequency of organ and tissue involvement 
in sarcoidosis is summarised in Table 1.2.
Table 1.1 First presenting symptoms of patients with sarcoidosis in the UK. Combined 
male and female data. Figures are percentages.
Ethnic Group
Feature White Black Asian
Abnormal chest radiograph 34 7 10
Respiratory symptoms 25 57 55
Constitutional symptoms 5 57 55
Erythema nodosum 20 8.5 17
Ocular symptom 7 12 3
Superficial lymphadenopathy 3 34 17
Based on Scadding and Mitchell (275 patients, London 1946-66); BTTA (567 patients in 
four geographical areas of the UK, 1961-66); Edmonstone and Wilson (156 patients, 
South London 1969-82)
27
Table 1.2 Percentage frequency of some clinical manifestations of sarcoidosis from 
various centres.
World Centre
Feature London
(275)
London
(537)
Paris
(379)
New York 
(311)
Los Angeles 
(150)
Tokyo
(282)
Hilar
lymphadenopathy
98 84 92 90 93 87
Peripheral
lymphadenopathy
31 29 23 37 31 23
Eyes 14 27 11 20 11 14
Skin 17 25 12 19 27 17
Spleen 11 12 6 18 15 1
Parotid 2 6 6 3 6 5
Central Nervous 
System
1 7 6 4 6 5
Bones 4 4 3.5 9 4 2
Erythema Nodosum 14 31 6.5 11 9 4
This data is summarised from the work of Siltzbach et al (1974). 
(Patient numbers are given in parenthesis).
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Two recognised entities are worthy of mention (James et al, 1976): Lofgren’s syndrome 
describes erythema nodosum and bilateral hilar lymphadenopathy in combination 
(Lofgren, 1953); Heerfordt-Waldenstrom syndrome (or uveoparotid fever) describes an 
uncommon condition which presents acutely and runs a chronic course with parotid 
gland enlargement, uveitis, fever and cranial nerve palsies (Heerfordt, 1909b; 
Hagerstrand and Linell, 1964). The facial nerves are particularly involved. Uveitis 
(redness of the eye, epiphora, cloudy vision and photophobia; circumcomeal congestion, 
pupillary irregularity, and keratotic precipitates in the anterior chamber) is a common 
manifestation of sarcoidosis, occurring in around 30% of patients, while parotid gland 
enlargement and nerve palsies are uncommon and occur in less than 5% of patients 
(James, 1994a).
Laboratory investigations are important in sarcoidosis. Full blood count may show a 
moderate reduction in peripheral blood lymphocyte numbers in active disease; 
thrombocytopoenia is also reported (James, 1994b). The erythrocyte sedimentation rate 
(ESR) is commonly elevated; C-reactive protein (CRP) shows no consistent pattern and 
is seldom elevated in sarcoidosis. Hypercalcaemia and hypercalciuria due to abnormal 
synthesis of vitamin D are well recognised in active sarcoidosis and occur in about 2- 
10% of patients (Scadding, 1987). The picture is similar to hypervitaminosis D with 
elevation of serum calcium, normal serum phosphate, and normal or slightly elevated 
alkaline phosphatase (Fuss et al, 1992). Hypercalciuria is commoner than 
hypercalcaemia (James, 1994a).
Total serum globulin and specific immunoglobulin levels are often raised above normal. 
In active disease, there is polyclonal increase in immunoglobulin levels, particularly in 
blacks and more often in females than males. High IgM levels are associated with 
erythema nodosum and other immunoglobulins variously raised, with IgA and IgG more 
commonly raised in blacks than whites. IgD is often depressed, the opposite to the 
common finding in tuberculosis. Circulating immune complexes are commonly detected 
in the early acute stage of the disease (James, 1994a; Scadding, 1987).
With respect to biochemical tests, such as liver function tests, and urea and electrolytes, 
there are no special features reported although alkaline phosphatase may be elevated as a 
consequence of bone or hepatic involvement (James et al, 1976).
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Some two-thirds of patients with active sarcoidosis have raised levels of serum 
angiotensin-converting enzyme, with the highest levels in those with clinically florid or 
radiographically extensive lung disease. This enzyme is produced by epithelioid cells 
and its activity is therefore a biochemical marker of cellular activity in the formation of 
granulomata (James, 1994b).
The management of sarcoidosis is determined by disease staging but is chiefly by oral 
corticosteroids (Klesper et al, 1994).
Orofacial lesions of sarcoidosis have assumed increasing importance in the literature. 
Reports of lymph node involvement around the head and neck region, as might be 
expected, outweigh all other reported manifestations (van Maarsseveen et al, 1982). 
The most frequently involved (extrathoracic) lymph nodes are the posterior cervical 
group and these tend to be bilaterally enlarged, mobile and non-tender (Martinez and 
Amedee, 1993). Head and neck manifestations are present in 10-15% of patients with 
sarcoidosis (Martinez and Amedee, 1993). Oral mucosal involvement has been reported 
in the lips, tongue, buccal mucosa, gingivae, palate and floor of mouth (Sharma, 1990). 
Oral lesions are usually described as well-circumscribed nodules or papular eruptions, 
sometimes ulcerated, of a purple or brownish-red colour (Lazarus, 1982). Oropharyngeal 
involvement is rare with the commonest manifestation being tonsillar hypertrophy (Dash 
and Kimmelman, 1988). Involvement of the major salivary glands occurs in 6% of 
patients (Hildebrand et al, 1990). The usual presentation is gland enlargement 
bilaterally and a dry mouth may be reported (Ellison and Canalis, 1986). Parotid gland 
disease is generally transient and self-limiting in 40% of cases (Hoggins and Allan, 
1969).
The oral lesions may be placed in four distinct categories :
(1) Patients with previously proven systemic sarcoidosis who also had lesions in the 
orofacial region:
In some patients with a previous diagnosis of sarcoidosis, oral involvement consisted of 
one or more nodules of the mucosa without preference for any specific site (Covel, 1954; 
Hobkirk, 1969; Orlean and O’Brien, 1966; Samitz et al, 1953). A few cases have been 
reported of involvement of the jaw bones (Betten and Koppang, 1976; Hillerup, 1976;
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Poe, 1943). Involvement of salivary gland tissue is a fairly common finding (Kalman, 
1954; Narang and Dixon, 1975). A decreased level of a-amylase and increased levels of 
albumin and lysozyme have been observed by Beeley and Chisholm (1976) in parotid 
saliva from a patient suffering from sarcoidosis with salivary gland involvement. Some 
years earlier, the value of salivary gland function tests in diagnosing sarcoidosis and in 
monitoring the response to possible therapy was described by Chisholm et al (1971).
(2) Patients with previously proven systemic sarcoidosis in which an oral biopsy o f  
apparently healthy tissue was taken:
Cahn et al (1964) described a group of 23 patients with known sarcoidosis in which 
palatal biopsies of clinically normal areas were performed. They demonstrated the 
presence of sarcoid granulomata in 38% of the cases. Tillman (1964) described a 66- 
year old male with sarcoidosis in whom a biopsy was performed of clinically normal 
gingival tissue to exclude amyloidosis. The histological findings were, in fact, consistent 
with sarcoidosis. The involvement of minor salivary gland tissue with sarcoid 
granulomata is well recognised (Chisholm et al, 1971; Tannenbaum et al, 1974; Tarpley 
et al, 1972). One study reported non-caseating granulomata in the labial gland biopsies 
of 58% of 75 patients with known sarcoidosis (Nessan and Jacoway, 1979). The 
presence of non-caseating granulomata in salivary tissue is a well recognised specific 
feature of sarcoidosis (Kerr, 1965).
(3) Apparently healthy patients in whom the findings o f the oral lesions o f sarcoidosis 
led to additional examination and the diagnosis o f systemic sarcoidosis:
A number of cases have been described in which an oral lesion, diagnosed histologically 
as sarcoidosis, led to the detection of generalised sarcoidosis (Greet and Sanger, 1977; 
MacDonald et al, 1969; Roche et al, 1967; Schroff, 1942). Vijay et al (1995) reported 
a healthy female who presented with a ranula related to the sublingual gland. This was 
diagnosed histologically as a sarcoid ranula and the patient progressed to widespread 
sarcoidosis over a 7 month period.
(4) Apparently healthy patients in whom the findings o f “sarcoid ” granulomata in the 
orofacial region led to additional examination but the diagnosis o f sarcoidosis remained 
unproven :
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Schroff (1942) described a 48-year old female with a full-thickness mucosal swelling 
affecting the cheek which revealed “tuberculoid changes” histologically. All other tests 
in this patient were negative for tuberculosis but a definitive diagnosis of sarcoidosis 
cannot be assumed from the case report. Other reports from buccal mucosa (Hoggins 
and Allan, 1969), tongue (Tillman et al, 1966) and gingivae (Watts, 1968) raise 
suspicions of sarcoidosis but no definitive diagnosis. Nitzan and Azar (1975) described 
a 62-year old female with an indurated submandibular mass, measuring about 3cm in 
diameter. Radiography revealed a sialolith and the submandibular gland was removed 
together with an adjacent lymph node. The lymph node showed features of sarcoidosis. 
No Kveim test was performed but all other tests were negative for sarcoidosis. The 
Mantoux test was also negative. The patient was also suffering from arthritis, 
xerophthalmia, dyspnoea and hypertension and so a diagnosis of systemic sarcoidosis 
was assumed. The authors mention that “specific treatment for sarcoidosis was of great 
benefit” and consider this as another supporting statement for their diagnosis. Orlian and 
Bimbaum (1980) described a 43-year old female with a swelling in the lower left 
anterior muco-buccal fold. There was no evidence of lymphadenopathy and histological 
assessment was consistent with the diagnosis of sarcoidosis. All additional tests were 
negative. It may well be that many of these latter reports of orofacial sarcoidosis would 
now be reclassified as orofacial granulomatosis and an alternative formal diagnosis and 
aetiology sought.
A search of the English literature revealed a plethora of well-documented cases of oral 
involvement of sarcoidosis supported by histological findings. Ten cases were in the 
buccal mucosa or vestibule (sulci) (Campbell, 1944; DeLuke and Sciubba, 1985; Gold 
and Sager, 1976; Greet and Sanger, 1977; Hobkirk, 1969; Hoggins and Allan, 1969; 
Kolas and Roche, 1960; Orlian and Bimbaum, 1980). Lesions at this site usually 
appeared as an irregular firm submucosal swelling fixed to the periosteum. In two cases, 
the lesions were encapsulated (Campbell, 1944). In eight, oral involvement was the first 
manifestation of the disease.
Six cases (Altman and Robinson, 1984; Caudill, 1988; Hayter and Robertson, 1988; 
Hogan, 1983; Sloan et al, 1983; Watts, 1968) were in the gingival tissues and manifested 
as red swellings, sometimes with superficial ulceration located mainly in the anterior 
labial gingivae. The enlarged gingivae occasionally exhibited a nodular pattern. In all 
cases, the lesions were the first clinical manifestation of the disease.
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Of the five cases in the lips (Bourgeois-Droin et al., 1993; Calderon et al, 1990; 
Steinberg and Mueller, 1994), two presented as a swelling and three as numerous 
submucosal nodules. In the floor of mouth, five cases (Narang and Dixon, 1975; Orlean 
and O'Brien, 1966; Roche et al, 1967; Takimoto et al, 1989; Vijay et al, 1995) 
presented as ranulas of the sublingual gland. In three, it was the first manifestation of the 
disease (Roche et al, 1967; Takimoto et al, 1989; Vijay et al, 1995). Monasebian et al 
(1997) described a recurrent, painful swelling in the submental region of a 32-year-old 
black woman. This was the first presentation of sarcoidosis in this patient who also had 
florid pulmonary involvement.
In the tongue, four cases (Macleod et al, 1985; Mendelsohn et al, 1992; Tillman et al, 
1966; van Maarsseveen et al, 1982) clinically appeared as a submucosal induration. In 
all cases, the tongue lesions were the first clinical manifestation of the disease. In the 
hard and soft palate, three cases (Cohen et al, 1981; Hildebrand et al, 1990; van 
Maarsseveen et al, 1982) presented as multiple nodules. All patients were known to 
have sarcoidosis. A more recent case described tongue involvement in a 56-year-old 
white woman with pre-existing pulmonary sarcoidosis (Soto et al, 1997). This was a 2 
x 3 cm erosive area on the ventral surface and was untypically asymptomatic. Biopsy 
confirmed the diagnosis of sarcoidosis.
With bony involvement, there were six cases in the maxilla (Aragon et al, 1988; 
Hildebrand et al, 1990; Kalman, 1954; Klesper et al, 1994; Rubin et al, 1991; van 
Maarsseveen et al, 1982), four in the body of the mandible (Betten and Koppang, 1976; 
Cohen and Reinhardt, 1982; Hillerup, 1976; MacDonald et al, 1969), one in the condyle 
(Thomas et al, 1976) and one in both jaws (Cohen et al, 1981). Radiographic 
examination revealed a radiolucency in the alveolar bone with ill-defined borders. The 
lesion eroded the cortical bone and never expanded the cortex. Teeth in the area of the 
lesion were usually vital and root resorption was not observed. In nine cases of the 
twelve recorded, the lesions in the jaws appeared in patients with known sarcoidosis.
The literature supports a true association between sarcoidosis and Sjogren’s syndrome 
(James and Sharma, 1985). Indeed, various autoimmune disorders have been linked with 
Sjogren’s syndrome and sarcoidosis such that the acronym TASS syndrome (thyroiditis, 
Addison’s disease, Sjogren’s syndrome, sarcoidosis) has been proposed (Seinfeld and 
Sharma, 1983). However, Cox and McCrea (1996) have postulated that the autoimmune
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link with sarcoidosis extends even further and may be even more memorable, coining the 
term TOASSUC syndrome (thyroiditis, other autoimmunity, Sjogren’s syndrome, 
sarcoidosis, ulcerative colitis).
Cranial neuropathies may be seen in sarcoidosis when the leptomeninges are involved in 
the granulomatous inflammatory process - the so-called neurosarcoidosis or 
cerebrospinal sarcoidosis (James, 1996). Although neurological manifestations of 
sarcoidosis occur in only 5% of cases, any part of the nervous system may be involved 
(Delaney, 1977). Peripheral neuropathies may be sensory, motor or mixed lesions. 
Colover (1948) reported on 115 cases of neurosarcoidosis and found that 58 patients had 
evidence of lower motor neurone palsies affecting the facial (seventh) cranial nerve. 
This was bilateral in 22 cases. The optic (second) nerve was the next most frequently 
involved cranial nerve. Other reviews have confirmed Colover’s findings (Delaney, 
1977; Wiederholt and Siekert, 1965; Silverstein et al, 1965). When present, cranial 
neuropathies tend to be an early feature of sarcoidosis and the prognosis is generally 
good; facial nerve palsies in particular often remit quickly and spontaneously (Boucher et 
al, 1994). In addition to CNS sarcoidosis, the possibility that a facial palsy is the result 
of parotid gland sarcoidosis should also be considered (Colover, 1948; Wiederholt and 
Siekert, 1965; Silverstein et al, 1965). Sarcoidosis involves the major salivary glands, 
primarily the parotid, in 6% of cases (Siltzbach et al, 1974).
Ng et al (1997) recently described 2 cases of patients who developed sarcoid-like foreign 
body reactions at the sites of body piercing performed for religious purposes. The 
granulomatous reaction involved the buccal mucosae in both cases and neither had any 
evidence of systemic granulomatous disorders.
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1.2.2 Crohn’s Disease
The manifestations of Crohn’s disease are protean and are determined largely by the 
anatomical location of the disease. The majority of patients complain of diarrhoea (70- 
90%), abdominal pain (45-66%) and weight loss (65-75%) (Bozdech and Farmer, 1990). 
Fever is also common (30-49%) (Farmer et al, 1975). Obstructive symptoms (colic and 
vomiting) are much more commonly associated with ileal disease than colonic disease 
(Nugent and Roy, 1989). Colonic disease causes rectal bleeding more commonly than 
ileal disease but even so, it is present in only about 50% of patients with Crohn’s colitis 
(Farmer et a l, 1985). Colonic disease is also associated with perianal disease in about 
one-third of patients and with extra-intestinal manifestations which are uncommonly 
seen when the disease is confined to the ileum (Fielding et al, 1970). Symptoms of 
anaemia are common and usually occur as a result of iron deficiency from intestinal 
blood loss or, less frequently, from vitamin B 12 or folate malabsorption (Mekjian et al, 
1979). Other nutritional deficiencies may also be present, for example magnesium, zinc, 
ascorbic acid and the B vitamins, but these are uncommon and usually due to inadequate 
intake rather than malabsorption (Lind et al, 1985a).
A few patients present with the clinical features of acute appendicitis, but at operation 
are found to have acute terminal ileitis (Farmer et al, 1972). A minority of these 
patients prove to be due to Crohn’s disease. Diagnostic difficulties may also occur when 
the disease presents without gastrointestinal symptoms. These include patients 
presenting with fever, weight loss and anaemia without diarrhoea or abdominal pain, and 
those with ileo-caecal disease presenting with urinary frequency and dysuria due to 
ureteric involvement (Bozdech and Farmer, 1990).
Physical examination may be normal but many patients will show signs of anaemia, for 
example glossitis, aphthous ulcers in the mouth or pharynx, beaking or frank clubbing of 
the nails, evidence of weight loss, and a tachycardia are common features (Farmer et al, 
1975). Abdominal examination usually reveals tenderness over the affected bowel, 
which may feel thickened. A mass is frequently palpable when small intestinal disease is 
present. Anal examination often shows the presence of fleshy skin tags, which have a 
characteristic violaceous hue. Anal fissures, perianal fistulae and abscesses are 
particularly associated with colonic disease (Farmer et al, 1985). The extra-intestinal 
manifestations of Crohn’s disease are shown in Table 1.3 (Hastings and Weber, 1993).
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Table 1.3 Extra-intestinal manifestations of Crohn’s disease
Manifestation Frequency (%) Comment
Related to disease activity
Aphthous ulceration 20
Erythema nodosum 5-10
Pyoderma gangrenosum 0.5
Acute arthropathy 6-12 Large joints affected; 
transient, non-destructive
Eye complications 
(conjunctivitis, episcleritis, 
uveitis)
3-10
Unrelated to disease activity
Sacroileitis 15-18 Usually asymptomatic; 
may be present in up to 
50% using isotope 
scanning; unrelated to 
HLA-B27
Ankylosing spondylitis 2-6 75% have the HLA-B27 
phenotype
Primary sclerosing 
cholangitis
5-6
Gallstones very common Due to malabsorption of 
bile salts from ileum
Chronic active hepatitis 2-3
Cirrhosis 2-3
Fatty change of liver 6 Very common in ill 
patients requiring surgery
Amyloid rare
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Carcinoma of the colon may complicate Crohn’s colitis. The incidence is about 3-5%, a 
frequency similar to that associated with ulcerative colitis. The risk factors are not yet 
established, however, although histological dysplasia has been reported in some cases of 
Crohn’s disease (Munkholm et al, 1993). Small bowel carcinomas have been reported 
in association with ileal Crohn’s disease (Munkholm et al., 1993).
Examination of the oesophagus, stomach and duodenum is best done endoscopically 
because the radiological appearances are often non-specific and biopsies are required for 
histological confirmation (Tanaka and Riddell, 1990). The small intestine may be 
examined with a standard barium meal and follow-through, but more information is 
obtained with the barium infusion technique (small bowel enema). The classical features 
of Crohn’s disease of the small intestine (early) are thickening of the valvulae coniventes 
and small, discrete aphthoid ulcers. In more severe cases, cobblestoning, fissure ulcers 
and thickening of the wall occur. Longitudinal ulcers, areas of stenosis, dilatation, sinus 
tracts and fistulae may also be evident (Morson, 1990).
Radiological examination of the colon is made with double-contrast barium enema after 
a thorough but gentle preparation. Characteristically, there is rectal sparing but 
otherwise the radiological appearance is similar to that of the small intestine (Bozdech 
and Farmer, 1990).
Sigmoidoscopy and rectal biopsy tend to be performed routinely in all patients (Tytgat 
and Lygidakis, 1990). Although the rectal mucosa is frequently normal or shows 
evidence of a granular proctitis, histological examination often shows an inflammatory 
infiltrate which is focal and may contain granulomata (Morson, 1990). Endoscopically, 
the earliest signs of Crohn’s disease are small aphthoid ulcers surrounded by normal 
mucosa. In more severe disease, the mucosa is erythematous and penetrated by Assuring 
ulcers to give a cobblestone appearance. The ulcers are often linear and eventually 
become confluent (Tytgat and Lygidakis, 1990). Upper gastrointestinal endoscopy is not 
routinely required and pertinent only if the symptoms dictate or abnormalities are 
detected on barium meal. Although Crohn’s disease of the stomach and duodenum may 
occur as an isolated phenomenon, most cases are associated with disease elsewhere in 
the gastrointestinal tract. Deep, longitudinal ulcers may occur in the stomach together 
with rugal hypertrophy and a cobblestone appearance. Multiple biopsies are usually 
helpful although granulomata are found infrequently (Fielding et al., 1970).
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From a laboratory viewpoint, anaemia is common and often due to mixed deficiencies. 
Iron deficiency from gastrointestinal blood loss is the most common but serum folate and 
vitamin B 12 may also be low. A neutrophil leucocytosis is usually associated with active 
disease and there may also be a thrombocytosis. The total lymphocyte count and 
absolute numbers of circulating T-lymphocytes may be reduced (Bartholomeusz and 
Shearman, 1989).
Hypokalaemia is associated with severe diarrhoea. Serum albumin is reduced in active 
disease, largely due to down-regulation of albumin synthesis by cytokines such as 
interleukin IL-1 and IL-6, and tumour necrosis factor (TNF) but studies with 51Cr- 
labelled albumin often demonstrate a protein-losing enteropathy (Farmer et al, 1985). 
Serum immunoglobulins are normal or mildly elevated but there may be a rise in the 0L2- 
globulins. A low serum calcium, when corrected for albumin, is unusual unless there is 
extensive small bowel disease. Liver function tests are frequently abnormal, consisting 
of mild elevations of aspartate transaminase and alkaline phosphatase. Persistent 
abnormality of the liver function tests suggest associated liver disease and should be 
investigated by liver biopsy and radiographic visualisation of the biliary tree (Mekjian et 
al, 1979).
There is no satisfactory method of assessing disease activity (Lind et al, 1985a). 
Symptoms such as fever or weight loss are obvious indicators but severe disease can be 
present in the absence of any major symptoms. Laboratory evidence of activity includes 
a reduced serum albumin, a rise in the acute-phase reactants (such as C-reactive protein) 
and in the ESR. A number of disease activity indices (e.g. American Crohn’s disease 
activity index and the Dutch activity index) have been developed to standardise 
assessment but they are too complex for routine use and tend to measure different 
aspects of disease activity (Issenman et al, 1993).
Much interest recently has centred around the use of indium-labelled neutrophil scanning 
to assess disease activity (Giaffer, 1996). The labelled cells preferentially migrate to 
inflamed mucosa and the increased uptake of the isotope can be detected using a gamma- 
camera. Labelling leucocytes with technetium-99 using hexamethylpropylemeamine 
oxime (HMPAO) as a chelator is gradually replacing indium since it is easier, cheaper 
and quicker. It appears to provide similar sensitivity and specificity (Li et al, 1994) and 
is now endorsed for use in the paediatric patient population (Charron, 1997).
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The treatment of Crohn’s disease is complex and requires attention to patient education, 
psychosocial support, diet and nutrition, cancer surveillance and drug therapy (Shanahan 
and Targan, 1992). The commonly used drugs are (Selby, 1993):
salicylates (sulphasalazine, mesalazine (5-ASA), olsalazine, and coated preparations of 
mesalazine), corticosteroids (topical, oral or parenteral - hydrocortisone, prednisolone, 
prednisone, and budesonide), immunosuppressive agents (azathioprine, 6- 
mercaptopurine, cyclosporin, and methotrexate), antibiotics (metronidazole, 
ciprofloxacin, co-trimoxazole, vancomycin, and gentamycin) and anti-tuberculous 
agents. Recently, the use of thalidomide has been investigated with success (Wettstein 
and Meagher, 1997).
Other therapies currently undergoing evaluation are oral fish oil preparations (Belluzzi et 
al, 1994), lymphocyte apheresis (Lerebours et al, 1994), and hyperbaric oxygen (Brady, 
1993). A major area of international interest is nutritional therapy and diet modification 
in the treatment of Crohn’s disease (Russell, 1991). Nutritional therapy can be 
considered from two viewpoints: (1) adjunctive, aimed at maintaining adequate nutrition 
and replacing losses; and (2) primary, having a direct modifying effect on the disease 
itself (Selby, 1993).
Elemental diets have been used for the treatment of Crohn’s disease since their efficacy 
was first noticed in patients being prepared for surgery. Their benefit has subsequently 
been confirmed in a number of controlled trials comparing them with corticosteroids - in 
adults (Gorard et a l, 1993; Riordan et al, 1993) and children (Ruuska et al, 1994). 
Elemental diets consist of nutrients in their simplest forms - amino acids, glucose and 
fatty acids. The initial trial comparing these elemental diets with polymeric diets, which 
contain intact proteins, was not able to demonstrate a consistent benefit (Giaffer et al, 
1990). The overall comment from these studies is that an hypothesis emerges - Crohn’s 
disease may be caused by allergens in food or drink (Koretz, 1994). Similarly, resting 
the gut may reduce the antigenic load (Woolner et al, 1998).
Despite these medical therapies, 80% of patients with Crohn’s disease will require 
surgery at some stage in the disease process (Selby, 1993).
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The extra-intestinal manifestations of Crohn’s disease are myriad and multi-system 
(Hyams, 1994). With respect to lesions affecting the head and neck, the 
pharyngolaryngeal localisations and temporomandibular joint arthropathies are well 
recognised (Wilder et al., 1980) but nasal manifestations are extremely rare (Pochon et 
al, 1995). Other specific entities worthy of note are reports linking Crohn’s disease with 
Sjogren’s syndrome (Gainey et al, 1985), oral T-cell lymphocytic lymphoma (fatal) 
(Scully et a l, 1993), and vulvitis granulomatosa, with labial swelling at two anatomical 
sites (Guerrieri et al, 1995). The aggressive nature of Crohn’s disease in many patients 
is demonstrated by the report of the disease affecting a hitherto “normal” myocutaneous 
(rectus abdominis) flap after surgical closure of an abdominoperineal defect (Reed et al., 
1993).
Orofacial lesions are common in patients with proven Crohn’s disease of the intestine 
and case reports in the international literature now run to several hundred in number 
(Plauth et al, 1991). The lesions include recurrent aphthous stomatitis (Croft and 
Wilkinson, 1972; Basu, 1976; Emery Jnr et al, 1979; Simpson et al, 1974; Estrin and 
Hughes Jnr, 1985; Tydesley, 1983; Bernstein and McDonald, 1978; Tyldesley, 1979; 
Weiss et al, 1991; Fedotin et al, 1974; Stankler et al, 1972), diffuse swellings of the 
cheek and/or lips (Basu, 1976; Varley, 1972; Snyder and Cawson, 1976; Kano et al, 
1990; Talbot et al, 1984; Estrin and Hughes Jnr, 1985; Tydesley, 1983; Tyldesley, 1979; 
Kolansky et al, 1993; Clayton, 1975), cobblestoning of the oral mucosa (Issa, 1971; 
Eisenbud et al, 1972; Tydesley, 1983; Weiss et al, 1991; Clayton, 1975), mucosal tags 
(Basu, 1976; Eisenbud et al, 1972; Irvine and Fisher, 1982; Simpson et al, 1976; 
Ghandour and Issa, 1991; Bishop et al, 1972; Tydesley, 1983), vertical fissures of the 
lips (Schiller et al, 1971; Tydesley, 1983), full-thickness (extending to the muco- 
gingival margin or beyond) gingivitis (Frankel et al, 1985; Eisenbud et al, 1972;Frost et 
al, 1981; Ghandour and Issa, 1991; Bottomley et al., 1972; Tydesley, 1983; Tyldesley, 
1979) and gingival swelling (Misra and Ament, 1996; Holmes and Smith, 1985; Giller et 
al, 1997), angular cheilitis (Field and Tyldesley, 1989; Estrin and Hughes Jnr, 1985; 
Tydesley, 1983), perioral erythema and scaling of the skin (Field and Tyldesley, 1989), 
and persistent cervico-facial lymphadenopathy (Field and Tyldesley, 1989). Erythema 
migrans has also been described in association with Crohn’s disease (Basu et al., 1975; 
Issa, 1971; Simpson et al, 1976) as has altered taste sensation (Frankel et al., 1985) and 
minor salivary gland enlargement (Schnitt et al., 1987). The prevalence of oral
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manifestations of inflammatory bowel diseases is higher in the paediatric than adult 
population (Barnard and Walker-Smith, 1994).
Four types of stomatitis have also been described in Crohn’s disease :
1. Pyostomatitis vegetans was first described by McCarthy in 1949. It affects all 
age groups with a male to female ratio of 3:1 (Hansen et al, 1983). Affected patients 
characteristically have multiple miliary pustules overlying erythematous and oedematous 
oral mucosa (McCarthy, 1949). The labial gingivae and buccal and labial mucosae are 
most frequently involved. The floor of mouth and tongue are rarely affected (Calobrisi 
et al, 1995). These pustules often rupture leading to erosions and ulceration, with 
Assuring of a pattern described as snail track ulceration (Forman, 1965). The 
histopathological features are hyperkeratosis, acanthosis, dense cellular infiltrates 
(neutrophils and eosinophils) in the lamina propria and the epithelium which aggregate 
to form small abscesses with necrosis and ulceration (Forman, 1965). 
Immunofluorescence studies are negative which distinguishes the disease from oral 
forms of pemphigus (Chan et al, 1991). Pyostomatitis vegetans is a highly specific 
marker for inflammatory bowel disease (van Hale et al, 1985) and all of the 33 case 
reports to date have occurred in patients with Crohn’s disease or ulcerative colitis 
(Calobrisi et a l, 1995;Ficarrae/a/., 1993).
2. Pseudo-pyostomatitis vegetans was described by Lewis and Beutner in 1995, 
making the first recorded association between Crohn’s disease and mucous membrane 
pemphigoid. They described a 45 year-old white female with biopsy-proven Crohn’s 
disease of the colon who developed “classical” pyostomatitis vegetans with snail track 
gingivitis affecting the anterior maxillary and mandibular gingivae. However, direct 
immunofluorescence of lesional tissue revealed deposits of IgG in the basement 
membrane zone in a linear pattern. Indirect immunofluorescence performed on the 
patient’s serum also revealed IgG reactive to the basement membrane zone at a titre of 
1:1280. It is clear therefore that pyostomatitis vegetans cannot simply be diagnosed 
clinically but immunofluorescence studies are essential. The authors state that 
misdiagnoses between these two conditions may have occurred previously (Lewis and 
Beutner, 1995).
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3. Stomatitis gangrenosum was first described by Margoles and Wenger in 1961 
who noted atypical oral (stomal) ulceration in two patients with ulcerative colitis and 
pyoderma gangrenosum. Fourteen years elapsed before the next description (Basu et al, 
1975) of irregular, deep ulcers of varying sizes. They are deep with rolled margins and a 
greyish fibrinous base. They are often foul-smelling. Histopathological findings are 
ulceration with a fibrino-purulent membrane. The lamina propria is heavily infiltrated by 
chronic inflammatory cells with histiocytes and giant cells (Basu and Asquith, 1980).
4. Chronic stomatitis was introduced by Dunlap et al in 1997 to describe the finding 
in an 11 year-old boy of generalised erythema of the oral mucosa, with chronic ulceration 
(of three months’ duration) affecting the hard palate. Microbiological and viral cultures 
from the lesions were consistently negative but a biopsy of the palatal mucosa revealed 
non-caseating granulomata. This patient was subsequently shown to have asymptomatic 
Crohn’s disease of the caecum.
Any of these lesions may occur individually or together and may antedate bowel 
symptoms by several years (Scully et al, 1982). Indeed, according to some reports, the 
mouth and peri-oral tissues may be the only identifiable site of the disease process - the 
so-called “orofacial Crohn’s disease” (Williams et al, 1990). However, it is unclear on 
the evidence presented whether these patients genuinely have Crohn’s disease or some 
other granulomatous disorder. Several case reports make the observation that the mouth 
and anus are often involved in the Crohn’s disease process (not infrequently to a severe 
degree) in isolation with no apparent involvement of the gastrointestinal tract in between 
(Ward etal., 1985).
The orofacial lesions of Crohn’s disease may be classified (Talbot et al, 1984) as :
1. Specific lesions of Crohn’s disease (e.g. mucosal cobblestoning; stomatitis 
gangrenosum)
2. Non-specific lesions of Crohn’s disease (e.g. lip swelling)
3. Lesions related to nutritional deficiencies (e.g. aphthous stomatitis; erythema 
migrans)
Several studies have investigated the dental health status of patients with Crohn’s disease 
of the gastrointestinal tract. One study (Meurman et al, 1994) found higher scores of
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gingivitis in patients with active disease over those with inactive disease. Lactobacillus 
counts and numbers of decayed tooth surfaces are consistently higher in patients with 
Crohn’s disease (Sundh et al, 1993). Similarly, periodontal disease (Lamster et al, 
1978; Halme et al, 1993) and periapical periodontitis (Halme et al, 1993) are commoner 
in patients with Crohn’s disease than control populations - as is the consumption of 
refined carbohydrate in the diet (Halme et al, 1993).
Some patients with only oral lesions - between 10% and 48% in various studies - are 
reported to have symptomless intestinal Crohn’s disease (Wiesenfeld et al, 1985). 
However, the investigations used in some such studies to arrive at this understanding are 
not without criticism. It has been suggested that 55% of patients with oral Crohn’s 
disease have involvement at four or more oral sites and that such multifocal oral 
involvement is more commonly associated with systemic disease (gastrointestinal 
Crohn’s disease) (Barnard and Challacombe, 1995).
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1.2.3 Orofacial Granulomatosis
OFG can present as recurrent facial swelling which may affect the lips, cheeks, eyelids 
and forehead (Henry, 1994). Facial swelling - affecting the upper half of the face - has 
been described as extensive but this appears to be rare with only a few cases being 
reported (Patton et al, 1985; Homstein, 1973). However, prominent enlargement of the 
lips is the most common sign with little difference in prevalence between the upper and 
lower lips (Wiesenfeld et al., 1985). Lip swelling may initially occur unilaterally. 
Because the lip swelling is soft, non-tender, non-pitting and initially of sudden onset, it 
may in the acute phase resemble angioedema (Nally, 1970; Vistnes and Kemahan, 1971; 
Homstein, 1973). However, with repeated episodes, progressive chronic and permanent 
enlargement occurs, secondary to fibrosis (Alexander and James, 1972).
The prevalence of facial palsy associated with OFG has ranged from 13% to 50%, 
depending on the series reported (Wiesenfeld et al, 1985; Vistnes and Kemahan, 1971; 
Worsaae and Pindborg, 1980). The facial paralysis is probably a result of direct 
granulomatous infiltration of the facial nerve or sheath, or it may be secondary to 
compression of the nerve by oedema within the bony canal of the temporal bone or at the 
stylomastoid foramen (Wiesenfeld et a l, 1985; Nally, 1970). Some authors suggest that 
the palsy is due to sarcoidosis of the pia-arachnoid (Cohen et al, 1981; van Maarsseveen 
et al, 1982). Facial nerve palsy may occur alone when it may precede or follow 
orofacial swelling by years (Worsaae and Pindborg, 1980; Worsaae et al, 1982; 
Homstein, 1973).
The incidence of lingua plicata has varied between 40% and 77% according to the series 
reported (Worsaae et al, 1980; Worsaae et al, 1982; Alexander and James, 1972; 
Homstein, 1973).
The study conducted by Wiesenfeld et al (1985), which coined the term orofacial 
granulomatosis, examined 60 West of Scotland patients with the condition. The clinical 
features at presentation are listed in Table 1.4.
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Table 1.4 Clinical features in 60 patients presenting with orofacial granulomatosis
(Wiesenfeld et al, 1985) 0  / / (>, 'J
CLINICAL FEATURES No. OF PATIENTS % OF PATIENTS
Facial swelling 28 47
Total lip swelling 41 68
Upper lip swelling 27 45
Lower lip swelling 30 50
Mucosal oedema 14 23
Mucosal tags 12 20
Gingival lesions 13 22
Angular cheilitis 11 18
Oral ulceration 19 32
Geographic tongue 3 5
Fissured tongue 1 2
Facial nerve palsy (unilat) 8 13
The extent and duration of facial swelling was variable; in some cases there was diffuse 
enlargement of the entire lower half of the face, whereas in others swelling was restricted 
to just one lip or to a localised patch on the cheek. The lower lip was more commonly 
involved than the upper lip. Many patients with swollen lips developed painful vertical 
fissures from which a range of organisms were isolated. Of the 11 patients with angular 
cheilitis, 10 could not be attributed to nutritional deficiency or inadequate vertical 
occlusal dimension.
The nature of the mucosal abnormality ranged from widespread thickening to small, firm 
tags. Buccal mucosa was most frequently affected with the tissue developing into broad 
folds. Gingival involvement had an appearance quite distinct from non-specific 
inflammatory gingivitis. The gingivae were erythematous and enlarged, often with a 
patchy distribution, with the anterior region most commonly affected. The gingival 
changes extended from the free gingivae to the non-keratinised mucosa of the sulci - a 
“full thickness” pattern.
One patient had oral ulceration typical of aphthae but the other patients with ulceration 
had more irregular lesions which were predominantly superficial, although some became 
deep and persistent (Wiesenfeld et al, 1985).
Sainsbury et al (1987) reported the findings in 8 children (all under 15 years of age at 
presentation) with OFG. Their findings are summarised in Table 1.5.
Table 1.5 Clinical features of eight children with orofacial granulomatosis.
(Sainsbury et al, 1987)
CLINICAL FEATURES No. OF PATIENTS % OF PATIENTS
Swollen lips 7 88
Swollen cheeks 6 75
Angular cheilitis 3 38
Oral ulceration 6 75
Swollen gingivae 6 75
Lymphadenopathy 4 50
Facial palsy (unilateral) 0 0
Anal fissure/Skin tag 3 38
Intestinal involvement 1 13
Sainsbury et al highlighted the fact that half of the patients observed in South Wales with 
OFG have been children. This study also demonstrated, for the first time, the 
involvement of dental pulp with granulomatous inflammation (Sainsbury et al, 1987).
One study (James and Ferguson, 1986) reported a 19-year-old Indian male (resident in 
UK since one year of age) who presented with the classical lip swelling and histological 
features of OFG. However, 3 years previously he had presented with enlarged lymph 
nodes in the posterior triangles of the neck bilaterally, and the left submandibular region. 
Histopathology of the lymph nodes showed discrete granulomata with multinucleate 
giant cells, histiocytes and lymphocytes. Minimal central necrosis was present: no 
acid/alcohol-fast bacilli were demonstrated in tissue sections, and inoculation of 
homogenate into a guinea pig failed to grow any mycobacteria. A chest radiograph was 
also normal. Despite this, the patient was treated with anti-tuberculous chemotherapy for 
11 months and no further adenitis was noted.
Enlarged cervical lymph nodes have been reported in patients with OFG (Tyldesley, 
1979; Homstein, 1973). In 9 cases described by Tyldesley (1979), 5 were found to have 
enlarged and indurated submandibular lymph nodes. Lewis and Morley (1969) 
documented a case with intermittent enlargement of the cervical nodes over a period of 
18 years.
The presentation of cervical lymphadenitis raises the possibility of atypical 
mycobacterial infection (Saitz, 1981). Atypical mycobacteria (AMB) infection is an 
important cause of lymph node enlargement in children. Akhtar et al (1997) recently
reviewed the casenotes of 17 children seen in Glasgow with lymphadenitis due to AMB. 
The mean age at presentation was 5.37 years (range 1.5-10.6 years). The patients had a 
short history (1-11 weeks) of unilateral single focus, usually cervicofacial (16/17) 
disease. The tuberculin skin test was negative in 14/15 patients. Primary excision was 
curative (11/11). Incision and drainage of an abscess or drainage with partial excision 
led to chronically discharging sinuses in all cases (6/6). AMB were seen on staining of 
drained or excised material in 11/17 cases and cultures were positive in 9 cases. The 
AMB cultured were avium intracellulare or AMB avium complex. The diagnosis was 
made in the remaining cases on the basis of clinical features and particular 
histopathological pattern (granulomatous inflammation with or without caseous 
necrosis).
Haase et al (1994) have described facial lymphadenitis in a 15-month-old boy which had 
histological features compatible with the diagnosis of AMB lymphadenitis. The AMB 
was subsequently identified, by DNA probing, as the recently described M. celatum.
James (1991a) made a comparison of the clinical findings in sarcoidosis and OFG (see 
Table 1.6) and drew the conclusion that these were two distinct disease entities.
Table 1.6 A comparison of Sarcoidosis and OFG (James, 1991)
FEATURES SARCOIDOSIS OFG
Gender Equal Equal
Age at presentation 20-45 20 (3-60)
Swelling of lips No Characteristic
Buccal mucosal oedema No Frequent
Oral ulceration No Yes
Gingival hyperplasia No Yes
Fissured tongue No Occasional
Facial palsy 4% (may be bilateral) 13% (unilateral)
Oral biopsy helpful + +
Associated Crohn’s Very rare Frequent
Ocular lesions Yes No
Skin lesions Yes No
Chest radiograph Abnormal Normal
Kveim test Positive Negative
Serum ACE Raised Normal
47
Worsaae et al (1982) studied 16 patients with established OFG and found none with 
gastrointestinal Crohn’s disease. Scully et al (1982) reviewed 19 patients with OFG and 
found 7 (37%) to have gastrointestinal Crohn’s disease. These authors suggested that an 
elevated ESR, in conjunction with haematological evidence of malabsorption (iron 
studies, whole blood folate, serum albumin and calcium), were suggestive of 
gastrointestinal Crohn’s disease (Scully et al, 1982). Taylor and Smith (1975), having 
reviewed the world literature and presented 1 case report, make the bold statement on the 
inevitability of patients with OFG subsequently developing gut Crohn’s disease. This 
view is clearly not endorsed by other authors.
Wiesenfeld et al (1985) found 6 patients (10%) had definite gastrointestinal Crohn’s 
disease. A further 3 patients with possible Crohn’s disease were followed-up for 5 years 
and remained well. Importantly, all 9 patients with positive gastrointestinal 
investigations had symptoms referable to the gastrointestinal tract at the time of 
presentation. A further 13 patients with gastrointestinal symptoms had no evidence of 
Crohn’s disease on investigation. Furthermore, in 22 control patients with no 
gastrointestinal symptoms, no evidence of gastrointestinal disease was found.
In the study by Wiesenfeld et al (1985), no patients had a history suggestive of systemic 
sarcoidosis. Two patients had cutaneous lesions suggestive of sarcoidosis and a Kveim 
test in both supported this diagnosis. A total of 8 patients had Kveim tests performed 
and 34 had serum ACE levels estimated - all were within normal limits. However, the 2 
patients who were diagnosed with sarcoidosis did not have serum ACE levels measured. 
Indeed, it is not clear how the diagnosis was arrived at.
A recent case report has linked OFG and syringomyelia (Sabroe and Kennedy, 1996). A 
66-year-old male patient presented 15 years after a diagnosis of syringomyelia with 
marked right-sided facial swelling, particularly around the orbit. Histology showed 
granulomatous inflammation and all investigations for Crohn’s disease and sarcoidosis 
were negative. The authors propose that syringomyelia may be a further neurological 
abnormality associated with OFG, to join those previously reported - facial palsy, 
headache, migraine, other cranial nerve palsies, Homer’s syndrome, salivary gland 
dysfunction, psychoses, epilepsy, and abnormalities in the electroencephalogram (EEG) 
(Homstein, 1973; Greene and Rogers, 1989; Zimmer et al, 1992; Worsaae et al, 1982).
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In the localised form of OFG, it is unusual to encounter any other systemic 
manifestations. A few studies have commented on a general malaise or joint pains in 
patients in association with their facial swelling, which suggests the presence of 
circulating immune complexes (Ferguson and MacFadyen, 1986a). Six patients with 
joint pain and seropositive or seronegative arthritis have been described with OFG 
(Sabroe and Kennedy, 1996; Greene and Rogers, 1989; Zimmer et al, 1992; Worsaae et 
al, 1982; Eggelmeijer et al, 1989).
Management of patients with OFG should include biopsy of the lesion and exclusion of 
intestinal Crohn’s disease by haematological and biochemical investigations; if  there are 
abdominal symptoms, radiographic bowel imaging with possible subsequent endoscopy 
and biopsy are indicated (Anonymous, 1991b). Sarcoidosis should also be excluded by 
chest radiography, serum ACE measurements and possibly a Kveim test (Anonymous, 
1991b).
Treatment of symptoms in patients with OFG is often unsatisfactory (Miele,1994). In 
dealing with children, Sainsbury et al (1987) considered the natural history of OFG to be 
often one of gradual improvement. For ulceration they recommended chlorhexidine 
mouthwash (0.2%); 1% hydrocortisone ointment for angular cheilitis and lip Assuring. 
Intralesional corticosteroids were not well tolerated by children and a short course of 
systemic prednisolone could only be justified in children with severe disease (Sainsbury 
et al, 1987).
Patients with minor symptoms may not require active treatment, apart from 
encouragement and clinician support (Armstrong and Burrows, 1995). Intralesional and 
systemic corticosteroids generally have a beneficial effect although relapse is common 
on cessation of therapy (Zimmer et al, 1992; Allen et al, 1990). In one study 
(Sakuntabhai et al, 1993), five patients with biopsy-proven OFG (aged 10-24 years) 
were injected with high-volume intra-lesional triamcinolone (3- 10ml of lOmg/ml; mean 
60mg) after first numbing the lips with infra-orbital and mental local anaesthesia nerve 
blocks. Lip swelling immediately after injection was dramatic but started to subside 
after 5-6 days. After 6 weeks, the lip size returned to normal in 4 patients and was 
reduced in the fifth. One patient was injected on 4 occasions over a 2-year period; in the 
4 other patients treated once, lip size remained reduced for over 10 months (Sakuntabhai 
e ta l, 1993; Sakuntabhai et al, 1992).
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In adult patients, the use of low dose prednisolone (5mg daily) may reduce symptoms to 
cosmetically acceptable levels (Ingram, 1993). Other agents for which some success has 
been claimed include clofazimine, hydroxychloroquine and danazol (Zimmer et al., 
1992; Allen et al., 1990; Podmore and Burrows, 1986). Treatment with sulphasalazine, 
metronidazole, azathioprine and cyclosporin has been disappointing (Armstrong and 
Burrows, 1995).
Ferguson and MacFadyen (1986b) suggested, on reviewing their cases of OFG over a 10 
year period, that the mainstay of management should be identifying potential allergens 
rather than loading patients up with anti-inflammatory drugs, simply to control 
symptoms.
Several authors have reported good responses to the introduction of very low-allergen 
diets or elimination diets that identify and exclude putative provoking dietary factors 
(McKenna et al, 1994; Haworth et al., 1986). Armstrong and Burrows (1995) report 
that improvement in symptoms with dietary manipulation seems to involve only a sub­
group of patients and they contend that this may reflect the heterogeneity in the aetiology 
of the condition.
Sanderson et al (1996) have reported the ileo-colonoscopic findings in ten patients with 
OFG and no gut symptoms. Abnormalities were detected in the ileum or colon (by direct 
vision and/or histology) in 8/10 cases. Macroscopic abnormality was present in only two 
cases (ileal aphthae and ileal erythema). Microscopic inflammation was detected in a 
further six cases and seven cases had identifiable granulomata. They concluded that 
ileocolonoscopy detected previously undiagnosed gut inflammation in the majority of 
patients with OFG, especially those presenting at a younger age.
The vast differences between studies in reporting gut inflammation in OFG is a 
concerning feature of the literature and requires clarification and standardisation of 
assessment.
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1.2.4 Melkersson-Rosenthal Syndrome
The Melkersson-Rosenthal Syndrome (MRS) is a triad of lower motor neurone (facial 
nerve) palsy, facial oedema and fissured tongue (lingua plicata). The original report 
linking lower motor neurone facial nerve palsies and facial oedema came from 
Hubschamann in 1894. This was further clarified by a similar case described by 
Rossolimo in 1901 who also noted that the patient suffered from migraine. However, 
the syndrome is credited to Melkersson (1928) and Rosenthal (1931) and numerous case 
reports of MRS have been reported in the world literature since (Worsaae et al, 1980; 
Levenson e ta l, 1984; Cohen et al., 1994; Pisanty and Sharav, 1969;Nally, 1970;Vistnes 
and Kemahan, 1971; Alexander and James, 1972; Homstein, 1973; Worsaae and 
Pindborg, 1980; Azaz and Nitzan, 1984; Worsaae et al, 1982; Storrs, 1975; Dhar and 
Kanwar, 1995).
In keeping with many such entities described in the medical literature, the syndrome has 
been modified and “downgraded” by subsequent authors who failed to acknowledge the 
strict diagnostic criteria for the syndrome as originally described. Thus, the literature 
becomes confused with references to “monosymptomatic” and “oligosymptomatic” MRS 
(Levenson et al, 1984; Jain et a l, 1990; Cheng e ta l,  1993; Stosiek et al, 1992;Minelli 
et al, 1991; Mainetti et al, 1994; Rubino and Ficarra, 1994; Mendez et al, 1991; 
Archibaldo and Alfredo, 1995; Mahler and Kiesewetter, 1996; Marques et al, 1994; 
Labarthe et al, 1995; Pellegrino et al, 1993; John et al, 1992; Benavides, 1990; Orlando 
and Atkins Jnr, 1990).
Further confusion enters the discussion with case reports clearly referring to sarcoidosis 
with a raised angiotensin converting enzyme level (Orlando and Atkins Jnr, 1990). 
Indeed, in 1984 without any justification whatever, Azaz and Nitzan stated that “..not all 
the symptoms (of MRS) need appear (together)” - presumably in a feeble attempt to 
justify their case report of a man with “MRS” in whom “(the neurological examination) 
disclosed no facial paresis or neurologic disorders”. This lack of stringency is endorsed 
by Winnie and DeLuke in 1992 who state that “the presence of 2 (of the original three) 
findings should suggest a clinical diagnosis of MRS, subject to histopathologic 
confirmation.” Similar lack of stringency of definition is demonstrated by other authors 
(Mahler et al, 1995) allowing “trigeminal nerve paralysis” as part of the Syndrome.
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Homstein (1973) stated that MRS “is not so much a rare disease as one seldom 
diagnosed”. An extensive review of the literature suggests that 262 cases have been 
reported since the syndrome was originally described. Combining the data from these 
262 cases, the orofacial manifestations are listed in Table 1.7.
Table 1.7 Orofacial manifestations during the course of MRS.
MANIFESTATION NUMBER PERCENTAGE
Labial swelling 216 82
Upper 157 60
Lower 108 41
Facial swelling 68 40
Facial palsy 65 25
Migraine/headache 63 24
Gingival swelling 28 11
Gingival pain 5 2
Gingival erosions 2 <1
Buccal mucosal swelling 41 16
Buccal mucosal erosions 3 1
Palatal swelling 22 8
Lingua plicata 154 59
Lingual swelling 27 10
Lingual dysaesthesia 11 4
Alteration of taste 7 3
Hyposalivation 5 2
Note * Only 127 patients from the literature review were included because of insufficient 
data in the original reports.
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In most cases, the facial or lip swelling occurs before the facial palsy, but in others, it 
may occur some time after or simultaneously with it (Bataineh et al, 1995; Kettel, 1949). 
The disease may have an acute, a recurrent, or a chronic course (Daoud and Rogers III, 
1995). On the strength of combined data from various studies, Daoud and Rogers (1995) 
have suggested major and minor criteria for the diagnosis of MRS as follows:
Major criteria
Recurrent or persistent orofacial swelling 
Minor criteria
Relapsing facial paralysis 
Fissured tongue (lingua plicata)
Histological evidence of granulomatous inflammation
However, on this basis it would be difficult or impossible to differentiate MRS from the 
orofacial manifestations of systemic diseases such as sarcoidosis and Crohn’s disease.
Greene and Rogers (1989) commented on the laboratory findings in 36 patients with 
MRS. Leucocytosis or eosinophilia were not present in any case; nor were titres of anti­
streptolysin O and anti-deoxyribonuclease B. No abnormalities in serum concentrations 
of calcium, creatinine, or phosphate were recorded. Liver function tests were normal. 
Three patients had increased levels of IgM (unspecified) and one patient had an elevated 
level of IgE at 3089 IU/ml (normal 20-367 IU/ml). This elevated IgE was unspecified in 
terms of target antigen but could easily indicate an allergic state. Other isolated findings 
(each in one patient) were: raised ESR; a positive ANA (speckled 1:80); iron deficiency 
anaemia, and hypokalaemia. These last two findings were not expanded upon but could 
easily be found in patients with advanced Crohn’s disease. Elevated blood glucose 
levels were present in two patients with previously diagnosed diabetes mellitus, a 
systemic disease which could account for the neurological palsies.
MRS has been reported in association with other local conditions such as gustatory 
sweating, epiphora, tinnitus, and disturbed taste sensation (Bataineh et al, 1995), 
geographic tongue (Nally, 1970), masseteric myopathy (Saito et al, 1994), laryngeal 
swelling with obstruction and respiratory arrest (Jayamaha, 1993), and granulomatous 
blepharitis (Manganaro and Holmes, 1997). MRS has also been linked with systemic 
diseases: distant-site neoplasia (Nifosi and Scassa, 1997); facial rosacea (Bose, 1996);
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malignant pharyngeal lymphoma (Kanda, 1996); vulvitis granulomatosa (Samaratunga et 
al, 1991); perivulvitis granulomatosa (Knopf et al, 1992); Horton’s temporal arteritis 
(Stabler et al, 1990); juvenile rheumatoid arthritis (Eggelmeijer and Dijkmans, 1990); 
sero-negative oligoarthritis (Eggelmeijer et al, 1989); Crohn’s disease (Lloyd et al, 
1994; Worsaae et al, 1980); oral Crohn’s disease (Diamond et al, 1990); orofacial 
granulomatosis (Rogers III, 1996); and sarcoidosis (Alexander and James, 1972; Altman 
and Robinson, 1984). Basal sarcoid arachnoiditis has been postulated as an aetiological 
factor in MRS and would certainly explain the facial nerve palsy (Graff-Radford, 1981).
James (1994b) made a comparison of the clinical findings in Melkersson-Rosenthal 
Syndrome (MRS) and sarcoidosis (Table 1.8). He made the comment that, on the basis 
of these clinical findings, MRS and sarcoidosis must be two separate disease entities 
(James, 1994b).
Table 1.8 Comparison of Melkersson-Rosenthal Syndrome and Sarcoidosis
Feature MRS Sarcoidosis
Male: Female equal equal
Age of onset (years) any 20-40
Multiple Granulomata + +
Facial Paralysis + +
Facial Oedema + -
Swollen Lips + -
Fissured Tongue + -
Angular Cheilitis + -
Granulomata o f :
Face + +
Oral Mucosa + -
Gingivae + +
Lips + +
Eyelids + +
Tongue + -
Pharynx + +
Vulva + -
Salivary Gland Dysfunction + +
Uveitis - +
Abnormal Chest X-ray - +
Positive Kveim Test - +
Angiotensin Convertase Normal Elevated
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There is some concern expressed in the literature about long-term follow-up of patients 
with MRS, or indeed any chronic lymphoedematous state (Kanda, 1996). This is due to 
the recognised association of MRS and subsequent development of lymphoma (Breuchat 
et al, 1985; Kanda, 1996). The literature clearly highlights established links between 
lymphoedema and subsequent lymphomatous change (Breuchat et al., 1985; Tatnall and 
Mann, 1985; Waxmann et al, 1984; d’Amore et al, 1990; Peyron et al, 1993) - the so- 
called Stewart-Traves syndrome (d’Amore et al, 1990).
Treatment of MRS is largely symptomatic given that the aetiology of the syndrome is 
unknown (Tausch and Sonnichsen, 1992). In addition, the confusion in the literature 
over diagnostic criteria for MRS make it likely that a number of different granulomatous 
disorders are being classified as MRS, leading to an erroneous assessment of treatment 
outcome measures. Similarly, partial or complete spontaneous remission is reported in 
around 27% of patients (Sussman et al, 1992) and this will also confuse treatment 
outcome scores.
The mainstay of treatment is corticosteroids - topical, oral, parenteral, or intra-lesional 
(Greene and Rogers, 1989), although effects are often temporary (Daoud and Rogers III, 
1995). Multiple injections over weeks or months are often required (Greene and Rogers, 
1989).
The elimination of odontogenic foci of infection was followed in one study by regression 
or disappearance of swelling in 11 of 16 patients (Worsaae et al, 1982), suggesting that 
foci of infection may play some role in aetiopathogenesis.
Henderson and Tschen (1988) reported a patient whose MRS responded well to 
treatment with intra-lesional corticosteroids and a hydroxyquinolone antibiotic. Other 
authors have suggested the use of tetracycline (500mg daily) in combination with 
prednisone (lOmg alternate days) in the treatment of the full triad of MRS (Fisher, 1990). 
The patient described continued this treatment regime for 2.5 years and the lip oedema 
improved by 60%; the tongue remained unaltered and the facial palsy did not recur. 
Tetracycline has been used successfully in the treatment of certain dermatoses that 
produce non-specific sarcoid-like histopathological patterns (Falk, 1985), such as 
perioral dermatitis, periocular dermatitis (Fisher, 1987), and sarcoid-like ochronosis
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(Fisher, 1988). The combination of prednisone and tetracycline together appears to work 
better than either alone (Fisher, 1990).
The first report using the anti-leprosy drug clofazimine appeared by Neuhofer and 
Fritsch in 1984. Seven cases were treated with clofazimine in a dosage of lOOmg daily 
for 10 days, then 200-400mg weekly. Of the seven cases, three had the complete triad 
and four had cheilitis only. There was an excellent initial response after two weeks in 
those patients in whom the swelling was still fluctuant, but in those cases with persistent 
swelling the response was slower, continuing for up to 3 months. Three cases relapsed 
on discontinuing treatment, but responded on re-introduction of the drug. The overall 
duration of treatment was 5-7 months. Other reports have claimed partial or complete 
remission with low dose clofazimine therapy with low toxicity and good side-effect 
profile (Tausch and Sonnichsen, 1992; Sussman et al, 1992; Amezaga et al, 1991). Pre- 
and post-treatment biopsy results in a trial of four patients with clofazimine revealed 
histological evidence of resolution of granulomatous inflammation but persistence of 
oedema (Podmore and Burrows, 1986).
Clofazimine is a phenazine iminoquinone derivative which is metabolised to a red dye- 
stuff with oxygen (Podmore and Burrows, 1986). It is taken up by the reticulo­
endothelial system and fatty tissue. The mechanism of action is not fully known but is 
thought to be related to its ability to stimulate phagocytosis (Neuhofer and Fritsch, 
1984). Clofazimine has proved effective in the treatment of pyoderma gangrenosum, 
discoid lupus erythematosus, leprosy and pustular psoriasis (Sarracent and Finlay, 1982).
Treatment of MRS with thalidomide was suggested in 1995 (Safa et al, 1995). Two 
patients with MRS were treated with thalidomide lOOmg daily for 3 and 6 months 
respectively. In the first case, there was suppression of episodes of facial oedema and 
reduced lip swelling but the treatment was stopped after 3 months since the patient could 
not guarantee adequate contraception. In the second case, there was complete clinical 
and histological resolution. Thalidomide is thought to work by suppressing the 
formation of tissue necrosis factor (TNF-a) (Powell, 1996).
Other drugs have been tried in the management of MRS with varying degrees of success. 
These include hydroxychloroquine, dapsone and colchicine (Rey et al, 1996), 
sulfasalazine, penicillin, erythromycin, clindamycin, ranitidine, and diphenhydramine
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(Zimmer et al., 1992), ketotifen, and cromoglycate (Pachor et al., 1989). All have been 
noted at the level of case reports and none have been subjected to rigorous scientific trial.
The option of surgical reduction cheiloplasty has been investigated by several authors 
(Ellitsgaard et al, 1993; Glickman et al., 1992; Rey et al, 1996). This is only 
recommended when conservative treatments have failed and the lip swelling has become 
stabilised and associated with permanent aesthetic deformity (Ellitsgaard et al, 1993). 
Intralesional corticosteroid injections after a cheiloplastic procedure have been 
recommended to minimise the tendency to recurrence (Krutchkoff and James, 1978b).
Decompression of the facial nerve is indicated for the treatment of long-standing facial 
nerve paralysis, following failure of systemic corticosteroid therapy (Daoud and Rogers 
III, 1995). This procedure was effective in 11 of 13 patients reported by Kettle (1959) 
without evidence of recurrence.
Homstein (1997) has recently appealed for multi-disciplinary professional involvement 
to ascertain the most appropriate way to treat patients with MRS.
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1.2.5 Cheilitis Granulomatosa of Miescher
When Miescher first reported his granulomatous cheilitis in 1945, in the proceedings of 
26th Congress of the Swiss Society of Dermatology and Venereology held in Zurich in 
September 1944, he described six cases of macrocheilia. One or both lips were affected 
and, in some cases, the inner surface of the cheeks. There was no local septic focus and 
microscopic examination revealed peri- and paravascular aggregations of a tuberculoid 
character as the cause of the swelling. He stated that aetiology and pathogenesis were 
unknown but the possibility of a localised tuberculous lesion should be borne in mind, 
although he could not identify active tuberculosis (pulmonary, gastrointestinal or 
miliary) in any of the six patients.
Since that original description, numerous case reports have been presented world-wide of 
cheilitis granulomatosa of Miescher (CG) (Allen et al, 1990; Shaikh et al, 1989; 
Williams and Greenberg, 1991; Hirshberg et al, 1989; Kuno et al, 1992; Alpert and 
Nelson, 1974; Hernandez et al, 1986; Tatnall and Dodd, 1987; Brook, 1984; Carr, 1974; 
Brook et al, 1983; Kano et al, 1990; Guerrieri et al, 1995; Bourgeois-Droin et al, 1993; 
Kano et al, 1993; Veller Fomasa et al, 1992; Eisenbud et al, 1971; Miralles et al, 
1995; Liu, 1994; Takeshita et al, 1995; Liu, 1993a; Liu, 1993b; Creus et al, 1994; 
Shehade and Foulds, 1986). However, great confusion exists in the literature as to 
whether CG is a disease entity in its own right or whether it is a “monosymptomatic” 
variant of MRS or orofacial granulomatosis (Homstein, 1973; Wiesenfeld et al, 1985; 
Field and Tyldesley, 1989; Hernandez et al, 1986). It is important to differentiate CG 
from cheilitis glandularis (enlargement of the lower lip due to hyperplasia of the mucous 
glands) by histological assessment, since the clinical presentation may be similar (Doku 
et al, 1965). Similarly, the condition known as actinic cheilitis granulomatosa should be 
excluded (Kuno et al, 1992). This is an entity similar to CG in clinical and histological 
appearance but caused by UVB-photosensitivity
It is now clearly accepted in the literature that many authors consider CG to be a 
monosymptomatic variant of MRS (Worsaae et al, 1982; Allen et al, 1990), although 
this has been a subtle erosion of the clear diagnostic criteria established by Melkersson 
(1928) and Rosenthal (1931). Indeed, some authors now blatantly assert that “a 
diagnosis of oligosymptomatic Melkersson-Rosenthal syndrome is accepted as being 
synonymous with CG.” (Allen et al, 1990).
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CG is characterised by diffuse, non-tender, soft to firm swelling of one or both lips; the 
swelling may be unilateral or symmetrical (Allen et al., 1990). Initially, the swelling 
may be episodic but eventually the enlargement persists (Shaikh et al., 1989). Gingival 
involvement was noted in 21% of patients in a Danish study (Worsaae et al., 1982) and 
in 33% of patients in a North American study (Allen et al, 1990). Depending on the 
view of the authors, additional oral, peri-oral, or facial manifestations may be described 
as part of CG, MRS or orofacial granulomatosis.
Vesicular lesions have been described in association with CG and the assumption made 
that these were associated with Herpes simplex infection (Homstein, 1973). However, 
microscopic examination of these vesicles has demonstrated that they are actually 
superficial dilated lymphatic vessels (Allen et al, 1990).
CG has been described in association with advanced periodontitis with the periodontium 
and lip biopsies exhibiting non-caseating epithelioid granulomata histologically 
(Takeshita et al, 1995). Interestingly, the lip swelling resolved following periodontal 
therapy and antibiotics.
Despite the obvious confusion in the literature over establishing the diagnosis of CG, 
clear links have been established in some cases with sarcoidosis and Crohn’s disease. In 
a French study, two children with CG were subsequently found to have sarcoidosis 
(Bourgeois-Droin et al, 1993). Similarly, there are a number of reports where patients 
with CG have a positive Kveim test (Shehade and Foulds, 1986; Nelson and Stevenson,
1988). In most cases, there is a preceding history of multiple symptoms prior to the 
onset of CG. Shehade and Foulds (1986) report a 43-year-old Caucasian female with a 
long-standing history of multi-system complaints who subsequently developed cheek and 
lip swelling. Her Kveim test was positive, giving a well defined dermal epithelioid 
granulomatous response on the right forearm. Her chest radiograph, serum angiotensin 
converting enzyme level, Mantoux test and gastrointestinal investigations were all within 
normal limits. A Kveim test is regarded as specific for sarcoidosis (Sharma, 1984); 
however, cross-reactivity between sarcoidosis and Crohn’s disease can occur (Mitchell et 
al, 1970), and in other conditions - notably tuberculous lymphadenitis, non-specific 
lymphadenitis and lymphomas (Israel and Goldstein, 1971). In view of the fact that 
Kveim test reactivity is low among patients in whom the manifestation of sarcoidosis is 
confined to a single organ (Bradstreet et al, 1976), and that the reactivity decreases
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sharply with the passage of time (Mikhil and Mitchell, 1970), a positive Kveim test 
response obtained at this early stage in the disease and a negative Mantoux test (possibly 
due to cutaneous anergy) strengthen the possibility that this patient had cutaneous 
sarcoidosis. The authors suggest that, recognising the limitations of Kveim test 
reactivity and taking into account the occasional spontaneous remission of sarcoidosis, 
more cases of CG, MRS and orofacial granulomatosis may have eluded a diagnosis of 
cutaneous sarcoidosis in the past (Shehade and Foulds, 1986).
If numbers of publications are indicative of strength of association, then there are even 
stronger links between CG and Crohn’s disease (Tatnall and Dodd, 1987; Brook, 1984; 
Carr, 1974; Brook et al, 1983; Kano et al, 1990; Guerrieri et al, 1995). In cases of 
gastrointestinal Crohn’s disease, treatment of the gut condition has been reported to lead 
to an improvement in the lip swelling (Brook et al, 1983) although this is not always so 
(Carr, 1974). Brook et al (1983) make the recommendation that patients with CG be 
screened at presentation and at 6-month intervals for malabsorption as a warning of 
development of granulomatous inflammation in the gut. Kano et al (1990) reported five 
cases of CG which subsequently developed gastrointestinal Crohn’s disease. They make 
the recommendation that patients presenting with CG require gastrointestinal 
investigations and long-term follow-up.
CG would appear to be particularly prevalent in patients who have widespread or 
metastatic Crohn’s disease - notably of perineum, vulva (Guerrieri et al, 1995), and skin 
(Tatnall and Dodd, 1987).
A rational approach to treatment for CG is problematic because the cause is unknown 
and the lip swelling may be a manifestation of various disease states, for example 
Crohn’s disease (Kano et al, 1990) or sarcoidosis (Bourgeois-Droin et al, 1993). 
Although removal of odontogenic foci of infection may elicit a good response in some 
patients (Worsaae et al, 1982; Rintala et al, 1973), most therapeutic regimes include 
corticosteroid therapy, either systemic or intra-lesional, as an empirical approach to the 
inflammatory infiltrate (Williams and Greenberg, 1991; Hernandez et al, 1986; Bishop 
and Garcia, 1979; Eisenbud et a l, 1971; Krutchkoff and James, 1978a; Levenson et al, 
1984). Eisenbud et al (1971) are credited with the first recorded use of triamcinolone 
injections to an upper lip affected with CG. They used 20mg of triamcinolone at 
intervals of 2 weeks to 1 month for a total of 20 doses. Efforts were made to distribute
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the solution over a broad area of the lip from a single puncture site. Total treatment time 
extended over 1 year. Reduction of the swelling became evident after several weeks and 
complete resolution was the result. No side-effects were reported, except for a small 
haematoma on one occasion. Follow-up continued for 9 months after cessation of 
treatment with no recurrence of swelling or discomfort.
The response to such treatment is generally favourable but temporary and requires 
multiple injections for months or even years. It is reported that the patients’ acceptance 
of the intra-lesional therapy is increased if local anaesthetic blocks are given before the 
corticosteroid injections (Allen et al., 1990; Eisenbud et al., 1971).
Intralesional corticosteroids may cause degenerative changes in skeletal muscle 
(William, 1959), necrosis of granulomata, and scar tissue formation (Krutchkoff and 
James, 1978a). In addition, some reports have suggested that a threshold may be reached 
beyond which no further reduction in lip size can be achieved (Krutchkoff and James, 
1978a).
Hydroxychloroquine sulphate has been used with limited effect (Allen et al., 1990). One 
patient responded well to 200mg daily for three months, increasing to 400mg daily for an 
additional three months. However, retinopathy is an established side-effect of anti- 
malarial agents and so an ophthalmologic assessment is required at baseline and every 4- 
6 months during treatment (Portnoy and Callen, 1983). The rationale for using 
hydroxychloroquine is based on the well-documented improvement of the specific 
cutaneous lesions of sarcoidosis with anti-malarial therapy (Gibson and Winkleman, 
1986). Some authors consider CG and sarcoidosis to be indistinguishable (Veien, 1986), 
although a world authority on sarcoidosis has claimed that lip enlargement is not a 
feature of sarcoidosis (James, 1994b).
The use of antibiotics in the treatment of CG has generated some interest in the literature 
(Veller Fomasa et a l, 1992; Kano et al, 1992; Miralles et al, 1995). This is on the basis 
that, in addition to their antibacterial properties, antibiotics may act as biological 
response modifiers (Anonymous, 1991a). One study (Veller Fomasa et al, 1992) found 
minocycline at a dose of lOOmg daily for 4-6 months to be ineffective in reducing lip 
swelling in five patients with CG; however it was effective in one patient with chronic 
granulomatous disease (type 1, X-linked form).
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The response of CG in some patients to metronidazole (Kano et al, 1992; Miralles et al, 
1995) has prompted some authors to draw comparisons between CG and gastrointestinal 
Crohn’s disease - the latter often responding to metronidazole when other therapies have 
failed (Brandt et al, 1982; Duhra and Paul, 1988). Kano et al (1992) reported a female 
patient whose CG had failed to respond to ketotifen and triamcinolone. She was found 
to have colonic and rectal changes diagnostic of Crohn’s disease and was treated with 
oral metronidazole - 500mg twice daily for 3 months. Complete resolution of lip 
swelling and gastrointestinal ulceration was achieved with no recurrence at follow-up 
after 2 years.
The successful use of metronidazole in the treatment of CG in patients without 
gastrointestinal Crohn’s disease has been emphasised in one study (Miralles et al, 1995). 
A black female with CG (upper and lower lips) and no evidence of Crohn’s disease on 
sigmoidoscopy, barium meal and follow-through, and rectal biopsy was treated 
unsuccessfully with oral doxycycline and triamcinolone injections. She was then 
commenced on oral metronidazole - 750mg daily for 1.5 months, increased to lg daily 
for three months. This was then tapered down to complete eight months of treatment 
and the lip enlargement has improved progressively.
Wiesenfeld et al (1985) did not detect any improvement in 2 patients with CG treated 
with metronidazole. However, in this study neither the exact clinical circumstances nor 
the dose of the drug were described by the authors.
The mechanism of action of metronidazole is unknown but may be related to anti­
inflammatory rather than antibiotic properties. It is known to suppress granuloma 
formation around parasite eggs and to inhibit cell-mediated immunity (Grove et al, 
1977).
In addition to dental and medical management, surgical reduction of the lips has also 
been advocated (Krutchkoff and James, 1978a; Shaikh et al, 1989). Most authors 
recommend that this procedure is carried out only after failed medical management and 
when the lip has reached a quiescent phase (Rintala et al, 1973). In addition, intra­
lesional triamcinolone injections or suppressive medical treatment should continue after 
surgery for an indefinite period to reduce the considerable risk of recurrence (Krutchkoff 
and James, 1978a).
62
It has recently been stated, without much evidence, that CG is a pre-malignant condition 
with between 20% and 35% of patients eventually developing squamous cell carcinoma 
of the lip (Manganaro and Holmes, 1997). This would appear to be another myth borne 
out of much case reporting and little proper research.
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1.2.6 GLUS Syndrome (Granulomatous Lesions of Unknown
Significance)
Cases of hepatic granulomata, often termed “granulomatous hepatitis”, collectively 
represent one of the largest biopsy-defined groups of granulomata of various aetiologies. 
Collective data from six studies, shown in Table 1.9, demonstrate that amongst such 
patients, 92 cases of GLUS presented with one or more of the following features : fever 
(43%), anorexia/weight loss (34%), abdominal pain (28%), hepatomegaly (28%), 
splenomegaly (28%), and lymphadenopathy (7%). There were no consistent biochemical 
abnormalities, but hypergammaglobulinaemia was frequent (66%). Liver function tests 
showed abnormalities in the following parameters: bilirubin (21%), alkaline phosphatase 
(51%) and aminotransferases (51 %) (Harrington et al, 1982).
STUDY/FEATURES 1 2 3 4 5 6 TOTAL
No. of cases 13 10 13 18 14 24 92
Male patients 6 4 9 10 8 9 50%
Anorexia/ 
Weight loss
5 0 8 ? 3 9 34%
Fever 5 10 13 3 6 3 43%
Abdominal pain 1 0 6 ? 7 7 28%
Hepatomegaly 10 2 7 6 8 10 47%
Splenomegaly 3 1 7 4 4 7 28%
Lymphadenopathy 5 0 0 0 0 1 7%
Hypergamma­
globulinaemia
7/7 6/10 5/13 10/14 10/14 ? 66%
Kveim test 
Positive
? ? 0/13 0/5 0/? 0/8 0%
Table 1.9 The frequency of various clinical features in six studies of granulomatous 
lesions of unknown significance, diagnosed by liver biopsy.
Studies : l=Guckian and Perry, 1966; 2=Terplan, 1971; 3=Simon and Wolff, 1973; 
4=Mir-Madjlessi etal, 1973; 5=Neville etal, 1975; 6=Cunningham eta l, 1982.
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A minority of cases had a relatively short, benign, self-limiting, “mononucleosis­
like” course with peripheral lymphocytosis (Eliakim et al, 1968; Gelb et al, 1970). 
These cases were EBV-negative but were not tested for CMV. The majority of the 
remaining cases did not exhibit a lymphocytosis and often showed a prolonged 
course sometimes of several years’ duration, with exacerbations and remissions. The 
latter type generally responded well to treatment with systemic corticosteroids 
(Simon and Wolff, 1973).
In a study of granulomatous lesions in peripheral lymph nodes in 85 children, no obvious 
aetiology could be found in 39 cases (46%). The proportion of GLUS varied according 
to body site: there were 19/60 cases of GLUS in the head and neck and 20/25 cases in 
peripheral lymph nodes (Benjamin, 1987). The majority of cases of GLUS occurred in 
children over 10 years old; atypical mycobacterial infections predominated in younger 
children and among the head and neck cases. If cases of atypical mycobacteria are 
excluded, the frequency of GLUS in the head and neck rises to 76% - the same level as 
in peripheral lymph nodes (80%). Apparently, the cases showed no distinctive clinical 
features apart from lymphadenopathy, and no instance of recurrence of GLUS was 
recorded; however, two cases of recurrent lymphadenopathy with GLUS were observed 
in another study (Brincker, 1990).
In 1989, Telenti and Hermans described 20 patients with prolonged fever of unknown 
origin, associated with idiopathic granulomatosis of the liver, lymph nodes, spleen or 
bone marrow. Initially, half the patients also had anorexia, arthralgia or myalgia, and a 
few had unspecified skin rashes. Granulomata were found in 6/9 spleens, 14/16 livers, 
8/14 lymph nodes and 11/16 bone marrows. Nevertheless, there was only minor 
enlargement of liver, spleen and lymph nodes. Half the patients had abnormal liver 
function tests and hypergammaglobulinaemia. Serological tests were negative for EBV 
and CMV in 8/8 and 8/10 patients so studied. Fourteen of 15 patients responded 
favourably to corticosteroid treatment. In about half the patients, complete resolution 
occurred within a few years but after 5-10 years of follow-up, six patients still required 
corticosteroids for control of symptoms; however, the disease was not lethal in any 
patient. An aetiological diagnosis was established in five patients : Crohn’s disease, 
sarcoidosis, temporal arteritis, CMV and hypergammaglobulinaemia; in the remaining 
15 patients, the lesions remained unexplained.
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In 1990, Friedland et al described nine cases of GLUS. In addition to granulomata in 
liver, spleen, lymph nodes and bone marrow, they were also present in kidney and skin. 
A total of 5/5 patients had a negative Kveim test, and 4/4 had normal levels of serum 
angiotensin converting enzyme. The syndrome had a prolonged history of episodic 
exacerbations; in some patients it resolved spontaneously and in others it responded to 
immunosuppressive therapy with corticosteroids and alkylating agents. One patient died 
of renal failure, probably unrelated to the granulomatous disorder.
In summary, several studies support the existence of a febrile, granulomatous, multi­
system disease with moderate abnormalities of liver function, 
hypergammaglobulinaemia, responsive to immunosuppressive therapy and splenectomy, 
and a favourable prognosis. Although the combination of features described conforms to 
a diagnosis of extra-pulmonary sarcoidosis, it is distinguished from the latter by the 
absence of hypercalcaemia, elevated serum ACE and negative Kveim test.
There are no specific orofacial features described in any studies related to GLUS 
although clearly the lymphadenopathy may affect any body site.
Generally, the prognosis appears to be good in GLUS with spontaneous remission in 
most cases; in others, however, intermittent signs of disease activity may be present for 
months or even years. In such cases, corticosteroid therapy is almost always helpful 
(Simon and Wolff, 1973; Telenti and Hermans, 1989; Friedland et al, 1990). Responses 
to cytotoxic drugs (Friedland et al, 1990) and splenectomy have also been reported (Kuo 
and Rosai, 1974).
66
1.3 The epidemiology o f chronic granulomatous disorders
1.3.1 Sarcoidosis
There are large numbers of epidemiological studies showing the prevalence and 
incidence of sarcoidosis (most commonly related to the respiratory system since that is 
the likeliest system to be affected) among various population groups world-wide. See 
Table 1.10.
Table 1.10 The prevalence of pulmonary sarcoidosis (per 100 000 of the population)
Country Prevalence
Sweden 64
Denmark 48
West Germany 43
East Germany 41
Ireland 40
USA (New York) 39
England 27
Norway 27
Holland 22
Switzerland 16
Yugoslavia 12
France 10
Italy 9
Scotland 7
Finland 5
Japan 2.5
Spain 1.2
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The true prevalence of sarcoidosis in any country is uncertain since many cases are 
known to be asymptomatic. Necropsy studies on 6706 patients in Malmo, Sweden 
revealed evidence of sarcoidosis completely unrelated to the cause of death with a 
prevalence of 640 per 100 000, ten times the local prevalence of sarcoidosis as 
determined by mass miniature radiography (MMR) (Hagerstrand and Linell, 1964).
Since most cases of sarcoidosis show characteristic chest radiographic abnormalities, 
MMR (often taken for purposes of screening for pulmonary tuberculosis) gives some 
indication of its frequency within the population. Average findings for MMR in 1959 
for England and Wales suggested sarcoidosis in 13.8 men and 19.8 women per 100 000 
population, with the highest prevalence, irrespective of sex, in the age group 25-34 years 
(British Thoracic and Tuberculosis Association, 1969).
MMR screening in London in 1958 showed a high prevalence of pulmonary sarcoidosis 
in the immigrant populations with rates per 100 000 of 197 for West Indian men and 170 
for West Indian women; and 97 for Irish men and 213 for Irish women (Edmonstone and 
Wilson, 1985). This compared with an overall rate of 27 per 100 000 for those bom in 
the UK (with similar gender rates) and a rate of 39 per 100 000 for UK women over the 
age of 16 years (Edmonstone and Wilson, 1985).
Four areas of the UK were studied in depth during the years 1961-66 to ascertain the 
annual incidence of sarcoidosis. The incidence was found to increase from north to 
south and was highest in the age group 24-34 years. The annual incidence was 2.1-4.1 
per 100 000 men and 3.5-4.5 per 100 000 women (British Thoracic and Tuberculosis 
Association, 1969).
Two recent studies have demonstrated the variation in incidence and course of the 
disease in different racial groups in the same geographical area (Scadding and Mitchell, 
1985; Edmonstone and Wilson, 1985). A ten-fold increase in the incidence of 
sarcoidosis in West Indian and Asian immigrants living in London has been reported in 
comparison with the indigenous white population. The immigrant patients also had an 
increased incidence of extra-pulmonary disease, a greater need for corticosteroid 
treatment and full recovery was less likely in comparison to their white neighbours.
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Sarcoidosis is common in South Africa with a prevalence of 23 per 100 000 in the black 
population, 11.6 per 100 000 in the mixed race population and 3.7 per 100 000 in the 
white population (Siltzbach et al, 1974; James et al, 1976).
In the USA, sarcoidosis is at least ten times commoner in the black than in the white 
population, regardless of birthplace or residence with prevalence rates per 100 000 
variously estimated at 8.7-81.8 and 0.5-7.5 for the black and white populations 
respectively in military and veterans administration studies (Siltzbach et al, 1974; 
James, 1994b). Sarcoidosis is rarely reported in Middle Eastern Arabs, Chinese, 
Southeast Asians, Eskimos or North American Indians (Siltzbach et al, 1974).
The prevalence in age groups at the extremes of life is difficult to ascertain. It is rare in 
European children who tend to present with extra-pulmonary symptoms; Japanese 
children, however, show a moderate frequency of asymptomatic pulmonary sarcoidosis, 
as reported by MMR (Siltzbach et al, 1974; Scadding and Mitchell, 1985). Frequency 
increases in later childhood and from adolescence onwards, presentation and prognosis 
are similar to the adult population. Interestingly, sarcoidosis is commoner in non- 
smokers than in smokers (Siltzbach et al, 1974; James, 1994b).
With respect to orofacial manifestations of sarcoidosis, there is a slight female 
preponderance (ratio 1.5:1). Patients ranged from 5 to 69 years with the highest 
prevalence between 30 to 40 years (Blinder et al, 1997).
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1.3.2 Crohn’s Disease
A review of the current world literature suggests that Crohn’s disease is most common in 
North America and northern Europe, emerging in southern Europe and least common in 
other parts of the world. Scandinavian studies have produced the highest prevalence 
figures (75 and 54 per 100 000 of the population) (Kraft, 1975; Basu, 1976) while high 
British figures are between 26 and 56 per 100 000 (Henry, 1994; James, 1991a). These 
are demonstrated in Figure 1.11.
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Table 1.11 Studies of the incidence (cases/ 105/year) and prevalence (cases/105 of the 
population) of Crohn’s disease
Place of study Reference Incidence Prevalence
UNITED KINGDOM
Oxford (Evans and Acheson, 1965) 0.8 9
London (Wright, 1970) - 13
Gloucester (Tresadem et al, 1973) 1.5 -
Nottingham (Miller et al, 1974) 3.6 26.5
North East Scotland (Kyle, 1971; Kyle and Stark, 1980) 2.1 32.5
Clydesdale (Smith etal., 1975) 1.5 -
Northern Ireland (Humphreys and Parks, 1975) 1.3 -
1 Belfast (Humphreys and Parks, 1975) 3.5 -
2 County Down (Humphreys and Parks, 1975) 0.3 -
North Tees (Devlin et al., 1980) 5.3 35
Cardiff (Mayberry et al., 1979) 4.8 56
NORTH AMERICA
Baltimore White male (Monks et al., 1967) 2.5 -
Baltimore White female (Monks et al., 1967) 1.2 -
California (Gelpi,1978) - 13
USA - 15 towns study (Garland et al., 1981) 2.4 -
Olmsted County, Minn (Sedlack etal., 1980) 6.6 106
Sherbrooke, Quebec (Nootens and Devroede, 1972) 0.7 6.3
NORWAY
Norway (Myren etal., 1971) 1.03 -
Bergen (Skarstein et al., 1982) 3.5 -
SWEDEN
1 Uppsala and Vastmanland (Norlen et al., 1970) 3 27
2 Gothenburg (Kewenter etal., 1974) 6.3 -
3 Malmo (Brahme et al., 1975) 6 75.2
4 Stockholm (Hellers, 1979) 5 54.2
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Place of study Reference Incidence Prevalence
DENMARK
Copenhagen (Hoj et al., 1973; Binder et al., 
1982)
2.7 32
FINLAND
Turku (Havia and Thomasson, 1972) 0.27 -
SWITZERLAND
Basle (Fahrlander and Baerlocher, 1971) 2.6 -
ITALY
Bologna (Lanfranchi etal., 1976) 0.8 -
SPAIN
1 Galicia (Ochoa, 1977) 0.14 1.22
2 Madrid (Paredes and Garcia, 1981) 0.7 -
CZECHOSLOVAKIA
Northern Bohemia (Bitter and Zuvacova, 1981) 1.6-2.0 12
SOUTH AFRICA
1 Western Cape Jewish (Novis et al., 1975; Wright et al., 
1981)
7.2
2 Western Cape White (Novis et al., 1975; Wright et al., 
1981)
1.2
3 Western Cape Black (Novis et al., 1975; Wright et al., 
1981)
1.3
4 Pretoria White (Mienyefa/., 1981) 1.1 -
5 Pretoria Black (Mieny et al., 1981) 0.2 -
NEW ZEALAND
1 Whole Country (Couchman and Wigley, 1971) - 49
2 Auckland Caucasians (Tasman-Jones et al., 1982) 1.8 -
3 Auckland Polynesians (Tasman-Jones et al., 1982) 0 -
ISRAEL
Tel-Aviv (Rozen etal., 1979) 1.3 12.3
Beersheba (Rozen etal., 1979) 1.8 12.3
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It is clear that the incidence of Crohn’s disease is rising steeply in the Western world for 
reasons that remain largely unexplained. In Wales, between 1931 and 1985, the 
incidence has increased from 0.18 per 100,000 population per year to 8.3 per 100,000 
population per year (Rhodes, 1988). This study also highlighted a biphasic age 
distribution with peaks in young adults and the elderly.
The type of health care available in terms of investigative and diagnostic protocols, 
particularly in Scandinavia and the United Kingdom, may partly account for the high 
figures from these geographical areas. The health care is largely free and information 
technology may facilitate collection of epidemiological data. However, the type of 
health care provision alone cannot explain the high prevalence figures since comparable 
countries in the southern hemisphere, such as Australia (Newcombe et al, 1983), have 
apparently low figures although good data to substantiate this is lacking. The incidence 
of Crohn’s disease in New Zealand (Couchman and Wigley, 1971; Tasman-Jones et al, 
1982) and South Africa (Novis et al, 1975; Wright et al, 1981; Mieny et al, 1981) is 
lower than in Europe despite many of their citizens being of European extraction. The 
major difference between countries is therefore unlikely to be due to ethnic factors alone. 
Attempts to examine the disease in different racial groups within the same country do 
suggest that prevalence figures are higher in subjects of northern European origin (Novis 
et al, 1975; Wright et al, 1981; Mieny et al, 1981; Couchman and Wigley, 1971; 
Tasman-Jones et al, 1982; Rozen et al, 1979). Figures of prevalence from developing 
countries are less reliable for various reasons. Diarrhoea of unclassified aetiology and 
gastrointestinal tuberculosis are common among such populations and in areas with a 
limited medical service, the true incidence of Crohn’s disease would be masked.
Few cases have been reported from Africa (Segal et al, 1981). Similarly, there is only a 
single series of 44 cases from India (Gupta et al, 1962), and small groups of cases have 
been reported from Chile (Castillo, 1959; Quintana et al, 1978). There appears to be 
relatively low incidence figures for West Indian (O'Donoghue and Clark, 1976) and 
Asian populations resident in the UK (Burke and Zafar, 1975).
The incidence of Crohn’s disease in children in the UK is around 10 per 100 000 and 
increasing (Ferguson et al, 1986). Interestingly, Crohn’s disease is never seen in infants 
less than two years of age and only rarely in children less than ten. The incidence 
increases rapidly through childhood and adolescence so that the peak incidence of
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around 20 per 100 000 occurs during late adolescence and early adulthood (Ekbom et al,
1991).
Studies from different parts of the world support the view that Crohn’s disease is 
commoner in towns than country areas as shown in Table 1.12. This has been 
demonstrated in Wales where prevalence was examined throughout the country, 
involving 1100 patients (Mayberry et al, 1980). Similar findings were also reported in 
Ireland (Humphreys and Parks, 1975), Scotland (Kyle, 1971), New Zealand (Couchman 
and Wigley, 1971), the USA (Sedlack et al., 1980), Spain (Paredes and Garcia, 1981) 
and Italy (Lanffanchi et al, 1976). These differences, however, have not been observed 
in central Sweden where the incidence is particularly high (Norlen et al, 1970; Hellers, 
1979). The differences observed in Aberdeen (Kyle, 1971) and Minnesota (Sedlack et 
al, 1980) were against a background of a marked rise in incidence during the previous 
decade, which was most marked in urban areas.
Table 1.12 Urban-rural distribution of Crohn’s disease
Place Measurement Urban Rural
Wales Period prevalence (cases/105) 47.6 34
Northern Ireland Incidence (cases/ 105/yr) 3.5 0.29
Aberdeen Prevalence (cases/105) 49 29
Olmstead County, USA Prevalence (cases/105) 116.7 84.2
New Zealand Mean rates/yr 119 59
Madrid Province, Spain % Composition 94.2 5.8
Bologna, Italy % Composition 77.8 22.2
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Therefore, most studies show that Crohn’s disease is commoner in urban than rural areas 
and one explanation for this might be an environmental factor.
With respect to oral Crohn’s disease, the largest group studied is that of Plauth et al 
(1991) with 79 patients in a West German study. Their data relied on histological 
confirmation from intestinal biopsies before the patients were included for analysis. 
They noted a male preponderance of 1.85:1 which increased to 3.0:1 in the 16-30 year- 
old age group. Almost two-thirds of patients had experienced oral lesions in the first 
three decades of life as shown in Table 1.13.
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Table 1.13 Clinical data on 79 patients with oral Crohn’s disease (Plauth et al., 1991).
M:F 50:27 (1.85:1)
<16 years 18:12 (1.50:1)
16-30 years 15:5 (3.00:1)
>30 years 16:10 (1.60:1)
Age at presentation of oral lesions (%)
(years)
<16 30/76 (39)
16-30 20/76 (26)
>30 26/76 (34)
Median (and range) 22 (6-57)
Mean + SD 4.4 + 12.9
For 2/79 cases, data on sex, and, for 3/79 cases, data on age at presentation were not 
available
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1.3.3 Orofacial Granulomatosis
OFG is assuming increasing importance in the world literature - immunological, 
dermatological and dental. The epidemiology is not well established with isolated case 
reports being the order of the day. However, a number of UK centres have published 
data on groups of patients (Patton et al, 1985; Sweatman et al, 1986; Field and 
Tyldesley, 1989; Sainsbury et al, 1987) and there is growing evidence of increased 
reporting world-wide. For example, two cases in Nigeria (Odukoya, 1994), two cases in 
Italy (Rubino and Ficarra, 1994) and six cases in India (Dhar and Kanwar, 1995).
Sainsbury et al (1987) reported their series of patients in South Wales and noted that half 
of the sixteen cases occurred in children under the age of 15 years. Of eight patients, six 
were male and two were female with a mean age of 8.5 years (range 4-14 years). Four of 
the children came from Social Class I, the parents of three children being in the medical 
profession (Sainsbury et al, 1987).
In the West of Scotland study by Wiesenfeld et al (1985) 60 patients were examined and 
an equal gender distribution was noted. The median age at presentation was 20 years 
(range 3-61 years). The mean time interval between onset of symptoms and presentation 
was two years (range one month to eight years). Fifty-nine patients were white 
Caucasians and one was of Indian origin.
Armstrong and Burrows (1995) in reviewing the literature state that the onset of OFG is 
highly variable with the median in most series in the second and third decades; the 
gender distribution was approximately equal.
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1.3.4 Melkersson Rosenthal Syndrome
MRS generally appears in the second to fourth decades of life but a wide age range at 
onset of symptoms has been reported (2 to 81 years) (Zimmer et al, 1992; Minor et al, 
1987; Grosshans and Pfeffer, 1991). An overall female preponderance has been reported 
in some studies - particularly in Spain (Amezaga et al., 1991; Hernandez et al., 1987; 
Seasone et al, 1990). A most extensive recent study (Zimmer et al, 1992) supported a 
slightly increased prevalence among females. However, MRS is commoner in females 
during the first, second and sixth decades of life, and it usually occurs in males in the 
other decades (Homstein, 1973).
MRS would appear to be without racial preference (Worsaae et al, 1982; Grosshans and 
Pfeffer, 1991; Levenson et al., 1984; Seasone et al., 1990) although most cases have been 
reported in northern Europe from a white Caucasian population(Minor et al., 1987; 
Meisel-Stosiek et al., 1990; Patton et al, 1985). This may simply represent a reporting 
bias or a lack of uniform criteria for diagnosing MRS.
A report from Germany calculated the incidence of MRS to be 1:2100 cases referred to a 
dermatology clinic (Homstein, 1973). Muller (1952) followed 209 cases of facial palsy 
for 15 years and found 29 patients with symptoms of recurrent facial palsy. Four of these 
29 patients had facial oedema and one patient had lingua plicata.
In one study, MRS had a median duration of 6.5 years with a range of 6 months to 31 
years (Worsaae et al., 1982).
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1.3.5 Cheilitis Granulomatosa of Miescher
Due to the diagnostic confusion over MRS, CG and OFG, the world literature reveals 
very little direct information on the epidemiology of this condition. In a North American 
study looking solely at CG, the median age of onset was 28.5 years, with an equal gender 
ratio (Allen et al, 1990).
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1.3.6 GLUS syndrome
The epidemiology of GLUS syndrome is a little difficult to pursue. Since routine 
biopsies are often obtained from liver, bone marrow, lung and lymph nodes, it is not 
surprising that the occurrence of granulomata of various aetiologies has been reported in 
these sites. Less commonly studied sites include the spleen, nasal and gastric mucosa, 
and connective tissue. In many cases, granulomata can be accounted for by evidence of 
granulomatous disease elsewhere in a patient with a known granulomatous condition. 
However, in almost all studies, there is a residual group of cases in which the presence of 
granulomata remains unexplained. It should be remembered, however, that biopsies are 
not generally taken from any tissue unless the patient has symptoms or signs indicating 
disease involvement. Thus, any figure on the incidence of granulomatous lesions in any 
body site will be imprecise and based on highly selected biopsy material.
With that in mind, an indication of the observed frequency of GLUS in various sites was 
summarised by Brincker (1994). In liver, bone marrow and lung, where more than 300 
cases of granulomata have been reported at each site, the overall percentages of GLUS 
were 14%, 19%, and 21% respectively. Thus overall, from 15 to 20% of histologically 
verified granulomatous lesions may be characterised as GLUS for these three sites 
(Brincker, 1994). The incidence of GLUS syndrome in mucosa is unknown since so few 
series have been reported.
Thus, the epidemiology of GLUS syndrome in patients with granulomatous 
inflammation of mucosa is largely under-researched and poorly documented in the 
scientific literature.
80
1.4 The histology o f chronic granulomatous disorders
1.4.1 Sarcoidosis
The characteristic feature histologically in sarcoidosis is the presence in affected tissues 
of non-caseating epithelioid granulomata (Hagerstrand and Linell, 1964). In the early 
stages, the granulomata consist of focal, close-packed collections of macrophages and 
epithelioid cells which often fuse to form multi-nucleate Langhans’ type giant cells. A 
peripheral ring of lymphocytes is commonly seen around the granuloma and a few 
lymphocytes may be present in the central portion (Thomas and Hunninghake, 1987). 
Monoclonal antibody studies show that B lymphocytes are present in small numbers; 
CD4 helper cells predominate over CD8 suppressor cells. CD4 helper cells and 
activated macrophages penetrate to the centre of the granuloma where the latter coalesce 
into epithelioid and multinucleate giant cells. In the peripheral mantle, CD8 cells lie 
adjacent to numerous antigen-presenting macrophages (Hagerstrand and Linell, 1964). 
Central fibrinoid necrosis may occur in florid granulomatous reactions but true caseation 
is never seen, a finding that differentiates sarcoidosis from tuberculosis (Hagerstrand and 
Linell, 1964).
Cytoplasmic inclusions are not infrequently seen within the cells of the granulomata, 
particularly the multi-nucleated giant cells (Hagerstrand and Linell, 1964). Three types 
of inclusion bodies are described: crystalline, conchoidal and asteroid. Crystalline 
inclusions are composed of calcium carbonate and are birefringent to polarised light. 
Conchoidal (Schaumann’s) bodies are densely basophilic, stain with haematoxylin, and 
are probably formed when lipoglycoproteins and amorphous calcium and iron salts 
become deposited around a small birefringent crystalline focus. Conchoidal and 
crystalline bodies are more commonly identified in the granulomata of sarcoidosis than 
in other granulomatous disorders, but they are not diagnostic. Star-shaped asteroid 
bodies are composed of lipoprotein, occur within giant cells, and are present in many 
granulomatous diseases (Thomas and Hunninghake, 1987).
When the disease remits, either spontaneously or with corticosteroid therapy, the 
granulomata disperse and the mononuclear infiltrate settles. The granulomata are 
capable of complete resolution but those that remain are usually slowly replaced with
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featureless hyaline scar tissue. Granulomata resolve by dispersion of cells or by 
centripetal proliferation of fibroblasts from the periphery of the granuloma inwards to 
form a scar which may either disappear or result in fibrosis with permanent tissue 
damage (Siltzbach et a l, 1974).
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1.4.2 Crohn’s disease
Microscopic assessment of tissue from the gastrointestinal tract reveals transmural 
inflammation and ulceration. Non-caseating granulomata, once thought to be 
pathognomonic, are seen in only 10-40% of cases overall (Brinberg and Berkeley, 1989) 
and in two-thirds of resected specimens and a smaller proportion of mucosal biopsies 
(Thompson, 1990). The granulomata vary in appearance, ranging from rather loose 
collections of epithelioid macrophages through sarcoid-like densely cellular aggregates 
to larger tuberculoid granulomata with Langhans’ type multinucleate giant cells. Small 
foci of central necrosis and occasional clusters of neutrophils or eosinophils may be 
present but areas of caseation are not seen (Brinberg and Berkeley, 1989).
The submucosa is usually oedematous and contains dilated lymphatics and blood vessels. 
Fibrosis, which may be present throughout the bowel wall, is usually maximal in the 
submucosa. The regional lymph nodes in Crohn’s disease show granulomata in 25-50% 
of cases (Cook, 1972); those without granulomata show non-specific changes such as 
follicular hyperplasia or sinus dilatation. Nodal granulomata without intestinal 
granulomata are almost never seen in Crohn’s disease.
There is now some evidence that Crohn’s disease is a heterogeneous condition and that 
subdividing it on histopathological grounds may help with determining prognosis, 
requirements for surgery and likely response to anti-mycobacterial chemotherapy 
(Prantera e ta l,  1991).
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1.4.3 Orofacial granulomatosis
Wiesenfeld et al (1985) obtained 58 mucosal biopsies from their series of 60 patients. In 
only one case was no abnormality detected but this was clinician error. The remaining 
57 cases showed a range of histological features. The most frequent change was oedema 
of the superficial corium with prominent dilated lymphatic vessels. In 47 biopsies 
granulomata were recorded and these varied considerably in appearance, number and 
location within the tissue. Most granulomata were small and ill-defined consisting of 
epithelioid histiocytes and lymphocytes. Multinucleate giant cells were seen in many 
granulomata but were not always present - this being particularly the case in the more 
superficial lesions in the lamina propria. In only one case was central necrosis seen in 
the granulomata but special stains failed to reveal any acid/alcohol fast bacilli in this or 
indeed in any other case in the series.
The morphology of the granulomata was variable ranging from follicular with 
multinucleate giant cells to more loosely formed types, comprised of epithelioid cells, 
macrophages and lymphocytes. Occasional birefringent intracellular foreign material 
was noted in some granulomata. The numbers of granulomata varied from specimen to 
specimen and in some cases were only seen on examining multiple sections. The 
location of granulomata varied from the superficial lamina propria, throughout the 
corium to small numbers of granulomata in the minor salivary glands and the striated 
muscle. These granulomata are histologically similar to those found in Crohn’s disease 
and systemic sarcoidosis (James, 1991a).
Sainsbury et al (1987) reported the histological features in OFG affecting the pulp of a 
deciduous tooth. They make the assertion that the intensity of the lymphocytic infiltrate 
and foreign body giant cell reaction present in the biopsies from patients with OFG 
would point to a possible allergic reaction to a dietary or topical allergen (Sainsbury et 
al, 1987).
The granulomata are identified in 46-81% of oral mucosal biopsies and vary in size, 
number and location; they are normally non-caseating epithelioid type, small and ill- 
defined, and may be sparsely distributed (Armstrong and Burrows, 1995).
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1.4.4 Melkersson-Rosenthal Syndrome
It should be emphasised at the outset that although granulomatous inflammation is 
considered a typical histological finding in MRS, it is not required to establish a 
diagnosis since MRS is a clinical syndrome (Zimmer et al., 1992). However, on the 
basis of histological findings, Bazex and Dupre (1957) subdivided MRS into two types - 
the sarcoid type and the lymphoedematous type. The sarcoid type is characterised by 
granulomata with chronic inflammation of varying degrees; Langhans’ giant cells are 
found perivascularly and are surrounded by a connective tissue capsule. The 
lymphoedematous type is characterised by marked oedema and cellular infiltration. 
Oedematous fibrous connective tissue may replace the muscle fibres in the longer term 
and thus the term idiopathic fibroedema was suggested by Stevens (1954).
Similarly, the granulomata were described by Homstein (1973) as two distinct types. 
First, tuberculoid-type granulomata appear as tiny epithelioid cell granulomata 
surrounded by lymphocytes and other mononuclear cells with a diffuse oedema of the 
interstitial connective tissue. Second, lymphonodular-plasmocytic-type granulomata 
appear as central lymphocytic nodules surrounded by plasma cells and histiocytes in an 
oedematous connective tissue. These two types of granulomata were found in 67% of 
Homstein’s biopsy specimens and non-specific inflammation in 33%.
In a Danish study of 30 patients with MRS, gingival biopsy specimens were found to 
have non-caseating epithelioid granulomata, dominated by lymphocytes with a varying 
number of plasma cells and epithelioid cells interspersed in an oedematous connective 
tissue with several dilated vessels (Worsaae and Pindborg, 1980). In addition, peri­
vascular aggregations of lymphocytes, plasma cells and histiocytes were found - thought 
by the authors to represent early granuloma formation. Multinucleated giant cells of the 
Langhans’ type were seen occasionally, but no birefringent material was observed in any 
of the specimens.
In a sizeable and up-to-date study of 42 patients with MRS (Zimmer et al, 1992), 
granulomatous inflammation was noted in 46% of lip biopsy specimens; 36% showed 
non-specific inflammation; 11% showed incidental findings (such as solar elastosis); 7% 
were histologically normal. Zimmer et al (1992) noted that some patients had obvious
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clinical MRS although biopsy specimens showed non-specific histological features, 
whereas other patients showed only mild symptoms although the histology revealed 
typical granulomatous inflammation. Zimmer and his colleagues then go on to say “it is 
reasonable to state that the histologic picture of typical tuberculoid granulomata confirms 
the clinical diagnosis even when the clinical picture is monosymptomatic. Negative 
histologic findings in the presence of typical clinical symptoms, on the other hand, do 
not refute the diagnosis”. They base this supposition on the basis that granulomata may 
form and vanish within days to weeks and do not strictly coincide with the clinical 
course of swelling (Zimmer et al., 1992; Homstein, 1973). However, this fails to 
recognise that MRS is a purely clinical syndrome - a triad of clinical entities. This 
further lack of diagnostic stringency may have set back the emergence of a new clinical 
entity such as orofacial lymphoedema by some years.
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1.4.5 Cheilitis granulomatosa of Miescher
In a North American study of six patients concerned solely with CG, all patients 
histologically showed non-caseating granulomatous inflammation in the submucosal 
connective tissue of the lip (Allen et al, 1990). Special stains for mycobacterial and 
fungal organisms were negative in each case. In one case, the granulomata were 
exceedingly sparse and were identified only after examining multiple sections. In a 
recent study of six Greek patients with CG, all patients had lip biopsies performed 
(Kolokotronis et al, 1997). One biopsy showed non-specific chronic inflammation with 
hyperplasia of the overlying squamous epithelium. In all other cases, the formation of 
non-caseating granulomata, consisting in some areas solely of epithelioid giant cells and 
in others of epithelioid cells and Langhans’ giant cells, were observed.
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1.4.6 GLUS syndrome
Histopathologically, granulomata in the GLUS syndrome have been found to be 
remarkably uniform when found in the liver (Mir-Madjlessi et al, 1973). However, 
some series of hepatic granulomata include both caseating and non-caseating 
granulomata (Guckian and Perry, 1966), whilst others have excluded cases with 
caseating necrosis on the assumption that these were tuberculous (Mir-Madjlessi et al, 
1973).
Using immunohistochemical methods, it has been demonstrated that granulomatous 
lesions occurring in lymph nodes can be divided into two different families according to 
the presence or absence of B lymphocytes in the granulomata (Brincker and Pedersen,
1991). Old, chronic granulomata associated with a high rate of fibrosis and a high rate of 
transformation of macrophages into giant cells are B-cell negative; this family includes 
sarcoidosis and mycobacterial infections. The B-cell positive family of young, 
inflammatory granulomata include GLUS, tumour-related sarcoid lesions,
toxoplasmosis, and Crohn’s disease. Thus, sarcoid granulomata are rather loose and less 
densely cellular whereas GLUS and Crohn’s granulomata are tightly packed and densely 
cellular.
Among the various diseases studied by Brincker and Pedersen (1991), only the 
granulomata of mycobacterial infections and GLUS demonstrated significant degrees of 
necrosis. It was also demonstrated that the granulomata of GLUS contained NK cells in 
addition to B lymphocytes, whereas sarcoid granulomata did not (Brincker and Pedersen,
1989).
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1.5 Aetiological factors in chronic granulomatous 
disorders
1.5.1 Sarcoidosis
The occasional occurrence of familial sarcoidosis, predominantly in the Irish and West 
Indian populations, has suggested possible genetic influences. Sharma et al (1976) 
reported 16 families in whom 33 persons had sarcoidosis and demonstrated it was 
commoner in monozygotic than dizygotic twins. However, sarcoidosis in spouses is not 
unique, suggesting a common environmental basis. Sarcoid arthritis and erythema 
nodosum are most likely to occur in patients who are HLA-B8, A l, CW7, and DR3 
positive, whereas chronic disease is commoner in HLA-B13 type.
In 1961, Mankiewicz reported that bacteriophages, lytic for mycobacteria, could be 
isolated with great frequency from stool and resection specimens from patients with 
tuberculosis and sarcoidosis, whereas patients with other diseases were seldom found to 
harbour mycobacteriophages. Chapman and Speight (1964) reported the high incidence 
of serum anti-mycobacterial antibodies in sarcoidosis patients.
More recently, the polymerase chain reaction (PCR) has been used to detect 
mycobacterial DNA in clinical samples from patients with sarcoidosis (Saboor et al.,
1992). Broncho-alveolar lavage samples, bronchial washings and tissue specimens were 
assayed by PCR to detect DNA from M. tuberculosis and other mycobacteria. M. 
tuberculosis DNA was found in half the sarcoidosis patients and non-tuberculous DNA 
in 70% of sarcoidosis patients. However, these results are fiercely contested by Scottish 
(Thakker et al, 1992) and French (Bocart et al, 1992) investigators. The Glasgow group 
failed to detect mycobacterial DNA in sarcoid lymph nodes (Thakker et al, 1992). The 
French workers rarely found DNA from M. tuberculosis in sarcoid tissue (Bocart et al,
1992). The Danish group also discounted the role o fM  paratuberculosis in sarcoidosis 
by enzymatic gene amplification techniques (Lisby et al, 1993).
Other suspected causal agents have been put forward but without convincing evidence 
(James, 1991b). These are shown in Table 1.14.
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Table 1.14 Proposed aetiological factors in sarcoidosis (after James, 1991).
Class of Aetiological Factor Type of Aetiological Factor
Bacterial Mycobacteria
Streptococcal cell wall
Propionibacterium acnes
Borrelia burgdorferi
Mycoplasma
Nocardia
Viral EBV (including Herpes group, CMV)
Rubella
Measles
Coxsackie B
Retrovirus
Chemicals Beryllium
Zirconium
Pine pollen
Peanut dust
Clay eating
90
There is considerable evidence accumulating that some antigen (or antigens), as yet 
unidentified, induces a cell-mediated immune response involving a macrophage-CD4 
cellular axis, perpetuated by a cascade of cytokine production progressing to granuloma 
formation (James, 1991b). The inciting antigens, as the above list might suggest, may be 
diverse exogenous stimuli with differing regional localisation; and indeed an internal 
auto-antigen clearly cannot yet be excluded. Thus the co-factor may be Borrelia 
burgdorferi (Bing et al, 1992) in China and clay in the USA (Comstock et al, 1961). 
Regardless, the granulomata may be the result of an antigen-driven process together with 
an exaggerated cell-mediated immune response. Herein may lie a unifying hypothesis 
for the range of granulomatous disorders.
Kiely and Rees (1994) make the suggestion that Crohn’s disease and sarcoidosis are part 
of the same disease spectrum, triggered by the same (possibly mycobacterial) pathogen 
in immunogeneticaily similar subjects, disease expression being dependent on the route 
of entry of the triggering pathogen. They base this supposition on a 42-year-old female 
Sri Lankan patient who presented initially with Crohn’s disease of the small bowel and 
developed renal and multi-system sarcoidosis 9 years later. The absence of the usual 
pulmonary manifestations of sarcoidosis, and profound gut symptoms and signs, at initial 
presentation made Crohn’s disease the most likely diagnosis; the subsequent recurrence 
of symptoms with additional granulomatous renal impairment and hypercalcaemia 
represented a shift “along the disease spectrum” towards sarcoidosis. This, they 
postulate, may have followed reactivation of gut infection (possibly related to the 
withdrawal of sulphasalazine), or alternatively reinfection via the lungs (Kiely and Rees, 
1994).
Oakley et al (1983) described a further association between sarcoidosis and Crohn’s 
disease. A 32-year-old Caucasian female patient presented initially with Crohn’s disease 
of the ileum which was biopsy-proven. One year later, she developed sarcoidosis with 
bilateral hilar lymphadenopathy on chest radiograph and a positive Kveim test. Her 
sarcoidosis gradually resolved but she presented 3.5 years later with Crohn’s disease 
affecting the mouth and oesophagus, but without active gut involvement.
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1.5.2 Crohn’s disease
Crohn’s disease is an idiopathic inflammation of the gastrointestinal tract anywhere from 
mouth to anus, but predominantly ileocaecal. There are currently three main theories for 
the causation of Crohn’s disease :
• Mycobacterium paratuberculosis infection
• Measles virus-induced vasculitis causing mucosal ischaemia
• Local immune-mediated response to an unidentified allergen (e.g. normal flora, food 
substances) - the so-called mucosal immunological dysregulation.
There are also other theories, such as food hypersensitivity or a reaction to toothpaste or 
cornflakes but the evidence is scant (Sullivan, 1990). Interestingly, a recent large study 
(Wurzelmann et a l, 1994) has indicated that persons with Crohn’s disease in adulthood 
were more likely to report an increased frequency of childhood infections in general and 
pharyngitis specifically. The same study (Wurzelmann et al, 1994) noted that urban 
living in childhood also increased the risk for Crohn’s disease.
1.5.2.1 Mycobacterium paratuberculosis infection
Following his original description of the disease in 1932, in which Crohn addressed the 
histopathological similarities between the eponymous disease and intestinal tuberculosis 
(Crohn et al, 1932), interest in the putative mycobacterial origin of the disease was 
rekindled in 1984 by the isolation of an organism by Chiodini, later identified as a slow- 
growing Mycobacterium paratuberculosis, from two North American children with 
Crohn’s disease (Chiodini et al, 1984c). Chiodini subsequently gave the bacteria to 4 
infant goats by the oral route and all the goats acquired intestinal lesions resembling 
those of Johne’s disease (Van Kruiningen et al, 1985). Johne’s disease is considered by 
some authors to be the animal equivalent of Crohn’s disease and was described by Johne 
and Frothingham in 1895. Mycobacterium johnei (subsequently renamed M. 
paratuberculosis) was isolated from affected animals and was deemed the infectious 
cause of this condition (Morgan, 1987).
The similarities between Johne’s disease and Crohn’s disease have long been noted. In
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1913, Sir Thomas Kennedy Dalziel, a surgeon at Glasgow’s Western Infirmary, made the 
connection when describing the pathological features in nine patients whose clinical 
features would now be recognised as Crohn’s disease (Dalziel, 1913). That he should 
draw this conclusion was doubtless due to the fact that his knowledge of cattle farming 
rivalled that of surgery. In 1906 he had purchased the estate of Nether Kinnedar, near 
Dunfermline, and bred his own herd of shorthorn cattle there (Hampson and MacFadden, 
1987). Granulomatous enteritis due to AMB infection has recently been reported in a pig 
(Sigurdardottir et a l, 1994) and Mycobacterium paratuberculosis infection in a colony 
of stumptail macaques (McClure et al, 1987) - the latter extending the natural host range 
of Mycobacterium paratuberculosis to include non-human primates, adding support to 
current suggestions that Mycobacterium paratuberculosis may be pathogenic for 
humans.
M. paratuberculosis is part of the atypical mycobacterial (AMB) group. According to 
the Runyon Classification, AMB are divided into four groups (Akhtar et al, 1997) as 
shown in Table 1.15.
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Table 1.15 The Runyon Classification of atypical mycobacteria.
CLASSIFICATION OF AMB ACCORDING TO RUNYON
I Photochromogens: M. kansasii, M. marinum
(Do not produce pigment in the dark; become bright yellow on exposure to light)
II Scotochromogens: M. scrotulaceum 
(Produce bright orange pigment in dark as well as light)
III Non-photochromogens: M. avium intracellulare complex 
(Do not produce pigment in dark or light)
IV Rapid growers: M. chelonei, M. fortuitum 
(Visible growth within several days)
In 1984, unidentified mycobacteria were isolated from 3/14 patients with CD but none of 
6 patients with ulcerative colitis and other disease controls. The organism was 
fastidious, mycobactin dependent and required at least 18 months for growth in primary 
culture (Chiodini et al, 1984a). The organisms were postulated to be a sub-species of 
the Mycobacterium avium-intracellulare (MAI) complex - most likely M. 
paratuberculosis. In a follow-up paper later in the same year (Chiodini et al, 1984b), 
the organisms were identified as belonging to Runyon group III and did not conform to 
any already recognised mycobacterial species but were most closely related to M. 
paratuberculosis. Inoculation of the organisms revealed a pathogenicity for mice and 
goats but not rats, chickens or guinea pigs (Chiodini et al., 1984b). Thorel (1989) stated 
his frustration for current bacteriological methods, believing them sub-optimal for 
primary isolation of putative Crohn’s disease mycobacteria. However, he considered the 
cultural and biochemical characteristics so akin to the mycobacteria of Johne’s disease 
that he was confident to name the causative bacterium of Crohn’s disease in humans as 
Mycobacterium paratuberculosis (Thorel, 1989).
With the advent of molecular biological techniques, samples could be studied at the 
DNA level and the confirmation came that Chiodini’s isolates were in fact M. 
paratuberculosis (Green et al., 1989). The molecular biology of Mycobacterium
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paratuberculosis continued to be investigated and breakthrough came with the discovery 
of the complete nucleotide sequence of a unique insertion element IS 900 (Green et al, 
1989). This paved the way for the application of the newly established polymerase chain 
reaction (PCR) for the detection of Mycobacterium paratuberculosis in CD tissue 
samples. The PCR is a way of amplifying or making multiple copies of any desired 
piece of nucleic acid (Tyrrell, 1997). Thus it would appear ideal for identifying 
Mycobacterium paratuberculosis which may be in tissue samples in small numbers.
The first signs of progress in the molecular biological search for Mycobacterium 
paratuberculosis came with the paper by Vary et al (1990). They used DNA sequences 
from IS900 to prepare DNA primers for detection and identification of Mycobacterium 
paratuberculosis by PCR. Highly specific direct detection of Mycobacterium 
paratuberculosis DNA in faeces from cattle with Johne’s disease was obtained - taking 
only hours compared with 6 to 12 weeks for culture of the organism (Vary et a l, 1990).
Then in 1992 came a perceived breakthrough with the identification of Mycobacterium 
paratuberculosis DNA in intestinal lesional tissue from human subjects with Crohn’s 
disease (Sanderson et al, 1992). This came from the laboratory of Hermon-Taylor - a 
prominent name in the scientific search for mycobacteria in Crohn’s disease. These 
workers used PCR technology based on the 5’ region of IS900 and capable of the 
specific detection of a single Mycobacterium paratuberculosis genome. This was 
applied to DNA extracts of fresh (unfixed) full thickness samples of intestine removed at 
surgery from 40 patients with CD, 23 patients with UC, and 40 control patients without 
inflammatory bowel disease. Stringent precautions were taken to exclude contamination 
artefact. Mycobacterium paratuberculosis DNA was detected in 26/40 (65%) CD, 1/23 
(4.3%) UC, and 5/40 (12.5%) control tissues. All PCR internal control reactions were 
negative. These findings, the authors contended with much excitement, were consistent 
with an aetiological role for Mycobacterium paratuberculosis in Crohn’s disease 
(Sanderson et al, 1992).
Close on the heels of this study came reports from another centre, using DNA probes, to 
identify the Wood Pigeon strain of Mycobacterium avium and Mycobacterium 
paratuberculosis from fresh (unfixed) human intestinal tissue (McFadden et al, 1992). 
Although the results were from a small group of 4 patients, they added further 
independent support to Hermon-Taylor’s work. Hermon-Taylor pleaded with the
scientific community to move on from “static bewilderment” (Sanderson and Hermon- 
Taylor, 1992). And move on they did.
Fidler et al (1994) used IS900 PCR technology in a double-blind control study on 
paraffin-embedded tissue. Four of 31 Crohn’s disease tissues and none of the 30 control 
and UC derived tissues amplified Mycobacterium paratuberculosis DNA. Crohn’s 
disease tissues containing granulomata were significantly more likely to amplify 
Mycobacterium paratuberculosis-specific DNA than tissues without granulomata (Fidler 
eta l, 1994).
Berche’s group in Paris used PCR to detect the presence of IS900 DNA sequences 
specific to Mycobacterium paratuberculosis genomes in biopsies and surgical resections 
(fresh, frozen tissue) from 53 children with various gastrointestinal diseases and 
disorders (Dell’Isola et al., 1994). IS900 sequences were found in 13/18 samples from 
patients with Crohn’s disease (72%; p<0.01 versus samples from patients without CD), 
in 1/5 with UC, in 2/6 with severe unclassified colitis, and in 7/24 with other 
gastrointestinal disorders. This generated further evidence to support the hypothesis that 
Mycobacterium paratuberculosis is involved in the pathogenesis of CD.
Lisby et al (1994) in Denmark used a more sensitive variant of PCR technology - nested 
primer PCR - on fresh lesional tissue and found Mycobacterium paratuberculosis DNA 
in 11/24 patients with CD, in 2/10 patients with UC, and in 3/28 patients with other 
colonic disorders. Treatment before surgery with prednisolone did not affect detection 
levels. DNA extracted from paraffin-embedded intestinal tissue was also analysed and 
4/58 patients with Crohn’s disease (and no control patients) produced a specific signal at 
the expected size. The authors conclude that the lower occurrence of Mycobacterium 
paratuberculosis DNA in paraffin-embedded intestinal resections from patients with 
Crohn’s disease may be explained by a general loss of DNA during the extensive 
extraction procedure applied to paraffin-embedded tissue (Lisby et al, 1994). The 
authors further postulate the following possibilities from their results :
1 Crohn’s disease is directly caused by a toxic property of Mycobacterium 
paratuberculosis and, since direct microscopy carried out in several studies has failed to 
reveal mycobacteria in lesional tissue, very small numbers of bacteria are required to 
exert this toxic effect;
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2 Mycobacterium paratuberculosis is only present in a sub-population of CD 
patients and causes an immune response in such patients. This is analogous to the 
pathologic findings in tuberculoid-type leprosy;
3 Mycobacterium paratuberculosis is present initially in all patients developing CD 
but may be cleared in some patients, although the immunological reaction persists and 
perpetuates the disease;
4 The presence of Mycobacterium paratuberculosis DNA in CD patients could be a 
mere coincidence, not reflecting any aetiological relationship to CD; to which could be 
added,
5 The current PCR techniques are not yet sufficiently sensitive to identify 
Mycobacterium paratuberculosis DNA in all tissue specimens, or this could be a fault of 
specimen handling.
The source of Mycobacterium paratuberculosis in the human food chain is believed by 
some authors to be cows’ milk, and that current pasteurisation regimes allow the 
bacterium to pass through unaffected (Millar et al, 1996). Shedding of Mycobacterium 
paratuberculosis occurs in the milk of asymptomatic infected cows but, apparently, less 
frequently than in symptomatic cows (Sweeney et al, 1992).
Van Kruiningen et al (1993) described the clustering of Crohn’s disease in two families 
in northern France. In the first family, the father, mother, and all children (3 sons and 1 
daughter) developed Crohn’s disease. One of the sons who developed Crohn’s disease in 
1974 met a girl 3 years later whom he subsequently married in 1983. She developed 
Crohn’s disease in 1991. In the second family, neither the mother nor the father had 
Crohn’s disease; however, four of the five sons and three of the six daughters developed 
Crohn’s disease. These events represent the most concentrated clustering of CD ever 
reported and suggests a role for an infectious agent (Hermon-Taylor, 1993).
Comes et al (1994) reported 10 pairs of husband-wife couples with Crohn’s disease in 
the Nord Pas de Calais region of France and in Liege county of Belgium. In 9/10 
couples, neither spouse had symptoms before marriage but Crohn’s disease subsequently 
developed in both. In the final couple, one spouse had CD before marriage and the other
partner experienced symptoms afterwards. This clustering adds further weight to a 
transmissible agent in Crohn’s disease.
Some studies would appear to support the role of Mycobacterium paratuberculosis in the 
aetiology of CD by the response to anti-mycobacterial chemotherapy. Prantera et al 
(1989) reported the use of dapsone at a dose of lOOmg daily in 5 patients with Crohn’s 
ileocolitis. The therapy was effective in 2/5 patients - one patient showing clinical 
improvement and the other showing complete healing of all cutaneous and rectal ulcers. 
In the two responders, antibody levels to a soluble extract of Mycobacterium 
paratuberculosis were significantly higher than in the other three patients; moreover, in 
the first patient there was a rise of 39% in antibody titres following treatment. Such a 
rise, as may occur following the death of a pathogen with release of antigen, is similar to 
that observed after treatment of tuberculosis.
Other studies are somewhat scathing of the role of anti-mycobacterial chemotherapy in 
Crohn’s disease and demand further stringently controlled trials (Pallone et al, 1992). 
One such study (Swift et al, 1994) ran a double blind randomised controlled trial with 
rifampicin, isoniazid, and ethambutol or placebos with 126 patients over 2 years. The 
conclusion was that the active treatment group derived little tangible benefit from the 
trial treatment (Swift et al, 1994). Another smaller study (Prantera et a l, 1994) of 40 
patients randomised to treatment with rifampicin, ethambutol, clofazimine and dapsone, 
or placebo over 9 months, showed effective relief of symptoms and maintenance of 
remission in some patients. Substantial endoscopic or radiographic healing did not occur 
(Prantera et al, 1994).
Recently, the concept of a mycobacterial susceptibility gene has gained credence (Levin 
et al, 1995; de Groot et al, 1995) and this might explain why, if an external pathogen is 
involved, not everyone exposed to the pathogen subsequently manifests the disease.
However, not all studies have agreed with the Mycobacterium paratuberculosis theory in 
the causation of Crohn’s disease and the literature exemplifies some vociferous 
opponents (Wu et al, 1991; Suenaga et al, 1995; Morgante et a l, 1994). Other 
commentators accept the growing volume of evidence but state the need for further 
rigorous molecular biological and microbiological studies (Jones, 1994; Hawkey, 1994; 
Thompson, 1994).
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1.5.2.2 Measles virus-induced vasculitis causing mucosal ischaemia
It has been recognised for many years that there are vascular changes in the mucosa and 
submucosa in active Crohn’s disease, although it was assumed that these were secondary 
to the inflammation originating in the mucosa. However, extremely detailed studies by 
Wakefield et al (1989) have suggested that vascular injury and focal arteritis were early 
events, even occurring in the submucosa underlying apparently normal mucosa. In 
subsequent studies, it was shown that many of the granulomata were associated with 
vessels in the mucosa (Wakefield et al, 1991), and that microthrombi and fibrin 
deposition was evident in small vessels in the lamina propria in apparently normal 
mucosa from patients with disease elsewhere (Sankey et al., 1993).
However, blood flow is higher in the proximal bowel (Ottaway and Parrott, 1980) so 
why should a vasculitis affect the ileocaecum? Wakefield et al felt they had found the 
answer in 1993 when they demonstrated measles virus-like particles in a cell adhering to 
the vascular endothelium in Crohn’s affected intestine. Hermon-Taylor et al (1995) 
contended that measles virus could not be responsible for Crohn’s disease since the 
incidence of measles infection was continuing to fall while the incidence of Crohn’s 
disease continued to rise throughout the UK. Thompson et al (1995) then suggested that 
it may be the measles vaccine itself which is causing the problem. They followed a 
cohort of 3545 people who had received live measles vaccine in 1964 and found that 
there was a significantly increased risk of developing Crohn’s disease and ulcerative 
colitis, but not coeliac disease or peptic ulceration, in the vaccinated cohort compared 
with their unvaccinated partners.
Of further interest is the recent report from the Israel defence force soldiers (Katz et al., 
1996). It is reported that during an outbreak of measles in 1994, 20% of patients 
presented during their illness with severe oral ulceration, similar to that seen in Crohn’s 
disease and easily distinguishable from Koplik’s spots. The authors suggest this may be 
a further hint of an association between measles virus and Crohn’s disease (Katz et al, 
1996). However, this attempt to diagnose a systemic disease from transient oral 
manifestations defies scientific scrutiny.
More recently, there have been vociferous cries in the literature that the original link 
between Measles virus and inflammatory bowel disease was entirely artefactual (Fisher
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et al., 1997; Metcalf, 1998). Furthermore, it has been clearly stated that there is a great 
need for rigorous methodological reviews when causal associations are proposed 
(Metcalf, 1998).
1.5.2.3 Immunological hypersensitivity disease
This notion is not incompatible with the a distinct infectious aetiological agent, such as 
that considered above, since the local immune reaction has to be driven by antigen(s), 
which may be of microbiological, dietary, or endogenous origin.
The intestinal immune system is only a few micrometers away from the lumen of the gut 
and increased permeability, either genetic or as a result of pathogenic influences, might 
allow ingress of antigen(s) and initiate chronic mucosal inflammation. There is good 
evidence that patients with CD have increased intestinal permeability as do their relatives 
(Hollander et al, 1986), thereby providing a mechanism whereby immunological 
sensitisation to lumenal antigens could occur (May et al., 1993).
There is no doubt that the tissue damage and mucosal ulceration in CD are due to 
immunological hyperactivity and every branch of the immune system is activated 
(Brandtzaeg, 1991). Examination of normal areas of the intestine, distant from ulcers, in 
sufferers of CD shows focal accumulations of mononuclear cells (T cells and 
macrophages) in the lamina propria (Rickert and Carter, 1980). When these underlie 
epithelium there may be granuloma formation and disruption of the epithelium 
(Rappaport et al., 1951). These focal accumulations are presumably in response to 
antigen in the lamina propria being processed and presented by dendritic cells to lamina 
propria CD4+ T-cells. These then release cytokines which upregulate endothelial 
adhesion molecules in the adjacent vessels (Dogan et al., 1993) and monocytes and 
neutrophils move into the mucosa from the blood. Granuloma formation requires 
persistent antigen and therefore antigens must be constantly crossing the epithelium, or 
be persistent in the lamina propria.
Diseased mucosa contains large numbers of activated T-cells and macrophages 
(Schreiber et al, 1992), together with large numbers of IgG plasma cells (Kett et al., 
1987); there is extensive local complement activation (Haltensen et al., 1992) and non­
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specific effector cells such as mast cells, eosinophils and neutrophils are abundant and 
functionally active (Oshitani et al, 1993).
Pathogens such as Yersinia enterocolitica and Mycobacterium paratuberculosis in 
animal models clearly enter the mucosa from the lumen and cause transmural intestinal 
inflammation, setting up chronic infection with antigen persistence and the result of this 
is a Crohn’s-like mucosa. Repeated feeding of enterotoxin-secreting staphylococci to 
dogs also produces a terminal ileitis (Prohoska, 1963). Therefore, it is clear that 
transmural inflammation can result from antigen persisting in the mucosa. It has been 
demonstrated recently that an ongoing T-cell-mediated immune response is functionally 
present in the mucosa of CD, but not UC, by quantitative PCR and functional 
lymphokine analysis (Mullin et a l, 1992; Breese et al, 1993). This observation that 
activated T-cells are not seen in the mucosa in UC shows that T-cell activation in CD is 
not a non-specific secondary effect due to increased antigen uptake across a damaged 
epithelium, but a primary event. However, until the specificity of these T-cells is 
identified, the stimulus for the local T-cell hypersensitivity will remain unknown. That 
antigenic specificity is likely to come from the faecal stream. Recent work has shown 
that after resection of diseased bowel, there is no disease in the neoterminal ileum if Hie 
segment is bypassed. After reconstruction to the faecal stream, aphthous-like ulceration 
and inflammatory changes develop (Rutgeerts et al, 1991).
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1.5.3 Orofacial granulomatosis
The aetiology of OFG, in the absence of Crohn’s disease or sarcoidosis, is largely 
unknown. However, in view of the obvious confusion in the literature over nomenclature 
and diagnosis of the various clinical entities, orofacial granulomatosis, Melkersson- 
Rosenthal syndrome and cheilitis granulomatosa of Miescher will be considered here 
together under the heading of orofacial granulomatosis.
Allergic, infectious and hereditary causes have been proposed (James et al., 1986; Pachor 
et al, 1989; Pachor et al., 1989; Lygidakis et al, 1979). Elimination diets to diagnose 
food intolerance and allergy have been used with some success, suggesting an 
immunological mechanism (Hernandez et al, 1986; Pachor et al, 1989). However, the 
great criticism of such studies is that they generally lack definitive control groups. 
Morales et al (1995) subjected 6 patients with MRS to extensive skin prick tests and 
patch tests under the Standard European Series with uniformly negative results. When 
asymptomatic, the patients were subjected to double-blind oral challenge, under placebo 
control, with various food additives (monosodium glutamate, tartrazine, sulphites, 
erythrosine, paraoxybenzoate, sodium benzoate, lactose, aspirin and annate) with 
negative results. In no case did patients relate their condition to exposure to dietary or 
environmental agents and the course of the disease was unaffected by exclusion diets and 
the elimination of environmental agents. Interestingly, three patients had circulating 
immune complexes identified and two had elevated C-reactive protein (CRP) levels. The 
immune complexes were unspecified and the degree of elevation of CRP not recorded; 
neither finding is specific nor indicative of any disease process or abnormality.
Pachor et al (1989) reported a male patient with upper lip swelling, gingival hypertrophy 
and fissured tongue whom they labelled as having “MRS”, despite no neurological 
abnormality. A lip biopsy did show granulomatous inflammation. Sodium benzoate and 
tartrazine were identified as precipitants of the swellings by direct oral challenge. 
Elimination of these substances from the patient’s diet brought about a progressive 
improvement in his symptoms until complete resolution which lasted more than a year 
(at the time of the report).
An association between OFG and atopy was established by James et al (1986) when 60% 
of a group of 75 patients with OFG were found to be clinically atopic (having infantile
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eczema, hay fever or extrinsic asthma) compared with 15% of a control group of 200 
patients drawn from the same geographical area. Patton et al (1985) suggested an 
association between OFG and allergy to foodstuffs with 14 out of 80 patients with OFG 
reported having “intolerance to foods or flavourings”, all but one of whom clinically 
were atopic. In five cases the history of a specific provoking factor was so clear that 
patch testing “was not deemed necessary”. The chief “allergen” identified on patch 
testing was cinnamon or its principal constituent, cinnamonaldehyde. The authors 
concluded that OFG may be related to some form of cell-mediated allergic response, 
with the allergen being derived from food, toothpaste flavourings or micro-organisms.
The role of food additives in OFG was further endorsed by Sweatman et al (1986) who 
reported a female child with OFG and clinical atopy in whom a relapse of her condition 
was shown to be related to exposure to the food additives carmoisine, sunset yellow and 
monosodium glutamate (MSG). This was shown with double-blind diet provocation 
tests and the use of an elemental diet. Oliver et al (1991) again endorsed the role of 
MSG in OFG with a positive scratch test result to MSG in a 15-year old female with 
OFG who experienced significant clinical improvement following institution of a low- 
allergen exclusion diet.
Sakuntabhai et al (1993) reported nine patients (six males and three females; aged 10-47 
years) with OFG. No evidence of an allergic cause was found using patch or contact 
urticaria tests and yet eating chocolate produced lip swelling in one man, and his lip 
shrank in size after avoiding this for 12 months.
Reed et al (1993) reported two cases of Australian patients who responded to elimination 
diet. A 37-year-old female Pakistani had “plasma cell gingivitis” and used a 
combination spice product containing cinnamon, cloves, cardamon, cumin seeds, 
coriander seeds and leaves, green and red chillies, ginger, and mint leaves. Eliminating 
this product from her diet produced marked decrease in gingival swelling and resolution 
of pain. A 47-year-old white Caucasian male presented with upper lip swelling which 
showed non-caseating granulomatous inflammation. His diet analysis revealed 
significant consumption of carbonated drinks and chewing gum. When these were 
eliminated from the diet, the lip swelling resolved. The authors assume the provoking 
allergen to be aspartame (Reed et a l, 1993), but these foods also contain cinnamon and
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benzoic acid (McKenna et al., 1994; Patton et al, 1985). This patient’s swollen lip 
returned 1 year later following lapses in his dietary avoidance regime.
The antipodean patient profile with OFG continued in 1993 with reports from New 
Zealand (Frisken, 1993). However, no histological confirmation is reported for the 
patients in this series. All were female (aged 19, 20 and 70 years); the first had upper 
and lower lip swelling and gingivitis; the second had lip swelling and mucosal tags; the 
third had profound upper lip swelling. The first patient identified dairy products as a 
precipitant to the swelling and her symptoms resolved rapidly and completely with 
dietary exclusion. The second patient could identify no dietary precipitants but her signs 
resolved completely after cessation of ACE -inhibitor drug therapy for hypertension. 
The third patient’s problems resolved completely when she stopped rubbing sage, 
rosemary and parsley from her neighbour’s garden onto her labial gingivae. The 
neighbour was using substantial quantities of pesticides in his garden (Frisken, 1993).
Pryce and King (1990) introduced non-dietary “allergens” into the arena by reporting 
OFG in an 8-year old male who had delayed hypersensitivity to cobalt (1% cobalt 
chloride) demonstrated on patch testing. He had a habit of sucking plastic pens and 
crayons and cobalt is present in polyester plastics as cobalt naphthenate, an accelerator; 
cobalt is also present in crayons as a dye.
More recently, Armstrong et al (1997) investigated 48 patients with OFG and subjected 
them to patch-testing to the European Standard Series and an “oral battery” of test 
substances. Ten patients showed positive skin reactions on patch-testing and, of these, 7 
showed improvement on an elimination diet. Adequate control subjects were lacking in 
this study of an Irish population. The major problem of absence of controls is a 
prominent feature throughout the literature on OFG, particularly in studies claiming to 
investigate hypersensitivity reactions, and too much store has been put upon the volume 
of unsatisfactory case reports. The desire for controlled studies in food allergy generally 
has been expressed recently in the medical community (Sampson, 1997).
Henry (1994) presented a patient with OFG in whom the lymphocyte CD4/CD8 ratio 
was decreased. He suggested that this demonstrated evidence for involvement of the 
cellular immune system in the disease process. However, many diseases are known to
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affect lymphocyte subpopulations, including sarcoidosis and Crohn’s disease (Siegel, 
1984; Romer et al, 1984; Carney et al, 1981).
Ivanyi et al (1993) introduced the possibility of an infective origin for OFG by building 
on the work of Elsaghier et al (1992) who had demonstrated the presence of elevated IgG 
antibody levels to mycobacterial stress protein (with a molecular weight of 65kDa) in 
52% of patients with Crohn’s disease. Stress proteins are produced in response to many 
forms of cellular stress, including viral and bacterial infections, cytokines and 
temperature change and have been implicated in the pathogenesis of autoimmune 
diseases and bacterial inflammation. IgG antibody titres to the mycobacterial stress 
protein (mSP65) were determined by ELISA in sera from 10 patients with OFG. Seven 
patients had titres ranging from 180-950, whilst no serum antibody to this antigen could 
be detected in 3 patients (Ivanyi et al, 1993). Although the aetiology of gastrointestinal 
Crohn’s disease remains largely unknown, the involvement of mycobacteria has been 
suspected for several years and much scientific evidence supports this view (Morgan, 
1987;Hampson et al., 1988; Prantera etal., 1991).
A family study on MRS (73 patients) suggested a multifactorial origin to the syndrome, 
based on an hereditary predisposition and a genetic basis is postulated since several cases 
among related individuals are recorded (Meisel-Stosiek et al, 1990). Some authors 
describe a high, but not significant, level of HLA B16 and CW3 antigens in cases 
thought to have a genetic basis (Stosiek et al, 1992). An autosomal dominant 
inheritance with variable expression has been well documented (Carr, 1966; Lygidakis et 
al, 1979). Work by Smeets et al (1994) further categorised MRS as an autosomal 
dominant disorder with variable expression and suggested that the “Melkersson- 
Rosenthal gene” is located at 9pl 1.
Homstein (1973) characterised MRS as a polyaetiological syndrome in which an 
hereditary or acquired disposition to a functional disturbance of the autonomic nervous 
system occurs, with a granulomatous reaction in the oedematous tissue resulting from an 
allergic response to different non-specific circulating antigens.
Recently, Lim et al have examined the lymphocytes from peripheral blood and lesional 
tissue in a 12-year-old boy with OFG to determine the T cell receptor (TCR) VB gene
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usage of the T cell infiltrate associated with the primary lesion (swollen right buccal 
mucosa) (Lim et al, 1997). They used a molecular method involving reverse 
transcriptase (RT)-polymerase chain reaction (PCR), DNA cloning, single strand 
conformation polymorphism (SSCP), length analysis, and nucleotide sequencing. 
Compared with the peripheral blood, lesional lymphocytes had notably restricted TCRVB 
gene usage. Only three of the 24 major TCRVB gene families were represented in the 
repertoire. There was preferential usage of the VB6 gene. In addition, more than 20% of 
the VB6 TCR transcripts exhibited an identical V-D-J junctional sequence, suggesting a 
local antigen driven VB6 T cell clonal expansion in vivo, a phenomenon not observed in 
normal oral mucosa. Although these data were presented from only one patient with 
OFG, they provide a unifying hypothesis on the immunopathology of OFG - namely, 
genetics playing a role in the development of abnormal T cell clonal expansion, yet 
driven by a local antigen (whether microbiological, food or environmental).
Challacombe et al (1997) found that there were detectable disturbances in mucosal 
immunity in patients with OFG with significantly greater serum titres of both IgA and 
IgG against Candida albicans (p<0.002; p<0.01) and Saccharomyces cerevisiae (bakers’ 
yeast) (p<0.05; p<0.005) compared with the control group.
106
1.5.4 Melkersson-Rosenthal syndrome
The possibility that MRS is a variant of sarcoidosis is discussed elsewhere in this 
literature review but Kveim tests were reported as negative in seven patients with MRS, 
making sarcoidosis unlikely (Lindelof et al, 1985). In the same study, levels of serum 
angiotensin converting enzyme and calcium were normal.
The elimination of odontogenic infection has also been reported to cause regression and 
disappearance of the lip swelling in some cases of MRS (Worsaae et al, 1982). The 
presence of herpetic eruptions on the lips and oral mucosa of some patients has been 
used by some authors to suggest a viral aetiology (Pisanty and Sharav, 1969;Nally, 1970; 
Alexander and James, 1972; Worsaae et al, 1982) but such findings are by no means 
universally reported.
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1.5.5 Cheilitis granulomatosa of Miescher
The cause of CG remains unknown, except for its association with sarcoidosis 
(Bourgeois-Droin et al, 1993) and Crohn’s disease (Brook et al., 1983). It has been 
observed in persons who had been in contact with sodium silicate, which was believed to 
be of aetiological significance (Forman and Shuttleworth,1956). Infectious factors have 
also been proposed and lesions similar to CG occurring on the vulva and penis (preceded 
by recurrent infection) have been described (Larsson and Westermarch, 1978; 
Westermark and Henriksson, 1979), suggesting a common pathogenic mechanism 
(Larsson and Westermarch, 1978). Westermark and Henriksson (1979) indicated that 
bacteria of low-grade pathogenicity could play a role in the development of CG - 
although if this were the case then immunosuppressive states (e.g. HIV) might be 
expected to bring an increased prevalence of CG; this has not been reported.
Other infections of the face, such as chronic parotitis (Bishop and Garcia, 1979), Herpes 
simplex (Poex et al., 1974), and paranasal infections with anaerobic bacteria (Frederick 
and Burde, 1974) have been observed before or after the development of CG.
An association with CG and food allergy was demonstrated in a patient allergic to 
almonds and hazelnuts (Hernandez et al., 1986). Oral rechallenge with the identified 
food substances resulted in a recurrence of lip swelling; histological confirmation of 
granulomatous inflammation was recorded. The authors suggested a Type I or Type IV 
hypersensitivity reaction - the latter would explain the presence of granulomata and giant 
cells; the former would explain the degree of oedema evident on biopsy. An 
immunological basis would be fiirther substantiated with GC followed by Crohn’s 
disease (Carr, 1974), Hodgkin’s disease (Mulvehill et al., 1973) and Anderson-Fabry 
disease (Young et al., 1978) - all of which have had an immunological basis established. 
Other authors suggest that the obstruction of lymphatic vessels by the granulomata may 
be a factor in the pathogenesis and a constitutional tendency to form epithelioid cell 
granulomata in chronic infections has also been suggested (Westermark and Henriksson, 
1979).
Homstein (1973) suggested that the granulomatous reaction was an allergic reaction to 
circulating antigens (non-specific); and the oedema a result of disturbance in the
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autonomic nervous system, with an increase in vascular permeability. The non-specific 
allergy theory in CG was taken up by Liu and colleagues (1994; 1993a) but then focused 
more specifically on the spirochaetal cause of Lyme’s disease, Borrelia burgdorferi (BB) 
(Liu, 1993b). They reported the serum anti-BB antibody titres in 18 patients with CG 
and 5 patients with MRS at 77.8% and 80.0% respectively. They conclude that these 
results, coupled with histological features suggestive of spirochaetal involvement, 
suggest that CG and MRS are caused by BB.
Creus and colleagues (1994) reported a case of ulcerous CG in a 43-year-old 
immunocompetent male patient. The saprophytic fungal species Scopulariopsis 
brevicaulis was cultured from the labial swelling and submaxillary lymph nodes. The 
patient experienced an excellent response to oral itraconazole.
A report from Japan (Kano et al.t 1993) has made the suggestion that all patients with 
CG are genetically predisposed to Crohn’s disease - an idea extrapolated from HLA 
antigen status in three patients! These three patients with CG and no evidence of 
gastrointestinal disease had the following HLA antigens in common : HLA-DR4, 
DRw53, and DQw3. In Japanese patients with Crohn’s disease, 94% express HLA-DR4 
(or DRw9), DRw53, and DQw3 (Kano et al., 1990).
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1.5.6 GLUS syndrome
If a specific GLUS syndrome is to be differentiated from sarcoidosis, then the features of 
GLUS - the occurrence of fever and constitutional symptoms, multisystem involvement, 
and evidence of immunological upset leading to granuloma formation - suggest an 
infectious aetiology (Benjamin, 1987). The GLUS syndrome demonstrates many 
features of infection caused by DNA viruses such as EBV and CMV, and one study 
suggests that cases of GLUS may be particularly frequent at a young age, coincident with 
a viral aetiology (Kuo and Rosai, 1974). This is shown in Table 1.16.
Table 1.16 Comparison of features of EBV and CMV infection with GLUS.
EBV = Epstein-Barr virus; CMV = Cytomegalovirus
FEATURE EBV/CMV INFECTION GLUS SYNDROME
Occurrence Children/young adults Children
Subclinical course May occur May occur
Latency/reactivation Characteristic Prolonged course
Granuloma formation May occur Defining feature
Constitutional symptoms 
(e.g. fever)
Yes Yes
Multisystem disease Yes Yes
Skin rash Yes Occasional
Abnormal liver function 
tests
Yes Yes
Hypergammaglobulinaemia Yes Yes
Peripheral lymphocytosis Characteristic Occasional
Prognosis Good Good
There is good evidence to suggest that infections with EBV and CMV are associated 
with granuloma formation, but apparently in such a way that the granulomata in EBV 
tend to be localised to bone marrow, whereas those of CMV preferentially affect the liver 
(Cohen and Corey, 1985; Fiala et al., 1987). Furthermore, mononucleosis-like 
conditions without serological evidence of EBV or CMV infection may also be 
associated with granuloma formation (Telenti and Hermans, 1989; Krause and Kaplan, 
1982). Both EBV and CMV are associated with a decrease in the normal ratio of 
CD4:CD8 T lymphocytes in the peripheral blood, as in sarcoidosis (Carney et al, 1981). 
It could be speculated that the occurrence of natural killer cells within the granulomata of 
GLUS (Brincker and Pedersen, 1989) might indicate an immunological response directed 
against cells carrying the aetiological agent - and, on the strength of current literature,
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that agent may well be a DNA virus or other infectious agent - such as toxoplasmosis, 
catch-scratch disease and Yersinia (Weitberg et al, 1979; Lenoir et al, 1988).
For the sake of completeness, the other granulomatous disorders which may present 
around the orofacial region should be mentioned - Wegener’s granulomatosis, foreign 
body reactions, toothpaste reactions, myiasis, pulse (vegetable) granuloma, deep mycoses 
and syphilis - and discounted due to aetiological factors having been established 
previously (Eveson, 1996).
I l l
CHAPTER 2
PATIENT AND CONTROL GROUPS
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2.1 Patients
A total of 443 patients with a diagnosis of orofacial granulomatosis attended the 
Department of Oral Medicine at Glasgow Dental Hospital & School during the twenty 
year period 1978-1998. These patients were referred from general dental and medical 
practitioners, consultant physicians (including dermatology, gastroenterology and general 
medicine), hospital dental practitioners (including the institution’s Accident and 
Emergency Department, previously called the Receiving Clinic). Initially, data from 
historical case notes were assessed retrospectively and were deemed to be incomplete in 
142 patients; these data were discarded. Useful data were available on 301 patients 
(consecutive referrals) -  50 of whom were initially retrospective assessments (from the 
eight year period 1978-1986) and 251 of whom were prospective assessments (from the 
twelve year period 1986-1998). Thus, the patients were selected historically (50 
patients) only on the basis of completeness of data; all patients analysed prospectively 
were entirely unselected.
All the patients enrolled in the clinical aspects of this study were attending the 
Department of Oral Medicine at Glasgow Dental Hospital & School, later called 
Glasgow Dental Hospital & School NHS Trust, and/or the Contact Dermatitis 
Investigation Unit, Belvidere Hospital, later housed at Glasgow Royal Infirmary 
University NHS Trust. Of the 301 patients enrolled, 50 had historical data collated from 
casenotes (with 36 subsequently being contacted personally by telephone or letter to 
clarify some aspects of their history and presentation; 28 patients’ general medical 
practitioners and/or hospital specialists were contacted personally by telephone or letter 
to clarify some aspects of their history, investigations or laboratory results). The 
remaining 251 patients were interviewed and examined personally by the investigator.
The total of 301 patients included in the clinical aspects of the study all had symptoms 
and signs constituting a diagnosis of orofacial granulomatosis (Anonymous, 1991b; 
Wiesenfeld et al, 1985). The patients were primarily from the west of Scotland but 
included a wide geographical referral area from the islands of Barra and Lewis in the 
west, the towns of Fort William in the north west, Inverness in the north, Edinburgh and 
the Borders in the east, Newcastle in the south and Castle Douglas in the south west.
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The demographic details are shown in Table 2.1 and Figure 2.1. 
Table 2.1 Demographic details of patients with OFG
(total no/age in years) Male Female
Total (%) 172
(57.1)
129
(42.9)
Mean age at presentation 24
Age range at presentation 3-66
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Where patients underwent invasive procedures (including venepuncture) beyond those 
deemed necessary for normal patient management, informed, written consent was 
obtained and the necessary documentation signed by patient, parent or guardian as 
appropriate. Application was made to, and granted by, the Ethics Committees of each of 
the participating hospitals, viz. Glasgow Dental Hospital & School NHS Trust, Glasgow 
Royal Infirmary NHS Trust, and Yorkhill Hospitals NHS Trust.
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2.2 Controls
Where appropriate, informed written consent was obtained and the necessary 
documentation signed by the control subject, parent or guardian. Application was made 
to, and granted by, the Ethics Committees of each of the participating hospitals, viz. 
Glasgow Dental Hospital & School NHS Trust, Glasgow Royal Infirmary NHS Trust, 
and Yorkhill Hospitals NHS Trust.
Control subjects were allocated to various groups :
2.2.1 Haematological, biochemical and immunological studies - 
whole blood, plasma and serum analysis
The reference ranges for these parameters were obtained from the diagnostic laboratories 
used in West Glasgow Hospitals NHS Trust and Glasgow Royal Infirmary NHS Trust. 
Reference was also made to the results of the Scottish Health Survey 1995.
2.2.2 Technetium-99m-HMPAO leucocyte labelling
Fifteen patients (8 male, 7 female; mean age 153 months, range 93-202 months) with 
objective evidence of inflammatory bowel disease (radiological +/- histological) were 
used as controls for this study. These were patients attending the clinic of Dr. John 
Evans, Consultant Paediatric Gastroenterologist, at the Royal Hospital for Sick Children, 
Glasgow.
2.2.3 Patch-Testing and Contact Urticaria Testing
To standardise methodology, all patch-testing and contact urticaria testing for the control 
population was carried out by the same clinician throughout, Dr. Shiona Rees, who had 
been trained and calibrated by Dr. Angela Forsyth, Consultant Dermatologist. Dr. 
Forsyth patch-tested the entire patient population.
One hundred and fourteen volunteers made up of staff and students at Glasgow Dental 
Hospital & School NHS Trust, and their friends and family members, applied to be 
enrolled in the study. Volunteers were provided with an Information Sheet and signed a
Consent Form. A short questionnaire was completed by each volunteer to determine age, 
gender, area of residency, occupation and past medical history.
Control subjects were excluded for the following reasons:
• Previous exposure to patch-testing or currently awaiting patch-testing.
• History of, or clinical evidence of, mucosal or cutaneous lichen planus or lichenoid 
reaction.
• History of recurrent aphthous stomatitis (defined as an episode of oral ulceration 
affecting the non-keratinised mucosa, occurring more than twice per year).
• History of orofacial granulomatosis or inflammatory bowel disease.
• History of erythema multiforme.
• History of angioedema.
As a result, 14 volunteers were excluded and 100 were formally enrolled as control 
subjects (29 male, 71 female; mean age 33.3 years, range 19-60 years). All were patch- 
tested in the Department of Oral Medicine, Glasgow Dental Hospital & School NHS 
Trust between July and December 1996.
2.2.4 Detection of anti-gliadin antibodies
Seven patients (4 female, 3 male; mean age 28 years, range 14-43 years) with coeliac 
disease (proven by jejunal biopsy), and 11 patients (8 female, 3 male; mean age 25 years, 
range 22-42 years) with no gastrointestinal or oral mucosal disorders acted as controls 
for this study. The coeliac disease group was attending the gastroenterology clinic of Dr. 
Robin I. Russell, Department of Medicine, Glasgow Royal Infirmary; the disease-free 
group was made up of staff of the Department of Oral Medicine, Glasgow Dental 
Hospital & School.
2.2.5 Molecular Biological Studies
Twelve patients (6 male, 6 female; mean age 36 years, range 22-63 years) with a history 
of recurrent aphthous stomatitis (minor variant) attending the Department of Oral 
Medicine, Glasgow Dental Hospital & School NHS Trust, for investigation and
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management of their oral disease acted as controls for this study. An aphthous ulcer 
(less than 24 hours old) was excised under local anaesthesia from each patient, following 
the signing of informed consent documentation.
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CHAPTER 3
CLINICAL METHODS I :
INVESTIGATION OF PATIENTS & CONTROLS
120
3.1 Introduction
This thesis focuses on the clinical aspects of orofacial granulomatosis and, as such, the 
author’s personal involvement was chiefly in the clinical aspects of the patients’ care, 
namely haematological, biochemical, immunological, microbiological and 
histopathological sampling, and patch-testing and contact urticaria testing. As a result, a 
number of diagnostic NHS laboratories were involved in processing the specimens, 
relying on the expertise of many support and technical staff Due recognition is made of 
this throughout the text. Some aspects of the investigative protocol were part of a 
service commitment; others were entirely research orientated. Again, due recognition is 
made of this throughout the text.
For the 301 patients included in the study, history and examination were recorded for 
each on a proforma which was updated at each clinic attendance, and subsequently 
analysed. A diagnostic label was given to each patient on the basis of clinical, 
histological, haematological, biochemical, immunological, and radiographic findings as 
follows:
1 orofacial granulomatosis (with no evidence of systemic granulomatous disease).
2 gastrointestinal Crohn’s disease (pre-existing and subsequently diagnosed).
3 sarcoidosis.
4 Melkersson-Rosenthal syndrome.
The diagnosis for each group followed recognised guidelines laid down in the current 
medical scientific literature as follows:
1 orofacial granulomatosis
Clinical appearance of chronic soft tissue swelling of the orofacial region at one or more 
sites with, ideally, histological confirmation of non-caseating granulomatous 
inflammation and/or lymphoedema. No clinical, haematological, biochemical, 
immunological and/or radiographic evidence of other systemic granulomatous disorders 
(Wiesenfeld e ta l, 1985).
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However, many case reports in the literature to date rely on clinical appearance only, 
with no histological findings reported. Therefore, it would be appropriate to use the 
clinical term Orofacial Lymphoedema (OFL) as presumptive OFG; i.e. “histological” 
OFG is a subset of “clinical” OFL. This convention will be developed throughout this 
study.
2 gastrointestinal Crohn’s disease
Assessment by a consultant physician in gastroenterology to demonstrate clinical 
features associated with the disease and, directly, transmural chronic granulomatous 
inflammation of the gut or, indirectly, the results of this process (deep ulceration, fistulae 
and strictures of the gut; haematological and/or biochemical abnormalities associated). 
Whilst accepting that a histological assessment is the gold-standard for diagnosis, 
radiographic imaging of the gut may supply supportive information, particularly in 
children where direct visualisation of the gut may be a hazardous process (Bozdech and 
Farmer, 1990).
3 sarcoidosis
Assessment by a consultant physician, including (a) full history and detailed clinical 
examination, including ophthalmoscopy and slit-light examination of the eyes; (b) chest 
radiography and/or CT or MRI imaging of the thorax and cranium; (c) haematological 
(including ESR) and biochemical (including serum calcium and 24 hour urine collection; 
serum angiotensin converting enzyme assay) tests; (d) tuberculin skin reactivity test; (e) 
sputum sampling and/or bronchoalveolar lavage; (f) histological confirmation by specific 
organ biopsy, bronchial or transbronchial lung biopsy, or a Kveim skin test; (g) 
respiratory function tests (James et al, 1976).
4 Melkersson-Rosenthal syndrome
This is a clinical diagnosis of a triad of signs, namely chronic swelling of the soft tissues 
of the face, fissured tongue, and unilateral or bilateral lower motor neurone facial palsy 
(Rosenthal, 1931).
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Such a diagnosis was therefore subject to review for each patient as they progressed 
through investigations and follow-up. However, for the purposes of final analysis, these 
four patient groups were employed.
A standard haematological, biochemical and immunological profile was performed on all 
patients, except the first 50 for whom incomplete test data was obtained. Similarly, 
incomplete information on patch-testing was available on some of the earlier patients.
Patients with evolving evidence of systemic disorders, such as sarcoidosis and 
gastrointestinal Crohn’s disease on the basis of clinical findings and/or the results of 
investigations, were further investigated to establish a correct diagnosis. Such medical 
evaluations were performed by the Department of Medicine at Glasgow Royal Infirmary 
NHS Trust or, in the case of paediatric patients, at The Royal Hospital for Sick Children, 
Glasgow.
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3.2 Clinical History
A clinical history was obtained from each patient (or parent) with regard to age of onset 
and duration of the condition, medical history (with specific questioning on atopy), 
dental history, drug history (including disease modifying drugs such as 
immunosuppressants), social history (including family history, smoking and alcohol 
consumption, and dietary fads), and systemic enquiry (with specific questioning on facial 
palsy, weight loss, altered bowel habit, number of stools passed daily, rectal bleeding, 
and abdominal pain).
Patients were asked to grade their orofacial symptoms at presentation and throughout the 
study using a visual linear analogue scale. Patients were asked to imagine a line 10cm 
long with graded marks at centimetre intervals, giving a possible score of 0-10. Patients 
were advised that 0  meant no symptoms at all, and 1 0  meant their symptoms could not 
be worse.
124
3.3 Physical Examination
Patients were assessed at initial consultation for evidence of local and systemic disease. 
General examination was carried out selectively at initial consultation where indicated 
on the basis of symptoms; thereafter, all patients attending the joint dental-dermatology 
clinic after patch-testing at Glasgow Royal Infirmary had a full medical examination 
performed. This included the presence or absence of abdominal pathology, perianal and 
general skin changes, lymphadenopathy, and finger clubbing. A more detailed 
examination was performed where indicated by symptoms, signs or the results of 
haematological or other special investigations, correlated with the findings of a 
consultant physician when referral was instituted.
Orofacial examination included the presence or absence of lymphadenopathy, facial and 
perioral skin changes, angular cheilitis, facial swelling, lip swelling, oral ulceration, full­
thickness gingivitis, mucosal tags, mucosal oedema (cobblestoning), fissured tongue, and 
papillary hyperplasia of the palate (Figures 3.1-3.12).
Patients were assessed at initial consultation and throughout the study using a scale 
graded from 0 (minimum) to 16 (maximum). This scale simply demonstrated the 
presence (1 mark) or absence (0 mark) of disease at various sites as shown in Table 3.1. 
This was deemed to be the most objective method of assessing disease activity, rather 
than attempting to quantify a graded record of changes in each individual clinical sign.
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Table 3.1 Sign score used in assessing patients with OFG.
SITE/CONDITION GRADE
ANGULAR CHEILITIS - LEFT 0  or 1
ANGULAR CHEILITIS - RIGHT 0  or 1
LIP SWELLING - UPPER Oor 1
LIP SWELLING - LOWER 0  or 1
FACIAL SWELLING 0  or 1
ULCERATION -  APHTHOID 0  or 1
ULCERATION -  OTHER Oor 1
FULL THICKNESS GINGIVITIS 
(UPPER ARCH)
0  or 1
FULL THICKNESS GINGIVITIS 
(LOWER ARCH)
0  or 1
MUCOSAL TAGS 
(RIGHT SIDE OF MOUTH)
0  or 1
MUCOSAL TAGS 
(LEFT SIDE OF MOUTH)
0  or 1
MUCOSAL OEDEMA 
(RIGHT SIDE OF MOUTH)
0  or 1
MUCOSAL OEDEMA 
(LEFT SIDE OF MOUTH)
0  or 1
FISSURED TONGUE Oor 1
PAPILLARY HYPERPLASIA 0  or 1
FACIAL PALSY Oor 1
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Figure 3.1 Patient with OFG and angular cheilitis
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Figure 3.2 Patient with OFG and upper lip swelling
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Figure 3.3 Patient with OFG and lower lip swelling
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Figure 3.4 Patient with OFG and facial swelling
130
Figure 3.5 Patient with OFG and recurrent aphthous ulceration
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Figure 3.6 Patient with OFG and non-aphthoid oral ulceration
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Figure 3.7 Patient with full thickness gingivitis
Figure 3.8 Patient with buccal mucosal tags
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Figure 3.9 Patient with OFG and buccal mucosal oedema
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Figure 3.10 Patient with OFG and Assuring o f the tongue
• '  .
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Figure 3.11 Patient with OFG and papillary hyperplasia
137
Figure 3.12 Patient with OFG and lower motor neurone facial (VII) palsy
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3.4 Haematological Investigations
Two hundred and twenty-seven patients had venous blood removed at the first or second 
clinic visit and sent to the Department of Haematology at the Western Infirmary, 
Glasgow, for measurement of haematological parameters. This was repeated, if required, 
to verify results at subsequent visits. The haemoglobin concentration (Hb) and Mean 
Cell Volume (MCV) were determined by automated techniques and stained blood films 
were examined according to standard methods. Total white and red blood cell counts, 
and differential white cell counts and platelets numbers were obtained by automated cell 
counting techniques.
Serum ferritin, whole blood folate, and serum vitamin B 12 were measured by 
radioimmunoassay. Erythrocyte sedimentation rates were measured by the Westergren 
method.
The normal ranges of these haematological parameters are shown in Table 3.2. 
Subsequent statistical analysis took in to account the age- and gender-matched 
differences in haematological indices between adult and paediatric populations.
Patients were regarded as being deficient in iron, folate or vitamin B 12 only if they 
showed two consecutive results below the normal range.
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Table 3.2 Normal ranges of haematological parameters measured.
Laboratory Test Normal Range
Haemoglobin (Hb) Male 13-18 g/dl
Female 12-16 g/dl
Mean Corpuscular Volume (MCV) 80-100 fl
Red Cell Count 4.6-6.2 x 10^/1
White Cell Count 4.0-11.0 x 109/1
Neutrophils 2.5-7.5 x 109/1
Lymphocytes 1.5-3.5 x 109/1
Monocytes 0 .2 -0 . 8  x 1 0 9/1
Eosinophils 0.04-0.44 x 109/1
Basophils 0.015-0.1 x 109/1
Platelets 150-400 x 109/1
Serum Ferritin 25-300 ng/ml
Serum Vitamin B 12 150-900 pg/ml
Whole Blood Folate 160-640 ng/ml
Erythrocyte Sedimentation Rate (ESR) Age and Sex dependant
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3.5 Biochemical Investigations
One hundred and forty-six patients had venous blood removed at the first or second 
clinic visit and sent to the Department of Biochemistry at the Western Infirmary, 
Glasgow, for measurement of biochemical parameters. This was repeated, if required, to 
verify results at subsequent visits. Estimation of urea and electrolytes, calcium, albumin 
and phosphate, liver function tests, and serum angiotensin converting enzyme was 
carried out by standard laboratory methods.
The normal ranges of these biochemical parameters are shown in Table 3.3.
Patients were regarded as being abnormal in any or all of these parameters only if they 
showed two consecutive results outwith the normal range.
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Table 3.3 Normal ranges of biochemical parameters measured.
Laboratory Test Normal Range
Calcium 2.2-2.65 mmol/1 (corrected)
Albumin 36-50 g/1
Phosphate 0.80-1.45 mmol/1
Alkaline Phosphatase 70-260IU/1
Alanine-amino Transferase (ALT) 10-50 U/L
Aspartate-amino Transferase (AST) 10-35 U/l
Bilirubin 3-18 pmol/1
Gamma-glutamyl Transferase (yGT) 5-50 IU/1
Protein (total) 60-77 g/1
Serum Angiotensin Converting Enzyme (SACE) <80 IU/1
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3.6 Immunological Investigations
One hundred and forty-six patients had venous blood removed at the first or second 
clinic visit and sent to the Department of Immunopathology at the Western Infirmary, 
Glasgow, for measurement of immunological parameters. This was repeated, if required, 
to verify results at subsequent visits. Quantitative estimation of immunoglobulins (IgA, 
IgG and IgM) was carried out by standard laboratory methods. Qualitative estimation of 
IgE was carried out by Radio-allergo-sorbent Testing (RAST). Quantitative assessment 
of Complement C3 and C4 and Ci esterase inhibitor was carried out by routine 
immunological assay. Where abnormal results were found in any or all of these 
estimates of complement cascade activity, a functional (qualitative) assessment of Ci 
esterase inhibitor was carried out to exclude hereditary angioedema as a cause of 
orofacial swelling.
The normal ranges of these immunological parameters are shown in Table 3.4.
Patients were regarded as being abnormal in any or all of these parameters only if they 
showed two consecutive results outwith the normal range.
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Table 3.4 Normal ranges of immunological parameters measured.
Laboratory Test Normal Range
Immunoglobulin A (IgA) 0.8-5.0 g/1
Immunoglobulin G (IgG) 7.2-19 g/1
Immunoglobulin M (IgM) 0.5-2.0 g/1
Immunoglobulin E (RASTs) Grades 1-4
Complement C3 0.739-1.69 g/1
Complement C4 0.218-0.588 g/1
Ci-esterase Inhibitor Level 0.187-0.392 g/1
Ci-esterase Inhibitor Function 80-110%
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3.7 Oral mucosal biopsy
Oral mucosal biopsies were carried out by the staff of the Department of Oral Medicine, 
Glasgow Dental Hospital and School on 165 patients. Biopsies were carried out under 
local anaesthesia with the exception of three, which were carried out under general 
anaesthesia. Areas of obvious mucosal involvement were selected as appropriate biopsy 
sites -  chiefly lip and buccal mucosae. Biopsy material was placed in formalised saline 
and paraffin processed prior to staining with Haematoxylin and Eosin. For the purposes 
of histological assessment, biopsies were considered adequate if a full-thickness sample 
(down to, and including, muscle) was evident microscopically.
Interpretation of histological material was carried out by Professor Gordon MacDonald 
and Dr. James Rennie, Consultant Oral Pathologists, Glasgow Dental Hospital & School.
Biopsy reports were assessed for:
1 presence or absence of granulomata
2 presence or absence of caseation in the granulomatous inflammatory infiltrate
3 presence or absence of lymphoedema
These features were graded on a score of 1 (present) or 0 (absent).
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3.8 Patch-testing and contact urticaria testing
3.8.1 Introduction
Patch-testing is a recognised and accepted way of identifying allergens responsible for 
Type I and Type IV allergic reactions of the skin and aerodigestive tracts (Cronin, 1980; 
Mailing, 1993).
Two hundred and seventy-one patients were subjected to patch-testing for delayed 
hypersensitivity reactions (Type IV) and contact urticaria reactions (Type I). All were 
tested with the modified European Standard Series plus food additives, perfumes and 
flavourings, and chocolate. Most patients were also tested with other allergens e.g. 
dental materials, medicaments or other substances identified in the initial consultation as 
potentially playing a role in the patient’s disease process.
All allergens were mixed with petrolatum as the carrying vehicle, except for 
formaldehyde and one of the chocolate essence preparations which were carried in 
aqueous solution. Both the carrying vehicles have low antigenic, irritant and 
sensitisation potential and a petrolatum test site was included on all subjects as a control.
The Standard European Series was used in all subjects for both the delayed 
hypersensitivity and contact urticaria tests. This consists of 23 test allergens and a 
control (petrolatum, PMF). See Table 3.5 for the concentrations, carrying vehicle and 
manufacturers of the various allergens.
The food additives used in both the delayed hypersensitivity and contact urticaria tests 
were: Benzoic acid, salicylic acid, tartrazine, glutamic acid, butylated hydroxytoluene, 
propylene glycol, sorbic acid and sodium metabisulphite. See Table 3.6 for the 
concentrations, carrying vehicle and manufacturers of the various allergens.
The perfumes and flavourings used in both the delayed hypersensitivity and contact 
urticaria tests were: Cinnamyl alcohol, cinnamaldehyde, eugenol, amyl cinnamaldehyde, 
hydroxycitraonella, geraniol, isoeugenol, oak moss absolute, benzyl alcohol and musk 
ambrette. Sorbitan sesquiolate was included as an independent test substance as it was
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added as an emulsifier to the fragrance mix in the European Standard Series. See Table 
3.7 for the concentrations, carrying vehicle and manufacturers of the various allergens.
Essence of chocolate was tested with 2 different carrying media in both the delayed 
hypersensitivity and contact urticaria tests. See Table 3.5 for the concentrations, carrying 
vehicle and manufacturers of the chocolate test substances
All patients attending for patch-testing at the Contact Dermatitis Investigation Unit were 
interviewed and examined by a consultant dermatologist with many years experience in 
the field of contact dermatitis. They were asked detailed questions about symptoms and 
exposure to dietary and environmental allergens. In particular, dietary fads and 
occupational exposure were explored in depth. Patients were questioned about their 
general medical, allergy and dermatological history. Informed consent was obtained 
from each patient prior to testing.
3.8.2 Delayed hypersensitivity testing
Petrolatum (Paraffin Molle Flavum or PMF) was used as the carrying vehicle of choice 
where possible since this facilitates handling and avoids the “edge effect” which can 
complicate the reading of patch-tests carried out with solutions (Fyad et al, 1987). The 
test substances suspended in petrolatum were dispensed from plastic disposable syringes 
and placed in Finn chambers™ (Epitest, Hyryla, Finland) -  8mm diameter aluminium 
wells -  and arranged on Scanpor™ surgical tape (Scanpor, Norgesplaster, Oslo, 
Norway). Figure 3.13 demonstrates the testing system prior to application to a patient.
A 4mm length of the test substance was expressed into the aluminium well. Those 
carried in aqueous solution were dispensed from plastic dropper bottles and placed on a 
5mm disc of filter paper (Bio Diagnostics Ltd, London, UK) in the bottom of the well. 
One drop was used to wet the filter paper immediately prior to the placement of the tests. 
The tapes were applied to the upper back, avoiding the vertebral column, and a 
hypoallergenic skin marker was used to mark the skin immediately adjacent to each test 
site. Figure 3.14 demonstrates the testing system in place. The tapes remained in place 
for 48 hours and patients were instructed not to wash or otherwise disturb the test sites.
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Patients were instructed to remove the tapes and attached chambers one hour prior to 
their clinic attendance at 48 hours. Figure 3.15 shows a positive skin reaction at 48 
hours. The test sites were examined and the Swedish Multicenter Study System (SMCS) 
grading system applied (Bruze et al., 1995). This system uses scores as shown in Table 
3.8.
Table 3.8 The scoring system for patch-test results.
Score Appearance
0 Negative
1 (allergic) Erythema (with inflammatory infiltration around the test site)
2 (allergic) Erythema plus papules
3 (allergic) Erythema plus papules plus vesicles
4 Irritant
E Equivocal
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Figure 3.13 Patch-testing system prior to skin application.
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Figure 3.14 The patch-testing system in place.
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Figure 3.15 Patient showing a positive skin reaction at 48 hours.
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Irritant responses to cutaneous patch tests can be misleading and cause the examiner to 
treat these reactions as allergic in nature (Nater and Hoedemaker, 1976). Irritant 
reactions were identified if the appearance was as follows (Klas et al., 1996):
• a smooth glazed appearance or slight erythema; or
• sharp borders confined to the patch-test site; or
• cracked superficial surface; or
• minimal induration or no induration.
The test sites were re-examined and scored as above on Day 5, a total of 96 hours after 
initial exposure to the allergens.
3.8.3 Contact urticaria testing
Patch-testing was also used to elicit immediate (Type I) hypersensitivity reactions in 
patients. The same technique as above was used with a smaller number of test 
substances (food additives, perfumes and flavourings, and chocolate). On Day 1, the test 
substances were placed on the anterior surface of the patient’s forearms. On the skin 
next to each test site, a number was clearly marked with a skin marking pen to identify 
each test substance clearly. After 20 minutes, the Scanpor™ surgical tape and test 
chambers were removed and the test sites examined. A score of 0 (no reaction) or 1 
(reaction clearly visible or palpable) was given for each test substance. The patient was 
instructed to observe the test sites at hourly intervals over the subsequent 6 hours and 
record any redness or itchiness associated with any of the sites. At the 48 hour clinic 
visit, the patient’s written record of the test sites was examined and a final score 
allocated as above i.e. 0 (no reaction) or 1 (reaction clearly visible or palpable).
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3.8.4 Control Group
Patch-testing and contact urticaria testing of the control group was carried out by Dr. 
Shiona Rees. Her contribution to this part of the study is gratefully acknowledged. Thus 
to standardise methodology, all patch-testing and contact urticaria testing for the control 
population was carried out by the same clinician throughout.
The demographic details and selection criteria were described in Chapter 2.
A total of 48 different allergens (46 suspended in yellow soft paraffin; 2 suspended in an 
aqueous solution) were placed on the backs of volunteers on Day 1 of the study. The 
patches were reviewed at 48 and 72 hours.
In order to identify Type I hypersensitivity reactions, test substances (food additives, 
chocolate, perfumes and flavourings) were placed on the volunteers’ forearms on Day 1 
of the study. On the skin adjacent to each forearm site, a number was clearly marked 
with a skin marker pen to identify each individual test. The test substances and carriers 
were removed after 20 minutes and the test sites examined. The volunteers were 
instructed to observe the test sites at hourly intervals over the following 6 hours and to 
record any changes in sensation (e.g. pruritus), colour or texture associated with any of 
the sites. At the 48-hour visit, the volunteers’ records of the test sites were examined 
and a further score allocated.
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Table 3.5 Concentrations and carrying vehicles of the dietary allergens used in patch- 
testing
ALLERGEN CONCENTRATION
(%)
VEHICLE MANUFACTURER
Food Additives
Benzoic Acid 5 PMF Crawford
Butylated Hydroxytoluene 2 PMF Trolab
Butylated Hydroxyanisole 2 PMF Trolab
Glutamic Acid 2 PMF GRI
Propylene Glycol 5 PMF Crawford
Salicylic Acid 1 PMF GRI
Sodium Metabisulphite 1 PMF Trolab
Sorbic Acid 2 PMF Trolab
Tartrazine 0.1 PMF GRI
Perfumes and Flavourings
Amyl Cinnamaldehyde 1 PMF Trolab
Benzyl Alcohol 1 PMF Crawford
Cinnamonaldehyde 1 PMF Trolab
Cinnamyl Alcohol 1 PMF Trolab
Eugenol 1 PMF Trolab
Geraniol 1 PMF Trolab
Hydroxy Citraonella 1 PMF Trolab
Isoeugenol 1 PMF Trolab
Musk Ambrette 5 PMF Trolab
Oak Moss Absolute 1 PMF Trolab
Sorbital Sesquiolate 20 PMF Trolab
Chocolate
Essence of Chocolate 5 Aqueous GRI
Essence of Chocolate 5 PMF GRI
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PMF = Paraffin Molle Flavum (Yellow Soft Paraffin)
Crawford Pharmaceuticals 
71a High Street 
Stony Stratford 
Milton Keynes 
MK11 1BA
GRI Glasgow Royal Infirmary 
Department of Pharmacy 
84 Castle Street 
Glasgow 
G4 0SF
Trolab Patch Test Allergens 
Hermal Diagnostics Department 
D-21462 Reinbek 
Germany
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Table 3.6 Concentrations and carrying vehicles of the environmental allergens used
ALLERGEN CONCENTRATION (%) VEHICLE MANUFACTURER
Balsam of Peru 25 PMF Trolab
Caine Mix 12 PMF Trolab
Carba Mix 3 PMF Trolab
Cobalt Chloride 1 PMF Trolab
Colophony 20 PMF Trolab
Epoxy Resin 1 PMF Trolab
Ethylene Diamine 1 PMF Trolab
Formaldehyde 1 Aqueous Trolab
Fragrance Mix 8 PMF Trolab
Mercaptomix 2 PMF Trolab
Neomycin 20 PMF Trolab
Nickel Sulphate 5 PMF Trolab
Parabens Mix 16 PMF Trolab
Paraphenylene 
Diamine (PPD)
0.5 PMF Trolab
Paratertiarybutyl 
Phenol (PTBP) 
Formaldehyde Resin
1 PMF Trolab
Potassium Dichromate 0.5 PMF Trolab
PPD Mix 0.6 PMF Trolab
Primin 0.01 PMF Trolab
Quatemium 15 1 PMF Trolab
Quinoline 6 PMF Trolab
Thiomersal 0.1 PMF Trolab
Thiuram Mix 1 PMF Trolab
Wool Alcohols 30 PMF Trolab
Control PMF 100 - Trolab
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Table 3.7 Concentrations and carrying vehicles of the mixed preparations used
(a) Mercapto-mix supplied by Trolab ready mixed.
Allergen Concentration (%) Vehicle Manufacturer
Dibenzothiazyl
Disulphide
1 PMF Trolab
Morpholinyl-
mercaptobenzo-
thiazole
0.5 PMF Trolab
N-Cyclohexyl-
benzothiazyl
Sulphenamide
1 PMF Trolab
(b) Paraben-mix supplied by Trolab ready mixed.
Allergen Concentration (%) Vehicle Manufacturer
Butyl
Parahydroxy­
benzoate
3 PMF Trolab
Ethyl Parahydroxy­
benzoate
3 PMF Trolab
Methyl
Parahydroxy­
benzoate
3 PMF Trolab
Propyl
Parahydroxy­
benzoate
3 PMF Trolab
(c) Thiuram-mix supplied by Trolab ready mixed.
Allergen Concentration (%) Vehicle Manufacturer
Dipentamethylene- 
thiuram Disulphide
0.25 PMF Trolab
T etraethylthiuram 
Disulphide
0.25 PMF Trolab
T etramethylthiuram 
Disulphide
0.25 PMF Trolab
T etramethylthiuram 
Monosulphide
0.25 PMF Trolab
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(d) PPD-mix prepared by GRI pharmacy.
Allergen Concentration (%) Vehicle Manufacturer
Cyclohexylphenyl PPD 1 PMF Crawford
Diphenyl PPD 0.25 PMF Trolab
Isopropylphenyl PPD 1 PMF Trolab
(e) Fragrance-mix supplied by Trolab ready mixed.
Allergen Concentration (%) Vehicle Manufacturer
Amylcinnamaldehyde 1 PMF Trolab
Cinnamonaldehyde 1 PMF Trolab
Cinnamyl Alcohol 1 PMF Trolab
Eugenol 1 PMF Trolab
Geraniol 1 PMF Trolab
Hydroxycitraonella 1 PMF Trolab
Isoeugenol 1 PMF Trolab
Oak Moss Absolute 1 PMF Trolab
(f) Carba-mix prepared by GRI pharmacy.
Allergen Concentration (%) Vehicle Manufacturer
Dibutyldithiocarbamol 1 PMF Trolab
Diethyldithiocarbamol 1 PMF Trolab
Diphenylguanidine 1 PMF Trolab
(g) Caine-mix prepared by GRI pharmacy.
Allergen Concentration (%) Vehicle Manufacturer
Benzocaine 5 PMF Trolab
Cinchocaine 5 PMF Trolab
Lignocaine 15 PMF Trolab
Tetracaine 1 PMF Trolab
158
3.9 HLA typing
The discovery of associations between certain diseases and the major histocompatibility 
complex (MHC) represents one of the most important recent advances in medicine (Lund 
and Festenstein, 1991). The human MHC is known as the HLA (human leucocyte 
antigen) locus and is located on chromosome 6, and spans 3000 kbp. There are at least 
four blocks of genes within the complex:
• MHC class I genes, which are expressed on all nucleated cells;
• MHC class II genes, expressed on cells which may present antigens to CD4+ T- 
lymphocytes;
• MHC class III genes, which include the complement components of C4, C2 and 
Factor B, and the isoenzyme of 21-hydroxylase;
• MHC class IV genes, which encode molecules with a similar structure to class I, but 
with restricted distribution. They are thought to act as differentiation antigens during 
embryogenesis.
There are three loci, or genes, encoding class I molecules in the HLA region, termed 
HLA-A, HLA-B and HLA-C. Class I antigens are all defined by serological reactions 
and typing is performed using standard serological (antigen-antibody) techniques. The 
antibodies may bind uniquely to a particular molecule from a single locus, or they may 
bind to a group of molecules which share some common structures. Many specificities 
have been found to consist of different subtypes - the original haplotype then said to be 
split. Subtypes are identified by isoelectric focusing. International guidelines have been 
laid down for the nomenclature of genes and alleles of class I and II based on nucleotide 
or amino acid sequencing (Bodmer et al., 1989).
There are at least three class II regions: HLA-DP, HLA-DQ and HLA-DR. The term DR 
was originally used to describe the HLA tissue types detected by antibody testing which 
approximate to those lymphocyte activating determinants (LADs) assigned by their 
ability to stimulate T-cell proliferation in mixed lymphocyte reactions (MLR). The 
LADs were originally termed alleles of the HLA-D locus, and the HLA-DR specificities 
were related to the particular HLA-D allele. Thus antibody which identified HLA-DR4
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recognised the HLA-D4 allele identified in MLR. The LADs of the HLA-DR subregion 
belong to an independently segregated series known as the HLA-D types. Since the D 
determinants activate a large subpopulation of helper T-cells, they are critical in 
controlling the basis of immunological disease.
The MHC region on chromosome 6 is referred to as the haplotype and is inherited in a 
Mendelian manner. The likelihood of a recombination event occurring between the 
parental chromosomes within the MHC region is dependent on the size of the MHC 
region. Thus with the standard 3000 kbp size of the MHC region, the likelihood is 
estimated at 1%.
There is a substantial difference in the frequency of the main alleles at each of the HLA 
loci, and in some cases considerable variation between different populations. HLA-A2 is 
present at relatively high frequency (27%) in all populations, however HLA-A1 and 
HLA-A3 are present in most ethnic groups but absent in the Japanese. In African blacks, 
A ll is absent, whereas HLA-Aw43 and -Aw42 are present and seem to be specific for 
that one ethnic population (Bodmer et al, 1989).
On the basis of the importance of HLA type in immunologically-mediated disease, 16 
Caucasian patients with OFG (and no evidence of other systemic granulomatous diseases) 
underwent HLA typing. There were 8 male patients (mean age 30 years; age range 9-55 
years) and 8 female patients (mean age 32 years; age range 17-58 years).
Twenty millilitres of venous blood were withdrawn into potassium EDTA vials and 
transported to the Tissue Typing (Clinical Immunology) Laboratory at Glasgow Royal 
Infirmary. HLA phenotypes were identified on the basis of antigen-antibody reactions 
and, where appropriate, by isoelectric focusing.
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3.10 Lymphocyte subpopulation studies
The expert technical assistance of Mr. Matthew Small, Chief Technician, Department of 
Oral Medicine, Glasgow Dental Hospital & School, in this part of the study is gratefully 
acknowledged
Eighteen patients (9 male, 9 female; mean age 22 years, range 12-30 years) were selected 
for this part of the study. All had biopsy-proven OFG of at least 1 year’s duration with 
no evidence of other systemic granulomatous disorders. None were taking topical or 
systemic corticosteroid preparations, immunosuppressant drugs or anti-histamines.
Thirty-four age control subjects (20 male, 14 female; mean age 22 years, range 16-37 
years) were selected from staff in the Department of Oral Medicine and Pathology, 
Glasgow Dental Hospital & School. All haematological and biochemical indices were 
normal.
Ten millilitres of venous blood were obtained in a lithium-heparin blood vial. No 
attempt was made to standardise the time of day of venepuncture. Personal or parental 
consent was obtained in each case. The 10ml blood sample was added to a universal 
container with 15ml of tissue culture medium. The cells were separated by standard 
density gradient techniques (Boyum, 1968). A 1:20 dilution of cells in phosphate- 
buffered saline (PBS) was added to a haemocytometer slide and dilution adjustments 
made to give a count of 5 x 106 cells/ml.
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Lucham tubes (Neil et al., 1994) were then prepared in duplicate with monoclonal 
antibody preparations as follows:
o k t 3 (Ortho-Mune) 5 pi
o k t 4 (Oxoia) 5 pi
OKT8 (SAPU) 20pl
HLA-DR (SAPU) lOpl
PBS control lOpl
To each of these, 200pl of the cell suspension were added. The contents of the tubes 
were mixed gently and incubated on ice for 60 minutes. The cells were then washed 
twice with PBS, centrifuging at 1,400 rpm for 10 minutes. The cells were further 
incubated on ice for 60 minutes with 100pi (1:10 dilutes) of FITC-conjugated rabbit anti­
mouse immunoglobulin.
Further washing occurred twice with PBS, as above, centrifuging again at 1,400 rpm for 
10 minutes. Finally, the washed cells were stored in 150pl 1% formalin at 4°C and 
quantified in the fluorescent activated cell sorter (Neil et al, 1994).
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3.11 Technetium-99m-HMPAO leucocyte labelling
Leucocyte labelling with 99Tc-HMPAO (hexamethylpropylemeamine oxime) is an 
established way of investigating patients who may have inflammatory bowel disease 
(Charron, 1997).
Ten consecutive paediatric patients (9 male, 1 female; mean age 166 months, range 109- 
204 months) with OFG underwent 99Tc scanning. Fifteen paediatric patients (8 male, 7 
female; mean age 153 months, range 93-202 months) with objective evidence of 
inflammatory bowel disease (radiological +/- histological) were used as positive 
controls.
The assistance in this part of the study of the consultant and technical staff of the 
Department of Nuclear Medicine, Glasgow Royal Infirmary University NHS Trust, is 
gratefully acknowledged. The sequential steps in this part of the study are shown in 
Figures 3.16-3.19.
To a tissue culture flask were added 10ml of Plasmasteril or Hespan starch solution and 
2ml of heparin (5,000 units per 5ml). The solutions were mixed gently and used to coat 
the internal surface of the flask.
A 19G butterfly needle was inserted to the patient’s hand or arm vein and, with the open 
end of the butterfly tube in the flask, blood was dripped into the mixture until the 50ml 
mark was reached. The blood and anti-coagulant/starch solution were gently mixed 
throughout the procedure.
The flask was placed in the laminar flow cabinet and the cells allowed to settle for 30 
minutes at room temperature. The resultant leucocyte-rich plasma (LRP) was removed 
with a sterile pipette and placed in a sterile container, marked with the patient’s name 
and study number, for centrifuging. As much as possible of the LRP was removed 
without disturbing the red cell layer, and this was centrifuged for 10 minutes at lOOOrpm.
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800 MBq of Technetium pertechnetate (1ml of 99mTc) were added to a commercially 
available vial of hexamethylpropylemeamine oxime (HMPAO) and the resultant mixture 
allowed to stand for a maximum period of 30 minutes while the LRP was centrifuging.
The supernatant platelet-rich plasma (PRP) was decanted into a sterile universal 
container and kept for preparation of cell-free plasma (CFP). The resultant white cell 
pellet was resuspended in 0.5ml of sterile normal saline.
The 99mTc-HMPAO mixture was added to the white cell suspension, mixed gently and 
incubated at room temperature for 10 minutes. The flask was placed within a lead shield 
in the laminar flow cabinet.
During this 10 minute period, the PRP was centrifuged for 5 minutes at 3,000rpm. The 
resultant supernatant was CFP. After 10 minutes incubation, 3ml of CFP was added to 
the labelled white cell suspension, mixed gently and centrifuged at room temperature for 
10 minutes at 700rpm. The resultant supernatant was decanted and kept to assess 
activity.
The white cell pellet was further resuspended in 3ml of CFP as before. The activity of 
the 99mTc was measured in the supernatant and WBC suspension by Geiger counter and 
the percentage labelling efficiency calculated as follows:
WBC activity X 100 
WBC activity + Supernatant activity
Labelling efficiency <40% was deemed to be unacceptable and the procedure repeated 
on a subsequent occasion.
The labelled WBC suspension was then drawn into a 5ml syringe and injected 
intravenously.
Scanning of the abdomen took place at 1 hour, 2 hours and 4 hours post-injection using a 
gamma camera. Interpretation of the scans was carried out blindly (without reference to 
the patient’s clinical details) by Dr. Brian Neilly, Consultant Physician, Department of 
Nuclear Medicine, Glasgow Royal Infirmary NHS Trust.
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The resultant images were graded on a scale 0 — 4 (Li et al., 1992) as follows:
Grade 0 No uptake
Grade 1 Uptake less than bone marrow
Grade 2 Uptake equal to bone marrow
Grade 3 Uptake greater than bone marrow
Grade 4 Uptake equal to, or greater than, spleen
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Figure 3.16 Patient having blood sample removed for leucocyte labelling.
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Figure 3.17 Patient having labelled leucocytes reintroduced.
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Figure 3.18 Gamma camera in place.
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Figure 3.19 Patient relaxing after imaging at four hours.
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3.12 Endoscopy and barium studies
Endoscopy and barium studies were considered, at the planning stage, an essential and 
integral part of the study in order to identify which patients had gastrointestinal Crohn’s 
disease and which did not.
However, it became apparent early on that the Ethical Committees of participating 
hospitals were not prepared to allow patients (whether paediatric or adult) to be 
subjected to endoscopy or barium studies as part of a routine investigative protocol. This 
view was endorsed by the participating consultant physicians in paediatric and adult 
gastroenterology.
This part of the study is therefore flawed by the fact that only those patients considered 
by consultant gastroenterologists to have clear indications for barium studies and/or 
endoscopy were subjected to these tests. The “clear indications” were symptoms and 
signs of gastrointestinal disorders and/or abnormalities in haematological and 
biochemical parameters.
It is accepted that this is unsatisfactory in terms of seeking objective scientific evidence 
but, on this occasion, compromise was unavoidable and governed by the decision of the 
relevant Ethical Committees.
Where clinical and/or laboratory parameters indicated the requirement for barium studies 
of the upper or lower gastrointestinal tract, these were carried out as “barium meal and 
follow-through” and “barium enema” studies respectively. These were conducted 
according to accepted national protocols (Bozdech and Farmer, 1990; Winship et al., 
1979) and the radiographic films were reported by consultant radiologists.
Where clinical and/or laboratory parameters indicated the requirement for endoscopy of 
the upper or lower gastrointestinal tract, this was carried out as simple endoscopy and 
colonoscopy/sigmoidoscopy respectively. Such procedures were normally performed 
subsequent to barium studies when an abnormality had been evident on radiographic 
films.
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These procedures were conducted according to accepted national protocols (Bozdech and 
Farmer, 1990; Winship et a l, 1979), under general anaesthesia in the paediatric 
population and under sedation and/or topical anaesthesia in the adult population.
On the basis of clinical findings, 57 patients (excluding the 20 patients who had entered 
the study with a pre-existing diagnosis of gastrointestinal Crohn’s disease) underwent 
imaging of the gastrointestinal tract.
Of these 57 patients, 37 underwent barium studies (“meal and follow-through” and 
enema) alone; 18 patients underwent barium studies and endoscopic procedures; and two 
patients underwent endoscopic procedures alone.
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CHAPTER 4
CLINICAL METHODS II : 
TREATMENT AND MANAGEMENT
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4.1 Exclusion of allergens
4.1.1 Background
Preventive therapy in the management of the patient group with OFG centred around the 
identification of dietary and environmental allergens by skin reactivity testing (patch- 
testing and contact urticaria testing).
Two hundred and seventy-one patients underwent patch-testing and contact urticaria 
testing to identify putative dietary and environmental allergens according to the methods 
described previously.
When dietary and/or environmental allergens were identified in this group, exclusion 
advice was offered to the patient (and accompanying adult, in the case of children). Such 
dietary and environmental exclusion advice was issued verbally and reinforced with 
written advice sheets. Dietary exclusion advice was issued by the Senior Dietician in the 
Contact Dermatitis Investigation Unit, Glasgow Royal Infirmary, Mrs. Karen Milligan. 
The dietary exclusion advice sheets are published in Appendix II, courtesy of Mrs. Karen 
Milligan and with her permission.
Environmental exclusion advice was issued by the nursing staff in the Contact 
Dermatitis Investigation Unit, Glasgow Royal Infirmary, Sister Jean Reid and her team 
of three staff nurses. Dietary and environmental exclusion advice was reinforced and 
expanded upon, where required, at each subsequent review appointment by the medical, 
nursing and dietetics staff.
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4.1.2 Compliance scores
Compliance with dietary and environmental exclusion advice was determined at the end 
point of individual patient follow-up using the subjective self-rating score shown in 
Table 4.1.
Table 4.1 Score of patient compliance with dietary and/or environmental exclusion 
advice.
COMPLIANCE SCORE DESCRIPTION
0 Patch-test not done or negative
1 Poor compliance
2 Compliance (incomplete)
3 Good compliance
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4.2 Follow-up time
All patients were excluded from using symptomatic therapies (such as topical and 
systemic corticosteroid preparations) until patch-testing had been performed and, where 
appropriate, until the effect of allergen exclusion had been determined. This period 
varied considerably from patient to patient.
Patients were followed-up over varying periods of time (mean 3.8 years; minimum 0.5 
years, maximum 23 years) with periodic recall assessment visits to the joint Dental- 
Dermatology Clinic at Glasgow Royal Infirmary and/or the Department of Oral 
Medicine, Glasgow Dental Hospital & School NHS Trust.
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4.3 Assessment of response
4.3.1 Exclusion of allergens
The effect of dietary and/or environmental exclusion advice was determined by direct 
comparison, on enrolment into the study and at the end of the follow-up period, of:
• The patient’s subjective symptom score
• The investigator’s objective sign score.
These scoring systems are described fully in Chapter 3.
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CHAPTER 5
LABORATORY METHODS
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5.1 Detection of anti-gliadin antibodies
5.1.1 Background
The validity of using raised serum IgG to alpha-gliadin as a serological screening test for 
Coeliac disease is well documented (O'Farrelly et al, 1983; Watson et al, 1986; Kelly et 
al, 1987). Similarly well documented is the lack of IgG response to alpha-gliadin in 
patients with inflammatory bowel disease (Paganelli et al, 1985).
There is some evidence to suggest that alpha-gliadin antibody levels may be elevated in 
patients with chronic lip enlargement in an Irish population (12 out of 20 cases; 
McCartan, BE, Personal Communication, 1995). The diagnosis underlying the lip 
enlargement in this population was unspecified.
5.1.2 Methodology
Pooled sera from 4 patients (2 female, 2 male; mean age 24.5 years, range 14-35 years) 
with OFG (and no evidence of other systemic granulomatous or gastrointestinal 
disorders) were used for this part of the study. Pooled sera from 7 patients (4 female, 3 
male; mean age 28 years, range 14-43 years) with coeliac disease (proven by jejunal 
biopsy), and 11 subjects (8 female, 3 male; mean age 25 years, range 22-42 years) with 
no gastrointestinal or oral mucosal disorders acted as controls for this study. The coeliac 
disease group was attending the gastroenterology clinic of Dr. Robin I. Russell, 
Department of Medicine, Glasgow Royal Infirmary; the disease-free group was made up 
of staff from the Department of Oral Medicine, Glasgow Dental Hospital & School.
The laboratory work was carried out in the Oral Biochemistry Laboratory, Glasgow 
Dental Hospital & School. I am indebted to the laboratory training given by Mr. Daniel 
Sweeney, Senior Technician.
Immunoblot techniques were employed to identify antibodies to crude gliadin 
components in each of the pooled sera according to the following technique. Crude 
gliadin (from wheat gluten), and antiserum to gliadin conjugated to peroxidase were
178
obtained from Sigma (Fancy Road, Poole, Dorset, UK). Sheep anti-human IgG 
conjugated to horseradish peroxidase, sheep anti-human IgG, donkey anti-sheep/goat 
IgG, and sheep peroxidase anti-peroxidase complex (PAP) were obtained from The 
Scottish Antibody Production Unit (Law Hospital, Carluke, UK).
SDS (sodium dodecyl sulphate) polyacrylamide gel electrophoresis was carried out in 
12.5% gels according to the method of Laemmli (Laemmli, 1970). Crude gliadin was 
dissolved in sample buffer (2% w/v) SDS, 25ml of dithiothreitol (DTT) and boiled for 2 
minutes prior to loading onto the gels. Molecular weight markers (14,400-94,000) were 
used and electrophoresis carried out at 60v for 18 hours at 10°C. Tracks from the gel 
were stained with 0.1% Coomassie Blue R250 (Sigma, Fancy Road, Poole, Dorset) in 
50% (v/v) ethanol and 10% (v/v) acetic acid for at least 3 hours and destained in 10% 
acetic acid.
The SDS gels were blotted onto nitrocellulose (NC) membranes (Hybond-C, Amersham 
International, Aylesbury, Bucks, UK) on an LKB Multiphor II Nova Blot according to 
the manufacturer’s instructions. After blotting, the NC membranes were blocked for 1 
hour at room temperature in 5% skimmed milk powder (Marvel, Premier Brands UK 
Ltd., Birmingham, UK) in phosphate-buffered saline-Tween (PBST; NaCl 8.0g/l, KC1 
0.2g/l, Na2HPC>4 0.2g/l, Tween 20 5g/l, pH 7.4), cut into triplicate tracks which were 
placed in test sera diluted 1:5 with the same solution. After standing overnight at 4°C, 
the membranes were washed in three changes of PBST and placed in sheep anti-human 
IgG diluted 1:200 with PBST. The use of anti-human IgG peroxidase conjugate 
followed by addition of substrate produced only faint immunostaining and so further 
amplification was carried out to increase the sensitivity. After standing for 2 hours at 
room temperature, the membranes were washed as before and placed in a solution of 
1:200 donkey anti-sheep/goat IgG for 2 hours. After washing, the membranes were 
transferred to 1:200 solution of sheep PAP for 2 hours and further washed.
Sequential addition of donkey anti-sheep/goat and sheep PAP was repeated twice more. 
Finally, the washed membranes were placed in peroxidase substrate solution of hydrogen 
peroxide (0.3% w/v) and 4-chloro-l-naphthol (0.015% w/v) in phosphate/citrate buffer 
(pH 6.0, prepared using 0.2M Na2HPC>4 and 0.1M citric acid) until bands developed. 
The reaction was stopped by washing the membrane in purified water.
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5.2 Molecular biological studies -  the polymerase chain
reaction
5.2.1 Background
The polymerase chain reaction (PCR) is an in vitro technique which allows the 
amplification of a specific deoxyribonucleic acid (DNA) region that lies between two 
regions of known DNA sequence (“primers”). This allows for sensitive and specific 
detection of particular genetic sequences against a large background of irrelevant DNA 
(Newton and Graham, 1994). Nested PCR primers are ones that are internal to the first 
primer pair. The larger fragment produced by the first round of PCR is used as a 
template for the second round of PCR. The sensitivity and specificity of both DNA and 
RNA amplification can be dramatically increased by using the nested method, since it 
almost always eliminates any spurious non-specific amplification products (Newton and 
Graham, 1994).
“Hot start” is a modification of PCR whereby there is an initial separation of one or more 
important components of the reaction by a wax barrier. Thus, when the wax melts and 
all the components mix together, the template is already denatured and the reaction well 
underway. This causes a more efficient PCR reaction (Newton and Graham, 1994).
Polymerase chain reaction (PCR) is a highly sensitive and specific technique which has 
been successfully used to detect M. paratuberculosis DNA in Crohn’s disease tissue 
(Sanderson et al, 1992; Dell'Isola et al, 1994; Lisby et al, 1994; Fidler et al, 1994). In 
this part of the study, PCR using primers directed against the multicopy IS900 DNA 
insertion element of the M. paratuberculosis genome (Green et al, 1989) was carried out 
on DNA extracted from paraffin-embedded tissue sections of oral mucosal biopsies from 
30 patients (24 male, 6 female; mean age 30.8 years, range 9-66 years) with OFG (and no 
evidence of other granulomatous or gastrointestinal disorders) and oral mucosal biopsies 
from 7 patients (6 male, 1 female; mean age 21.2 years, range 10-48 years) with biopsy- 
proven gastrointestinal Crohn’s disease.
Twelve patients (6 male, 6 female; mean age 36 years, range 22-63 years) with a history 
of recurrent aphthous stomatitis (minor variant) attending the Department of Oral 
Medicine, Glasgow Dental Hospital & School NHS Trust, for investigation and
management of their oral disease acted as controls for this study. An aphthous ulcer was 
excised under local anaesthesia from each patient, following the signing of informed 
consent documentation. These tissue specimens were paraffin processed to ensure 
uniformity of tissue handling.
The expertise of Dr. Marcello Riggio, Lecturer in Molecular Biology, Glasgow Dental 
Hospital & School, is gratefully acknowledged. This work was carried out in his 
laboratory.
5.2.2 Tissue processing and DNA extraction
Samples were paraffin-embedded sections of oral tissue, which had been examined 
histopathologically and non-caseating granulomata identified. In each case the paraffin 
block showing the best demonstration of granulomata was selected for study. In all cases 
duplicate samples were obtained from the paraffin blocks, cut on two separate occasions.
For each sample to be analysed by PCR, five 10 pm sections were cut. The microtome 
knife blade was thoroughly cleaned between cutting of each different sample with xylene 
to prevent sample-to-sample contamination. The paraffin-embedded sections were 
placed in 1.5 ml centrifuge tubes and DNA was extracted using a method developed 
specifically for obtaining mycobacterial DNA from paraffin-embedded tissue sections as 
previously described (Cook et a l, 1994). Tissue sections were deparaffinised in xylene, 
resuspended in 200 pi proteinase K (200 pg/ml)/50mM Tris-HCl pH 8.3 and incubated 
overnight at 37°C. Samples were frozen in dry ice for 1 minute, boiled for 8 minutes, 
placed on ice for 5 minutes and centrifuged at 700rpm for 2 minutes to remove insoluble 
debris. 40 pi of the supernatant was used for each PCR reaction.
5.2.3 PCR Primers
The primers used for PCR (P90+ and P91+) targeted the IS900 DNA insertion element 
of M. paratuberculosis as previously described (Millar et al, 1995), and were similar to 
primers P90 and P91 used in another study (Sanderson et al, 1992) except that each 
primer contained an additional 6 or 7 bases at its 5’ end. The primer sequences were 5'- 
GAAGGGTGTTCGGGGCCGTCGCTTAGG-3' (P90+; IS900 nucleotides 15-41) and 
5'-GGCGTTGAGGTCGATCGCCCACGTGAC-3' (P91+; IS900 nucleotides 427-401).
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The expected size of the amplification product using primer pair P90+/P91+ is 413 base 
pairs (bp). PCR was also used to generate an internal IS900 probe for use in subsequent 
Southern blot hybridisation. The sequences of the primers used for probe generation 
were 5’-CCAGGGACGTCGGGTATGGC-3’ (P25; IS900 nucleotides 53-72) and 5’- 
GGTCGGCCTTACCGGCGTCC-3 ’ (P26; IS900 nucleotides 281-262), which give an 
expected amplification product of 229 bp.
5.2.4 Nested PCR
PCR was carried out in a total reaction volume of 100 pi, with conditions essentially as 
previously described (Sanderson et al, 1992; Millar et al., 1995). Each PCR consisted 
of 10 pi of extracted DNA and 90 pi of PCR reaction mixture comprising 1 x PCR 
buffer (10 mM Tris-HCl, pH 8.8, 50 mM KC1, 1.5 mM MgCl2, l%Triton X-100), 2.0 U 
Dynazyme I DNA polymerase (Flowgen Instruments Ltd., Lichfield, UK), 0.2 mM of 
each of the four deoxynucleotide triphosphates and primers P90+ and P91+ each at 6 
ng/pl. The primers were separated from the other components of the reaction mixture by 
a layer of wax (DynaWax; Flowgen Instruments Ltd.). This ‘hot start’ PCR method 
improves the specificity and yield of reaction products by preventing the reaction from 
starting until the wax has melted following the commencement of thermal cycling. PCR 
was carried out in an OmniGene thermal cycler (Hybaid Ltd., Teddington, UK). The 
cycling conditions comprised an initial denaturation step at 94°C for 5 minutes, followed 
by 40 cycles of denaturation at 94°C for 5 minutes, primer annealing at 58°C for 2 
minutes and extension at 72°C for 3 minutes, and a final extension step at 72°C for 10 
minutes. A second round of PCR was then carried out using identical conditions, except 
that 5 pi of the first round product were used as a template (nested PCR).
For generation of the internal 229 bp probe, PCR was set up as described above except 
that a MgCl2 concentration of 1.0 mM and the primer pair P25/P26 were used in a single 
round of PCR. Target DNA was 10 ng of plasmid pPN14 which contains the cloned M  
paratuberculosis IS900 DNA insertion element. After an initial denaturation step at 94°C 
for 5 minutes, 30 cycles of denaturation at 94°C for 1 minute, annealing of primers at 
50°C for 1 minute and extension at 72°C for 2 minutes was carried out, followed by a 
final extension step at 72°C for 10 minutes. The 229 bp PCR product was purified using 
the Wizard PCR Preps Purification System (Promega Corporation, Southampton, UK).
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5.2.5 Sensitivity of PCR assay
The sensitivity of the PCR assay was determined by spiking of DNA extracted from 
paraffin-embedded tissue sections of OFG, which were PCR-negative for M. 
paratuberculosis DNA, with serial ten-fold dilutions of M. paratuberculosis DNA in the 
range 100 pg to 1 fg. PCR was carried out as described above.
5.2.6 PCR quality control
Several anti-contamination procedures were employed when carrying out PCR. Setting 
up of PCR reactions, thermal cycling and post-PCR analysis of reaction products was 
carried out in separate rooms. Pipette filter tips were used at all stages, except when 
adding template DNA in which case positive displacement tips were used. Positive and 
negative PCR controls were included with each batch of samples being analysed; the 
positive control used was 1 pg of M. paratuberculosis DNA instead of sample, whereas 
the negative control contained sterile molecular biology grade water instead of sample.
In order to serve as an internal control for the successful isolation of PCR-amplifiable 
DNA from tissue sections, amplification of the B-haemoglobin gene was carried out for 
each sample analysed using nested primer PCR as previously described (Frank et al., 
1992).
5.2.7 Agarose Gel Electrophoresis
PCR reaction products were fractionated by electrophoresis of 20 pi aliquots on 2% 
agarose gels containing ethidium bromide (0.5 pg/ml) and visualised under ultraviolet 
(UV) illumination. A 100 bp DNA ladder (Pharmacia Biotech, Milton Keynes, UK) was 
used as a size marker.
5.2.8 Southern Blot Hybridisation
Amplified products were electrophoresed on 2% agarose gels as described above and 
transferred to positively charged nylon membranes (Boehringer Mannheim, Lewes, UK)
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by Southern blotting. Briefly, gels were prepared for blotting by soaking in denaturation 
solution (0.5 M NaOH/1.5 M NaCl) for 2 x 20 minutes followed by soaking in 
neutralisation solution (0.5 M Tris-HCl, pH 7.4/3.0 M NaCl) for 2 x 20 minutes. DNA 
was transferred to membranes using a capillary transfer blotting unit (Anachem Ltd., 
Luton, UK) with 20 x SSC (3.0 M NaCl, 0.3 M sodium citrate, pH 7.0) as transfer 
buffer. Following transfer, membranes were rinsed in 2 x SSC and DNA immobilised by 
exposure to an optimal dose of UV energy in a crosslinker (UVC-508, Anachem Ltd.).
Membranes were hybridised overnight at 68°C with the 229 bp internal IS900 PCR 
product labelled with digoxigenin (DNA Labelling and Detection Kit; Boehringer 
Mannheim) at 25 ng/ml in standard hybridisation buffer (5 x SSC, 1% blocking reagent, 
0.1% N-laurylsarcosine, 0.02% sodium dodecyl sulphate [SDS]). Membranes were 
washed at room temperature in 2 x SSC/0.1% SDS for 2 x 5 minutes, and at 68°C in 0.1 
x SSC/0.1 % SDS for 2 x 20 minutes. Immunological detection was carried out 
according to the manufacturer’s instructions using an anti-digoxigenin antibody 
conjugated to alkaline phosphatase and colorimetric detection with 4-nitro blue 
tetrazolium chloride/5-bromo-4-chloro-3-indolyl-phosphate as a colour substrate.
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CHAPTER 6
STATISTICAL ANALYSIS
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6.1 Statistical analysis
6.1.1 Software data handling
Statistical analysis was carried out using the Minitab® for Windows® PC package for 
data handling and statistical analysis.
6.1.2 Data analysis
Categorical data were analysed using the Chi-square test. Continuous variables showing 
normal distribution were analysed using the Analysis of Variance (ANOVA) test. 
Continuous variables not showing normal distribution were analysed using the Kruskal- 
Wallis test. One set of results, the lymphocyte sub-population study, was analysed using 
the student t-test.
6.1.3 Independent statistical analysis
Due to the large quantity of data collected, independent data analysis was deemed to be 
appropriate. This was carried out by staff at the Robertson Centre for Biostatistics, 
University of Glasgow. A logistic regression analysis was used to model the data as the 
outcome variable was essentially binary (namely, the patient had gastrointestinal Crohn’s 
disease or not). The prime objective of the analysis was to obtain the best fitting and 
most parsimonious, yet biologically reasonable model to describe the relationship 
between outcome and the set of independent variables. The presence of gastrointestinal 
Crohn’s disease versus not having Crohn’s disease was used as the outcome measure. 
The patients with sarcoidosis (n=6) and Melkersson-Rosenthal syndrome (n=10) were 
excluded from the regression analysis due to the small numbers. Therefore, the patients 
studied either had Crohn’s disease or allergic orofacial granulomatosis. Hence, if a 
patient failed to have the outcome event (Crohn’s disease), by default the patient had 
orofacial granulomatosis.
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CHAPTER 7
CLINICAL RESULTS I : 
CLINICAL OBSERVATIONS
187
7.1 Introduction
Of the 301 patients, at the time of presentation, 20 had a pre-existing diagnosis of 
gastrointestinal Crohn’s disease, and 10 had clinical features sufficient to make the 
diagnosis of complete Melkersson-Rosenthal syndrome. It was deemed inappropriate, 
for analytical purposes, to make the diagnosis of incomplete Melkersson-Rosenthal 
syndrome or cheilitis granulomatosa of Miescher.
Thus, for the purposes of analysis, four diagnostic groups emerged: orofacial 
granulomatosis, Crohn’s disease, Melkersson-Rosenthal syndrome, and sarcoidosis. 
Patients were allocated to these diagnostic categories according to the clinical and 
laboratory-based criteria given in Chapter 3.
The following key will apply throughout the chapters containing results:
OFG Orofacial Granulomatosis
CD Gastrointestinal Crohn’s disease
MRS Melkersson-Rosenthal syndrome
SARC Sarcoidosis
ALL All patient groups together
Patient numbers were as follows:
Diagnosis OFG CD MRS SARC ALL
No. of 240 45 10 6 301
patients
(%)
(79.7) (15.0) (3.3) (2.0) (100.0)
These data are presented graphically in Figure 7.1.
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7.2 Clinical history
7.2.1 Age
The ages of patients at presentation were as follows:
Diagnosis
OFG CD MRS SARC ALL
Age in 
years
Mean 24.0 20.8 38.5 27.2 24.0
Minimum 3.0 4.0 3.0 14.0 3.0
Maximum 69.0 50.0 69.0 40.0 69.0
This is represented graphically in Figure 7.2.
A Kruskal-Wallis statistical test was performed on these data with the following results: 
H = 0.31; DF = 1; p = 0.579. There is therefore no statistically significant difference 
between the disease groups (CD and OFG) in terms of age at presentation.
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7.2.2 Gender
The gender of patients was as follows:
Diagnosis
OFG CD MRS SARC ALL
Gender Patient Numbers (%)
Male 136 (56.7) 29 (64.4) 4 (40.0) 3 (50.0) 172 (57.1)
Female 104 (43.3) 16(35.6) 6 (60.0) 3 (50.0) 129 (42.9)
This is represented graphically in Figure 7.3.
Chi-square analysis of these data gave a value of 0.940; DF = 1; p = 0.332. This 
indicated a normal distribution of gender within each disease category with no 
significant gender differences evident.
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7.2.3 Ethnic origin
The ethnic origin of patients was as follows:
Diagnosis
OFG CD MRS SARC ALL
Ethnic
Origin Patient Numbers (%)
White
Caucasian 232 (96.7) 41 (91.1) 10(100.0) 6(100.0) 289 (96.0)
Asian 8 (3.3) 4 (8.9) 0 (0.0) 0 (0.0) 12 (4.0)
The data on ethnic origin were not included in overall statistical analysis due to the small 
numbers of ethnic groups other than Caucasians represented. The data were deemed to 
be simply representative of ethnic groupings within the study population (west of 
Scotland).
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7.2.4 Geographical area
The geographical area of residence of each patient was as follows:
Diagnosis OFG CD MRS SARC ALL
Health
Board
Area
Patient Numbers (%)
England 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
Grampian 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
Fife 2 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7)
Dumfries & 
Galloway
3(1.3) 2 (4.4) 0 (0.0) 0 (0.0) 5(1.7)
Lothian & 
Borders
5(2.1) 1 (2.2) 0 (0.0) 0 (0.0) 6 (2.0)
Highlands 
& Islands
4(1.7) 3 (6.7) 0 (0.0) 0 (0.0) 7 (2.3)
Forth Valley 26(10.8) 6(13.3) 1 (10.0) 0 (0.0) 33(11.0)
Ayrshire & 
Arran
25(10.4) 8(17.8) 1 (10.0) 0 (0.0) 34(11.3)
Lanarkshire 34(14.2) 3 (6.7) 2 (20.0) 2 (33.3) 41 (13.6)
Argyll & 
Clyde
39(16.3) 6(13.3) 2 (20.0) 2 (33.3) 49(16.3)
Greater
Glasgow
100
(41.7)
16(35.6) 4 (40.0) 2 (33.3) 122 (40.5)
TOTAL 240
(100.1)
45 (100.0) 10(100.0) 6 (99.9) 301 (100.0)
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The data on geographical location of patients were not included in the overall statistical 
analysis since referral patterns will influence the outcome. It is not known how many 
other Oral Medicine/Oral Surgery departments deal with patients with OFG in Scotland.
Similarly, any analysis of the data for possible geographical clustering would be biased 
since precise post-code data was not available on all patients. This recognises the 
potential variation in addresses within each Health Board area (e.g. Argyll and Clyde 
region stretches from Greenock in the south to Oban in the north, a distance of over 100 
miles).
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7.2.5 Occupation
The occupations of patients were as follows:
Diagnosis
OFG CD MRS SARC ALL
Occupational
Category
Patient Numbers (%)
Full-time
education
126 (52.5) 27 (60.0) 0 (0.0) 0 (0.0) 153 (50.8)
Manual 27(11.3) 10(22.2) 2 (20.0) 3 (50.0) 42 (14.0)
At home (incl. 
Pre-school and 
retired)
29(12.1) 2 (4.4) 4 (40.0) 2 (33.3) 37(12.3)
Managerial & 
office
23 (9.6) 3 (6.7) 1 (10.0) 0 (0.0) 27 (9.0)
Professional 21 (8.8) 3 (6.7) 2 (20.0) 1 (16.7) 27 (9.0)
Unemployed 9 (3.8) 0 (0.0) 1 (10.0) 0 (0.0) 10(3.3)
Disability 5(2.1) 0 (0.0) 0 (0.0) 0 (0.0) 5(1.7)
TOTAL 240
(100.2)
45
(100.0)
10
(100.0)
6
(100.0)
301
(100.1)
197
These data are presented graphically in Figure 7.4. These data were not included in any 
statistical analysis since substantial numbers of patients (> 50%) were in full-time 
education and this fact is already represented in the age profile of patients (Section 
7.2.1).
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7.2.6 Past medical history
The past medical histories for each patient revealed that 20 had a pre-existing diagnosis 
of gastrointestinal Crohn’s disease; all other diagnoses (OFG, CD, MRS and SARC) 
were made prospectively, following investigation and during follow-up.
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7.2.7 Atopy
The term “atopy” was introduced by Coca and Cooke in 1923 from the Greek word 
meaning “out of place” to describe the difference between the anaphylactic animal and 
the allergic human (Brostoff and Scadding, 1991). Atopy is now used to describe the 
tendency of 10-15% of the UK population to suffer from allergic diseases such as 
asthma, eczema, hay fever, urticaria and demonstrable food allergy i.e. diseases 
associated with the production of specific IgE following exposure to low concentrations 
of allergen (Brostoff and Scadding, 1991).
For the purposes of this study, atopy was defined by a history of, or current evidence of, 
asthma, eczema, hay fever or urticaria.
The atopic status of patients was as follows:
Diagnosis OFG CD MRS SARC ALL
Atopic (%) 119(49.6) 18 (40.0) 6 (60.0) 3 (50.0) 146 (48.5)
Non-atopic (%) 121 (50.4) 27 (60.0) 4 (40.0) 3 (50.0) 155 (51.5)
Chi-square analysis of the data gave a value of 1.394; DF = 1; p = 0.238. This indicated 
no differences in the atopic status of each patient group.
These data are presented graphically in Figure 7.5.
These data are at variance with that of James et al (1986) who found 60% of a group of ^  
75 patients with OFG to be clinically atopic compared with 15% of a control group of 
200 from the same geographical area (west of Scotland). Similarly, the figure of 40% of 
the CD group being atopic is substantially higher than the 15% area average and higher 
than the figure from other CD studies.
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7.2.8 Associated gastrointestinal symptoms
The associated symptoms revealed by systematic enquiry were as follows:
(I) Weight loss
Diagnosis OFG CD MRS SARC ALL
Weight loss
(%) 9 (3.8) 11 (24.4) 0 (0.0) 0 (0.0) 20 (6.6)
No weight loss
(%) 231 (96.3) 34 (75.6) 10(100.0) 6 (0.0) 281 (93.4)
Chi-square = 24.871; DF = 1; p = 0.000
These data are presented graphically in Figure 7.6.
(II) Altered bowel habit
Diagnosis OFG CD MRS SARC ALL
Altered bowel 
habit
(%) 16(6.7) 25 (55.6) 4 (40.0) 0 (0.0) 45(15.0)
No altered 
bowel habit
(%) 224 (93.3) 20 (44.4) 6 (60.0) 6(100.0) 256 (85.0)
Chi-square = 73.539; DF = 1; p = 0.000
These data are presented graphically in Figure 7.7.
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(Ill) Number of stools passed daily:
Diagnosis OFG CD MRS SARC ALL
No. of stools 
per day
Patient Numbers (%)
0 0 (0.0) 2 (4.4) 0 (0.0) 0 (0.0) 2 (0.7)
1 227 (94.6) 18 (40.0) 6 (60.0) 6 (100.0) 257 (85.4)
2 8 (3.3) 5(11.1) 0 (0.0) 0 (0.0) 13 (4.3)
3 4(1.7) 13 (28.9) 2 (20.0) 0 (0.0) 19(6.3)
4 1 (0.4) 1 (2.2) 1 (10.0) 0 (0.0) 3(1.0)
5 0 (0.0) 3 (6.7) 1 (10.0) 0 (0.0) 4(1.3)
6 0 (0.0) 3 (6.7) 0 (0.0) 0 (0.0) 3(1.0)
Kruskal-Wallis analysis gave the following values: 
H = 69.79; D F = l ; p  = 0.000
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(IV) Bleeding per rectum (fresh blood reported):
Diagnosis OFG CD MRS SARC ALL
Bleeding PR
(%) 6(2.5) 10 (22.2) 0 (0.0) 0 (0.0) 16 (5.3)
No bleeding 
PR
(%) 234 (97.5) 35 (77.8) 10(100.0) 6(100.0) 285 (94.7)
Chi-square = 27.817; DF = 1; p = 0.000 
These data are presented graphically in Figure 7.8.
(V) Abdominal pain:
Diagnosis OFG CD MRS SARC ALL
Abdominal
pain
(%) 5(2.1) 19 (42.2) 2 (20.0) 0 (0.0) 26 (8.6)
No abdominal 
pain
(%) 235 (97.9) 26 (57.8) 8 (80.0) 6(100.0) 275 (91.4)
Chi-square = 79. 
These data are pr
168; DF = l ;p  = 0.000 
esented graphically in Figure 7.9.
207
Fi
gu
re
 
7.8
 
Bl
ee
di
ng
 
pe
r 
rec re
co
rd
ed
 
by 
pa
tie
nt
s
(% 
of 
pa
tie
nt
s 
in 
eac
h 
gr
ou
p)
CL
£ U)0. c
U)c CD
■
~G 0
CD J Q
CD O
m z
□ ■
o o o o o o o o o o o
00)CON(t>l0^t(0(Nr
208
OF
G 
CD
 
MR
S 
SA
RC
 
A
LL
Fi
gu
re
 
7.9
 
A
bd
om
in
al
 p
ain
 
re
co
rd
ed
 
by 
pa
tie
nt
s
(% 
of 
pa
tie
nt
s 
in 
eac
h 
gr
ou
p)
£
asc Q.
OS
a 75c
asc
■ m m t
Eo
E "O
o
"D
JQas
-Q o
< z
■ ■
o o o o o o o o o o o
00)CONlDlOTf(0(Mr
209
OF
G 
CD
 
MR
S 
SA
RC
 
AL
L
7.2.9 Social habits
(I) Smoking:
The smoking habits of each patient group was recorded as follows:
Diagnosis OFG CD MRS SARC ALL
Smoker
(%) 32(13.3) 2 (4.4) 3 (30.0) 0 (0.0) 37 (12.3)
Non-smoker
(inc. ex-smoker) 
(%) 208 (86.7) 43 (95.6) 7 (70.0) 6 (100.0) 264 (87.7)
Chi-square = 2.850; DF = 1; p = 0.91
These results are presented graphically in Figure 7.10.
Given the age profile of the patients in the study, perhaps these results are not surprising. 
Since the vast majority in each patient group was non-smoking, it is proposed that 
smoking plays little role in the individual disease processes, except for the patients in 
whom cigarette smoke was identified as an allergen (see Section 7.8).
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(II) Alcohol:
The alcohol consumption of each patient group was recorded as follows:
Diagnosis OFG CD MRS SARC ALL
No. of units 
of alcohol 
per week
Patient Numbers (%)
No record 2 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7)
0 187 (78.0) 37 (82.2) 5 (50.0) 4 (66.7) 233 (77.4)
2 1 (0.4) 0 (0.0) 1 (10.0) 0 (0.0) 2 (0.7)
3 0 (0.0) 1 (2.2) 0 (0.0) 0 (0.0) 1 (0.3)
4 2 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7)
5 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
10 3 (1.2) 1 (2.2) 1 (10.0) 0 (0.0) 5(1.7)
12 4(1.7) 0 (0.0) 0 (0.0) 0 (0.0) 4(1.3)
14 15(6.2) 3 (6.7) 2 (20.0) 2 (33.3) 22 (7.3)
15 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
21 24(10.0) 1 (2.2) 0 (0.0) 0 (0.0) 25 (8.3)
25 0 (0.0) 1 (2.2) 1 (10.0) 0 (0.0) 2 (0.7)
60 0 (0.0) 1 (2.2) 0 (0.0) 0 (0.0) 1 (0.3)
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7.2.10 Clinical complaint
The patients’ original clinical complaints (i.e. at first presentation) were recorded as 
follows:
Diagnosis
OFG CD MRS SARC ALL
Clinical
complaint
Patient Numbers (%)
Swollen lips 
(upper and 
lower)
75 (31.3) 14(31.1) 1 (10.0) 1 (16.7) 91 (30.2)
Swollen upper 
Up
50 (20.8) 9 (20.0) 5 (50.0) 4 (66.7) 68 (22.6)
Swollen lower 
lip
48 (20.0) 9 (20.0) 1 (10.0) 0 (0.0) 58(19.3)
Swollen face 37(15.4) 3 (6.7) 5 (50.0) 0 (0.0) 45(15.0)
Swollen
mucosa
23 (9.6) 3 (6.7) 2 (20.0) 0 (0.0) 28 (9.3)
Oral ulcers 50 (20.8) 21 (46.7) 1 (10.0) 0 (0.0) 72 (24.0)
Sore, swollen 
or bleeding 
gums
15(6.3) 3 (6.7) 0 (0.0) 0 (0.0) 18(6.0)
Sore mouth 7 (2.9) 6(13.3) 0 (0.0) 0 (0.0) 13 (4.3)
Angular
cheilitis
9 (3.8) 1 (2.2) 0 (0.0) 0 (0.0) 10(3.3)
Facial nerve 
palsy
0 (0.0) 1 (2.2) 0 (0.0) 1 (16.7) 2 (0.7)
TOTAL 314 70 15 6 405
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These data are presented graphically in Figure 7.11 and analysed statistically in Section 
7.2.11.
It is evident from the Table that none of the ten patients labelled as MRS recorded a 
facial palsy as the main problem at presentation. However, their histories, verified from 
other documented sources, confirmed that facial palsies had been part of their disease 
experience, either as single or repeated events.
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7.2.11 Symptom scores
The patients’ initial symptom scores (i.e. at first presentation), using a possible score 
from 0 to 10 on a Visual Linear Analogue Scale, were recorded as follows:
Diagnosis OFG CD MRS SARC ALL
Original 
symptom score 
(0-10)
Mean 7.8 8.4 6.7 8.7 7.9
Minimum 0 0 4 6 0
Maximum 10 10 10 10 10
Kruskal-Wallis analysis gave the following results: 
H = 2.98; DF = l ;p  = 0.069
These data are presented graphically in Figure 7.12.
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7.3 Physical examination
7.3.1 Findings
7.3.1.1 Systematic examination
Systematic examination of patients was largely unrewarding in terms of clinical signs 
elicited. Summary data is as follows:
Diagnosis
No. of patients
(%)
OFG
182
(75.8)
CD
40
(88.9)
MRS
8
(80.0)
SARC
6
(100.0)
ALL
236
(78.4)
Clinical sign Patient Numbers (%)
Abdominal 12 12 0 0 24
pain (6.6) (30.0) (0.0) (0.0) (10.2)
Peri-anal skin 10 23 0 0 33
tags (5.5) (57.5) (0.0) (0.0) (14.0)
Erythema 0 1 0 1 2
nodosum (0.0) (2.5) (0.0) (16.7) (0.8)
Lymphaden- 28 6 1 2 37
opathy (15.4) (15.0) (12.5) (33.3) (15.7)
These data are presented graphically in Figure 7.13.
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7.3.1.2 Staphylococcal mucositis
During the course of the study, four patients (2 OFG; 2 CD), three male and one female, 
presented with severe non-ulcer oral mucosal discomfort. Examination findings were as
Patient 1 - Crohn’s disease
Panoral mucosal erythema and bilateral angular cheilitis; on Prednisolone lOmg/day and 
ferrous sulphate.
Patient 2 - OFG
Panoral mucosal erythema and bilateral angular cheilitis; no current medication.
Patient 3 - OFG
Panoral mucosal erythema; no angular cheilitis; no current medication.
Patient 4 - Crohn’s disease
Panoral mucosal erythema and unilateral angular cheilitis; taking Prednisolone 
lOmg/day.
The appearance was highly suggestive of a radiation-induced mucositis and so 
microbiological investigations were instituted. Assessment of the oral flora was carried 
out using the oral rinse technique, whereby the patient was supplied with 10ml of sterile 
phosphate buffered saline (PBS: 0.1M, pH 7.2) in a universal container and requested to 
rinse the mouth vigorously for 60 seconds (Samaranayake et al., 1986). The patient then 
returned the mouth rinse to the universal container which was sent the Oral 
Microbiology Laboratory, Glasgow Dental Hospital & School for microbiological 
analysis.
The assistance in this part of the study of the consultant and technical staff of the Oral 
Microbiology Laboratory is gratefully acknowledged.
The oral rinse was concentrated by centrifugation for 10 minutes at 1,700G. The deposit 
was resuspended in 1ml of sterile PBS and the resultant solution mechanically dispensed
follows:
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onto appropriate media by a spiral plater (Spiral Systems Marketing Ltd, Maryland, 
USA) in an Archimedian spiral. The spiral plater delivered 25pi of each rinse sample 
onto the following media: Sabouraud’s dextrose agar (Candida count), mannitol salt agar 
(S. aureus count) and MacConkey’s agar (coliform count).
The Sabouraud’s plates were incubated aerobically for 48 hours while the other plates 
were incubated aerobically for 24 hours at 37PC. The number of colony forming units 
(cfu) of yeasts or bacteria in each plate was enumerated using a Gallenkamp Colony 
Counter (Gallenkamp, Leicestershire, England) and assessed by a Consultant 
Microbiologist. The counts were reported as mild, moderate or heavy growths of the 
relevant organism. Coliforms and Candida species were identified by standard sugar 
assimilation and fermentation techniques respectively while Staphylococci were 
identified using the coagulase test.
Results and outcome were as follows:
Patient 1 - Oral rinse: heavy growth of Staphylococcus aureus.
Treated with Flucloxacillin (250mg four times daily) orally with prompt resolution of 
oral symptoms and signs.
Patient 2 - Oral rinse: heavy growth of Staphylococcus aureus and a scanty growth of a 
Group B beta-haemolytic streptococcus.
Treated with Erythromycin (250mg four times daily) orally with prompt resolution of 
symptoms and signs.
Patient 3 - Oral rinse: heavy growth of Staphylococcus aureus.
Treated with Flucloxacillin (250mg four times daily) orally with prompt resolution of 
oral symptoms and signs.
This patients symptoms and signs returned four weeks later and the patient’s mother was 
unhappy for a further course of antibiotics to be prescribed. The patient was then left 
untreated for two weeks until his symptoms prompted further assessment. The 
symptoms and signs resolved promptly with a further course of Flucloxacillin (250mg 
four times daily) orally.
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Patient 4 - heavy growth of Staphylococcus aureus and Hafnia alvei.
Treated with Flucloxacillin (250mg four times, daily) orally with prompt resolution of 
oral symptoms and signs.
These four cases would appear to be the first documented events in the world literature 
of staphylococcal mucositis in patients with OFG and Crohn’s disease. The CD cases 
were both taking immunosuppressive drugs in the form of oral prednisolone - which may 
predispose to the development of bacterial infections. However, the two cases of OFG 
were taking no form of medication prior to presentation. None of the four cases had any 
demonstrable defects in their full blood counts.
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7.3.2 Sign scores
The patients’ initial sign scores in each group were recorded as follows:
Diagnosis
OFG CD MRS SARC ALL
Clinical sign Patient Numbers (%)
Angular 
cheilitis (L)
65 (27.1) 12(26.7) 0 (0.0) 0 (0.0) 77 (25.6)
Angular 
cheilitis (R)
67 (28.0) 13 (28.9) 0 (0.0) 0 (0.0) 80 (26.6)
Angular
cheilitis
(bilateral)
64 (26.7) 12 (26.7) 0 (0.0) 3 (50.0) 79 (26.2)
Upper lip 
swelling
119(49.6) 23 (51.1) 6 (60.0) 6(100.0) 154 (51.2)
Lower lip 
swelling
128 (53.3) 25 (55.6) 2 (20.0) 2 (33.3) 157 (52.2)
Facial swelling 66 (27.5) 7(15.6) 5 (50.0) 3 (50.0) 81 (27.0)
Aphthous
ulceration
85 (35.4) 31 (68.9) 2 (20.0) 0 (0.0) 118(39.2)
Non-aphthous
ulceration
6(2.5) 18 (40.0) 0 (0.0) 0 (0.0) 24 (8.0)
Full-thickness
gingivitis
71 (29.6) 19(42.2) 0 (0.0) 1 (16.7) 91 (30.2)
Mucosal tags 73 (30.4) 19 (42.2) 2 (20.0) 0 (0.0) 94 (31.2)
223
Diagnosis
OFG CD MRS SARC ALL
Clinical sign Patient Numbers (%)
Mucosal
oedema
107 (44.6) 33 (73.3) 5 (50.0) 2 (33.3) 147(48.8)
Fissured
tongue
21 (8.8) 3 (6.7) 10(100.0) 0 (0.0) 34(11.3)
Papillary
hyperplasia
12 (5.0) 8(17.8) 1 (10.0) 1 (16.7) 22 (7.3)
Facial palsy 
(lower motor)
0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 1 (0.3)
TOTAL 884 223 33 19 1159
In addition to the lower motor neurone facial palsy recorded in the table in one patient 
with sarcoidosis as a genuine sign evident on examination, the histories of all ten 
patients with MRS, two patients with CD, and two patients with OFG were sufficiently 
convincing to include them as part of the scoring system since they were documented as 
observed events in their case notes.
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Chi-square statistical analysis revealed the following results for each of the above 
parameters, comparing OFG and CD:
Clinical Finding Chi-square DF p-value
Angular cheilitis 0.000 1 1.000
Upper lip swelling 0.035 1 0.851
Lower lip swelling 0.075 1 0.784
Facial swelling 2.838 1 0.092
Ulceration - 
aphthoid
17.591 1 0.000*
Ulceration - 
non-aphthoid
69.100 1 0.000*
Full-thickness
gingivitis
2.802 1 0.094
Mucosal tags 2.416 1 0.120
Mucosal oedema 12.533 1 0.000*
Fissured tongue 0.213 1 0.644
Papillary
hyperplasia
9.482 1 0.002*
* statistically significant at the 5% level.
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The patients’ initial sign scores at first presentation (mean, minimum and maximum), 
using a possible score from 0 to 16, were recorded as follows:
Diagnosis OFG CD MRS SARC ALL
Original sign 
score (0-16)
Mean 3.7 5.0 3.8 3.8 3.9
Minimum 0 1 2 1 0
Maximum 11 13 6 6 13
Kruskal-Wallis analysis revealed the following results:
H =  13.25; DF= l ;p  = 0.000.
Thus, there was a statistically significant difference between OFG and CD in terms of the 
mean original sign scores, prior to intervention.
These data are presented graphically in Figure 7.14.
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7.4 Haematological investigations
7.4.1 Full blood count
The full blood counts yielded results for haemoglobin concentration, mean corpuscular 
volume, total and differential white cell count, red cell count, and platelet count as 
follows:
(A) Haemoglobin concentration
Diagnosis OFG CD MRS SARC ALL
Number of 
patients (%) 180 (75.0) 36 (80.0) 10(100.0) 1 (16.7) 227 (75.4)
Haemoglobin
Concentration
(g/dl)
Mean 13.7 13.2 15.1 15.0 13.7
Minimum 11.0 9.3 13.6 15.0 9.3
Maximum 18.2 17.0 18.3 15.0 18.3
Analysis using the Kruskal-Wallis test revealed the following results: 
H = 2.63; DF = 1; p = 0.105
These data are presented graphically in Figures 7.15 and 7.16.
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(B) Mean corpuscular volume (MCV)
Diagnosis OFG CD MRS SARC ALL
Number of 
patients (%) 178 (74.2) 36 (80.0) 10(100.0) 1 (16.7) 225 (74.8)
Mean
Corpuscular 
Volume (fl)
Mean 86.0 82.8 90.1 96.0 85.7
Minimum 70.4 63.0 82.4 96.0 63.0
Maximum 100.0 103.7 98.0 96.0 103.7
Analysis using the Kruskal-Wallis test revealed the following results:
H = 6.45; DF = 1; p = 0.011
Thus, there was a statistically significant difference between patients with OFG and CD 
in terms of their initial mean corpuscular volume (MCV).
These data are presented graphically in Figures 7.17 and 7.18.
231
Fi
gu
re
 
7.1
7 
M
ea
n 
co
rp
us
cu
la
r 
vo
lu
m
e 
(fL
) 
(a
bs
ol
ut
e 
va
lu
es
 f
or 
eac
h 
pa
tie
nt
 g
ro
up
)
3HCT
---------
OF
G 
CD
 
MR
S 
SA
RC
 
A
LL
Fig
ur
e 
7.1
8 
Me
an
 
co
rp
us
cu
la
r 
vo
lum
e 
(fL
), 
ac
co
rd
in
g 
to 
fin
al
 d
ia
gn
os
tic
 
ca
te
go
ry
Q
O
o
o
o
id
(TJ) AOIAI
233
OF
G 
M
RS
 
SA
R
C
 
FI
N
A
L 
D
IA
G
N
O
SI
S
(C) Differential White Cell Count
The differential white cell counts are demonstrated graphically in Figures 7.19, 7.20, 
7.21,7.22, 7.23 and 7.24.
(D) Red Cell Count
The red cell counts are demonstrated graphically in Figure 7.25.
(E) Platelet Count
The platelet counts are demonstrated graphically in Figure 7.26.
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7.4.2 Erythrocyte sedimentation rate (ESR)
The values obtained for Erythrocyte Sedimentation Rates in each group were as follows:
Diagnosis OFG CD MRS SARC ALL
Number of 
patients (%) 95 (40.0) 27 (60.0) 8 (80.0) 1 (16.7) 131 (43.5)
Erythrocyte 
Sedimentation 
Rate (mm/hr)
Mean 12.2 23.0 10.4 1.0 14.2
Minimum 1.0 1.0 2.0 1.0 1.0
Maximum 67.0 90.0 28.0 1.0 90.0
Analysis using the Kruskal-Wallis test revealed the following results:
H = 5.29; D F= l ;p  = 0.021
Thus, there was a statistically significant difference between patients with OFG and CD 
in terms of their erythrocyte sedimentation rate (ESR), a non-specific marker of 
inflammation.
These data are presented graphically in Figures 7.27 and 7.28.
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7.4.3 Serum ferritin
The serum ferritin assays recorded for each patient group were as follows:
Diagnosis OFG CD MRS SARC ALL
Number of 
patients (%) 174 (72.5) 39 (86.7) 8 (80.0) 3 (50.0) 224 (74.4)
Serum ferritin 
(ng/ml)
Mean 63.9 27.2 56.5 28.3 56.8
Minimum 1.0 1.0 11.0 25.0 1.0
Maximum 953.0 183.0 107.0 35.0 953.0
Analysis using the Kruskal-Wallis test revealed the following results:
H = 31.95; DF = l ;p  = 0.000
Thus, there was a statistically significant difference between patients with OFG and CD 
in terms of their serum ferritin level prior to intervention.
These data are presented graphically in Figures 7.29 and 7.30.
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7.4.4 Serum vitamin B J2
The serum vitamin B 12 assays recorded for each patient group were as follows:
Diagnosis OFG CD MRS SARC ALL
Number of 
patients (%) 174 (72.5) 38 (84.4) 8 (80.0) 3 (50.0) 223 (74.1)
Serum vitamin 
Bn (pg/ml)
Mean 477.2 547.3 387.8 375.3 484.6
Minimum 129.0 203.0 206.0 269.0 129.0
Maximum >2000.0 >2000.0 610.0 511.0 >2000.0
Analysis using the Kruskal-Wallis test revealed the following results: 
H = 2.72; DF= 1; p = 0.099
These data are presented graphically in Figures 7.31 and 7.32.
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7.4.5 Whole blood folate
The whole blood folate assays recorded for each patient group were as follows:
Diagnosis OFG CD MRS SARC ALL
Number of 
patients (%) 174 (72.5) 38 (84.4) 8 (80.0) 3 (50.0) 223 (74.1)
Whole blood 
folate (ng/ml)
Mean 242.8 290.7 168.13 233.0 248.2
Minimum 2.0 95.0 101.0 146.0 2.0
Maximum 600.0 635.0 244.0 338.0 635.0
Analysis using the Kruskal-Wallis test revealed the following results: 
H = 2.20; DF= 1; p = 0.138
These data are presented graphically in Figures 7.33 and 7.34.
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7.5 Biochemical investigations
7.5.1 Urea and electrolytes
Abnormalities in the patients’ urea and electrolyte profiles were evident as follows:
Diagnosis OFG CD MRS SARC ALL
Number of 
patients tested 
(%> 108 (45.0) 29 (64.4) 6 (60.0) 3 (50.0) 146 (48.5)
Abnormality 
in urea and 
electrolyte 
profile (%) 2(1.9) 0 (0.0) 0 (0.0) 0 (0.0) 2(1.4)
The specific abnormalities detected were noted as follows:
One patient with OFG had a marginally low albumin 
One patient with OFG had a marginally high urea
These data are presented graphically in Figure 7.35.
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7.5.2 Calcium, albumin and phosphate
Abnormalities in the patients’ calcium, albumin and phosphate profiles were evident as 
follows:
Diagnosis OFG CD MRS SARC ALL
Number of 
patients tested 
(%) 108 (45.0) 27 (60.0) 6 (60.0) 3 (50.0) 144 (47.8)
Abnormality 
in calcium, 
albumin and 
phosphate 
profile (%) 8(7.4) 4(14.8) 0 (0.0) 1 (33.3) 13 (9.0)
The specific abnormalities detected were noted in thirteen different patients as follows:
Two patients with OFG had high plasma protein levels (78 and 85g/L)
Three patients with OFG had low phosphate levels (0.51, 0.67 and 0.77mmmol/L)
One patient with OFG had low (corrected) serum calcium (2.16mmol/L)
One patient with OFG had a high phosphate level (1.48mmol/L)
One patient with OFG had a low serum albumin (33g/L)
One patient with CD had a high phosphate level (1.47mmol/L)
Three patients with CD had low (corrected) serum calcium levels (2.08, 2.16 and 
2.18mmol/L)
One patient with SARC had a high (corrected) serum calcium (2.70mmol/L)
These data are presented graphically in Figure 7.36.
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7.5.3 Liver function tests
Abnormalities in the patients’ liver function tests were evident as follows:
Diagnosis OFG CD MRS SARC ALL
Number of 
patients tested 
(%) 114(47.5) 29 (64.4) 6 (60.0) 3 (50.0) 152 (50.5)
Abnormality in 
liver function 
tests (%) 25 (22.0) 9(31.0) 2 (33.3) 0 (0.0) 36 (23.7)
The specific abnormalities detected were noted as follows:
Fourteen patients with OFG had increased levels of Alkaline Phosphatase
Three patients with OFG had increased levels of AST
One patient with OFG had decreased levels of AST
Two patients with OFG had decreased levels of ALT
Two patients with OFG had increased levels of yGT
Two patients with OFG had increased levels of bilirubin
One patient with OFG had an unspecified abnormality in liver function tests
Two patients with CD had increased levels of Alkaline Phosphatase
One patient with CD had increased levels of AST
One patient with CD had decreased levels of AST
One patient with CD had decreased levels of ALT
Two patients with CD had increased levels of yGT
Two patients with CD had increased levels of bilimbin
One patient with MRS had increased levels of Alkaline Phosphatase 
One patient with MRS had decreased levels of AST
These data are presented graphically in Figure 7.37.
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7.5.4 Serum angiotensin converting enzyme
The patients’ Serum angiotensin converting enzyme levels (U/L) were recorded for each 
group as follows:
Diagnosis OFG CD MRS SARC ALL
Number of 
patients (%) 99(41.3) 23 (51.1) 6 (60.0) 2 (33.3) 130 (43.2)
Serum 
angiotensin 
converting 
enzyme (U/L)
Mean 38.3 37.8 34.2 34.5 38.0
Minimum 0.0 12.0 24.0 26.0 0.0
Maximum 99.0 80.0 52.0 43.0 99.0
Analysis using the Kruskal-Wallis test revealed the following results:
H = 0.000; DF= l ;p  = 0.987
These data are presented graphically in Figures 7.38 and 7.39.
It should be noted that the statistical analysis was between OFG and CD and does not 
comment on the serum angiotensin converting enzyme levels for patients with 
sarcoidosis.
The low levels of serum ACE in the patients with sarcoidosis may be due to small 
patient numbers (n=2) and that their pulmonary disease was relatively inactive at the
261
time of sampling. Both patients had substantially higher levels of serum ACE recorded 
at other times in the disease process.
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7.6 Immunological investigations
7.6.1 Immunoglobulin levels
7.6.1.1 IgA
The patients’ Immunoglobulin A-levels (U/L) were recorded for each group as follows:
Diagnosis OFG CD MRS SARC ALL
Number of 
patients (%) 79 (32.9) 24 (53.3) 5 (50.0) 3 (50.0) 111 (36.9)
Immunoglobulin 
A-levels (U/L)
Mean 2.30 2.88 1.74 2.97 2.42
Minimum 0.20 0.20 0.79 2.07 0.20
Maximum 5.20 7.20 2.40 4.19 7.20
These data are presented graphically in Figures 7.40 and 7.41.
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7.6.1.2 IgG
The patients’ Immunoglobulin G-levels (U/L) were recorded for each group as follows:
Diagnosis OFG CD MRS SARC ALL
Number of 
patients (%) 80 (33.3) 24 (53.3) 5 (50.0) 3 (50.0) 112(37.2)
Immunoglobulin 
G-levels (U/L)
Mean 11.28 10.84 8.23 9.52 11.00
Minimum 7.28 1.10 5.79 9.15 1.10
Maximum 21.90 15.80 10.40 10.26 21.90
These data are presented graphically in Figures 7.42 and 7.43.
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7.6.1.3 IgM
The patients’ Immunoglobulin M-levels (U/L) were recorded for each group as follows:
Diagnosis OFG CD MRS SARC ALL
Number of 
patients (%) 79 (33.0) 24 (53.3) 5 (50.0) 3 (50.0) 111 (36.9)
Immunoglobulin 
M-levels (U/L)
Mean 1.32 1.51 1.37 1.53 1.37
Minimum 0.30 0.50 0.87 1.46 0.30
Maximum 3.00 6.90 1.71 1.66 6.90
These data are presented graphically in Figures 7.44 and 7.45.
271
Fi
gu
re
 
7.4
4 
IgM
 
lev
els
 (
U
/L
) 
(a
bs
ol
ut
e 
va
lu
es
 f
or 
eac
h 
pa
tie
nt
 g
ro
up
)
272
OF
G 
CD
 
MR
S 
SA
RC
 
AL
L
Fig
ur
e 
7.4
5 
Im
m
un
og
lo
bu
lin
 
M 
lev
els
 
(U
/L
), 
ac
co
rd
in
g 
to 
fin
al
 d
ia
gn
os
tic
 
ca
te
go
ry
Q
O
so cn <N
(i/n)
273
OF
G 
M
RS
 
SA
R
C
 
Fi
na
l
D
ia
gn
os
is
7.6.2 Radioallergosorbent (RAST) testing (IgE)
RAST (IgE) results are shown for each diagnostic category as follows:
Diagnosis OFG CD MRS SARC ALL
Number of 
patients tested 
(%) 136 (56.7) 29 (64.4) 10(100.0) 5 (83.3) 180 (59.8)
RASTS (IgE) 
Very high
House dust mite 4(2.9) 1 (3.4) 0 (0.0) 0 (0.0) 5 (2.8)
Tree pollen 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Peanut 1 (0.7) 1 (3.4) 0 (0.0) 0 (0.0) 2(1.1)
Grass pollen 1 (0.7) 1 (3.4) 0 (0.0) 0 (0.0) 2(1.1)
Fish 0 (0.0) 1 (3.4) 0 (0.0) 0 (0.0) 1 (0.6)
Total (%) 7(5.1) 4(13.8) 0 (0.0) 0 (0.0) 11(6.1)
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Diagnosis OFG CD MRS SARC ALL
Number of 
patients tested
(%) 136 (56.7) 29 (64.4) 10(100.0) 5 (83.3) 180 (59.8)
RASTS (IgE) 
High
House dust mite 29(21.3) 4(13.8) 1 (10.0) 0 (0.0) 34(18.9)
Grass pollen 6 (4.4) 0 (0.0) 0 (0.0) 0 (0.0) 6 (3.3)
Poa pratensis 4(2.9) 0 (0.0) 0 (0.0) 0 (0.0) 4(2.2)
Cat 5 (3.7) 0 (0.0) 0 (0.0) 0 (0.0) 5(2.8)
Dog 4(2.9) 0 (0.0) 0 (0.0) 0 (0.0) 4(2.2)
Tree pollen 3 (2.2) 1 (3.4) 0 (0.0) 0 (0.0) 4(2.2)
Cow’s milk 3 (2.2) 1 (3.4) 0 (0.0) 0 (0.0) 4(2.2)
Peanut 2(1.5) 0 (0.0) 0 (0.0) 0 (0.0) 2(1.1)
Wheat 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Soya 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Horse 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Feather 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Fish 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Total (%) 61 (44.9) 6 (20.7) 1 (10.0) 0 (0.0) 68 (37.8)
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Result of RASTs (Continued)
Diagnosis OFG CD MRS SARC ALL
Number of 
patients tested
(%) 136 (56.7) 29 (64.4) 10(100.0) 5 (83.3) 180 (59.8)
RAST (IgE) 
Moderate
House dust mite 6 (4.4) 0 (0.0) 2 (20.0) 1 (20.0) 9(5.0)
Grass pollen 3 (2.2) 0 (0.0) 0 (0.0) 0 (0.0) 3(1.7)
Poa pratensis 2(1.5) 0 (0.0) 1 (10.0) 0 (0.0) 3(1.7)
Cat 3 (2.2) 0 (0.0) 0 (0.0) 0 (0.0) 3(1.7)
Dog 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Tree pollen 4(2.9) 1 (3.4) 0 (0.0) 0 (0.0) 5 (2.8)
Cow’s milk 2(1.5) 1 (3.4) 0 (0.0) 0 (0.0) 3(1.7)
Peanut 2(1.5) 0 (0.0) 0 (0.0) 0 (0.0) 2(1.1)
Wheat 3 (2.2) 1 (3.4) 0 (0.0) 0 (0.0) 4(2.2)
Soya 1 (0.7) 1 (3.4) 0 (0.0) 0 (0.0) 2(1.1)
Egg white 0 (0.0) 1 (3.4) 0 (0.0) 0 (0.0) 1 (0.6)
Pork 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Potato 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Latex 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Almond 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Hazelnut 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Brazil nut 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Total (%) 33 (24.3) 5 (17.2) 3 (30.0) 1 (20.0) 42 (23.3)
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Diagnosis OFG CD MRS SARC ALL
Number of 
patients tested 
(%) 136 (56.7) 29 (64.4) 10(100.0) 5 (83.3) 180 (59.8)
RASTS (IgE) 
Low
House dust mite 3 (2.2) 0 (0.0) 0 (0.0) 0 (0.0) 3(1.7)
Wheat 2(1.5) 0 (0.0) 0 (0.0) 0 (0.0) 2(1.1)
Cow’s milk 2(1.5) 0 (0.0) 0 (0.0) 0 (0.0) 2(1.1)
Peanut 2(1.5) 0 (0.0) 0 (0.0) 0 (0.0) 2(1.1)
Soya 0 (0.0) 1 (3.4) 0 (0.0) 0 (0.0) 1 (0.6)
Tree pollen 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Egg white 1 (0.7) 1 (3.4) 0 (0.0) 0 (0.0) 2(1.1)
Total (%) 11(8.1) 2 (6.9) 0 (0.0) 0 (0.0) 13 (7.2)
GRAND 
TOTAL (%)
112(82.4) 17(58.6) 4 (40.0) 1 (20.0) 134 (74.4)
Whilst statistical analysis was deemed inappropriate for individual allergens, overall 
analysis using the Kruskal-Wallis test revealed the following results:
H = 0.000; D F= l ,p  = 0.000.
Although no difference was evident between the OFG and CD groups in terms of clinical 
atopy, the results of the RAST (IgE) are clearly statistically significant and add further 
credibility to the results elsewhere in this thesis suggesting an immunological (allergic) 
basis for OFG.
These results are presented graphically in Figure 7.46.
277
Fi
gu
re
 
7.4
6 
IgE
 
lev
els
 (
R
A
ST
s)
 
(% 
of 
pa
tie
nt
s 
in 
eac
h 
gr
ou
p)
-C oO)
■ 3H D
+-»as-C
CD"UOd)
X
U)
■ M
§o
> X §
B 0 □ □
<
i -o
278
OF
G 
CD
 
M
RS
 
SA
RC
 
A
L
L
7.6.3 Complement screen
The results for Complement screens in each of the patient groups is shown below:
(A) Complement C3
Diagnosis OFG CD MRS SARC ALL
Number of 
patients (%) 104(43.3) 24 (53.3) 7 (70.0) 3 (50.0) 138 (45.8)
Complement 
C3 (g /L )
Mean 1.29 1.35 1.26 1.11 1.30
Minimum 0.81 1.06 1.02 0.88 0.81
Maximum 1.94 2.15 1.54 1.22 2.15
These results are presented graphically in Figures 7.47 and 7.48.
(B) Complement C4
The results for Complement C4 levels are presented graphically in Figure 7.49.
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(C) C1 -esterase Inhibitor
Diagnosis OFG CD MRS SARC ALL
Number of 
patients (%) 102 (42.5) 24 (53.3) 6 (60.0) 3 (50.0) 135 (44.9)
Cl-esterase 
inhibitor level 
(g/L)
Mean 0.28 0.28 0.29 0.28 0.28
Minimum 0.17 0.22 0.23 0.27 0.17
Maximum 0.44 0.34 0.32 0.29 0.44
These data are presented graphically in Figures 7.50 and 7.51.
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7.7 Oral mucosal biopsy
Oral mucosal biopsies were performed on 165 patients -  120 with orofacial 
granulomatosis, 30 with gastrointestinal Crohn’s disease, 10 with Melkersson-Rosenthal 
syndrome, and 5 with sarcoidosis.
The histological assessment of these biopsies was as follows:
Diagnosis OFG CD MRS SARC ALL
Number of 
patients who 
underwent oral 
biopsy (%) 120 (50.0) 30 (66.7) 10(100.0) 5 (83.3) 165 (54.8)
Granulomata
present 83 (69.2) 24 (80.0) 5 (50.0) 3 (60.0) 115(69.7)
Granulomata
absent 37 (30.9) \ 2 O.O) 5 (50.0) 2 (40.0) 50 (30.3)
Lymphoedema
present 100 (83.3) 28 (93.3) 9 (90.0) 4 (80.0) 139 (84.2)
Lymphoedema
absent 20(16.7) 2 (6.7) 1 (10.0) 1 (20.0) 26(15.8)
'A
Chi-square analysis of OFG and CD revealed the following:
Presence of granulomas Chi-square = 6.310; DF = 1; p = 0.012 
Presence of lymphoedema Chi-square = 8.136; GF = 1; p = 0.004
Thus, there was a statistically significant difference in the histological findings between 
OFG and CD - more likely to find both granulomas and lymphoedema, either singly or in 
combination, in the biopsies from patients with CD.
These data are presented graphically in Figure 7.52.
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7.8 Patch-testing and contact urticaria testing
For the purposes of analysis, patch-testing and contact urticaria results are recorded 
together.
The results of skin reactivity testing for each of the patient groups are as follows:
(A) Benzoic Acid
Diagnosis OFG CD MRS SARC ALL
Number of 
patients who 
underwent patch- 
testing (%) 224 (93.3) 36 (80.0) 10(100.0) 4 (66.7) 274 (91.0)
Positive 
reaction to 
Benzoic acid 122 (54.5) 19(52.8) 3 (30.0) 2 (50.0) 146 (53.3)
Negative 
reaction to 
Benzoic acid 102 (45.5) 17 (47.2) 7 (70.0) 2 (50.0) 128 (46.7)
Chi-square analysis revealed the following results: 
chi-square = 0.871; DF = 1; p = 0.351
These results are presented graphically in Figure 7.53.
288
Fi
gu
re
 
7.5
3 
Sk
in 
re
ac
tiv
ity
 
tes
ts 
- b
en
zo
ic 
ac
id
(% 
of 
gro
up
 
to
ta
ls
)
(/) O)
m m m m
snodiNOo
o o o o o o o o o
O O N ( D l O ^ C O C N | t -
289
(B) Cinnamonaldehyde
Diagnosis OFG CD MRS SARC ALL
Number of 
patients who 
underwent patch- 
testing (%)
224 (93.3) 36 (80.0) 10(100.0) 4 (66.7) 274 (91.0)
Positive 
reaction to 
Cinnamon 100 (44.6) 15(41.7) 5 (50.0) 2 (50.0) 122 (44.5)
Negative 
reaction to 
Cinnamon 124 (55.4) 21 (58.3) 5 (50.0) 2 (50.0) 152 (55.5)
Chi-square analysis revealed the following results: 
chi-square = 0.886; DF = 1; p = 0.347
These results are presented graphically in Figure 7.54.
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(C) Others
Diagnosis OFG CD MRS SARC ALL
Number of 
patients who 
underwent patch- 
testing (%) 224 (93.3) 36 (80.0) 10(100.0) 4 (66.7) 274 (91.0)
Positive reactions 
to (%)
Chocolate 41 (18.3) 2(5.6) 0 (0.0) 0 (0.0) 43 (15.7)
Nickel 27(12.1) 5(13.9) 4 (40.0) 1 (25.0) 38 (13.9)
Sorbic acid 21 (9.4) 4(11.1) 0 (0.0) 0 (0.0) 25 (9.1)
Perfume/ 
Fragrance Mix
13 (5.8) 2 (5.6) 3 (30.0) 0 (0.0) 18(6.6)
Rubber and 
accelerators
10(4.5) 1 (2.8) 0 (0.0) 1 (25.0) 12 (4.4)
Balsams 8 (3.6) 0 (0.0) 0 (0.0) 0 (0.0) 8 (2.9)
Colophony 7(3.1) 0 (0.0) 0 (0.0) 0 (0.0) 7 (2.6)
Parabens 5 (2.2) 3 (8.3) 1 (10.0) 0 (0.0) 9 (3.3)
Lanolin 5 (2.2) 2 (5.6) 0 (0.0) 0 (0.0) 7 (2.6)
Thiomersal 4(1.8) 1 (2.8) 0 (0.0) 0 (0.0) 5(1.8)
Cobalt 4(1.8) 0 (0.0) 1 (10.0) 0 (0.0) 5(1.8)
Toothpaste 4(1.8) 2 (5.6) 2 (20.0) 0 (0.0) 8 (2.9)
Mercury and 
Compounds
3(1.3) 1 (2.8) 0 (0.0) 0 (0.0) 4(1.5)
Salicylic acid 3(1.3) 0 (0.0) 0 (0.0) 0 (0.0) 3(1.1)
Formaldehyde 3(1.3) 0 (0.0) 1 (10.0) 0 (0.0) 4(1.5)
Propylene glycol 3(1.3) 0 (0.0) 0 (0.0) 0 (0.0) 3(1.1)
Sodium
metabisulphite
3(1.3) 0 (0.0) 0 (0.0) 0 (0.0) 3(1.1)
Potassium
dichromate
2 (0.9) 0 (0.0) 2 (20.0) 0 (0.0) 4(1.5)
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(C) Others (continued)
Menthol 2 (0.9) 0 (0.0) 1 (10.0) 0 (0.0) 3(1.1)
Anethole 2 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7)
Vanilla 2 (0.9) 0 (0.0) 1 (10.0) 0 (0.0) 3(1.1)
Oak moss 2 (0.9) 1 (2.8) 0 (0.0) 0 (0.0) 3(1.1)
Paraphenylene
Diamine
2 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7)
Epoxy resin 2 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7)
Peppermint Oil 2 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7)
Gold and 
compounds
1 (0.4) 2(5.6) 1 (10.0) 0 (0.0) 4(1.5)
Palladium 2 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7)
Neomycin 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Eugenols 1 (0.4) 1 (2.8) 1 (10.0) 0 (0.0) 3(1.1)
Quinoline 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Thiuram 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Tartrazine 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Butylated
hydroxytoluene
1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Wood tar 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Coal tar 0 (0.0) 1 (2.8) 0 (0.0) 0 (0.0) 1 (0.4)
Caine mix 0 (0.0) 0 (0.0) 1 (10.0) 0 (0.0) 1 (0.4)
Kathon 1 (0.4) 1 (2.8) 0 (0.0) 0 (0.0) 2 (0.7)
Organic dyes 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Dettol mix 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Glutamic acid 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Spruce/pine
Essence
1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Methylphenyl-
Benzotriazole
1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Butylated
hydroxy-anisole
(margarine)
1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Cigarette smoke 0 (0.0) 0 (0.0) 1 (10.0) 0 (0.0) 1 (0.4)
Germall 0 (0.0) 1 (2.8) 0 (0.0) 0 (0.0) 1 (0.4)
Ginger 0 (0.0) 1 (2.8) 0 (0.0) 0 (0.0) 1 (0.4)
Chilli powder 0 (0.0) 1 (2.8) 0 (0.0) 0 (0.0) 1 (0.4)
TOTAL 197 32 20 2 251
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Twenty-two patients with OFG (9.8% of those tested) were noted to have a significant 
worsening of their orofacial condition (most notably lip swelling) during the test 
procedures.
Three patients with CD reacted to benzoic acid on patch-testing with worsening of lip 
swelling. These patients had been treated unsuccessfully with enteric-coated 
prednisolone; the enteric coating is known to contain benzoic acid (The Association of i 
the British Pharmaceutical Industry, 1998).
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CONTROL GROUP
Of the 100 volunteers who acted as a control population, results were obtained as 
follows:
(a) Food additives
33% gave positive reactions - 11 were delayed hypersensitivity 
20 were contact urticaria 
2 were both
Benzoic acid 
Sodium metabisulphite 
Sorbic acid
28%
6%
3%
(b) Perfumes and Flavourings
7% gave positive reactions 1 was delayed hypersensitivity 
5 were contact urticaria 
1 was both
Cinnamonaldehyde 
(c) Chocolate
7% (i.e. all volunteers who reacted)
1 volunteer (1%) gave a positive reaction (delayed)
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(d) Other substances
Substance % of volunteers who reacted
Nickel 23
Colophony 5
Cobalt 3
Formaldehyde -
Potassium dichromate 2
Paraphenylene diamine 1
Mercapto-mix -
Neomycin 1
Parabens -
Balsam of Peru 4
Thiuram-mix 1
PPD-mix -
Fragrance-mix 6
Primin -
Quatemium-15
Carba-mix -
Wool alcohols -
PTBP formaldehyde -
Caine-mix -
Epoxy resin 1
Quinoline -
Ethylene diamine -
Thiomersal 21
Control (PMF)
In summary, 73% of the control subjects reacted to one or more substances and 27% 
showed no reaction.
These data are presented graphically (with those of the disease groups) in Figures 7.53 
and 7.54.
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7.9 HLA typing
HLA typing of the sixteen patients with OFG gave results as follows:
HLA Phenotype
Class I Class II
A B C Bw DR
3 7,15 - 6 4
3, 11 W62, 18 W3, 5 6 4, W6
1,3 7,8 - 6 2,3
1,2 7,8 - 6 2
3, 11 7, 35 W4 6 4,5
23 17,44 W4 4 5,7
3, 24 7, 18 - 6 2,4
2 W62, 7 W3 6 2,4
2 27, 44 W5 4 3, W6
2, 11 W62, 14 W3, 8 6 W6
1,2 14,44 W8 4,6 2, W6
2, 11 7, 27 W2 4,6 3,5
3 7 - 6 2
1 8, 37 W6 4,6 2,3
1,2 8, 40 W3 6 3,4
2,3 7, 44 - 4,6 -
These results show that HLA Class I antigens were significantly expressed in patients 
with OFG as follows (West of Scotland serological genotype frequencies are shown in 
parenthesis; data from 516 patients):
A2 50.0% (26.4%)
A3 43.8% (17.0%)
B7 56.3% (16.8%)
Bw6 87.5% (now reclassified)
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HLA Class II antigens (DR) were significantly expressed in patients with OFG as 
follows:
DR2 43.8% (15.6%)
DR3 31.3% (22.4%)
DR4 37.5% (21.5%)
Using Chi-square analysis to compare the results of the OFG and control groups, the 
HLA alleles which show statistical significance are as follows:
A3 (odds ratio 3.800; p=0.0129)
B7 (odds ratio 6.6361; p=0.0005)
DR2 (odds ratio 4.216; p=0.0081)
It seems likely therefore, on the basis of this small sample size, that consistent HLA 
genotypes are evident in patients with OFG, in particular A2/3 B7 DR2/3/4. Such 
consistent percentages at significantly higher frequencies than the general West of 
Scotland population, would add credibility to the findings elsewhere in this thesis that an 
immunological mechanism underlies the clinical presentation of OFG. Importantly, 
genotypes A3, B7 and DR2 are known to occur in haplotypic association.
Furthermore, literature on HLA types in CD is somewhat confusing. Numerous studies 
have failed to prove consistent evidence of a significantly increased risk for the 
development of CD in any particular HLA phenotype of either Class I or Class II 
proteins. Even within families, CD does not follow HLA phenotypes (Lowes and Jewell, 
1990).
The typing for this study was done by serological methodology. It has been 
demonstrated more recently, by molecular analysis, that the genes responsible for HLA 
expression (on the short arm of chromosome 6) display a high degree of allelic 
polymorphism, not shown by serological methods alone (Satsangi et al., 1994).
Meta-analysis of published results of the pooled sera of 730 patients with CD has shown 
that HLA-A2 carries a comparative risk of 1.25, whereas HLA-A11 has a significant 
negative association (Satsangi et al., 1994). 50% of the OFG patients tested had HLA- 
A2 and 25% had HLA-A11. Interestingly, two patients (12.5%) had both A2 and Al 1.
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7.10 Lymphocyte sub-population studies
The results of the fluorescent activated cell sorting were available as percentage cell 
positivity for each of the subsets T3, T4, Tg, and HLA-DR. The total white blood cell 
count and total percentage of lymphocytes were also known for each sample. Thus, total 
numbers of lymphocytes in each of the categories could be calculated.
The results were as follows:
(A)
Group OFG CONTROL
T3
Monoclonal
Number of 
samples
16 34
Mean count/ml 1392 1489
Standard
deviation
369 435
Student t-test was used to analyse the above data, 
t = 0.818
p > 0.05 (not significant)
The percentage cells showing positive fluorescence is shown in Figure 7.55.
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Figure 7.55 T3 monoclonal (% lymphocyte subset)
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(B)
Group OFG CONTROL
T4
Monoclonal
Number of 
samples
16 33
Mean count/ml 920 891
Standard
deviation
311 263
Student t-test was used to analyse the above data. 
t = 0.321
p > 0.05 (not significant)
The percentage cells showing positive fluorescence is shown in Figure 7.56.
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Figure 7.56 T4 monoclonal (% lymphocyte subset)
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(C)
Group OFG CONTROL
T8
Monoclonal
Number of 
samples
16 31
Mean count/ml 484 665
Standard
deviation
155 221
Student t-test was used to analyse the above data, 
t = 3.263
p < 0.01 (statistically significant difference noted)
The percentage cells showing positive fluorescence is shown in Figure 7.57.
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Figure 7.57 Tg monoclonal (% lymphocyte subset)
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(D)
Group OFG CONTROL
HLA-DR
Monoclonal
Number of 
samples
16 31
Mean count/ml 182 234
Standard
deviation
102 15
Student t-test was used to analyse the above data, 
t = 2.028
p < 0.05 (statistically significant difference noted)
The percentage cells showing positive fluorescence is shown in Figure 7.58.
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Figure 7.58 HLA-DR monoclonal (% lymphocyte subset)
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It is therefore evident that the peripheral blood from patients with active OFG, as 
opposed to CD, exhibit no significant changes to a control population in terms of mean 
counts of T3 and T4 lymphocytes.
However, in terms of both T8 and HLA-DR expressed lymphocytes, patients with OFG 
exhibit a significant reduction of these cells in the peripheral blood at p<0.01 and p<0.05 
respectively. It has been suggested recently that patients with active gut CD will exhibit 
significant decreases in circulating CD8 lymphocytes (Neil et al., 1994). Further 
analysis of these T-lymphocyte sub-populations in the blood and, perhaps more 
importantly in affected tissues, might provide valuable insight into the immunological 
aberrations in inflammatory bowel diseases and may be of value in distinguishing OFG 
and CD.
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7.11 Technetium-99m-HMPAO leucocyte labelling
Leucocyte labelling efficiencies of between 15 and 60% were calculated for all subjects 
studied, according to the formula given in Chapter 3.
Resultant radiographic images are shown in Figures 7.59 and 7.60.
Of the ten consecutive paediatric patients referred for investigation of orofacial 
granulomatosis who underwent Technetium-99m-HMPAO leucocyte labelling of the 
gastrointestinal tract, the results were as follows:
(a) Seven subjects (70%) showed no uptake at all in the gastrointestinal tract
(b) One subject (10%) showed Grade 2 intensity uptake in the nasopharynx only
(c) Two subjects (20%) showed Grade 2 or 3 intensity uptake in the gastrointestinal 
tract and both were subsequently confirmed as Crohn’s disease histologically, 
affecting the colon and rectum.
Of the fifteen paediatric patients with objective evidence of inflammatory bowel disease 
(radiological +/- histological) who were used as positive controls, and who underwent 
Technetium-99m-HMPAO leucocyte labelling of the gastrointestinal tract, the results 
were as follows:
All 15 patients (100%) showed Grade 2 or 3 uptake in the small or large intestine.
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Figure 7.59 Negative result, showing no tracer uptake in the gastrointestinal tract but 
normal appearance o f liver and spleen.
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Figure 7.60 Positive result, showing tracer uptake in the gastrointestinal tract, with 
Grade 2 accumulation in the proximal ascending colon and Grade 3 accumulation in the 
terminal ileum.
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7.12 Endoscopy and barium studies
A total of 57 patients (excluding those who entered the study with a pre-existing 
diagnosis of gastrointestinal Crohn’s disease) underwent imaging of the gastrointestinal 
tract as follows:
Procedure Number of patients
Barium studies alone 37
Barium studies plus endoscopic procedures 18
Endoscopic procedures alone 2
Of the 37 patients who underwent barium studies alone, putative abnormalities were 
detected as follows:
Abnormality detected Number of patients
Oesophageal stricture (non-CD) 1
Old or active gastric ulceration 2
Old or active duodenal ulceration 2
Diverticular disease 5
Oesophageal CD i ’
Regional ileitis (CD) 2'
CD of colon (distal) 2’
*The five patients with CD all refused further imaging techniques. However, the clinical 
history and radiographic findings were consistent with CD and so they were labelled as 
such for the purposes of analysis.
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Of the 18 patients who underwent barium studies and endoscopic procedures, 
abnormalities were detected as follows:
Abnormality detected Number of patients
Features on barium consistent with CD; 
endoscopic features consistent with CD; 
histological features consistent with CD 13
Features on barium consistent with CD; no 
obvious endoscopic features; histological 
features consistent with CD 1
Features on barium consistent with CD; 
endoscopic features consistent with CD; 
histological features did not confirm nor 
refute CD 1
Features on barium non-specific; 
endoscopic features consistent with CD; 
histological features consistent with CD 3
Of the two patients who underwent endoscopic procedures alone, abnormalities were 
detected as follows:
Abnormality detected Number of patients
Endoscopic features consistent with CD; 
histological features consistent with CD 2
Thus, overall, of the 57 patients who were subjected to imaging of the gastrointestinal 
tract, 25 (43.9%) were identified as having active Crohn’s disease. The 57 patients, 
however, represented a biased population sample with symptoms and/or signs which 
could have represented active gastrointestinal disease. It will be recalled from Chapter 3 
that it was not considered ethical to subject all patients to imaging of the gastrointestinal 
tract, given the morbidity and mortality associated with such procedures.
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A total of 45 patients were thus identified with active gastrointestinal Crohn’s disease: 
25 from investigations inherent to the study and 20 enrolled with a pre-existing diagnosis 
of Crohn’s disease.
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7.13 Statistical Analysis
7.13.1 Logistic Regression
Log Transformations were taken when factors were non-normally distributed
7.13.1.1 Univariate Analyses
An obvious starting point in the modelling process was to ascertain which independent 
variables were useful indictors of outcome (i.e. development of gastrointestinal Crohn’s 
disease). Each of the independent variables were modelled individually against Crohn’s 
disease to establish whether the variable was significantly predictive of outcome.
7.13.1.2 Multivariate Analyses
Stepwise logistic regression operates in a sequential manner. It begins with NO terms in 
the predictive model for outcome. At this stage, the term which is the single most useful 
predictor of outcome is introduced into the predictive model for outcome. The 
significance of every other term adjusting for the most useful term is then calculated. If 
any of the remaining terms can add a significant amount of additional predictive 
information then the most significant of these terms is added into the predictive model at 
the next step. The process is repeated until none of the terms excluded from the model 
can add significantly to the predictive power of those terms included in the model. At 
this stage the process terminates and a set of independently useful predictors of outcome 
are obtained.
Given the sensitivity of the system for multivariate analysis, incomplete data sets cannot 
be used. The multivariate analysis was therefore only computed for factors with almost 
complete data.
Listed in Table 7.1 are all factors which had sufficiently complete data and were tested at
the univariate and multivariate levels. Table 7.2 lists only those factors which were
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tested on univariate analysis. A multivariate analysis was conducted on all factors 
presented in Table 7.1 in a stepwise fashion. The significant factors are presented in 
Table 7.3 in the order they entered the full model in the stepwise manner.
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Table 7.1 Data sets for univariate analysis.
Factor Univariate Analysis
Odds Ratio 
(Confidence Interval)
P-Value
Compliance (negative vs. good) 2.40(1.08, 5.35) 0.0832
(poor vs. good) 1.27 (0.46,3.51)
(partial vs. good) 0.78 (0.32, 1.91)
Allergy Blood Tests (abnorm vs. norm) 1.67 (0.71,3.92) 0.2416
Mucosal Tags (yes vs. no) 1.67(0.87,3.21) 0.1226
Upper Lip Swelling (yes vs. no) 1.06 (0.56, 2.01) 0.8508
Lower Lip Swelling (yes vs. no) 1.09 (0.58, 2.08) 0.7839
Fissured Tongue (no vs. yes) 0.74 (0.21,2.61) 0.6453
Facial Palsy (no vs. yes) 2.06 (0.88,4.84) 0.0976
Atopic (no vs. Yes) 1.48 (0.77, 2.82) 0.2395
Right Angular Cheilitis (yes vs. no) 1.05 (0.52, 2.12) 0.8940
Left Angular Cheilitis (no vs. yes) 1.02(0.50,2.10) 0.9539
Bilateral Angular Cheilitis (yes vs. no) 1.00 (0.49, 2.05) 1.0000
Allergens: Cinnamon (no vs. yes) 1.38 (0.70, 2.71) 0.3480
Allergens: Benzoates (no vs. yes) 1.36 (0.71,2.60) <0.0001
Gum Inflammation (yes vs. no) 1.74 (0.91,3.34) 0.0968
Altered Bowel Habits (yes vs. no) 17.51 (8.05,38.02) <0.0001
Weight Loss (yes vs. no) 8.31 (3.21,21.51) <0.0001
Non-Aphthoid Ulceration (yes vs. no) 25.97 (9.51, 70.92 <0.0001
Aphthoid Ulceration (yes vs. no) 4.04 (2.04,8.01) 0.0001
stools (abnormal vs. normal) 24.27 (10.64,55.25) <0.0001
Rectal Bleeding (yes vs. no) 11.15 (3.81, 32.57) <0.0001
Sex (male vs. Female) 1.39 (0.72, 2.69) 0.3335
Abdominal Pain (yes vs. no) 34.36 (11.83,100) <0.0001
Mucosal Oedema (yes vs. no) 3.42 (1.68,6.94) 0.0007
Papillary Hyperplasia (yes vs. no) 4.11 (1.57,10.73) 0.0039
Smoker (no vs. Yes) 3.31 (0.76, 14.31) 0.1098
Age 0.99 (0.96, 1.01) 0.2068
Initial Sign Score 1.28 (1.13,1.46) 0.0001
Initial Symptom Score 1.13(0.97, 1.34) 0.1216
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Table 7.2 Univariate Analysis - Factors not included in Multivariate Analysis due to the 
presence of missing data.
Factor Univariate Analysis
Odds Ratio 
(Confidence Interval)
P-Value
Haemoglobin Level g/dl 0.82 (0.64, 1.04) 0.1122
Mean Corpuscular Volume fl 0.905 (0.85, 0.97) 0.0028
White Cell Count 1.16(0.98, 1.37) 0.0874
Red Cell Count 1.21 (0.63, 2.20) 0.5519
Absolute number of Neutrophils 1.27 (0.99, 1.64) 0.0638
Absolute number of Lymphocytes 0.92 (0.56, 1.43) 0.7130
Absolute number of Monocytes 3.15(0.60, 16.46) 0.1654
Absolute number of Eosinophils 1.57 (0.21, 10.16) 0.6394
Absolute number of Basophils 0.007 (0.0001, 999.0) 0.4919
Absolute number of Platelets 1.002 (0.998, 1.007) 0.2642
Erythrocyte Sedimentation Rate 1.04 (1.02,1.08) 0.0033
Ferritin 0.98 (0.96, 0.99) 0.0024
Folate 1.003 (1.000,1.006) 0.0219
Vitamin B12 1.001 (1.000, 1.002) 0.1316
Serum Angiotensin Converting Enzyme 1.00 (0.97, 1.02) 0.7775
Immunoglobulin A 1.46 (1.01, 2.16) 0.0470
Immunoglobulin G 0.95 (0.81, 1.11) 0.5351
Immunoglobulin M 1.35 (0.75, 2.59) 0.2974
Complement Factor 3 2.95 (0.46, 17.39) 0.2360
Complement Factor 4 2.73 (0.05, 98.18) 0.5962
Esterase Inhibitor 3.77 (0.001,999.0) 0.8006
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Table 7.3 Multivariate Analysis
Factor Multivariate Analysis
Odds Ratio
(Confidence
Interval)
P-Value
Abdominal Pain (yes vs. no) 9.37 (1.94,45.25) 0.0054
Non-Aphthoid Ulceration (yes vs. no) 13.33 (3.23,54.95) 0.0003
Stools (abnormal vs. normal) 15.31 (4.59,51.28) <0.0001
Allergens: Cinnamon (no vs. yes) 3.94 (1.20,12.94) 0.0238
Aphthoid Ulceration (yes vs. no) 3.14 (1.09,9.04) 0.0338
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7.13.2 Conclusions
7.13.2.1 Descriptive Statistics
Crosstabulations are presented principally to give an indication of the patient 
characteristics with respect to all four types of disease studied. Evidently there was only 
a small number of patients with the diseases Melkersson-Rosenthal Syndrome and 
Sarcoidosis. Hence, it was not possible to compute formal statistical tests for each factor 
by disease type.
7.13.2.2 Formal Analysis: Logistic Regression
Univariate logistic regression analysis was performed at the 5 % level of significance for 
all factors. Odds ratios and their respective confidence intervals were computed, and are 
presented against a reference range in the positive direction. For example, if  a patient 
has rectal bleeding then the patient has 11.15 times greater odds of presenting for 
Crohn’s Disease than if no rectal bleeding is experienced. Sixteen factors were 
significant on univariate analysis at the 5% level.
Multivariate logistic regression analysis was conducted at the 5 % level of significance in 
a stepwise manner. Five factors were significantly predictive of outcome: abnormal 
stools, non-aphthoid ulceration of the mouth, the presence of abdominal pain, not 
allergic to cinnamon and aphthoid ulceration of the mouth. These factors are tabulated in 
the results section and in the same vein as the univariate analysis are presented against a 
reference range in the positive direction.
The final model had sensitivity and specificity values of 86% and 88% respectively.
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CHAPTER 8
CLINICAL RESULTS II : 
TREATMENT AND MANAGEMENT
320
8.1 Exclusion of allergens
8.1.1 Compliance scores
The compliance with dietary and environmental exclusion advice was recorded as 
follows:
Diagnosis OFG CD MRS SARC ALL
Compliance
score
Number of patients 
(%)
0 37
(15.4)
14
(31.1)
1
(10.0)
2
(33.3)
54
(18.0)
1 30
(12.5)
6
(13.3)
1
(10.0)
0
(0.0)
37
(12.3)
2 65
(27.1)
8
(17.8)
2
(20.0)
2
(33.3)
77
(25.6)
3 108
(45.0)
17
(37.8)
6
(60.0)
2
(33.3)
133
(44.2)
Total 240
(100.0)
45
(100.0)
10
(100.0)
6
(99.9)
301
(100.1)
Analysis of this data using the Kruskal-Wallis test revealed the following results: 
H = 2.95; DF = 1; p =0.069.
These date are presented graphically in Figure 8.1.
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The mean compliance scores were as follows:
OFG 2.1
CD 1.7
MRS 2.3
SARC 1.2
ALL 1.9
These data are presented graphically in Figure 8.2.
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8.2 Follow-up time
Follow-up times for each group were as follows:
Diagnosis
OFG CD MRS SARC ALL
Follow-up 
time (years)
Number of 
patients
240 45 10 6 301
Mean 3.5 4.7 4.8 6.5 3.8
Minimum 0.5 0.5 2.0 4.0 0.5
Maximum 18.0 23.0 9.0 11.0 23.0
Analysis of this data using the Kruskal-Wallis test revealed the following results: 
H = 2.43; DF = 1; p =0.116.
These data are presented graphically in Figure 8.3.
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8.3 Assessment of response
8.3.1 Symptom scores (final)
The final symptom scores for each group were recorded as follows:
Diagnosis OFG CD MRS SARC ALL
Final symptom 
scores
Number of 
patients
240 45 10 6 301
Mean 2.3 3.9 1.8 7.8 2.6
Minimum 0.0 0.0 0.0 0.0 0.0
Maximum 10.0 10.0 5.0 5.0 10.0
Analysis of this data using the Kruskal-Wallis test revealed the following results:
H = 6.18; DF = 1; p = 0.013, indicating statistical significance in Final Symptom Scores 
between the OFG and CD groups, the mean OFG symptom scores being lower.
These data are presented graphically in Figure 8.4.
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A comparison was then made between original and final symptom scores as follows:
Diagnosis
OFG CD MRS SARC ALL
Number of 
patients
240 45 10 6 301
Mean original 
symptom score
7.8 8.4 6.7 8.7 7.9
Mean final 
symptom score
2.3 3.9 1.8 7.8 2.6
%
improvement
70.5 53.6 73.1 13.3 67.1
These data are presented graphically in Figure 8.5.
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8.3.2 Sign scores (final)
The final sign scores for each group were recorded as follows:
Diagnosis OFG CD MRS SARC ALL
Final sign 
scores
Number of 
patients
240 45 10 6 301
Mean 1.2 2.6 0.6 2.8 1.4
Minimum 0.0 0.0 0.0 0.0 0.0
Maximum 10.0 10.0 2.0 5.0 10.0
Analysis of this data using the Kruskal-Wallis test revealed the following results:
H = 12.58; DF = 1; p = 0.000, indicating statistical significance in Final Sign Scores 
between the OFG and CD groups, the mean OFG sign scores being lower.
These data are presented graphically in Figure 8.6.
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A comparison was then made between original and final sign scores as follows:
Diagnosis OFG CD MRS SARC ALL
Number of 
patients
240 45 10 6 301
Mean original 
sign score
3.7 5.0 3.8 3.8 3.9
Mean final sign 
score
1.2 2.6 0.6 2.8 1.4
Percentage
improvement
67.6 48.0 84.2 26.3 64.1
These data are presented graphically in Figure 8.7.
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CHAPTER 9
LABORATORY RESULTS
335
9.1 Detection of anti-gliadin antibodies
9.1.1 SDS Polyacrylamide Gel Electrophoresis
Isoelectric focusing (IEF) of crude gliadin proved unsuccessful. The preparation was 
virtually insoluble in water and non-ionic detergent, and required 8M urea for complete 
dissolution. However, IEF in 8M urea-containing agarose and polyacrylamide gels 
produced no visible protein bands after fixation and staining. Even strong fixatives 
(10% trichloracetic acid; 4.4% sulphosalicylic acid) failed to produce acceptable bands.
SDS (sodium dodecyl sulphate) electrophoresis of crude gliadin showed a highly 
heterogeneous pattern of proteins (Figure 9.1) with components ranging in molecular 
weight from about 14kD to greater than 200kD with most of the Coomassie Blue (CBB) 
staining proteins in the region 20-30kD. Below 30kD, only one major protein band was 
visible -  at about 15-18kD. SDS/DTT (sodium dodecyl sulphate/dithiothreitol)- 
solubilised crude gliadin contained no highly aggregated protein; no CBB staining was 
visible in the stacking gel.
Kasarda et al (1974) found that a-gliadins were a major constituent in wheat proteins 
subjected to conventional electrophoresis at pH 3.2. Bemardin et al (1967) estimated the 
molecular weight of a-gliadin as 50-55kD by gel filtration and light scattering. 
Examination of Figure 9.1 suggests that this a-gliadin component was not present in 
significant amounts in the SDS-treated material in this experiment. However, Kasarda et 
al (1974) claimed that the molecular weight of purified a-gliadin estimated by SDS 
electrophoresis was 32 or 36kD, and Figure 9.1 does indeed show intense staining in this 
region. These authors did not account for the missing 20kD fragment and claimed to 
obtain only a single band. In Figure 9.1, there is a prominent component of molecular 
weight approximately 20,000 which could be the a-gliadin subunit released by DTT 
reduction of disulphide linkages in native a-gliadin.
Attempts were made to demonstrate the presence of antibodies to crude gliadin 
components in the sera of subjects with coeliac disease and orofacial granulomatosis, 
and also normal subjects, by immunodiffusion. No precipitin lines were observed, but 
these experiments were considered inconclusive due to the difficulties experienced in
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dissolving the crude gliadin preparation. Antibody-antigen reactions would, of course, 
not proceed at low pH or in the presence of strong dissociating agents such as urea.
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9.1.2 Western Blotting
See Figure 9.2a-d
Western blotting of crude gliadin using pooled sera from patients with coeliac disease 
(7), orofacial granulomatosis (4) and normal controls (11) produced interesting results. 
It is evident that IgG in pooled coeliac sera cross-reacts with all components in crude 
gliadin, with the exception of proteins in the molecular weight range 48-57kD (Figure 
9.2b). This latter region could simply represent the “missing” native a-gliadin 
(molecular weight about 50kD) dissociated to its subunits by DTT reduction of 
disulphide bonds.
Pooled normal sera were shown to contain IgG antibodies to all the major protein 
components (Figure 9.2c) except those in the range 48-57kD. Staining, however, was 
markedly less intense compared to the coeliac tracks.
Comparing the coeliac sera with the normal sera (Figure 9.2b and 9.2c), it is evident that
1. Antibody levels were much higher in the sera of patients with coeliac disease.
2. The coeliac sera contained additional immunoglobulins recognising minor gliadin 
components in the molecular range 14-30kD. It is suggested that this may represent 
anti-endomysial antibodies although this would require further clarification.
Whereas the 32-36kD a-gliadin may be raised in coeliac sera in a previously 
documented way (O’Farrelly et al, 1983) as indicated by increased intensity of 
immunostaining in this region, the more striking and novel observation is that the coeliac 
sera contain these additional bands. It is noteworthy that considering staining in the 17- 
20kD range, corresponding to the putative smaller a-gliadin fragment, there was no 
increased immunostaining with coeliac sera.
Gliadin tracks probed with pooled sera from patients with OFG showed highly intense 
staining compared with normal sera, but with a very similar pattern above 30kD (Figure 
9.2a). Again, the putative 18kD fragment of a-gliadin showed no increased staining 
compared with normal sera.
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However, OFG sera contained IgG recognising two additional components in the lower 
molecular weight range, one of which (arrowed Figure 9.2a) was not immunostained 
with normal or coeliac sera.
It would appear, therefore, that patients with OFG have circulating levels of IgG in 
excess of the normal population. The antigenic stimulus for this remains unidentified 
but is unlikely to be gliadin. Further work is required on a larger patient and control 
sample. <
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Figure 9.1 SDS Electrophoresis o f Crude Gliadin; Coomassie Blue stained gel.
Gliadin
(") Standard
Gliadin load 200pg 160pg 120pg
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94
k-
Figure 9.2 Western Blotting o f Crude Gliadin using pooled sera from (a) OFG patients; 
(b) Coeliac Disease patients; (c) Normal control subjects; (d) All 3 patient groups.
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9.2 Molecular biological studies -  the polymerase chain reaction
The purpose of this part of the study was to investigate the possibility of mycobacterial 
involvement in OFG and oral Crohn's disease tissue samples. M. paratuberculosis is a 
slow growing organism which has been shown to be the causative agent of Johne’s 
disease, a chronic enteritis of ruminants (Chiodini et al, 1984a; Vary et al, 1990). Due 
to the extreme difficulties encountered in attempting to isolate the organism by culture, 
many investigators have utilised the PCR technique for its detection in diseased tissue. 
Since M. paratuberculosis DNA has previously been demonstrated in the intestinal 
tissue of up to 72% of patients affected by Crohn's disease by PCR in several studies 
(Sanderson et al, 1992; Dell'Isola et al, 1994; Lisby et al, 1994; Fidler et a l, 1994), it 
seemed prudent to investigate the possible presence of this mycobacterial species in OFG 
and oral Crohn’s disease tissue. The primers used for PCR in this study targeted the 
same 5’ region of the IS900 DNA insertion element of M. paratuberculosis as primers 
previously described (Sanderson et al, 1992; Millar et al, 1995).
Duplicate sets of all the samples analysed demonstrated PCR positivity for the B- 
haemoglobin gene, as indicated by the amplification of a 165 bp product, after two 
rounds of PCR using nested primer pairs. This indicated that DNA extraction was 
successful for each tissue sample being analysed and that the extracted DNA was of 
sufficient purity and free of PCR inhibitors, thus rendering it suitable for use in 
subsequent PCR analysis.
The sensitivity of the PCR assay following two rounds of amplification was such that 10 
fg of M. paratuberculosis DNA was detectable by agarose gel electrophoresis, which is 
the equivalent of two mycobacterial genomes.
M. paratuberculosis IS900 PCR was performed on duplicate sets of samples. Following 
a single round of 40 cycles of PCR using the M. paratuberculosis IS900 P90+/P91 + 
primer pair, all of the samples were negative for the presence of M. paratuberculosis 
DNA both by agarose gel electrophoresis and Southern blot hybridisation, with only the 
positive control producing a product of 413 bp.
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In order to increase the sensitivity of the assay, a second round of PCR using identical 
conditions to the first round but with 5 pi of first round product as template was 
performed. A single OFG sample gave a PCR product, which was slightly smaller in size 
to that expected for M. paratuberculosis positivity (Figure 9.3). However, this product 
did not hybridise to the 229 bp IS900 probe in Southern blot hybridisation (Figure 9.4). 
No other samples were positive by gel electrophoresis and no samples previously 
negative by agarose gel electrophoresis following two rounds of PCR demonstrated 
positivity following Southern blot hybridisation.
For each batch of tissue samples being analysed, the M  paratuberculosis positive 
controls were always positive and the negative controls always negative, both by agarose 
gel electrophoresis and Southern blot hybridisation.
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Figure 9.3 2% agarose gel electrophoresis o f selected PCR products (20pl) obtained 
from tissue DNA samples following two rounds o f 40 cycles o f amplification with M. 
paratuberculosis IS900 primers P90+ and P91+. Lanel shows the lOObp DNA ladder; 
lanes 2-8 show the OFG samples; lanes 9-11 show the Crohn’s disease samples; lanes 
12-14 show the normal samples; lane 15 shows the negative PCR control and lane 16 
shows the positive PCR control. The single PCR product obtained from the sample 
analysed, which is slightly smaller in size than the positive control PCR product, is 
shown in lane 6 and is an OFG sample.
Figure 9.4 Corresponding Southern blot hybridisation to that shown in Figure 9.3. For 
orientation o f the membrane, lanes 1 and 16 correspond to the lOObp DNA ladder and 
PCR positive control lanes respectively. The PCR product in lane 6 (OFG) did not 
hybridise to the probe.
413 bp
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The results suggest that in this patient group, M. paratuberculosis does not appear to be 
associated with OFG or the oral lesions of Crohn’s disease. After two rounds of 40 
cycles of PCR followed by Southern blot hybridisation, all tissue samples were found to 
be negative. The IS900 PCR assay used in this study was similar to that previously 
described by Sanderson et al (Sanderson et al, 1992) who reported that as little as 5 fg 
of M. paratuberculosis DNA could be detected, which is equivalent to a single 
mycobacterial genome.
In view of the fact that the PCR assay used is as sensitive as can reasonably be expected 
by carrying out two rounds of PCR and Southern blot hybridisation, and no tissue sample 
was positive for M. paratuberculosis DNA it is clear that, at least in the group of 
patients used in this study, M. paratuberculosis DNA is rarely found in OFG and oral 
Crohn’s disease tissue.
However, an important consideration is the possibility that some areas of infection 
within the tissue may be excluded when using paraffin-embedded tissue sections for 
DNA extraction and analysis as opposed to homogenates of whole fresh tissue. In other 
studies, when using paraffin-embedded tissue sections as a tissue DNA source only 7 to 
13% of samples demonstrated PCR positivity for M. paratuberculosis (Lisby et al, 
1994; Fidler et al, 1994), which is in sharp contrast to positivity rates of 46 to 72% 
obtained when using fresh tissue for analysis (Sanderson et al, 1992; Dell'Isola et al, 
1994; Lisby et al, 1994). It is clearly more difficult to detect low-abundance M  
paratuberculosis DNA reliably in paraffin-embedded samples than when using fresh 
tissue, since the use of fresh tissue permits the extraction of DNA from a much larger 
volume of tissue and consequently increases the probability of sampling a discrete focus 
of infection. It would be most important and helpful to extend this aspect of the study by 
analysing both paraffin-embedded and, where possible, fresh tissue from patients with 
OFG or oral Crohn’s disease lesions in several geographical locations in the UK in order 
to investigate whether there is an altered distribution of the organism in different patient 
groups.
The potential involvement of M. paratuberculosis in Crohn’s disease is a controversial 
issue. Although some studies have demonstrated the presence of M. paratuberculosis 
DNA in Crohn’s disease tissue (Sanderson et al, 1992; Dell'Isola et al, 1994; Lisby et 
al, 1994; Fidler et al, 1994), PCR negativity for M. paratuberculosis DNA has been
reported in other studies (Frank and Cook, 1996; Rowbotham et al., 1995; Dumonceau et 
al., 1996). Frank and Cook (1996) failed to detect M. paratuberculosis DNA in any o f 
27 Crohn’s disease tissue samples examined using nested PCR primers, whilst the use o f 
a fluorescent PCR method demonstrated negativity in all o f  68 Crohn’s disease tissue 
samples analysed (Rowbotham et al., 1995). In a further study, PCR demonstrated the 
presence o f  mycobacteria with a similar frequency in the intestinal tissues o f patients 
with Crohn’s disease and o f  normal controls, although no M. paratuberculosis DNA was 
detected in any sample (Dumonceau et al., 1996). PCR negativity for M. 
paratuberculosis DNA has also been obtained in tissue samples o f sarcoidosis (Lisby et 
al., 1993), which is a generalised granulomatous disease involving multiple organs and 
which resembles mycobacterial infection histologically. However, the involvement o f 
other mycobacterial species could not be excluded, particularly in view o f the fact that 
Mycobacterium tuberculosis DNA was found in the bronchoalveolar lavage fluid 
(Saboor et al., 1992) and spleens (Mitchell et al., 1992) o f sarcoidosis patients in other 
studies. The potential involvement o f other mycobacterial species in OFG and oral 
lesions o f  Crohn’s disease would undoubtedly be worthy o f investigation.
The standard PCR protocols which have previously been used could be further refined by 
the use o f  a solid-phase hybridisation capture technique, which has recently been 
developed and applied to PCR detection o f  M. paratuberculosis and M. avium subsp. 
silvaticum (Millar et al., 1995). Solid-phase hybridisation capture o f mycobacterial 
DNA from tissue DNA extracts prior to PCR increases sensitivity and substantially 
eliminates false positives arising due to amplicon contamination. This method should 
prove valuable in detecting low abundance target DNA sequences in tissue samples, and 
its application in attempting to identify M. paratuberculosis DNA in oral tissue may 
further clarify the possibility o f any aetiological role for this organism in OFG and oral 
lesions o f Crohn’s disease.
CHAPTER 10 
DISCUSSION
10.1 Discussion
Orofacial granulomatosis is assuming increasing importance in the practice of Oral 
Medicine and in the medical and dental literature (Anonymous, 1991b). This is 
particularly evident in the west of Scotland where over 400 patients have been identified 
with the condition over a 10-year period. This study has analysed the clinical and 
immunological parameters in 301 patients with orofacial granulomatosis.
The main aim of this study was to identify clinical and/or biochemical parameters which 
could be used to determine whether or not there were various granulomatous disorders 
under the umbrella term of OFG, or if patients with OFG had a homogeneous disease 
process. Small numbers of patients with sarcoidosis (2.0%) and MRS (3.3%) excluded 
these conditions on the whole from statistical analysis. The major comparison was 
therefore made between patients with OFG and CD.
During the study, 240 patients were identified with OFG, 45 patients with 
gastrointestinal Crohn’s disease (20 having a pre-existing diagnosis; 25 having the 
diagnosis established during the study), ten patients with MRS and six patients with 
sarcoidosis.
The demographic details of patients in this study were in keeping with other published 
data. In particular, the overall mean age at presentation was 24.0 years with the category 
breakdown as follows: OFG 24.0 years, CD 20.8 years, MRS 38.5 years and sarcoidosis 
27.2 years.
This study’s results on smoking and alcohol consumption were inconclusive, given the 
age profile of the patient population, biased towards the younger age group. It is known, 
however, that smoking is implicated in worsening gastrointestinal Crohn’s disease 
(Bozdech and Farmer, 1990).
Working definitions of gastrointestinal Crohn’s disease have been used by large multi­
centre study groups to ensure homogeneity of patients and to provide a starting point for 
disease definition (Winship et al, 1979). It is, however, generally expressed in the
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literature that these definitions and criteria are imperfect (Bozdech and Farmer, 1990) 
with the diagnosis being an art rather than a purely scientific process.
The finding of non-caseating granulomata on biopsy or surgical specimens helps to 
confirm the clinical suspicion of intestinal Crohn’s disease; however, the rate of 
detection depends on the criteria used to define “granuloma”, and the vigour used in 
searching for such lesions. Therefore to assume that a histological diagnosis of Crohn’s 
disease, or indeed the absence of “classical” histological features, is beyond reproach is 
naive. Granulomata are actually seen in the minority of patients (Bozdech and Farmer, 
1990) and so their absence is of no utility. Therefore, the salient features of histology are 
chronic patchy inflammation, the predominance of submucosal involvement, and the 
long-term clinical sequelae of stricturing and fistula formation (Bozdech and Farmer, 
1990).
Intestinal Crohn’s disease is seen in four main clinical patterns: ileocolonic is the 
commonest presentation, seen in about 40% of patients; isolated small intestinal and 
isolated colonic involvement occurs in less than 30% of patients; and isolated anorectal 
involvement is seen in about 3% of cases. Although Crohn’s disease is quoted as 
exhibiting “skip lesions” and therefore may involve the stomach, oesophagus and even 
the skin as isolated processes, this is rare and accounts for less than 10% of all Crohn’s 
disease cases (Farmer et al, 1975; Farmer et al, 1985; Mekjian et al, 1979).
Seventy to eighty-five percent of patients with CD will have some degree of small 
intestinal involvement (Farmer et al, 1975; Mekjian et al, 1979; Lind et al, 1985a). 
The triad of abdominal pain, diarrhoea and weight loss is seen in approximately 90% of 
patients with small intestinal involvement (Bozdech and Farmer, 1990).
Colonic involvement by CD is seen in approximately 60% of all patients with CD 
(Farmer et al, 1975; Mekjian et al, 1979; Lind et al, 1985a). Diarrhoea, abdominal 
pain and weight loss are again seen in the majority of patients (Bozdech and Farmer, 
1990). Rectal-sparing of the disease process is seen in only 20-25% of patients with 
colonic CD (Bozdech and Farmer, 1990). It is known that peripheral manifestations of 
CD are commoner in patients with colonic involvement -  arthritis, perianal fistulae and 
skin lesions. This has been demonstrated in the current study with orofacial
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manifestations being seen more commonly in patients with anal and peri-anal disease
(peri-anal skin tags were identified in 57.5% of patients with CD). This could be
referred to as “top-and-tail” Crohn’s disease -  a new clinical entity.
A further new clinical entity was identified in four patients: staphylococcal mucositis. 
Two patients with this condition had CD and were taking oral prednisolone; two patients 
had OFG and were taking no medication.
Gastrointestinal symptoms were found to be of practical value in identifying patients 
who may have gastrointestinal Crohn’s disease. The following symptoms were all 
statistically significant in differentiating OFG from CD:
• weight loss (CD 24.4%; OFG 3.8%)
• altered bowel habit (CD 55.6%; OFG 6.7%)
• number of stools passed daily (higher in CD)
• rectal bleeding (CD 22.2%; OFG 2.5%)
• abdominal pain (CD 42.2%; 2.1%)
Similarly, systemic examination of patients yielded findings which aided differentiation 
of CD and OFG. Pain was identified on abdominal palpation in 30.0% of CD patients 
examined and only 6.6% of OFG patients. Peri-anal skin tags were present in 57.5% of 
CD patients and only 5.5% of OFG patients.
Two important features were evident in patients with sarcoidosis: erythema nodosum 
(16.7%) and lymphadenopathy (33.3%).
A landmark Scandinavian paper (Lind et al., 1985b) has reported that radiography was 
very sensitive (91-100%) for the identification of small intestinal or small intestinal and 
large intestinal (combined) CD. However, the sensitivity of barium enema for colonic 
CD was only 48%. Colonoscopy had a sensitivity of approximately 85% for the 
diagnosis of colonic CD, but was less sensitive for the diagnosis of small intestinal CD 
or combined small intestinal/colonic CD. These findings pertained to both the adult and 
paediatric populations. This study suggests that technetium-labelled leucocyte scanning 
of the gastrointestinal tract is a useful screening tool in differentiating OFG and CD.
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This has the advantage of being non-invasive, cheap, readily accessible, and delivering 
levels of radiation substantially less than conventional barium studies (Charron, 1997). 
Its diagnostic accuracy in inflammatory bowel disease is well established (Charron, 
1997). However, the data from this study, from a largely paediatric population, requires 
confirmation in an adult population with inflammatory bowel disease.
The importance in differentiating OFG and intestinal CD lies in future management 
options for the individual patient.
An immunological (allergic) basis for OFG has been postulated in this study. Despite 
similar compliance scores and follow-up periods between the two groups (CD and OFG), 
dietary and environmental exclusion advice for substances identified on positive skin 
testing led to statistically significant differences in changes of both final symptom and 
sign scores. This finding was on the background of no significant differences in atopy 
rates between the OFG (49.6%) and CD (40.0%) groups, the overall rate being 48.5% 
versus 15% of the general population. However, very strict criteria were applied in this 
study to establish a diagnosis of atopy.
Furthermore, 54.5% of the OFG group and 52.8% of the CD group were reactors to 
benzoic acid versus 28% of the control group; 44.6% of the OFG group and 41.7% of the 
CD group were reactors to cinnamonaldehyde versus only 7% of the control group.
Further weight to the allergic basis for OFG was added with the overall levels of IgE 
demonstrated by RAST testing being significantly higher in the OFG group (82.4%) over 
the CD group (58.6%). In addition, levels of IgG directed against unidentified proteins 
in the sera of the OFG group, comparable to coeliac disease and significantly higher than 
control groups, further strengthen the likelihood of immunological reactivity in the OFG 
group.
The consistent HLA haplotypes (A2/3 B7 DR2/3/4) and results of lymphocyte studies 
suggest an immunological mechanism to the clinical presentation in OFG patients. 
Recent work on T cell receptor 13 variability in a patient with OFG (Lim et al, 1997) has 
suggested that TCRVB gene usage by lesional T-lymphocytes is notably restricted. In 
addition, a recurrent transcript in the VB6 lesional lymphocytes was identified,
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suggesting a clonal T cell expansion in the vicinity of the lesion. The biological role of 
these T cells remains to be determined. However, it is likely that the restricted T cell 
repertoire and clonal T cells are involved in a delayed hypersensitivity reaction to an 
antigen.
The results of this study would suggest that the antigen may be dietary in origin. 
However, the negative findings in searching for Mycobacterium paratuberculosis require 
further analysis; the use of fresh tissue from orofacial biopsies instead of paraffin- 
processed sections would be a most appropriate next step using PCR technology (Millar 
eta l, 1995).
Laboratory findings were also of practical value in differentiating the disease categories. 
Whereas haemoglobin concentrations and serum vitamin B 12 levels were not statistically 
different between the groups, the mean corpuscular volume (lower in CD), ESR (higher 
in CD), whole blood folate, and serum ferritin (mean lower in CD) were statistically 
significant in highlighting differences between CD and OFG.
Biochemical parameters were largely redundant, with urea and electrolytes and calcium, 
albumin and phosphate levels revealing no real differences between the diagnostic 
groups. Liver function test abnormalities were recorded in 23.7% of patients overall 
(OFG 22.0%; CD 31.0%). Such levels of abnormality are similar to those recorded in 
CD studies previously (Mekjian et al, 1979). The appropriateness of serum angiotensin 
converting enzyme (SACE) as a screening test for sarcoidosis in patients with 
granulomatous disorders is not proven from this study. Only two patients with 
sarcoidosis had SACE levels measured in this study, and these were within the normal 
reference range.
Analysis of histological data revealed that patients with CD were much more likely to 
have lymphoedema (p=0.004) and/or granulomata (p=0.012), alone or in combination, 
on mucosal biopsy than patients with OFG. However, 20.0% of CD biopsies and 30.9% 
of OFG biopsies had no granulomas present; but only 6.7% of CD biopsies and 16.7% of 
OFG biopsies had no lymphoedema present. It therefore seems inappropriate to persist 
with the title Orofacial Granulomatosis, a histopathological term used to describe a 
clinical entity, and the alternative of Orofacial Lymphoedema is suggested on the basis 
of clinical findings alone.
Initial sign scores showed statistically significant differences between the disease 
categories at p=0.000 (overall mean 3.9; CD 5.0; OFG 3.7; MRS 5.8; sarcoidosis 3.8).
The clinical findings in patients with OFG would lend themselves to the development of 
clinical criteria for diagnosis. The commonest findings were (in decreasing rank order) 
lower lip swelling (52.2%), upper lip swelling (51.2%), mucosal oedema and 
cobblestoning (48.8%), aphthous ulceration (39.2%), mucosal tags (31.2%), full­
thickness gingivitis (30.2%), facial swelling (27.0%) and angular cheilitis (26.2%).
This leads to the helpful concept of Major and Minor diagnostic criteria for Orofacial 
Lymphoedema, with Major criteria being present in >30% of patients and Minor criteria 
being present in 7-29% of patients as follows:
Major: Chronic lower lip swelling 52.2%
Chronic upper lip swelling 51.2%
Mucosal oedema and cobblestoning 48.8%
Aphthous ulceration 39.2%
Mucosal tags 31.2%
Full-thickness gingivitis 30.2%
Minor: Chronic facial swelling 27.0%
Angular cheilitis 26.2%
Fissured tongue 11.3%
Non-aphthous ulceration 8.0%
Papillary hyperplasia 7.3%
The diagnosis would be based on 2 major criteria (i.e. present in at least 60.4% of 
patients) or 1 major plus 3 minor criteria (i.e. present in at least 56.8% of patients). As 
shown in the univariate logistic regression analysis, the need for further investigation for 
systemic CD would be based on the presence of weight loss, altered bowel habit, stool 
frequency, rectal bleeding, and abdominal pain. The presence of peri-anal skin tags and 
a high initial orofacial sign score are good markers of CD, indicating a requirement to 
exclude gastrointestinal Crohn’s disease.
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Univariate logistic regression highlighted a low MCV, high ESR, and a low serum 
ferritin as good markers of gastrointestinal Crohn’s disease.
Patch-testing to identify dietary and/or environmental allergens is shown by this study to 
constitute an essential aspect to the investigation and management of patients with 
Orofacial Lymphoedema.
This study demonstrated statistical significance in the percentage improvement in both 
symptom and sign scores following dietary and environmental allergen identification and 
avoidance advice. Compliance scores and follow-up times were similar across all patient 
groups. Final symptom scores were statistically significantly different between OFG and 
CD (p=0.013) as were final sign scores (p=0.000). Percentage improvements were noted 
in symptom and sign scores as follows: overall, 67.1% and 64.1%; OFG 70.5% and 
67.6%; CD 53.6% and 48.0%; MRS 73.1% and 84.2%; sarcoidosis 13.3% and 26.3% 
respectively.
Comparable results (above the mean) were obtained with OFG and MRS patients with 
respect to dietary and environmental exclusion, suggesting that MRS may have more of 
an allergic basis than reported in the literature to date (Greene and Rogers, 1989).
Results for comparison of the MRS and sarcoidosis groups make the hitherto held belief 
that MRS represents a variant of sarcoidosis (James, 1994b) most unlikely.
The genetic background to the development of such clinical entities and the exact nature 
of the antigenic stimulus and the nature of the immunological response in individual 
patients require elucidation.
On the basis of this study, OFG, sarcoidosis and Crohn’s disease are distinct clinical 
entities. OFG, or more appropriately Orofacial Lymphoedema, OFL, would appear to be 
primarily allergic in its pathogenesis (Type IV or delayed hypersensitivity), as would 
Melkersson-Rosenthal Syndrome.
Overall, 45 out of 301 patients in this study population had, or developed, evidence of 
gastrointestinal Crohn’s disease - some 15% over a 10-year period. This is an important
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advisory figure for new patients presenting with orofacial granulomatous disorders.
In summary, this study has demonstrated that patients with orofacial lymphoedema have 
evidence of an antigen-driven disorder. A number of possibilities should be considered. 
Firstly, the antigen may be a single entity, derived from dietary or environmental 
exposure. The commonest antigen identified was benzoic acid and response to dietary 
modification was statistically significant. This would seem highly probable given the 
chronic exposure to benzoic acid as a preservative molecule in many modem foods, 
particularly in the diets of the patients in this study population. In these circumstances, 
the granulomatous inflammation may simply be a cellular, delayed hypersensitivity (type 
IV) reaction.
Secondly, the antigen may be derived from Mycobacterium paratuberculosis or some 
other mycobacterial species. This would certainly explain the granulomatous 
inflammatory infiltrate evident on some biopsy specimens. However, the negative 
findings on PCR would require repetition with fresh tissue specimens.
Thirdly, there may be a combination antigen-driven response with granulomatous 
inflammation evident as a result of Mycobacterium paratuberculosis and the more 
prevalent lymphoedematous response due to subsequent exposure to other dietary or 
environmental antigen or antigens.
The identification of the true antigen and response will require further elucidation. 
Regardless, this study has established the likelihood of an allergic basis to the disorder 
orofacial lymphoedema.
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10.2 Management recommendations
Ideally, patients presenting with the symptoms and signs of Orofacial Lymphoedema 
should have the following management protocol. This would be in keeping with 
evidence-based good clinical practice.
• Full history, to include weight loss, altered bowel habit, stool frequency, rectal 
bleeding, and abdominal pain
• Full systematic examination, to include abdomen and perineum
• Haematological parameters, specifically full blood count, serum ferritin, and ESR
• Technetium-labelled HMPAO white cell scanning of the gastrointestinal tract
• Oral microbiological sampling where oral symptoms are present
• Patch tests and contact urticaria tests, with appropriate skilled professional advice on 
dietary and environmental exclusion, where allergens are identified
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APPENDIX I 
STUDY PROFORMA
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.OFG -  Proforma
Name ................................................................. . Age . . . .  y e a rs . Ifele/Fem ale
A d d r e s s ...................  * • ••
T elephone, H om e.....................   Work.........................  GDH No.  ..........
O ccupation  .....................................  ' Date o f  1 s *~ a tten d an ce
PMH C rohn1 s /  S a rco id  /  TB /  F a c ia l  p a lsy
D e ta i l s  ............................................................................................... ....................................
A topy Eczema /  Asthma /  Hay fe v e r  •
W e ig h t l o s s  Y /  N .......    Bowel h a b i t  N o rm a l/A lte re d
Smoker Y /  N    A lcoho l Y /  N . ................... ..
C l in ic a l  c o m p la in t:
S w ellin g  U lc e ra tio n  A. c h e i l i t i s  Y/N
Upper l i p  [ ] Upper l i p  [ ] O t h e r   ......... .
Lower l i p  [ ] Lower l i p  [ ] ....................................
B uccal mucosa [ ] B uccal mucosa [ ]...............................................
Tbngue [ ] Tbngue [ ]............................................... .
Face [ ]
C l in ic a l  f in d in g :  E x tra -o ra l  ...................................................................................
S w ellin g  Y /  N '............................... .............................................................................
U lc e ra tio n  Y /  N  '................................................................................................
G ingivae Y /  N  ....................................................................................... .................
M ucosal ta g s  Y /  N ........................................ ................................................................
F is s u re d  tongue  Y /  N ..................................................................................................
P a p i l l a r y  h y p e rp la s ia  Y /N .....................................................................................
Mucosal oedema Y /  N ....................................................................................................
I n v e s t ig a t io n s : Bioosv Y / N  S i t e .........................P a th . No......................
S tage o f  d is e a s e  ...............................................................
F in d in g s ; Granuloma Y / N  Lymphoedema Y / N  Not d ia g n o s tic  [ ].
Eaematolccry F e r r i t i n  . . . .  ng/m l B ^  • • • • pg/m l F o la te  . • . .  ng/m l
G lucose . . . . .  nm ol/1 O t h e r ..........................................................................................
Immunology BAST Y / N  ......................... ................... ...................................... ..
Iiim uncglobulins Y /  N  ............................................................................................
FACS Y / N     C o m p l e m e n t  Y / N ...........................
P a tch  t e s t  No...........................
A lle rg e n s : B enzoate /  Cinnamon /  o th e r  .............................................................
Comment......................................................................................................................................
3<>l'
F o ilc w  u p  
T re a tm e n t
D ie ta r y  a d v ic e  Y / N
R esp o n se ; 
D a te  . . . . . . .
. T b ta l  /  Ba*rt i a l  /  N il 
N ex t re v ie w  .................... ..
D a t e ............
: .sc o re . . .  /  10 . ,  .
- ■ ■ r-■: —
T o ta l  /  P a r t i a l  /  N il sc o re . . .  /  10
N ext review* ' .................... ..
D a t a ...............
T o ta l  /  P a r t i a l  /  N il 
N ext re v ie w  .............................
sc o re . . .  /  10
D a t a ...............
T o ta l /  PairtiaT /  Nil 
N ext r e v i s e  .............................
sco re . . .  /  10
E x a c e rb a tio n s  .......................‘ .......................... ...... .............................................................
"■ ’ -
. . .  * ........-
Garment ................. ................................
■* • • . .
.  . . —... . . .
D u ra tio n  o f  fo llo w  up ........... y ears
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APPENDIX n
DIETARY AVOIDANCE INFORMATION 
SHEETS FOR PATIENTS
363
Glasgow Royal Infirmary 
D ie te tic  D e p a r tm e n t  
B e n z o a te  F r e e  D ie t
As most of the Benzoates in the diet are added to foods as a PRESERVATIVE it is very 
important that you read the labels of any manufactured or prepared foods you consume. If 
Benzoates are added to the food, the manufacturer may name the particular Benzoate a 
serial number known as an E number, avoid those from E210 - E219 inclusive. If you are 
unsure whether a food / drink may contain Benzoate it is best to avoid it.
Avoid any food which just lists the word “Preservative” or “Permitted Preservative” as an 
ingredient.
Ike  Benzoates used in foods are :
E210 - Benzoic acid.
E211 - Sodium Benzoate.
E212 - Potassium Benzoate.
E213 - Calcium Benzoate.
E214 - Ethyl 4-hydroxybenzoate.
E215 - Ethyl 4-hydroxybenzoate sodium salt.
E216 - Propyl 4-hydroxybenzoate.
E217 - Propyl 4-hydroxybenzoate sodium salt.
E218 - Methyl 4-hydroxybenzoate.
E219 - Methyl 4-hydroxybenzoate sodium salt.
AVOID ANY ITEM CONTAINING THESE 
In general - AVOID
Commercially prepared meat and fish dishes of which the exact composition is not known 
- lasagne, pizza, curry, Chinese foods, flans, quiches. Keep to fresh or home cooked food 
wherever possible.
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Check Labels on
1. Squashes, cordials and diluting drinks
2. Fizzy drinks
3. Glucose drinks e.g. Lucozade
4. Non alcoholic grape juice drinks, e.g. Schloer
5. Slush puppies, ice poles, ice lollies, Tip Top
6. Bottles shandy. Avoid Tennants ‘L .A ‘ on draught
7. Chocolate drinks
8. Liquid coffee and chicory drinks e.g. Camp coffee
9. Flavoured milk drinks and milk shake syrup
10. Yoghurt
11. Colourings and flavourings used in home baking
12. Jams, marmalades, chocolate spreads and also diabetic jam
13. Liquid artificial sweetener, e.g. Sweetex liquid
14. Pickled products e.g. herring, onions, beetroot, pickles. Canned fish in tomato 
sauce, pickled herring.
15. Also check sauces - horseradish, brown sauce, tomato sauce, mustard and vinegar
16. Mayonnaise, salad cream and salad dressings. Coleslaw and any salads in
delicatessen counters. Potato salad.
17. Dried fruit. Tins or jars of fruit or fruit puree. Avoid ice cream with fruit/fruit 
sauce in it.
18. White bread. Avoid bead made with bleached flour - check labels.
19. Fruit sauces, toppings on cheesecakes, gateaux etc.
Fruit pie fillings. Dessert sauces. Bought dessert cakes and gateaux.
Fruit pies.
20. Crystallised or glace fruit. ANY preserved fruit.
The recommended toothpastes are:
1. Kingfisher.
2. Colgate Regular, Colgate Junior, Colgate Tartar Control;, Ultrabite, Colgate Blue 
Minty Gel
3. Crest - all types.
4. MacLeans Original, MacLeans Sensitive, MacLeans Milk Teeth, Aquafresh
Any queries please contact your Dietitian: 
Name;
Hospital:
KAM.Dec.1995.
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Glasgow Roval Infirmary University NHS Trust
Department of Nutrition & Dietetics
Non- Alcoholic Drinks -Free From Benzoates
Carbonated Drinks
Asda
Soda Water
Barr Cola
In cans & bottles
Britvic
Ribena
Citrus Spring Cans
Sparkling Blackcurrant Flavour 
Drinks in Cans, all varieties. 
Spring Sparkling Blackcurrant 
Juice Drink with Spring Water 
in bottles.
Schweppes
American Ginger Ale 
Canaada Dry Ginger Ale 
Dry ginger ale 
Ginger beer - in bottles 
Indian tonic water 
Schizan Sparkling drink 
with fruit and plant extracts 
Slimline Indian tonic 
water - low calorie
Soda water
St Clements All sparkling fruit drinks 
- in cans only
Seven-Up
Diet / ordinary - cans only.
Chocolate and Malt Drinks
Asda
Cocoa powder
Drinking chocolate - 25Og and 
500g.
Farm Stores instant hot chocolate. 
Fat reduced drinking chocolate 
granules - 500g 
Instant hot chocolate - 400g 
Cadburys
Boumvita
Boumvita Break Instant malted 
chocolate drink 
Choc-a-shake
Chocolate Break Milk chocolate
beverage
Cocoa
Drinking chocolate 
High Lights Low calorie chocolate 
beverage - coffee, mint creme, 
chocolate, hazelnut
Cadburys
Galaxy
Horlicks
Jubilee
Mars
Maxpax
High Lights Low Calorie 
chocolate beverage - dairy, 
fudge, tangerine.
Milk Drink
Galaxy drink
Low fat instant - All varieties 
in Cekacans / Sachets 
Malted food drink in glass 
jars / tins
Hot chocolate mix
Drink
Chocolate drink mix
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Chocolate and Malt Drinks ( Contd.)
Maxpax Suchard
Malted milk drink mix Chocolate flavour drink mix
Nestle
Chococino hot chocolate drink 
- standard & light, all types.
Coffee
Asda
Ground coffee - all varieties 
Instant coffee - all varieties 
Unsweetened capaccino
Maxpax
Kenco Smooth blend white 
instant coffee 
White instant coffee
Maxwell House
Cappuccino Instant cappuccino
Nestle
Espresso
Nescafe Instant Cappuccino - 
original, and unsweetened 
Nescafe Nescafe Instant Coffee 
- all varieties
Fruit Drinks ( including squashes and concentrates )
Asda
Apple C drink - UHT 
Grapefruit C drink - UHT 
Hi juice orange crush 3 x 250ml 
Orange & apricot juice drink 
( no added sugar) - 3 x 250ml 
Orange C drink - UHT 
Orange juice drink ( no added 
sugar) - UHT - 3 x 250ml 
Ready to drink lemon juice 
drink 3 x 250ml
Bird’s
Apeel Orange drink mix 
( foodservice only)
C-Vit
Ready-to-drink multi vitamin 
fruit drinks - all varieties 
in TetraPak
Kia-Ora
Ready to Drink Lemon Drink
Ready to Drink Mixed fruit drink
Ready to Drink Orange &
pineapple drink
Ready to Drink Orange drink
Ready to Drink Pear and
blackcurrant drink
Ready to Drink Summer Fruits
Drink
Ready to Drink Tropical Orange
Maxpax
Blackcurrant flavour drink mix 
Lemon flavour drink mix 
Orange flavour drink mix
Ribena
Ready-to-drink - all Tetrapak 
varieties
Robinsons
Special R Tropical fruit drink 
RTD in Tetrapak 
Whole orange drink RTD in 
Tetrapak
Rose’s
Diabetic Fruit squashes 
Lime juice cordial
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Fruit Drinks ( including squashes and concentrates )
Robinsons
Apple and blackcurrant drink - 
in Tetrapak RTD 
Pineapple juice drink RTD in 
Tetrapak
Special R Apple and blackcurrant
drink - RTD in Tetrapak
Special R Orange drink RTD in Tetrapak
Fruit Juices
Asda
All chilled and UHT pure fruit 
juices ( including Farm Stores)
Apple & blackcurrant fruit
drink ( no added sugar ) - 3 x 250ml
Britvic
Fruit juices - bottles, cans, Tetrapaks 
Orange juice - draught
Cawston Vale
Pure Fruit Juices - various blends
Copella
Chilled Freshly pressed chilled 
juice, vaarious blends - bottles 
First Press Freshly pressed 
juice, various blends - bottles
Schweppes
Dispensed orange juice 
Fruit juices - in bottles
Mineral Waters
Asda
Val blanc French natural 
mountain spring water
Schweppes
Blackcurrant flavour cordial 
Lime flavour cordial 
Oasis Still fruit drinks with 
spring water 
Peppermint cordial
Copella
Freshly pressed English apple 
juice - bottles and cartons 
Freshly pressed English juice, 
various blends - bottles and cartons
Libby
“C” fruit juice drinks - all varieties 
Fruit juices, unsweetened 
Tomato juice - canned, glass or 
carton
Um Bongo mixed fruit juice drink
Meridian
Fruit juice concentrates
Rowntree
Rowntree fruit juice drink, 
all varieties
Stlvel
Real Fruit juices
Schweppes
Malvern Still and sparkling 
mineral water
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Other Drinks ( including yeast extracts )
Bovril
Beef and vegetable extracts
Beef flavoured drink (vending only)
Chiucken
Snorts Drinks
Schweppes
Energade Isotonic sports drink
Tea
Asda
Tea loose and bags - all varieties
London Herb & Spice
Fruit and herbal teas - all varieties
Appletise
Grapetise
Or angina ( in cans )
Marmite
Yeast extract
Maxpax
Bovril Beef extract drink mix
Maxpax
Lemon tea 
White tea
Typhoo
All black teas 
QT Instant white tea
369
GLASGOW ROYAL INFIRMARY UNIVERSITY NHS TRUST
’ DEPARTMENT OF NUTRITION & DIETETICS
CINNAMON FREE DIET
You have been found to be allergic to cinnamon. This is a natural substance which does not require to be 
stated on food labels. Therefore, always look for the term ‘spices’ on food labels which are not included 
in the Manufactured Products List here.
Foods to be avoided
Soup: Tinned or packet soup with tomato or spices on the label
Meat: Canned meat in spicy sauce. Cold meat containing spices.
Avoid spice for beef ham
Fish: Canned fish in spicy sauce. Avoid made up meat or fish dishes containing
spices e.g. pies, bridies, fish pie, lasagne, pizza.
AVOID curries and Chinese food. Curry pastes, curry sauces.
Spices: Mixed spice, cinnamon, curry powder, Allspice.
Check labels on any other spice mixes.
Baked beans in tomato sauce, ravioli, spaghetti in tomato sauce. “Invaders”. Pork sauces and beans. 
Spaghetti Hoops.
Manufactured cakes and biscuits on list overleaf - and those containing spice. Check label 
Gingerbread.Coffee Buns. Rich Fruit Cake. Keep to home-baking whenever possible.
Pickles and ketchup - see list.
Nuts - Dry Roasted type, Bombay Mix, Spicy Nut Mixes.
Crisps + Snacks - avoid spices. Check labels and Products List.
Mincemeat and Christmas pudding. Mincemeat pies and Christmas cake. Apple Strudel.
Apple cake/tart with cinnamon or spices.
Soft drinks: Coca Cola, Red cola, Vimto, Pepsi Cola, Dr. Peppers.
Alcoholic drinks: Red wine, gin, red and white Martini and Cinzano. Avoid the perfumed
type of alcoholic drinks, e.g. Dubonnet, Malibu, Dark Rum, Tia Maria etc.
Mulled wine.
Toothpaste: All others apart from on Allowed List.. No ‘Tartar Controlled” toothpaste.
AVOID MOUTHWASHES ALSO, unless otherwise stated on Manufactured 
Products List.
Cola sweets: Cola cubes, Cola Chewits, cinnamon sticks, cola chews, etc.
Also see list of manufactured products containing cinnamon.
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- 2 -
Foods Allowed
S o u p s
Meat;
Fish:
Eggs:
Dairy Produce: 
Fats & Oils; 
Fruit:
Vegetables:
Bread:
Homemade or tinned or packet soup not containing spices or tomato. 
All fresh or frozen.
All fresh or frozen.
All types.
Milk - all types. Yoghurt. Butter, cheese, cream - all types. Ice cream. 
Margarine, cooking oils, lard.
All types.
All types including potatoes, salad vegetables.
All types.
Rice, pasta, pulses (peas, beans, barley, lentils), nuts (avoid dry roasted type).
Cereals: All cereals. Breakfast cereals, porridge. Also flour, tapioca, sago, custard 
powder, cornflour.
Cakes & Biscuits: Homemade. Shopbought cakes and biscuits avoiding spices on label
Drinks: Tea, coffee, Oxo, Bovril, Marmite, Boumvita, Cocoa, Drinking Chocolate, 
Horlicks. Squashes, lemonade and any other fizzy drinks apart from those on 
the ‘Avoid List’. Soda water, Appletise, fresh fruit juices. Spring waters.
Alcoholic Drinks: White wine, cider, lager, beer, whisky, vodka.
Miscellaneous: Sugar, salt, pepper, herbs, spices not mentioned on ‘Avoid List’, e.g. nutmeg, 
chilli powder, ginger etc. Jams,marmalade, honey, lemon curd, peanut butter, 
saccharin and other artificial sweeteners.
KAM/RS
12.12.95.
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m a n u f a c t u r e d  p r o d u c t s  in f o r m a t io n  f o r  c in n a m o n
ASDA; No information available.
BARR; Strike Cola only product containing cinnamon.
BATCHELORS: No information available.
BERNARD MATTHEWS: Turkey Tikka only product containing cinnamon.
CADBURY;(TNCL. Chocolate Cream, Old Jamaica only products containing cinnamon. 
SWEPPESI
*
CAMPBELLS: Avoid Tomato Soup only
COLMANS; Products containing cinnamon:
OK Fruit Sauce, Wholegrain Mustard, French Mustard, Dijon Mustard, 
Tikka Masala Dry Sauce Mix. Traditional Herb Mustard.
ANY Curry Sauce or Products.
CO-OP PRODUCTS 
CONTAINING
CINNAMON: Frozen: American Style Double Cream Apple Pie Ice Cream
Apple Strudel 
Summer Fruit Strudel
Canned Traditional Rice Pudding
Apple, Sultana & Cinnamon Custard Style Yoghurt
Apple & Cinnamon Fruit Filled Biscuits
Plain Chocolate Ginger Rings
Milk Chocolate Ginger Rings
Ground Mixed Spice
Ground Cinnamon
It is also recommended to avoid any product with SPICES in the 
ingredients.
DAIRY CREST; 
FARLEY’S:
No products containing cinnamon 
No products containing cinnamon
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GOLDEN WONDER: Products free from Cinnamon;
Crisps
HALLS:
Ready Salted 
Salt & Vinegar 
Cheese & Onion 
Smokey Bacon
Spring Onion 
Steak & Onion 
Pickled Onion 
Roast Chicken
Ringos
Wotsits
Salt & Vinegar Cheese & Onion 
Bacon Cheese Barbequed Beef
Golden Lights Lightly Salted
Pot Noodles Chicken & Mushroom 
Bolognaise 
Vegetable Korma
Fruit Pudding )
Economy Black Pudding )
Puritan Black Pudding )
Marks & Spencer Black Pudding )
Grilled Chicken
Chicken Curry 
Spicy Chicken
ALL CONTAIN 
CINNAMON
HEINZ: See attached list for products free from cinnamon.
H.P. FOODS: See attached list for products free from cinnamon
JACOBS: Fruit & Nut Crunch only product containing cinnamon
KELLOGS: Apple Pop Tarts and also Chocos contain cinnamon
KRAFT: Tomato Ketchup contains cinnamon
LYONS TETLEY: No products containing cinnamon 
MARS: Honey flavoured Tunes only product containing cinnamon
MARKS & 
SPENCER:
No information available.
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MR. KIPLING; Products containing cinnamon:
Mr. Kipling Country Fruit Lemon Tart 
“ “ Country Slices
“ “ Mince Pies
“ “ Luxury Mince Pies
“ “ Glazed Mince Tartlets
“ “ Mince + Brandy Sauce Pies
“ “ Country Fruit Cake
“ “ Christmas Slices
“ “ Christmas Cake
“ “ Stolen Slices
NESTLE: Ice Cream Division; No products containing cinnamon
Food Division: Creamola Foam - Raspberry flavour
Pan Yan Sandwich Piccalilli 
Pan Yan Original Pickle
NESTLEfincl.
ROWNTJKEE Rowntree’s Fruit Gums only product containing cinnamon
CONFECTIONERY):
ROWATS OR 
ROTHWELL:
SAFEWAY:
SAINSBURY:
Products containing cinnamon:
Tomato Ketchup 
Family Sauce
Pickles Silverskin & Cocktail Onions 
Pickled Chip Onions 
Pickled Red Cabbage 
Piccalilli
Hamburger Relish 
No information available at present 
Products containing cinnamon:
Soft Drinks: All products free from cinnamon
Confectionery: Milk chocolate covered almonds dusted with 
cinnamon
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SA1NSBURY - Cont’d.
ST. IVEL: 
TESCO:
Cakes & Biscuits: 1) Chocolate hearts - spicy jam filled Lebkuchen
2) Lebkuchen
3) Lebkuchen Gingerbread Men
4) Milk/Plain Chocolate Continental biscuit 
assortment
5) Pfeffemusse
6) Plum Pudding
7) Alcohol-free Christmas Pudding
8) Raisin & Walnut Malt Loaf
No products containing cinnamon
Follow general guidelines - avoid coke, baked beans, sauces, curried 
and spicy foods. Fresh Chicken Korma (in chilled cabinet) and 
Barbeque Sauce are free from cinnamon.
TREBOR BASSETT: No products containing cinnamon
THORNTONS: No products containing cinnamon
THOMAS TUNNOCK: Chocolate Perkins and Perkins contain cinnamon.
WALLS: ‘Country Fair’ Vermont Apple Cinnamon Pie contains cinnamon
FOX’S BISCUITS: Fruit Shrewsbury are only products containing cinnamon
WR1GLEY: Big Red and Juicy Fruit are only products containing cinnamon
TOOTHPASTE: Colgate/Palmolive - Products containing cinnamon
Colgate Blue Minty Gel 
Colgate Plax 
Colgate Actibmsh
Stafford Miller
Smith Kline Beecham 
Procter & Gamble
Search Dental Rinse contains 
cinnamon. All other products 
suitable for use.
All products free from cinnamon
All products free from cinnamon 
Le. Crest.
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The following Heinz products are free from Cinnamon 
WEIGHT WATCHERS FROM HEINZ PRODTTCTS
SAUCES, SALADS & PICKLES
Cooking Sauce, French White Wine & Dill 
Cooking Sauce, Indian Konna 
Cooking Sauce, Italian Tomato & Onion 
Cooking Sauce, Oriental Sweet & Sour 
Low Fat Dressing 
Low Fat Dressing, Mild Mustard 
Low Fat Dressing, Thousand Island 
Low Fat Dressing, Yoghurt & Herb 
Mayonnaise, Reduced Calorie
PASTA
Italiana, Bolognese Shells
Italiana, Pasta Tubes in Cheese Sauce with Bacon
Italiana, Tortellini
Italiana, Tuna Twists
Italiana, Vegetable Ravioli with Tomato Sauce 
Spaghetti in Tomato Sauce, No Added Sugar
DAIRY PRODUCTS
Cheese Slices, Reduced Fat
Dairy Spread with Cheese & Ham, Reduced Fat
Dairy Spread with Cheese, Reduced Fat
Dairy Spread, Cheese, Onions & Chives, Reduced Fat
Hard Cheese, Reduced Fat
FRENCH BREAD PIZZAS
French Bread Pizza, Cheese & Tomato 
French Bread Pizza, Ham & Mushroom 
French Bread Pizza, Ham & Pineapple 
French Bread Pizza, Pepperoni
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WEIGHT WATCHERS FROM HEINZ PRODUCTS Cont’d.
FROZEN READY MEALS
Beef Lasagne
Beef Oriental with Rice
Big Deal, Beef Goulash with Parsley Rice
Big Deal, Cajun Chicken
Big Deal, Chilli Con Came with Rice
Big Deal, Keema Curry with Cumin Rice
Cannelloni Filled with Vegetables
Cauliflower Cheese
Chicken & Broccoli Pasta Bake
Chicken Chasseur with Rice
Chicken Curry with Rice
Chicken Marengo with Rice
Chicken Supreme
Fish Provincale with Noodles
Mediterranean Chicken
Pasta Bolognese
Pasta Shells with Vegetables & Prawns
Salmon & Prawn Fricasse
Salmon Momay
Seafood Bake with Broccoli
Smoked Fish with Pasta Bows
Spaghetti Bolognese
Sweet & Sour Chicken with Rice
Sweet & Sour Vegetables
Tagliatelle Carbonara
Vegetable au Gratin
Vegetable Chilli with Rice
Vegetable Hotpot
Vegetable Lasagne
Vegetable Moussaka
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DESSERTS
Cheesecake, Blackcurrant
Cheesecake, Strawberry
Dairy Ice Cream, Chocolate Ripple
Dairy Ice Cream, Neapolitan
Dairy Ice Cream, Strawberry
Dairy Ice Cream, Vanilla
Dessert Bombes, Chocolate with Orange Liqueur
Dessert Bombes, Lemon
Dessert Bombes, Mint Chocolate
Dessert Bombes, Tropical Fruit
Premium Ice Cream, Lemon Meringue
Premium Ice Cream, Strawberries & Cream
Premium Ice Cream, Triple Chocolate Fudge
Premium Ice Cream, Triple Toffee Fudge
Rice Pudding, No Added Sugar, Low Fat
Torte, Orange & Lemon
Torte, Peach & Apricot
Torte, Raspberry
JAMS & MARMALADES
Apricot Jam, Reduced Sugar 
Blackcurrant Jam, Reduced Sugar 
Fruits of the Forest Jam, Reduced Sugar 
Marmalade, Reduced Sugar 
Morello Cherry Jam, Reduced Sugar 
Raspberry Jam, Reduced Sugar 
Strawberry Jam, Reduced Sugar
BREAD & ROLLS
Brown Bread
Danish Brown Bread
Danish Malted Softgrain Bread
Danish White Bread
Oat Danish Bread
Soft Brown Rolls
Soft White Rolls
White Bread
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CANNED SOUPS
Chicken & Ham with Rice Soup 
Chicken Noodle Soup 
Chicken Soup
Country Vegetable & Beef Soup 
Country Vegetable Soup 
Lentil & Carrot Soup 
Mushroom Soup 
Vegetable Soup
Wholesome Soup, Lentil & Chicken 
Wholesome Soup, Winter Vegetable
INSTANT SOUPS
Asparagus & Leek Soup, 40kcal
Chicken & Sweetcom Soup, 60kcal
Chicken & Vegetable Soup with Noodles, 60kcal
Chicken & Vegetable Soup, 40kcals
Chicken Soup, 40kcal
Minestrone Soup, 60kcal
Mushroom Soup, 40kcal
Mushroom Soup, 60kcal
Tomato Soup, 40kcal
Tomato Soup, 60kcal
Vegetable Soup with Croutons, 60kcal
Vegetable Soup, 40kcal
BISCUITS & SNACKS
Cookies, Dark Treacle 
Cookies, Real Chocolate Chip 
Cookies, Stem Ginger
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The following Heinz products are free from Cinnamon
CORE PRODUCTS
BAKED BEANS
Barbecue Beans 
Curried Beans with Sultanas
LUNCH BOWLS
Beef Curry with Rice 
Beef Goulash with Noodles 
Chicken Curry with Rice 
Chilli Con Came with Rice 
Lamb and Vegetable Casserole
PASTA
Chefs Specials, Chicken Ravioli in Tomato Sauce
Chefs Specials, Macaroni Cheese
Chefs Specials, Pasta Pipes with Tuna & Bacon
Chefs Specials, Ravioli in Spicy Sauce
Chefs Specials, Sausage Hotpot with Pasta
Chefs Specials, Spicy Beef Pasta Twists
Dinosaurs with Mini Meat Boulders
Dinosaurs, Pasta Shapes in Tomato Sauce
Magic Roundabout, Spaghetti Shapes in Tomato Sauce
Noodle Doodles, Spaghetti Shapes in Tomato Sauce
Spaghetti Hoops in Tomato Sauce
Spaghetti in Tomato Sauce
Spaghetti with Sausages
Super Mario, Spaghetti Shapes in Tomato Sauce
Thomas the Tank Engine, Spaghetti in Tomato Sauce
SAUCES, SALADS & PICKLES
Apple Sauce
Coleslaw Salad
Coronation Sauce
Mayonnaise
Mixed Bean Salad
Pasta Salad
Ploughman’s Piccalilli
Ploughman’s Pickle
Ploughman’s Tangy Sandwich Pickle
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CINNAMON FREE PRODUCTS
HEINZ CORE PRODUCTS Cont’d.
SAUCES, SALADS & PICKLES Cont’d.
Ploughman’s Tomato Pickle
Potato Salad
Salad Cream
Salad Cream, Spoonable
Salsa, Medium-Hot
Salsa, Milk-Medium
Sandwich Spread, Cucumber
Sandwich Spread, Spicy
Sandwich Spread, Sweetcom & Red Pepper
Silverskin Onions
Vegetable Salad
SPONGE PUDDINGS
Sponge Pudding, Banana with Toffee Sauce 
Sponge Pudding, Chocolate with Chocolate Sauce 
Sponge Pudding, Lemon 
Sponge Padding, Mixed Fruit 
Sponge Pudding, Strawberry Jam 
Sponge Pudding, Treacle
READY TO SERVE SOUPS
Beef Soup
Big Soup, Beef & Bacon Hotpot
Big Soup, Beef & Vegetable
Big Soup, Beef Broth
Big Soup, Chicken & Ham
Big Soup, Chicken & Vegetable
Big Soup, Chicken, Leek & Potato
Big Soup, Giant Minestrone
Big Soup, Spicy Tomato with Beef Pasta Parcels
Big Soup, Thick Country Vegetable with Ham
Chicken & Mushroom Soup
Cream of Asparagus Soup
Cream of Celery Soup
Cream of Chicken Soup
Cream of Mushroom Soup
Farmhouse Beef & Vegetable Soup
Farmhouse Beef Broth
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CINNAMON FREE PRODUCTS Cont’d.
READY TO SERVE SOUPS Cont’d.
Farmhouse Chicken & Vegetable Soup 
Farmhouse Potato & Leek Soup 
Farmhouse Scotch Broth 
Mulligatawny Soup 
Oxtail Soup
Pasta Soup, Beef & Tomato Bolognese
Pasta Soup, Chicken Pastini
Pasta Soup, Minestrone
Pasta Soup, Mushroom Carbonara
Pasta Soup, Tomato Napoli
Premium Soup, Bee£ Potato & Red Pepper
Premium Soup, Carrot, Potato & Coriander
Premium Soup, Chicken Sweet Pepper & Dill
Premium Soup, Chicken, Sweetcom & Asparagus
Premium Soup, Country Bean with Mushroom
Premium Soup, Seven Vegetable
Scottish Vegetable Soup with Lentils
Spicy Soup, Chilli Bean & Beef
Spicy Soup, Curried Chicken with Rice
Spring Vegetable Soup
Vegetable Soup
Wholesoup, Farmhouse Vegetable 
Wholesoup, Ham & Butter Bean 
Wholesoup, Lentil 
Wholesoup, Pea & Ham 
Wholesoup, Winter Vegetable
TOPPERS
Toast Toppers, Chicken & Mushroom 
Toast Toppers, Ham & Cheese 
Toast Toppers, Mushroom & Bacon
CANNED TUNA
Tuna Chunks, Canned in Brine 
Tuna Chunks, Canned in Vegetable Oil 
Tuna Steak, Canned in Brine 
Tuna Steak, Canned in Vegetable Oil
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HP FOODS LTD. NUTRITION INFORMATION 21-3.94.
CINNAMON CONTENT
PRESENT ABSENT 
HP SAUCE V
HP FRUITY SAUCE ^
HP TOMATO KETCHUP V
HP SPICY TOMATO SAUCE V
HP CHILLI SAUCE V
HP CURRY SAUCE V
HP FRUITY BARBECUE SAUCE V
HP SWEET & SOUR SAUCE V
HP ORIGINAL BARBECUE SAUCE V
HP MEXICAN SPICY BARBECUE SAUCE V
HP RICH JAMAICAN BARBECUE SAUCE V
HP MINT SAUCE V
HP MAYONNAISE (BULK) V
HP MALT VINEGAR V
HP BEANS IN TOMATO SAUCE V
HP HEALTHY BEANS V
HP BAKED BEANS IN TOMATO SAUCE (CATERING) V
v
HP HEALTHY BEANS IN TOMATO SAUCE (CATERING)
HP BEANS AND BEEFBURGERS V
HP BEANS AND SAUSAGE V
HP SAUCY BEANS V
HP BIG BREAKFAST BIG BEANS IN TOMATO SAUCE V
HP BIG BREAKFAST BIG BEANS & JUMBO SAUSAGES V
HP BATMAN BOLOGNESE V
HP PASTA SHAPES IN TOMATO SAUCE V
HP SPAGHETTI IN TOMATO SAUCE V
HP GLADIATORS IN TOMATO SAUCE (REDUCED SUGAR) V
HP GLADIATORS IN SMOKEY BACON SAUCE V
HP GLADIATORS IN PIZZA SAUCE WITH PEPPERONI V
HP SONIC AND SAUSAGES IN TOMATO SAUCE V
HP SONIC RAVIOLI SHAPES IN TOMATO SAUCE V
HP CHICKEN KORMA BISTRO BREAK V
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HP SWEET & SOUR BISTRO BREAK 
HP CANNELLONI BISTRO BREAK 
HP LASAGNE BOLOGNESE BISTRO BREAK
DADDIES TOMATO KETCHUP V
DADDIES BROWN SAUCE V
DADDIES BURGER RELISH V
DADDIES SALAD CREAM V
FLETCHERS TIGER SAUCE V
FLETCHERS TITBITS SAUCE V
FLETCHERS BROWN SAUCE V
FLETCHERS TOMATO KETCHUP V
FLETCHERS BAKED BEANS IN TOMATO SAUCE V
FLETCHERS SHORT CUP SPAGHETTI IN TOMATO SAUCE V
L & P WORCESTERSHIRE SAUCE V
L & P CHILLI & GARLIC SAUCE V
L & P GINGER & ORANGE SAUCE V
L & P GARLIC & SPRING ONION SAUCE V
L & P HOT PEPPER SAUCE V
L & P  MUSTARD & PEPPERCORN SAUCE V
L & P GARLIC SAUCE V
L & P  FRUIT SAUCE V
L & P  WORCESTER KETCHUP V
L & P  TOMATO KETCHUP WITH MILK CURRY SPICES V
L & P  SOY & GARLIC V
L & P  HOT PEPPER & UME V
L & P  SOY&FIVE SPICE V
L & P  CURRY CONCENTRATE V
L & P  ITALIAN VINAIGRETTE MAKER V
L & P  WHITE WINE & GARLIC VINAIGRETTE MAKER V
L & P  CLASSIC FRENCH VINAIGRETTE MAKER V
L&PPICKLE WITH WORCESTER SAUCE V
L & P  SWEET PEPPERS WITH CHILLI SAUCE V
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L &B P GINGER SAUCE 
L & P  GREEN JALAPENO SAUCE
Home Made Tomato Soup
4 Pints Vegetable Stock 
1/2 lb Onions 
tsp. Tomato Puree 
One small tin evaporated milk
1 1/2 oz Plain Cornflour } make to a fluid with a little water
2 oz granulated sugar }
Salt & Pepper
Mince onions finely.
Add to stock with tomato puree. Bring to boil, then simmer. 
Add cornflour and sugar. Simmer for about 1/2 hour.
Strain, re-heat, add evaporated milk and salt & pepper.
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Glasgow Royal Infirmary University NHS Trust
Department of Nutrition & Dietetics 
Benzoate <fe Cinnamon Free Diet
You have been found to be allergic to the above preservative - Benzoate, and the spice - 
Cinnamon.
Benzoate - As most of the benzoates in the diet are added to foods as a preservative it is 
very important that you read the labels of any manufactured or prepared foods you 
consume. If benzoates are added to the food the manufacturer may name the particular 
benzoate or use a serial number known as an E number. Avoid those containing E210 - 
E219 inclusive.
The E numbers and the benzoate names are listed below:
E210 - Benzoic Acid
E211 - Sodium Benzoate
E212 - Potassium Benzoate
E213 - Calcium Benzoate
E214 - Ethyl 4-hydroxybenzoate
E215 - Ethyl 4- hydroxybenzoate sodium salt
E216 - Propyl 4-hydroxybenzoate
E217 - Propyl 4-hydroxybenzoate sodium salt
E218 - Methyl 4-hydroxybenzoate
E219 - Methyl 4-hydroxybenzoate sodium salt
Avoid any food or drink which just lists the word Preservative or Permitted 
Preservative as an ingredient.
Cinnamon This is a natural substance which does not require to be stated on food labels. 
This diet sheet and accompanying manufactured product list will give you information on 
the foods to be avoided. Also, always look for the term “spices” on food labels which are 
not included in the manufacturer’s product list and avoid these.
Avoid Any Item Containing These
If you have any queries regarding the dietary information please contact:
Dietitian:
Hospital:
Telephone Number:
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MANUFACTURED PRODUCTS INFORMATION FOR CINNAMON
ASDA: No information available.
BARR: Strike Cola only product containing cinnamon.
BATCHELORS: No information available.
BERNARD MATTHEWS: Turkey Tikka only product containing cinnamon.
CADBURYrHNCL. Chocolate Cream, Old Jamaica only products containing cinnamon. 
SWEPPESt
CAMPBELLS:
COLMANS:
Avoid Tomato Soup only 
Products containing cinnamon:
OK Fruit Sauce, Wholegrain Mustard, French Mustard, Dijon Mustard, 
Tikka Masala Dry Sauce Mix. Traditional Herb Mustard.
ANY Curry Sauce or Products.
CO-OP PRODUCTS 
CONTAINING 
CINNAMON:
DAIRY CREST: 
FARLEY’S:
Frozen: American Style Double Cream Apple Pie Ice Cream
Apple Strudel 
Summer Fruit Strudel
Canned Traditional Rice Pudding
Apple, Sultana & Cinnamon Custard Style Yoghurt
Apple & Cinnamon Fruit Filled Biscuits
Plain Chocolate Ginger Rings
Milk Chocolate Ginger Rings
Ground Mixed Spice
Ground Cinnamon
It is also recommended to avoid any product with SPICES in the 
ingredients.
No products containing cinnamon 
No products containing cinnamon
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GOLDEN WONDER; Products free from Cinnamon: 
Crisps
HALLS:
HEINZ:
H.P. FOODS; 
JACOBS; 
KELLOGS: 
KRAFT:
Ready Salted 
Salt & Vinegar 
Cheese & Onion 
Smokey Bacon
Spring Onion 
Steak & Onion 
Pickled Onion 
Roast Chicken
Ringos
Wotsits
Salt & Vinegar Cheese & Onion 
Bacon Cheese Barbequed Beef
Golden Lights Lightly Salted
Pot Noodles Chicken & Mushroom 
Bolognaise 
Vegetable Korma
Fruit Pudding )
Economy Black Pudding )
Puritan Black Pudding )
Marks & Spencer Black Pudding )
Grilled Chicken
Chicken Curry 
Spicy Chicken
ALL CONTAIN 
CINNAMON
See attached list for products free from cinnamon.
See attached list for products free from cinnamon 
Fruit & Nut Crunch only product containing cinnamon 
Apple Pop Tarts and also Chocos contain cinnamon 
Tomato Ketchup contains cinnamon 
LYONS TETLEY: No products containing cinnamon 
MARS: Honey flavoured Tunes only product containing cinnamon
MARKS & 
SPENCER:
No information available.
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MR. KIPLING: Products containing cinnamon:
Mr. Kipling Country Fruit Lemon Tart 
“ “ Country Slices
“ “ Mince Pies
“ “ Luxury Mince Pies
“ “ (Hazed Mince Tartlets
“ “ Mince + Brandy Sauce Pies
“ “ Country Fruit Cake
“ “ Christmas Slices
“ “ Christmas Cake
“ “ Stolen Slices
NESTLE: Ice Cream Division: No products containing cinnamon
Food Division: Creamola Foam - Raspberry flavour
Pan Yan Sandwich Piccalilli 
Pan Yan Original Pickle
NESTLEfincl.
ROW NlKEE Rowntree’s Fruit Gums only product containing cinnamon
CONFECTIONER Yt:
ROWATS OR 
ROTHWELL:
SAFEWAY:
SAINSBURY:
Products containing cinnamon:
Tomato Ketchup 
Family Sauce
Pickles Silverskin & Cocktail Onions 
Pickled Chip Onions 
Pickled Red Cabbage 
Piccalilli
Hamburger Relish 
No information available at present 
Products containing cinnamon:
Soft Drinks: All products free from cinnamon
Confectionery: Milk chocolate covered almonds dusted with 
cinnamon
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SAJNSBURY -Cont’d.
ST. IVEL: 
TESCO:
Cakes & Biscuits: 1) Chocolate hearts - spicy jam filled Lebkuchen
2) Lebkuchen
3) Lebkuchen Gingerbread Men
4) Milk/Plain Chocolate Continental biscuit 
assortment
5) PfefFemusse
6) Plum Pudding
7) Alcohol-free Christmas Pudding
8) Raisin & Walnut Malt Loaf
No products containing cinnamon
Follow general guidelines - avoid coke, baked beans, sauces, curried 
and spicy foods. Fresh Chicken Korma (in chilled cabinet) and 
Barbeque Sauce are free from cinnamon.
TREBOR BASSETT: No products containing cinnamon
THORNTONS: No products containing cinnamon
THOMAS TUNNOCK: Chocolate Perkins and Perkins contain cinnamon.
WALLS: ‘Country Fair’ Vermont Apple Cinnamon Pie contains cinnamon
FOX’S BISCUITS: Fruit Shrewsbury are only products containing cinnamon
WRIGLEY; Big Red and Juicy Fruit are only products containing cinnamon
TOOTHPASTE: Colgate/Palmolive - Products containing cinnamon
Colgate Blue Minty Gel 
Colgate Plax 
Colgate Actibrush
Stafford Miller
Smith Kline Beecham 
Procter & Gamble
Search Dental Rinse contains 
cinnamon. All other products 
suitable for use.
All products free from cinnamon
All products free from cinnamon 
ie. Crest.
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The following Heinz products are free from Cinnamon
WEIGHT WATCTTFRS FROM HEINZ PRODUCTS
SAUCES, SALADS & PICKLES
Cooking Sauce, French White Wine & Dill 
Cooking Sauce, Indian Korma 
Cooking Sauce, Italian Tomato & Onion 
Cooking Sauce, Oriental Sweet & Sour 
Low Fat Dressing 
Low Fat Dressing, Mild Mustard 
Low Fat Dressing, Thousand Island 
Low Fat Dressing, Yoghurt & Herb 
Mayonnaise, Reduced Calorie
PASTA
Italiana, Bolognese Shells
Italiana, Pasta Tubes in Cheese Sauce with Bacon
Italiana, Tortellini
Italiana, Tuna Twists
Italiana, Vegetable Ravioli with Tomato Sauce 
Spaghetti in Tomato Sauce, No Added Sugar
DAIRY PRODUCTS
Cheese Slices, Reduced Fat
Dairy Spread with Cheese & Ham, Reduced Fat
Dairy Spread with Cheese, Reduced Fat
Dairy Spread,Cheese, Onions & Chives, Reduced Fat
Hard Cheese, Reduced Fat
FRENCH BREAD PIZZAS
French Bread Pizza, Cheese & Tomato 
French Bread Pizza, Ham & Mushroom 
French Bread Pizza, Ham & Pineapple 
French Bread Pizza, Pepperoni
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WEIGHT WATCHERS FROM HEINZ PRODUCTS Cont’d.
FROZEN READY MEALS
Beef Lasagne
Beef Oriental with Rice
Big Deal, Beef Goulash with Parsley Rice
Big Deal, Cajun Chicken
Big Deal, Chilli Con Came with Rice
Big Deal, Keema Curry with Cumin Rice
Cannelloni Filled with Vegetables
Cauliflower Cheese
Chicken & Broccoli Pasta Bake
Chicken Chasseur with Rice
Chicken Curry with Rice
Chicken Marengo with Rice
Chicken Supreme
Fish Provincale with Noodles
Mediterranean Chicken
Pasta Bolognese
Pasta Shells with Vegetables & Prawns
Salmon & Prawn Fricasse
Salmon Momay
Seafood Bake with Broccoli
Smoked Fish with Pasta Bows
Spaghetti Bolognese
Sweet & Sour Chicken with Rice
Sweet & Sour Vegetables
Tagliatelle Carbonara
Vegetable au Gratin
Vegetable Chilli with Rice
Vegetable Hotpot
Vegetable Lasagne
Vegetable Moussaka
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DESSERTS
Cheesecake, Blackcurrant
Cheesecake, Strawberry
Dairy Ice Cream, Chocolate Ripple
Dairy Ice Cream, Neapolitan
Dairy Ice Cream, Strawberry
Dairy Ice Cream, Vanilla
Dessert Bombes, Chocolate with Orange Liqueur
Dessert Bombes, Lemon
Dessert Bombes, Mint Chocolate
Dessert Bombes, Tropical Fruit
P rem ium  Ice Cream, Lemon Meringue
Premium Ice Cream, Strawberries & Cream
Premium Ice Cream, Triple Chocolate Fudge
Premium Ice Cream, Triple Toffee Fudge
Rice Pudding, No Added Sugar, Low Fat
Torte, Orange & Lemon
Torte, Peach & Apricot
Torte, Raspberry
JAMS & MARMALADES
Apricot Jam, Reduced Sugar 
Blackcurrant Jam, Reduced Sugar 
Fruits of the Forest Jam, Reduced Sugar 
Marmalade, Reduced Sugar 
Morello Cherry Jam, Reduced Sugar 
Raspberry Jam, Reduced Sugar 
Strawberry Jam, Reduced Sugar
BREAD & ROLLS
Brown Bread
Danish Brown Bread
Danish Malted Softgrain Bread
Danish White Bread
Oat Danish Bread
Soft Brown Rolls
Soft White Rolls
White Bread
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CANNED SOUPS
Chicken & Ham with Rice Soup 
Chicken Noodle Soup 
Chicken Soup
Country Vegetable & Beef Soup 
Country Vegetable Soup 
Lentil & Carrot Soup 
Mushroom Soup 
Vegetable Soup
Wholesome Soup, Lentil & Chicken 
Wholesome Soup, Winter Vegetable
INSTANT SOUPS
Asparagus & Leek Soup, 40kcal
Chicken & Sweetcom Soup, 60kcal
Chicken & Vegetable Soup with Noodles, 60kcal
Chicken & Vegetable Soup, 40kcals
Chicken Soup, 40kcal
Minestrone Soup, 60kcal
Mushroom Soup, 40kcal
Mushroom Soup, 60kcal
Tomato Soup, 40kcal
Tomato Soup, 60kcal
Vegetable Soup with Croutons, 60kcal
Vegetable Soup, 40kcal
BISCUITS & SNACKS
Cookies, Dark Treacle 
Cookies, Real Chocolate Chip 
Cookies, Stem Ginger
400
The following Heinz products are free from Cinnamon
CORE PRODUCTS
BAKED BEANS
Barbecue Beans 
Curried Beans with Sultanas
LUNCH BOWLS
Beef Cuny with Rice 
Beef Goulash with Noodles 
Chicken Curry with Rice 
Chilli Con Came with Rice 
Lamb and Vegetable Casserole
PASTA
Chefs Specials, Chicken Ravioli in Tomato Sauce
Chefs Specials, Macaroni Cheese
Chefs Specials, Pasta Pipes with Tuna & Bacon
Chefs Specials, Ravioli in Spicy Sauce
Chefs Specials, Sausage Hotpot with Pasta
Chefs Specials, Spicy Beef Pasta Twists
Dinosaurs with Mini Meat Boulders
Dinosaurs, Pasta Shapes in Tomato Sauce
Magic Roundabout, Spaghetti Shapes in Tomato Sauce
Noodle Doodles, Spaghetti Shapes in Tomato Sauce
Spaghetti Hoops in Tomato Sauce
Spaghetti in Tomato Sauce
Spaghetti with Sausages
Super Mario, Spaghetti Shapes in Tomato Sauce
Thomas the Tank Engine, Spaghetti in Tomato Sauce
SAUCES, SALADS & PICKLES
Apple Sauce
Coleslaw Salad
Coronation Sauce
Mayonnaise
Mixed Bean Salad
Pasta Salad
Ploughman’s Piccalilli
Ploughman’s Pickle
Ploughman’s Tangy Sandwich Pickle
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CINNAMON FREE PRODUCTS
HEINZ CORE PRODUCTS Cont’d.
SAUCES, SALADS & PICKLES Cont’d.
Ploughman’s Tomato Pickle
Potato Salad
Salad Cream
Salad Cream, Spoonable
Salsa, Medium-Hot
Salsa, Milk-Medium
Sandwich Spread, Cucumber
Sandwich Spread, Spicy
Sandwich Spread, Sweetcom & Red Pepper
Silverskin Onions
Vegetable Salad
SPONGE PUDDINGS
Sponge Pudding, Banana with Toffee Sauce 
Sponge Pudding, Chocolate with Chocolate Sauce 
Sponge Pudding, Lemon 
Sponge Pudding, Mixed Fruit 
Sponge Pudding, Strawberry Jam 
Sponge Pudding, Treacle
READY TO SERVE SOUPS
Beef Soup
Big Soup, Beef & Bacon Hotpot
Big Soup, Beef & Vegetable
Big Soup, Beef Broth
Big Soup, Chicken & Ham
Big Soup, Chicken & Vegetable
Big Soup, Chicken, Leek & Potato
Big Soup, Giant Minestrone
Big Soup, Spicy Tomato with Beef Pasta Parcels
Big Soup, Thick Country Vegetable with Ham
Chicken & Mushroom Soup
Cream of Asparagus Soup
Cream of Celery Soup
Cream of Chicken Soup
Cream of Mushroom Soup
Farmhouse Beef & Vegetable Soup
Farmhouse Beef Broth
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CINNAMON FREE PRODUCTS Cont’d.
READY TO SERVE SOUPS Cont’d.
Farmhouse Chicken & Vegetable Soup 
Farmhouse Potato & Leek Soup 
Farmhouse Scotch Broth 
Mulligatawny Soup 
Oxtail Soup
Pasta Soup, Beef & Tomato Bolognese
Pasta Soup, Chicken Pastmi
Pasta Soup, Minestrone
Pasta Soup, Mushroom Carbonara
Pasta Soup, Tomato Nap oh
Premium Soup, Beef Potato & Red Pepper
Premium Soup, Carrot, Potato & Coriander
P re m iu m  Soup, Chicken Sweet Pepper & Dill
Premium Soup, Chicken, Sweetcom & Asparagus
Premium Soup, Country Bean with Mushroom
Premium Soup, Seven Vegetable
Scottish Vegetable Soup with Lentils
Spicy Soup, Chilli Bean & Beef
Spicy Soup, Curried Chicken with Rice
Spring Vegetable Soup
Vegetable Soup
Wholesoup, Farmhouse Vegetable 
Wholesoup, Ham & Butter Bean 
Wholesoup, Lentil 
Wholesoup, Pea & Ham 
Wholesoup, Winter Vegetable
TOPPERS
Toast Toppers, Chicken & Mushroom 
Toast Toppers, Ham & Cheese 
Toast Toppers, Mushroom & Bacon
CANNED TUNA
Tuna Chunks, Canned in Brine 
Tuna Chunks, Canned in Vegetable Oil 
Tuna Steak, Canned in Brine 
Tuna Steak, Canned in Vegetable Oil
403
HP FOODS LTD. NUTRITION INFORMATION 21.3.94.
CINNAMON CONTENT
PRESENT ABSENT 
HP SAUCE V
HP FRUITY SAUCE V
HP TOMATO KETCHUP V
HP SPICY TOMATO SAUCE V
HP CHILLI SAUCE V
HP CURRY SAUCE V
HP FRUITY BARBECUE SAUCE V
HP SWEET & SOUR SAUCE a/
HP ORIGINAL BARBECUE SAUCE V
HP MEXICAN SPICY BARBECUE SAUCE a/
HP RICH JAMAICAN BARBECUE SAUCE 'I
HP MINT SAUCE V
HP MAYONNAISE (BULK) V
HP MALT VINEGAR a/
HP BEANS IN TOMATO SAUCE a/
HP HEALTHY BEANS V
HP BAKED BEANS IN TOMATO SAUCE (CATERING) V
HP HEALTHY BEANS IN TOMATO SAUCE (CATERING) ^
HP BEANS AND BEEFBURGERS a/
HP BEANS AND SAUSAGE V
HP SAUCY BEANS V
HP BIG BREAKFAST BIG BEANS IN TOMATO SAUCE V
HP BIG BREAKFAST BIG BEANS & IUMBO SAUSAGES V
HP BATMAN BOLOGNESE V
HP PASTA SHAPES IN TOMATO SAUCE a/
HP SPAGHETTI IN TOMATO SAUCE V
HP GLADIATORS IN TOMATO SAUCE (REDUCED SUGAR) V
HP GLADIATORS IN SMOKEY BACON SAUCE a/
HP GLADIATORS IN PIZZA SAUCE WITH PEPPERONI V
HP SONIC AND SAUSAGES IN TOMATO SAUCE a/
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HP SONIC RAVIOLI SHAPES IN TOMATO SAUCE V
HP CHICKEN KORMA BISTRO BREAK V
HP SWEET & SOUR BISTRO BREAK V
HP CANNELLONI BISTRO BREAK V
HP LASAGNE BOLOGNESE BISTRO BREAK V
DADDIES TOMATO KETCHUP V
DADDIES BROWN SAUCE V
DADDIES BURGER RELISH V
DADDIES SALAD CREAM V
FLETCHERS TIGER SAUCE V
FLETCHERS TITBITS SAUCE V
FLETCHERS BROWN SAUCE V
FLETCHERS TOMATO KETCHUP V
FLETCHERS BAKED BEANS IN TOMATO SAUCE V
FLETCHERS SHORT CUP SPAGHETTI IN TOMATO SAUCE V
L & P WORCESTERSHIRE SAUCE V
L & P CHILLI & GARLIC SAUCE V
L & P GINGER & ORANGE SAUCE V
L & P GARLIC & SPRING ONION SAUCE V
L & P HOT PEPPER SAUCE V
L & P MUSTARD & PEPPERCORN SAUCE V
L & P GARLIC SAUCE V
L& PFRU IT SAUCE V
L & P WORCESTER KETCHUP V
L&PTOMATOKETCHUP WITH MILK CURRY SPICES V
L & P SOY & GARLIC V
L & P HOT PEPPER & LIME V
L & P SOY & FIVE SPICE V
L & P  CURRY CONCENTRATE V
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L & P ITALIAN VINAIGRETTE MAKER V
L & P WHITE WINE & GARLIC VINAIGRETTE MAKER V
L & P  CLASSIC FRENCH VINAIGRETTE MAKER V
L& PPICKLE WITH WORCESTER SAUCE V
L & P  SWEET PEPPERS WITH CHILLI SAUCE V
L & B P  GINGER SAUCE V
L & P  GREEN JALAPENO SAUCE V
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Home Made Tomato Soup
4 Pints Vegetable Stock 
1/2 lb Onions 
tsp. Tomato Puree 
One small tin evaporated milk
1 1/2 oz Plain Cornflour } make to a fluid with a little water
2 oz granulated sugar }
Salt & Pepper
Mince onions finely.
Add to stock with tomato puree. Bring to boil, then simmer. 
Add cornflour and sugar. Simmer for about 1/2 hour.
Strain, re-heat, add evaporated milk and salt & pepper.
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Glasgow Roval Infirmary University NHS Trust
Department of Nutrition & Dietetics
Benzoate, Sorbic Acid and Cinnamon Free Diet
You have been found to be allergic to the above preservatives - Benzoate, Sorbic Acid 
and the spice - Cinnamon.
Benzoate - As most of the benzoates in the diet are added to foods as a preservative it is 
very important that you read the labels of any manufactured or prepared foods you 
consume. If benzoates are added to the food the manufacturer may name the particular 
benzoate or use a serial number known as an E number. Avoid those containing E210 - 
E219 inclusive.
Sorbic Acid is also added to foods as a preservative. It has 4 E numbers, E200. E201. 
E202 and E203. If a food contains this preservative it will be stated on the labels. The E 
numbers and the benzoate names are listed below:
Avoid any food or drink which justs lists the word preservative or permitted 
preservative as an ingredient.
Cinnamon - This is a natural substance which does not require to be stated on food 
labels. This diet sheet and accompanying manufactured product list will give you 
information on foods to be avoided. Also, always look for the term “spices” on food 
labels which are not included in the manufacturer’s product list and avoid these.
Avoid any item containing these.
E200
E201
E202
E203
E210
E211
E212
E213
E214
E215
E216
E217
E218
E219
Sorbic Acid
Sodium Sorbate
Potassium Sorbate
Calcium Sorbate
Benzoate Acid
Sodium Benzoate
Potassium Benzoate
Calcium Benzoate
Ethyl 4-hydroxybenzoate
Ethyl 4-hydroxybenzoate sodium salt
Propyl 4-hydroxybenzoate
Propyl 4-hydroxybenzoate sodium salt
Methyl 4-hydroxybenzoate
Methyl 4-hydroxybenzoate sodium salt
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GLASGOW ROYAL INFIRMARY UNIVERSITY NHS TRUST 
DEPARTMENT OF NUTRITION & DIETETICS 
LOW SALICYLATE DIET
Your condition is aggravated by SALICYLATE which is a substance found in aspirin, and also 
in some foods which we eat. It is recommended that you omit the foods listed in the FOODS 
TO AVOID column from your diet.
FOODS ALLOWED
All meats,fish,eggs,milk,butter,cheese,cream, 
yoghurt, margarine.
Soups - most types.
Cereals - all types.
Breakfast cereals not containing dried fruit.
Pasta - all types.
Rice - all types.
All nuts apart from those on ‘AVOID’ list.
Plain cakes.biscuits.scones and other baking 
not containing dried fruit or forbidden spices.
Chocolate caramels.toffee.boiled sweets not 
containing dried fruit or nuts.
Lemons,mangoes.bananas,lychees,pears, 
plums,pomegranate.rhubarb,fresh figs, 
passion fruit. Varieties of apple not on 
‘AVOID’ list, i.e.Golden Delicious,
Cox’s Pippin.
No more than half a pint of fresh orange, 
apple juice per day.
Tomato Juice.
FOODS TO AVOID
Tomato soup.
Breakfast cereals containing dried fruit, e.g. 
muesli.
Pasta dishes containing forbidden spices (see 
over)
Almonds,water chestnuts,peanuts,Brazil 
nuts.walnuts.pistacliio nuts.
Dried fruit - sultanas,raisins,currants,prunes, 
dates.apricots, dried figs.
Foods containing the nuts and dried fruit 
Mentioned above i.e. Christmas pudding, 
fruit cake. Garibaldi biscuits, Fruit & Nut 
chocolate.fruit scones,muesli,fruit loaves, 
fruit jams and marmalade.
Liquorice, peppermints,cinnamon balls, 
Chocolate caramels and toffees containing 
dried fruit or nuts.
Ap ric ot s, ra sp berries, strawberries, 
loganberries, melon, blackcurrants, 
boysen berries, guava, pineapple, oranges, 
cherries.Canteloupe melons,cranberries, 
gooseberries,grapefruit,redcurrants, grapes, 
mandarin oranges.nectarines,peaches, 
watermelon,Granny Smith’s apples,Jonathon 
apples, grapefruit.
Jam,jelly,marmalade etc.containing ‘ALLOWED’ Foods which contain the above fruits e.g.jam
fruits. Jelly,marmalade,fruit pie fillings, fruit
t op p in gs .
PAGE 2
FOODS ALLOWED
Lemon curd,syrup,maple syrup,sugar.
Fizzy drinks e.g.Coca Cola,lemonade. 
Orange, lemon or grapefruit drinks.
Coffee (no chicory),cocoa,herbal teas, 
Ovaltine,drinking chocolate,Oxo,Bovril, 
Marmite etc. Carob drinks.
Spirits,lager,white rum.
Dark rum 
Claret 
Vermouth 
Cointreau 
Tia Maria 
Sherry
All vegetables except those on ‘AVOID’ 
list
Salt, pepper.
Herbs and spices except those mentioned 
on the ‘AVOID' list.
Mayonnaise.
FOODS TO AVOrD
Honey.
Apple drinks, blackcurrant drinks, grape 
Juice.
Coffee with chicory. Tea -only 1-2 cups per 
day (depending on reaction)
B eer, win e. champ agn e,p ort, cider.
Drambuie. Benedictine liqueurs.
Avocado,aubergine,broad beans,broccoli 
carrot,cucumber,canned tomato,tomato 
paste, tomato puree,olives,okra,parsnips, 
sp in a ch, muslrro oms, endive, sweetcom, 
gherkins,yams (sweet potato).
An i se ed. b a s i I p o wd er, ca raway, cardamom, 
Celery powder,cumin powder,curry powder, 
cinammon.dill powder,garam masala,thyme, 
mixed h erb s. oregano,p aprika,rosemary, 
turmeric.
Avoid any foods which may contain any of 
these spices - including curry and curried 
foods.
Vinegar,bottled sauces containing vinegar 
and spices.tomato sauce,brown sauce, 
Worcestershire sauce,pickles,chutneys, 
salad cream.French dressing,mustard.
Aspirin and medicines containing aspirin. 
Check with your GP or local pharmacist.
only allowed occasionally 
i.e. once a week; 
amounts i.e. one measure 
(quarter gill)
Remember! Any queries regarding your diet, phone the Dietitian who explained it to you.
Name:
Hospital:
Telephone No. 
Extension No.:
Royal Infirmary 
84 Castle (Street 
Glasgow G4 0<SF
Switchboard 01412114000 
DirectDial 0141 211 4318 
Fax Number 
Department of Nutrition & Dietetics
1997
Dear
I have received correspondence from Dr. Forsyth regards your allergy.
She has found you to be sensitive to a substance called Butylated Hydroxytoluene 
(B.HLT. ). This has an “E” number - E321 and may be found in the following types of 
food
Packet convenience foods 
Packet breakfast cereals 
Vegetable oil 
Shortening 
Packet cake mix 
Gravy granules 
Chewing gum
Inner packaging ofbreakfast cereals
Please check the ingredient labels on the above types of foods for E321 and if found avoid 
same. When eating out where you are unsure whether a food may or may not contain this 
please err on the side of caution and avoid whenever possible. Please contact me if you 
have any queries regarding this.
Yours sincerely,
KA. Milligan
Senior Dietitian ( Mon. - W ed.)
Margarine 
Sachet marinade 
Dehydrated mashed potato 
Crisps
Salted peanuts 
Potato rings
AUSPICE 
.  G € L O v
• Glasgow Qoyal Infirmary •
• Glasgow Doyal Maternity Hospital •
• Canniesburn Hospital •
• Lightburn Hospital ■ Belvidere Hospital •
REF : KM / EB
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Glasgow Royal Infirmary University NHS Trust
Department of Nutrition & Dietetics 
E127
You have been found to be sensitive to a red dye called Erytriosine ( E l 27)  
which is found in the following foods in particular
Glace cherries 
Cocktail cherries
Tinned red cherries, strawberries and rhubarb
Scotch eggs
Packet trifle mix
Quick custard mix
Biscuits
Prepacked Swiss Roll 
Stuffed olives 
Chocolates
Dressed crab and salmon spread and pate 
Garlic sausage 
Luncheon meat 
Danish salami
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GLASGOW ROYAL INFIRMARY UNIVERSITY NHS TRUST 
DEPARTMENT OF NUTRITION & DIETETICS 
SORBIC ACID FREE DIET 
E.200 - SORBIC ACID E.201 - SODIUM SORBATE E.202 - POTASSIUM SORBATE
E.203 - CALCIUM SORBATE
You have been found to be allergic to a PRESERVATIVE called SORBIC ACID. Sorbic Acid has 4 E 
numbers - E200, E201, E202 E203. If a food contains this preservative it will be stated on the label; so it 
is important to read the labels of any manufactured or prepared foods you consume.
Avoid any food which just lists the ‘preservative’ or ‘permitted preservative’ as an ingredient.
FOODS ALLOWED FOODS TO CHECK LABELS OF
Milk, butter Low fat spreads e.g. Gold, Outline
Cheese spreads
Cheese slices
Margarine
Hard cheeses
Eggs
Meat - all fresh or frozen Made-up meat dishes
Poultry - meat and poultry
Fish - all fresh or frozen fish Made-up fish dishes
Fruit - all fresh or tinned fruit Fruit topping and fillings
Dried Fruit - all types except apricots, peel Dried apricots. Candied peel
Vegetables - all fresh and frozen vegetables Tinned vegetables in sauce
Cereals }
Nuts }
Pasta } All types 
Rice }
Pulses - peas, beans and lentils}
Soya sauce
Sauces, pickles, pickled products, chutneys
Preservative free jams, marmalade, pickles, 
chutneys and sauces
Preserves; jams, marmalade etc.
Gelatine capsules
Alcoholic drinks; apart from cider Cider
Soft drinks which are preservative free Check labels on fizzy and soft drinks as this 
is the main area in which these preservatives 
will be found + non and low alcoholic wines
All fresh fruit juices
Cakes, scones, biscuits Packet cake topping; prepacked cake mixes. 
Dessert sauces
Soup; Fresh, tinned or packet soup Soup concentrates
418
APPENDIX III
DIETARY AVOIDANCE INFORMATION 
SHEETS FOR CUSTOMERS (COMMERCIAL')
419
SAFEWAY
Safeway Stores pic 
6 Millington Road 
Hayes
Middlesex UB34AY
Telephone 01&1 848 8744 
■ Facsimile 0181 5731865
SAFEWAY PRODUCTS FREE FROM THE ADDITIVES 
DETAILED ON THE ATTACHED LIST
As far as we are aware, the following products do not contain any o f the additives identified on 
the attached list. Our manufacturers have been asked- to declare all additives used in the 
preparation o f Safeway products and also to identify any additive which is contained in the raw 
ingredients.
We will update this list as frequently as possible to allow you the full benefit of enjoying those 
Safeway products which are being developed to meet your important requirements.
SAFEWAY NUTRITION ADVICE SERVICE
(LIST001)
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SA FE W A Y  PRODUCTS FREE FROM 
T H E  ADDITIVES
DETAILED ON THE ATTACHED LIST 
BEV ER AG ES
Drinking Chocolate 
C ocoa
M alted Food Drink 
All Tea/Tea Bags 
All Coffee
FRU IT JUICE
All Fruit Juice - Chilled and Long Life 
B ISC U IT S
W holemeal Thins 
Poppy & Sesame Thins 
Savoury Wheat Crackers 
R ough Oat Cakes 
Cream Crackers 
Sesam e Crackers 
W ater Biscuits 
Cheese Savourys 
Cheese & Chive Sandwich 
L ow  Fat Cream Cracker 
Clown Shortbread 
Chocolate Chip & Nut Digestive 
D u o  Choc Chip Cookie 
H alf Coated Choc Chip Rings 
Chocolate Chip Cookie 
Chocolate Crunch Creams 
Cashew Cookie 
Malted Milk
M ilk Chocolate Malted Milk 
M ilk Chocolate Nice 
N ice
Highland Shorties 
All Butter Biscuits 
Almond Biscuits 
C hocolate Sundaes 
All Butter Fruit Biscuits 
Butter Crinkle Crisp Biscuits 
Chocolate Scrunchies 
Peanut Scrunchies 
Jaffa Cakes
Blackcurrant Jaffa Cakes
Shortcake
Milk Chocolate Digestives
Plain Chocolate Digestives
Party Rings
Lemon Puffs
Lemon Crisp
Coconut Rings
Syrup Crunch
Oaten Crunch
Ginger Nuts
Country Crunch
Milk Chocolate Country Crunch
Plain Chocolate Country Crunch
Duo Chocolate Chip & Nut Cookie
Chocolate Chip and Nut Cookie
Coconut Cookie
Milk Chocolate Wafers
Plain Chocolate Wafers
Milk Chocolate Orange Wafers
Vanilla Wafers
TakeTwo.Bar
Tea Cakes
Mini Snowballs
Plain Chocolate Ginger Crunch 
Plain Chocolate Orange Crunch 
Milk Chocolate Coconut Crunch 
Chocolate Bars x 6 
Mint Chocolate Biscuit Bar : 
Vanilla Chocolate Biscuit Bar 
Chocolate Bars x 7 (Bytes) 
Chocolate Shortcake 
Chocolate Cream Sandwich 
Chocolate Orange Sandwich 
Chocolate Mint Sandwich 
Chocolate Caramel 
Bourbon Fingers 
Bourbon Creams 
Lemon Finger Creams 
Orange Finger Creams 
Coconut Crumble Creams 
Orange Custard Crumble Creams 
Orange Crumble Creams 
Custard Creams 
Oaty Creams 
Ginger Crunch Creams 
Malted Milk Creams 
Jam Sandwich Creams 
Golden Crunch Creams 
Mocha Finger Creams 
Chocolate Crunch Creams
Stem Ginger Cookies Crunchy Sticks - Ready Salted
Chocolate Chunk and Pecan Cookies Crinkle Cut Crisps - Ready Salted
H alf Coated Hazelnut Cookies Cheese Curls
H alf Coated Brazil Cookies Potato Rings - Ready Salted
H alf Coated Chocolate Shortbread Triangles Pizza Slices
Milk Chocolate Orange Covered Sandwich Salt & Pepper Pipes
(x  14) Tortilla Chips
C hocolate Coated Malted Milk Creams (x 6) Garlic Mini Breads 
Salted Cashew Nuts
C A K E S Salted Pistachio Nuts 
Honey Roast Peanuts
Country Cake Monkey Nuts
Ginger Cake Natural Roast Peanuts
Raisin &  Orange Cake Mixed Nuts & Fruit
Cherry Bakewells Peanuts & Raisins
Trifle Sponges Salted Roasted Mixed Nuts
Custard & Apple Mini Pies Salted Roasted Peanuts
V iennese Whirls Peanuts, Raisins & Chocolate Chips
Coconut Square Trail Mix
Lem on Square
Luxury Swiss Rolls:
Red Cherry Conserve
CHILLED DESSERTS
Raspberry Conserve 'Pudding Club Puddings'
Strawberry Conserve Sticky Toffee
Chocolate Spotted Dick Syrup
Sponge Sandwiches: Fresh Cream Strawberry Trifle
Raspberry Jam Fresh Cream Raspberry Trifle
Apricot Jam & Butter Cream Chocolate Mousse .
Raspberry Jam & Butter Cream Savers Chocolate Mousse
Frangipanes Lemon Mousse
Almond Fingers White Chocolate Mousse
M ince Pies Chocolate Surprise Dessert
M eringue Nests Apricot Fool
All Butter Wheatmeal Fruit Cake Raspberry Fool
All Butter Coconut Cake Strawberry Fool
All Butter Madeira Cake Gooseberry Fool
D undee Cake Blackcurrant Cheesecake
Cherry Genoa Cake 
Cherry Madeira Cake
Strawberry Cheesecake
Cherry Genoa Bar 
Sticky Toffee Pudding
YOGHURTS
YoshurtsOriental Ginger Pudding
Mini Sponge Puddings x 3 
M ilk Chocolate Yule Log
All Flavours
All Butter Luxury Dundee Cake with Whiskey French Set Yoshurts
Luxury Rich Xmas Cake with Brandy
CRT S PS/SNA CKS/NUTS 
Potato Sticks - Ready Salted
All Flavours
V erv  I.nw Fat Yoehurts
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All Flavours
Rich and Creamv Yoghurts
All Flavours
Very Low Fat Yoghurts
All Flavours
Greek Yoghurt
Natural
Honey
Apricot
Bio Yoghurt
Peach & Passion Fruit
Strawberry
Plum
Black Cherry 
Natural
Fromage Frais
Fromage Frais
Fromage Frais with Fruit
Very Low Fat Fromage Frais with Fruit
ICE CREAM
Vanilla & Mint Choc Ice 
White Chocolate Choc Ice 
Traditional Vanilla Ice Cream 
Country Strawberry Ice Cream 
Toffee
Clotted Cream 
Chocolate
Vanilla, Lemon & Lime Swirl 
Soft Scoop: Honey & Almond 
Chocolate 
Strawberry 
Fruits o f  the Forest 
Peach & Raspberry 
Toffee Fudge Ripple 
Vanilla
Chocolate and Caramel
Sorbet: Mango
Peach Melba
Lemon
Biscuit & Caramel Ice Cream Bar 
FROZEN DESSERTS
Mousse - Chocolate and Mint Swirl
- Raspberry
• Raspberry Ripple
- Strawberry 
Bramley Apple Pie 
Blackberry & Apple Pie 
Deep Apple Pie 
Banoffee Pie
Apple Pie 
Bakewell Tart 
Rhubarb Crumble 
Apple Crumble 
Bombe au Chocolate 
Luxury Raspberry Pavlova 
Gateau St. Honore Bar 
Black Forest Gateau 
Strawberry Gateau 
Strawberry Gateau - Party Size 
Chocolate Meringue Gateau 
Mousse au Chocolat Gateau 
Chocolate Brownie Dessert 
Bread & Butter Pudding 
Profiteroles
Profiteroles with Grand Marnier 
Cheesecakes: Toffee & Pecan
Apricot & Orange 
Strawberry 
Blackcurrant 
Raspberry 
Fruits o f the Forest 
Chocolate 
Blueberry
Chocolate Roulade 
Summer Fruit Pavlova 
Raspberry Pavlova 
Strawberry Pavlova 
Chocolate Pavlova 
Dairy Cream Sponge 
Chocolate Dairy Cream Sponge 
Strawberry Cream Cake 
Black Forest Cream Cake 
Frozen Yoghurt: Natural
Strawberry
Blackcherry
423
OTHER DESSERTS
Creamed Rice Pudding 
Traditional Creamed Rice
BREAKFAST CEREALS
Frosted Flakes 
Coco Crunchies 
Square Malt Bites 
Wheat Honeys 
Cornflakes 
Bran Flakes 
Rice Crunchies 
Fibre Bran 
Crunchy Cereal 
Swiss Style Cereal 
Wholewheat Biscuits 
Hot Oat Cereal 
Quick Cooking Oats 
Wholewheat Flakes
BREAD
All Packaged Bread Range 
Garlic Bread
BUNS AND MORNING GOODS
Potato Cakes 
Cheese Potato Cakes 
French Croissants (4 s)
Raisin & Lemon Pancakes (6s)
Scotch Pancakes x 8
Fruit & Spice Pancakes (6s)
Crumpets (&s)
Muffins (6s)
Cheese Muffins (6s)
Wholemeal Muffins
Derby Scones x 6
Sultana Scones x 4
Fruit Scones (Scottish) x 4
Plain Scones (Devon) x 4
Currant Buns
Fruit Teacakes x 4
Spiced Fruit Buns
Hot Cross Buns (White, Wholemeal, Extra 
Spicy)
PRESERVES & SPREADS
All Honey 
All Conserves: Strawberry
Raspberry
Blackcurrant
Ginger Preserve 
Fresh Fruit Orange Marmalade 
Peanut Butter - Smooth 
Peanut Butter - Crunchy 
Chocolate Hazelnut Spread 
Chocolate Coconut Spread 
Sandwich Spread
SOUPS
Cup S oup: Minestrone 
Chicken & Leek 
Chicken 
Asparagus
Cup Soup with Croutons:
Slim Soups:
Dried:
Canned:
Chilled Soups:
Creamed Tomato 
Chicken & Leek
Tomato Slim Soup 
Vegetable Slim Soup 
Tomato & Beef Slim Soup 
Chicken Slim Soup 
Minestrone Slim Soup
Golden Vegetable 
Cream of Chicken
Cream of Celery 
Chicken & Sweetcom 
Cream of Smoked Trout 
Carrot & Orange 
Cream o f Tomato 
Country Vegetable Soup 
Cream of Mushroom
Brocolli and Cheddar 
Italian Tomato 
Mushroom
Cream of Pepper & Ginger 
Sweetcom Chowder 
Butter Bean and Blue Chees 
Carrot, Parsnip & Apple 
Country Vegetable
424
SA U C E S
Pesto Sauce 
Pasta Sauce
Pasta Sauce with Peppers
Pasta Sauce with Mushrooms
Cranberry Sauce
Tartar Sauce
Brown Sauce
Fruity Sauce
Creamed Horseradish
French Mustard
English Mustard
W holegrain Mustard with Honey
W holegrain Mustard with Whiskey
Traditional English Beer Mustard
Chilli Sauce
Tom ato Ketchup
Tom ato Puree
Canned Cooking Sauces:
Tom ato & Onion 
Red W ine Sauce 
Sw eet & Sour Sauce 
Chilli Sauce 
W hite W ine Sauce 
Curry Sauce
P IC K L E S & RELISHES
R ed W ine Vinegar 
W hite W ine Vinegar 
Cider Vinegar 
Distilled Vinegar 
Curried Fruit Chutney 
Peach Chutney 
M ango chutney 
Tomato Chutney 
Almond Stuffed Olives 
Stuffed Green Olives 
Green Olives 
Black Olives
SA L A D  DRESSINGS
Seafood Dressing
Reduced Calorie Vinegar & Oil Dressing 
Thousand Island Dressing 
Salad Cream
AJI Mayonnaises: Real
Lemon 
Mustard 
Garlic
Low Calorie
French Dressing 
Italian Dressing 
Garlic Dressing 
Mustard Dressing
DRIED PRODUCTS & BAKING AIDS
Sage & Onion Stuffing Mix 
Mushroom & Celery Stuffing Mix 
Cornflour 
Custard Powder
All Herbs & Spices *
All Varieties o f Pasta & Egg Pasta 
All Dried Pulses (Beans, Lentils, Peas)
Seed Pearl Tapioca 
Pearl Barley
Brown and White Rice (including Flaked & 
Ground)
Seeded Raisins
Currants
Sultanas
Desiccated Coconut 
All Nuts
All Flour (Elain, Self-Raising and Strong)
Salt
Sugar - All Varieties 
Puff Pastry
Shortcrust Pastry (Frozen)
Mincemeat
Almond'Peppermint/Vanilla Essence 
CANNED FRUIT
Peach Slices & Halves in Syrup/Juice
Pear Quarters & Halves in Syrup/Juice
Peaches & Pears in Syrup
Pineapple Rings, Slices, Pieces & Crushed in
Syrup/Juice
Mandarins Syrup/Juice
Prunes in Syrup/Natural Juice
Grapefruit Segments Syrup/Juice
Blackberries in Juice
Blackcurrants in Juice
Lychees in Syrup
Mango Slices in Sytup
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Tropical Fruit Cocktail in Fruit Juice
VEGETABLES
Canned
Petit Pois
Petit Pois & Baby Carrots 
Sliced Mushrooms 
W hole Button Mushrooms 
Jersey Royal Potatoes 
Small New Potatoes 
W hole Carrots 
W hole Baby Carrots 
Sliced Carrots 
Crinkle Cut Carrots 
Ratatouille 
Mixed Vegetables 
Mixed Summer Vegetables 
Baked Beans
Reduced Sugar/Salt Baked Beans
Barheque Baked Beans
Curried Baked Beans
Baked Beans and Beefburgers
Baked Beans and Sausages
Spaghetti in Tomato Sauce (shortcut, rings,
letters)
Wholewheat Spaghetti in Tomato Sauce
Cut Green Beans
W hole Green Beans
Butter Beans
Chick Peas
Boriotti Beans
Haricot Beans
Canellini Beans
Black Eye Beans
Flageolet Beans
Red Kidney Beans
Chilli Beans
Mixed Bean Salad
Sweetcom
Sweetcom & Peppers
W hole Tomatoes
Tomatoes
Chopped Tomatoes
Chopped Tomatoes with Herbs
Chopped Tomatoes with Hot Chilli
Passata
Frozen
Flame Roasted Vegetables (Plain)
Southern Fry Potato Wedges
Southern Fry Griddles
Saute Potatoes
Roast Potatoes
Hash Browns
Pommes Noisettes
Breaded Mushrooms
Cous Cous
CHTLLED SALADS 
Coleslaw
Reduced Calorie Coleslaw 
Coleslaw with Cheese 
Garlic & Herb Coleslaw 
Prawn Coleslaw'
Vegetable 
Greek Style 
Celery, Nut ^Sultana 
Carrot & Nut 
Crispy Vegatable 
Potato
Pasta & Pesto
CHILLED PIPS
Prawn 
Sat ay
Garlic & Herb
Tzatziki
Taramasalata
SANDWICHES
Coronation Chicken
Tuna & Cucumber
Chicken Tikka
Spicy Jamaican Chicken
Exotic Chicken Triple
Country Salad
Ploughmans
Tuna Italienne
Roast Beef
Prawn Mayonnaise
Cream Cheese, Fruit and Walnut
Egg Roll
Ploughmans Roll
All Frozen Vegetables
FATS & OILS
All Margarines & Spreads
All Butter
All Cooking Oils
MTLK & MTLK PRODUCTS
All Milk (Fresh Pasteurised, Sterilised & 
UHT)
All Cream 
Instant Dried Milk 
Evaporated Milk
Soya Milk (Sweetened, Unsweetened) 
Trimrite Evaporated Low Fat Milk
CHEESE
All varieties o f Cheese (hard, soft, cottage)
except Edam/Gouda
Processed Cheese Slices
Processed Cheddar Slices
Full Fat Soft Cheese
FISH  &  FISH PRODUCTS 
Frozen
All Plain Fish e.g. Cod Fillets
Cod Fillet in Breadcrumbs (Boxed)
Haddock Fillet in Breadcrumbs (Boxed)
Plaice Fillet in Breadcrumbs (Boxed)
Cod in Batter (Boxed)
Haddock in Batter (Boxed)
Fish Fingers
Prime Cod Fish Fingers
Breaded Scampi
Hoki Kiev
Fresh
All Fresh Chilled Fish 
Breaded Cod 
Breaded Plaice 
Breaded Haddock 
Kippers 
Smoked Cod 
Smoked haddock
CANNED FISH
Tuna in Oil/Brine
Sardines in Vegetable Oil
Sardines in Brine
Anchovies in Olive Oil
Anchovies with Capers in Olive Oil
Pink Salmon
Red Salmon
Skinless, Boneless Pink Salmon 
Salmon & Shrimp Paste 
Crab Paste
Sardine & Tomato Spread 
Tuna & Mayonnaise Spread
READY MEALS & MEAT PRODUCTS
Frozen
Grill Steaks 
Economy Burgers 
Quarter Pounder Beefburgers 
Beefburgers'
Cornish Pasties 
Premium Comish Pasties 
Cheese & Onion Flans 
Minced Steak Pie (with red wine)
Individual Minced Steak Pie (with red wine)
Steak & Kidney Pie
Individual Steak & Kidney Pie
Beef Stew & Dumplings
Cannelloni
Chilli Con Came with Rice 
Ocean Pie 
Seafood Lasagne 
Fish Crumble
Cod Crumble with Broccoli and Prawns 
Cauliflower and Broccoli Momay 
Moussaka
Bean & Cheese Enchilladas 
VegetableChilli 
Vegetable Rolls 
Cauliflower Cheese 
Macaroni Cheese 
Spaghetti Bolognese 
Canelloni
Vegetable Lasagne 
Potato & Cheese Gratin 
Spicy Chicken 
Potato Topped Pie 
Chicken Casserole 
Chicken Curry
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B e e f  Curry 
V egetable Curry
Chicken Tikka Masala with Pilau Rice
FRESH/CHTLLED MEAT PRODUCTS
Ail Fresh Meat and Poultry 
Chicken Kiev 
C ooked Turkey 
C ooked Topside of Beef 
C ooked Leg o f Pork 
Chargrill Whole Chicken 
Chargrill Chicken Drumsticks 
C ooked Roast Chicken - Whole
- Portions
Chinese Style Chicken
Tandoori Style Chicken
M elton Pork Pie (Medium, Large,
Individual)
C ottage Pie
Snack Pork and Mushroom Pies
Pies Individual
D eep  Filled Vegetable Pie 
Steak & Kidney Pudding 
Cornish Pastries x 4 
Individual Cornish Pastry 
Chicken Cibouette 
Chicken & Mushroom Slice 
B e e f  & Onion Slice 
M inced B eef & Onion Pasties
Pies/Laree/Familv
Lam b & Red Wine Pie 
Steak  & Vegetable Pie 
Steak & Ale Pie 
Salm on & Brocolli Pie 
Pork & Vegetable Pie with Cider 
Pork & Vegetable Cobbler 
B e e f  & Vegetable Cobbler
R E A D Y  MEALS & CONVENIENCE 
S N A C K S
Canned:
R avioli 
Irish Stew
Beef Madras 
Chicken Madras 
Chilli Con Came
Chilled
Basmati Rice
Gobi AIoo Saag
Vegetable Curry
Chicken Passanda
Chicken Curry with Pilau Rice
Chicken Korma
Chicken Dhansak
Chicken Saag
Chicken Biryani
Chicken Madras
Moussaka
Chicken Tikka Masala 
Chicken Chow Mein 
Special Fried Rjce 
Lasagne
Vegetable Lasagne 
Canelloni
Tagliatelle with Tuna & Sweetcom
Cauliflower Cheese
Liver & Bacon
Snack Meals
Chilli with Rice
Sweet & Sour Pork with Rice
Cauliflower Cheese
Macaroni Cheese
FRESH CHILLED PASTA
Tagliatelle Bianche 
Tagliatelle Verdi 
Tagliate (Garlic 8c Herbs)
Spaghetti 
Paglia e Fieno 
Agnolotti (Mushroom)
Agnolotti (Tuna & Onion)
Pappardelle (Herbs & Tomato)
Tortellini (Cheese & Tomato)
Tortellini (Chicken 8c Asparagus)
Tortellini (Garlic & Herb)
Capaletti (Blue Cheese & Chives)
CHILLED VEGETARIAN PRODUCTS
Cheese & Tomato Grill
428
Mushroom & Rice Escalope 
Creamy tomato Escalope 
Nut Cutlet 
Vegetable Cutlet
Mushroom Goujons with Garlic & Chive Dip 
Vegetable Goujons with Tomato Dip 
Vegetable Satay
Potato Vol au Vents (Brocolli & Garlic). 
Potato Vol au Vents (Creamy Mushroom)
Microwave Ready Meals
Chicken Korma with Rice
Chilli Con Came and Rice
B eef Madras with Rice
Sweet and Sour Chicken with Rice
Lasagne
Pasta Bolognese
PIZZAS
Cheese & Tomato 
Vegetable Chilli 
Chilli B eef & Spring Onion 
Spicy Pork & Cashew Nut 
Mozzarella
Chinese Pork & Cashew Nut 
Cheese Tomato & Mixed Peppers 
Tuna & Anchovy 
9 ” Pizza Breads 
7" Pizza Breads
FROZEN PIZZAS
Luxury Prawn and Tuna
Stoneoven 
Chicken & Vegetable 
Chicken & Pepperoni 
Cheese & Tomato Mini Pizzas 
Cheese & Onion Mini Pizzas
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THE FOLLOWING PERMITTED FOOD 
ADDITIVES ARE NOT INCLUDED IN 
THE FORMULATION OF THE 
PRODUCTS LISTED.
COLOURS
E l02 Tartrazine 
E l04 Quinoline Yellow 
E110 Sunset Yellow FCF 
E l20 Cochineal or Carmine Acid 
E l22 Carmoisine or Azorubine 
E l23 Amaranth 
El 24 Ponceau 4R or Cochineal 
E127 Erthyrosine BS 
128 Red 2G 
E l31 Patent Blue V 
E132 Indigo Carmine or Indigotine 
E133 Brilliant Blue FCF 
E l42 Green S (Acid Brilliant Green)
E l50 Caramel
E151 Black PN (Brilliant Black BN)
E l53 Carbon Black (Vegetable Carbon)
154 Brown FK (Kipper Brown)
155 Brown HT
E l 80 Pigment Rubine (Lithol Rubine BK)
FLAVOUR ENHANCERS 
Monosodium Glutamate/Sodium Glutamate
621 Sodium Hydrogen L-Glutamate
622 Potassium Hydrogen L-Glutamate
623 Calcium Dihydrogen di-L-Glutamate 
627 Guanosine 5 - (disodium phosphate) 
631 Inosine 5 - (disodium phosphate)
635 Sodium 5 - Robonucleotide
PRESERVATIVES
E210 
E211 
E220 
E250 
E251 
E221 
E222 
E223 
E224 
E226 
E227 
E212 
E213 
E214 
E215 
Salt 
E216 
E217 
SaltE 
218 
E219 
Salt
Benzoic Acid 
Sodium Benzoate 
Sulphur Dioxide 
Sodium Nitrite 
Sodium Nitrate 
Sodium Sulphite
Sodium Hydrogen Sulphite *
Sodium Metabishulphite
Potassium Metabishlphite
Calcium Sulphite
Calcium Bisulphite
Potassium Benzoate
Calcium Benzoate
Ethyl 4 Hydroxybenzoate
Ethyl 4 Hydroxybenzoate Sodium
Propyl 4 Hydroxybenzoate 
Propyl 4 Hydroxybenzoate Sodium
Methyl 4 Hydroxybenzoate '
Methyl 4 Hydroxybenzoate Sodium
ANTIOXTDANTS
E320 Butylated Hydroxyanisole (BHA) 
E321 Butylated Toluene (BHT)
E 310 Propyl Gallate 
E 311 Octly Gallate 
E312 Dodecyl Gallate
430
APPENDIX IV 
PUBLICATIONS
431
Publications
The following publications have been generated from the work carried 
out for this thesis:
Investigation of the potential involvement of Mycobacterium 
paratuberculosis in oral Crohn’s disease and orofacial granulomatosis 
by polymerase chain reaction.
Riggio MP, Gibson J, Lennon A, Wray D, and MacDonald DG.
Gut 1997; 41: 646-650
Angioedema and swellings of the orofacial region.
Rees SR, and Gibson J.
Oral Diseases 1997; 3: 39-41
Thiomersal sensitivity in Health Care Workers (letter).
Rees S, Gibson J, Forsyth A, and Wray D.
Brit Dent J 1997; 183: 395
Identification of Mycobacterium paratuberculosis by PCR in Orofacial 
Granulomatosis.
Gibson J, Riggio MP, MacDonald DG, and Wray D.
J  Dent Res 1995; 74: 843 (abstract)
Orofacial Granulomatosis - the role of Patch Testing.
Gibson J, Forsyth A, and Milligan KA.
Brit J  Dermatol 1995; 133: 25 (abstract)
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Dietary and Environmental Allergens in Patients with Orofacial 
Granulomatosis.
Gibson J, Forsyth A, and Milligan KA.
J  Dent Res 1996; 75: 334 (abstract)
Search for Mycobacterium paratuberculosis in OFG and oral Crohn’s 
disease.
Riggio MP, Gibson J, Lennon A, Wray D, and MacDonald DG.
J  Dent Res 1997; 76: 405 (abstract)
Prevalence of Food and Environmental Allergy in Oral Mucosal 
Disease.
Rees S, Gibson J, Forsyth A, and Wray D.
J  Dent Res 1998; 77: 895 (abstract)
Technetium-99m-HMPAO leucocyte labelling in OFG and intestinal 
Crohn’s disease.
Gibson J, Wray A, Neilly B, Evans J, MacKenzie R, and McKillop J. 
JDent Res 1998; 77: 895 (abstract)
Pre- and post-treatment outcome measures in patients with orofacial 
granulomatosis.
Gibson J, Forsyth A, and Wray D.
JDent Res 1998; 77: 1009 (abstract)
Identifying markers of systemic disease in patients with orofacial 
granulomatosis.
Gibson J, Smith G, Wray D, and Forsyth A.
JDent Res 1998\ 77: 1009 (abstract)
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